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 Siddha ,system ,is ,one ,of ,the ,ancient ,science ,of ,our ,nation ,with ,an ,almost ,unbroken 
,tradition ,of ,safety ,and ,efficacy. ,Siddha ,system ,of ,medicine ,considers ,human ,beings ,in ,their 
,totality ,and ,their ,subtle ,relationship ,with ,the ,universe. ,The ,beauty ,of ,this ,system ,is ,that ,it 
,doesn’t ,look ,at ,health ,as ,being ,merely ,the ,absence ,of ,disease, ,but ,in ,positive ,terms ,of ,balance 
,and ,harmony ,of ,body, ,mind,soul. 
 
   ,“Elements ,of ,macrocosm ,exists ,in ,microcosm , 
   , ,Elements ,of ,microcosm ,exists ,in ,macrocosm 
   , ,Macrocosm ,and ,microcosm ,are ,one , 
   , ,When ,realization ,is ,complete” 
- Chattamuni ,Gnanam1. , 
The ,human ,powers ,and ,the ,natural ,powers ,are ,responsible ,for ,the ,functions ,of ,the 
,universe, ,which ,are ,neither ,different ,nor ,variant ,in ,nature. ,The ,Siddhars ,explained ,all ,body 
,functions ,relative ,to ,the ,happenings ,in ,the ,universe.The ,body ,is ,made ,up ,of ,Udal ,thathus 
,(physical ,constituents), ,Uyir ,thathus ,( ,biological ,humors ,).If ,the ,inherent ,powers ,within ,the 
,human ,beings, , ,such ,as ,the ,Mukkunam,Mukkutram, ,Udal ,thathukal, ,Kosam ,and ,Aadharam ,act 
,against ,the ,natural ,powers ,to ,generate ,the ,diseases. ,1 
Noi ,or ,disease ,is ,the ,state ,arising ,from ,inability ,of ,bodily ,nature ,to ,meet ,with ,or 
,neutralize ,the ,increased ,or ,morbid ,effects ,resulting ,from ,the ,varied ,changes ,taking ,place ,in ,the 
,system. ,It ,is ,known ,as , ,pini,varutham,thunbam,vinai,rogam ,and ,sugaveenam.2 
The ,skin ,diseases ,are ,classified ,into ,18 ,varieties ,by ,Siddhar ,Yugi ,Munivar. ,One ,such 
,skin ,disease ,is ,Kalanjagapadai. ,The ,symptoms ,of ,Kalanjagapadai ,can ,be ,correlated ,to ,those ,of 
,the ,clinical ,entity ,Psoriasis ,in ,modern ,system ,of ,medicine. ,He ,has ,described ,under ,the 
,classification ,of ,vaatha ,diseases ,about ,“Kalanjagavatham” ,which ,may ,be ,correlated , ,with , 
,Psoriatic ,arthropathy.3 , , 
 , In ,the ,textbook ,“Siddha ,Maruthuvam ,Sirappu”, ,Dr.R.Thiagarajan ,has ,described ,about 
,Kalanjagapadai. ,The ,clinical ,features ,of ,Kalanjagapadai ,are ,correlated ,to ,psoriasis ,as ,described 
,in ,modern ,dermatology. ,In ,the ,Siddha ,system, ,skin ,disorders ,are ,brought ,under ,the ,clinical 
,entity ,“Kuttam”. , 
Psoriasis ,is ,common, ,chronic ,skin ,disease, ,affecting , ,approximately ,2% ,of ,the 
,population. ,Psoriasis , ,is ,associated ,with ,a ,high ,degree ,of ,morbidity ,; ,patients ,are ,embarrassed 
,about ,the ,appearance ,of ,their ,skin,and ,there ,side ,effects ,of ,medications.In ,addition, ,patients 
2 
 
,with ,psoriasis ,have ,reduced ,levels ,of ,employment ,and ,income ,as ,well ,as ,a ,decreased ,quality ,of 
,life.4 ,The ,prevalence ,of ,psoriasis ,to ,be ,0.44% ,to ,2.8% ,among ,the ,skin ,patients ,in ,India. ,Highest 
,incidence ,was ,noted ,in ,the ,age ,group ,of ,20-39 ,years ,and ,the ,mean ,age ,of ,onset ,is ,males ,and 
,females ,were ,comparable.5 
The ,exact ,cause ,of ,psoriasis ,remains ,unknown. ,There ,may ,be ,a ,combination ,of 
,elements, ,including ,genetic ,predisposition, ,environmental ,factors, ,stress ,also ,a ,trigger ,for ,a 
,psoriasis ,flare. ,Psoriasis ,independently ,associated ,with ,stress ,related ,disorders.6 
The ,Siddha ,system ,approaches ,diseases ,by ,holistic ,way ,to ,prevent ,and ,treat ,the 
,condition. ,Hence ,the ,proper ,assessment ,of ,disease ,through ,various ,diagnostic ,tools ,mentioned 
,in ,siddha ,literatures ,and ,with ,modern ,scientific ,methods. 
,The ,number ,of ,Kalanjagapadai ,patients ,attending ,the ,National ,Institute ,of ,Siddha 
,hospital ,is ,considerably ,increasing ,day ,by ,day. ,Patient ,is ,very ,much ,agitated ,and ,subjected ,to 
,physical ,and ,mental ,suffering. ,However ,encouraging ,results ,are ,obtained ,in ,our ,Siddha ,system. 
,With ,this ,back ,ground ,the ,disease ,Kalanjagapadai ,was ,chosen ,for ,the ,dissertation ,study. 
,However ,clinical ,symptoms ,can ,be ,relieved ,considerably ,with ,Siddha 
,treatment.Siddhars ,identified ,numerous ,number ,of ,herbal ,for ,treating ,psoriasis. ,One ,such 
,Siddha ,herbal ,formulation ,“Parangipattai ,Kudineer” ,(Internal) ,and ,“Sivappu ,Thylam” 
,(External) ,mentioned ,in ,“Pharmacopoeia ,of ,hospital ,of ,Indian ,medicine” ,which ,is ,said ,to ,be 
,efficacious ,and ,simple ,formulation. ,This ,formulation ,has ,not ,undergone ,any ,clinical ,trial ,so ,the 
















2.AIM ,AND ,OBJECTIVES 
2.1.PRIMARY ,OBJECTIVES ,: , , 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,To ,evaluate ,the ,safety ,and ,therapeutic ,efficacy ,of ,Siddha ,drugs, ,Parangipattai 
,kudineer ,(Internally) ,and ,Sivappu ,Thylam ,(Externally) ,in ,the ,treatment ,of ,Kalanjagapadai 
,(Psoriasis) 
 
2.2.SECONDARY ,OBJECTIVES ,: 
 
❖ To ,studied ,the ,Siddha ,diagnostic ,methods ,such ,as ,Envagai ,thervu ,, ,Manikkadai ,Nool, 
,Neer ,kuri ,and ,Nei ,kuri ,as ,complementary ,measures ,for ,diagnosis ,in ,Kalanjagapadai 
,patients. 
❖ To ,carried ,out ,the ,biochemical ,analysis ,of ,trail ,medicine ,Parangipattai ,kudineer 
,(Internally) , 
❖ To ,carried ,out , ,analytical ,specification ,of ,a ,trail ,medicine ,Parangipattai ,kudineer 
,chooranam ,(Internally) ,as ,per ,AYUSH ,protocol. 
❖ To ,evaluated ,the ,acute ,and ,sub-acute ,toxicity ,of ,the ,trial ,drug ,as ,per ,OECD ,guidelines. 
❖ To ,evaluated ,of ,pharmacological ,activities ,(In-vitro:Anti-Inflammatory, 
,Immunomodulator, ,Anti-proliferative) ,of ,trail ,medicine ,Parangipattai ,kudineer 
,chooranam ,(Internally) 
❖ To ,evaluated ,of ,docking ,analysis ,of ,trail ,medicine ,Parangipattai ,kudineer 
,chooranam ,(Internally) 
❖ To ,evaluated ,of ,In-vitro ,anti-inflammatory , ,activities ,of ,trail ,medicine ,Sivappu ,thylam 
,( ,Externaly ,) 
❖ To ,collected ,a ,detailed ,of ,literatures ,of ,trial ,drug ,and ,the ,disease ,“Kalanjagapadai” ,and 
,review ,the ,ideas ,mentioned ,in ,siddha ,literatures ,related ,to ,this ,disease. 
❖ To ,studied ,the ,effectiveness ,of ,Yogam , ,along ,with ,medicine ,in ,kalanjagapadai ,IPD 
,patients. , 
❖ To ,made ,a ,detailed ,clinical ,evaluation ,of ,the ,disease ,by ,examination ,on 
,aetiology,symptomology,complication, ,treatment,and ,prognosis. 
❖ To ,studied ,the ,incidence ,of , ,“Kalanjagapadai” ,with ,reference ,to ,age, ,sex, ,family 
,history, ,occupation, ,socio-economic , ,status ,, ,habit,and ,also ,related ,to ,psychosomatic 





3.REVIEW ,OF ,LITERATURE 
3a.SIDDHA ,ASPECT , 
3a.1.KALANJAGAPADAI 
3a.1.1.SYNONYMS ,: 
 Venparu ,sedhil, ,Sedhiludhir ,noi,Sambal ,padai ,,Sedhil ,udhirpadai3 
3a.1.2.DEFINITION ,: 
According ,to ,the ,text ,book ,of ,“Siddha ,Maruthuvam ,Sirappu” ,Kalanjagapadai ,is ,a 
,chronic ,non-infectious,recurrent, ,inflammatory ,disorder ,of ,the ,skin ,characterized ,by,reddish ,, 
,slightly ,elevated ,dry ,patches ,covered ,with ,silvery ,white ,scales.In ,Siddha ,system,Skin ,disorder 
,are ,brought ,under ,the ,clinical ,entity ,“Kuttam.7 
,In ,the ,textbook ,“Siddha ,medical ,dictionary”- ,Mr.T.V.Sambasivam ,pillai ,has 
,described ,about ,“Kuttam” ,means ,cutaneous ,affections ,and ,so ,it ,is ,a ,comprehensive ,term ,used 
,for ,various ,skin ,diseases. ,In ,this ,book ,“Sori ,kuttam” ,has ,been ,compared ,to ,psoriasis, ,a ,kind ,of 
,leprosy ,with ,diffuse ,papular ,eruption ,with ,ulceration ,on ,the ,entire ,surface ,of ,the ,body ,marked 
,by ,intense ,itching ,and ,burning ,sensation ,followed ,by ,exfoliation ,of ,the ,epidermis ,or ,browny 
,scales ,(Eczematous ,psoriasis, ,lepra ,icthyosis). , 
,In ,the ,text ,book ,“Aathma ,Ratchamirtham ,ennum ,Vaithiya ,saarasangiragam” ,the 
,characteristics ,of ,kuttam ,are ,described ,as; ,white ,scaly ,patches ,will ,appear ,in ,foot, ,wrist ,and 
,typical ,extensor ,distribution. , 
3a.1.3.FACTS ,OF ,SKIN ,DISEASES: 
It ,is ,a ,disease ,believed ,due ,to ,a ,reflection ,of ,one’s , ,previous ,births ,(karma). 
Some ,authors ,of ,Indian ,medical ,science ,attribute ,the ,origin ,of ,this ,disease ,to ,several 
,pathological ,causes ,such ,as ,venereal ,diseases,syphilis, ,ring ,worm, ,snake ,bite ,, ,poisonous 
,insects ,bite ,or ,sting,infection,inheritance. 
3a.1.4.AETIOLOGY ,: 
"Å¡¾ÁÄ¡Ð ,§ÁÉ¢ ,¦¸¼¡Ð" 
 
- ,§¾Ãý ,§º¸ÃôÀ¡8 
 





The ,Siddha ,literatures ,explain ,the ,aetiology, ,clinical ,features , ,of ,Kuttam ,have ,been ,mentioned 
,in ,below ,; 
The ,text ,book ,Siddha ,Maruthuvam ,Sirappu, 
➢ Unknown ,etiology 
➢ Genetic ,cause 
The ,text ,Agathiyar ,Paripooranam ,– ,400 ,describes ,the ,Psycho-social ,causes ,(Kanma 
,Varalaru); 
  “ÀÆÅ¢¨ÉÂ¡ø ,Å¢„ôâîº¢ ,¸Êò¾ ,§¾¡„õ 
  , , , , , ,  À¡¾¸÷ìÌ ,´Õ ,¿¡Ùõ ,¾£÷Å¾¢ø¨Ä 
 ,¯ÇÅ¢¨ÉÂ¡ ,æ¼¡À¢ì ,¦¸¡ûÇ ,Åó¾ 
 ¯ñ¨ÁÂÐ ,«È¢Â¡Áøã÷ì¸ï ,¦ºöÅ¡÷ , 
 ,¸ÇÅ¢¨ÉÔó ,¾£÷Å¾¢ø¨Ä ,¸ÊÉ¦Áò¾ 
 ¸Õ¨½ÔûÇ ,âÃ½ò¾¢ø ,¸ñ¸¡ðº¢ 
 ,«¼Å¢¨É ,¿£¸¡ÏÓý¦É ,«¸Äî ,¦º¡øÄ¢ 
 «¨¼Â¡Çõ ,Å¢Ãø ,ÌÚÌ ,Á¢ýÉí¸§¸§Ç”. 
 
“Å¢ÃøÌÚÌí¸¡ø¾¢Á¢Õõ ,Å¢„õ§À¡§ÄÚõ 
  ,¦ÁöÂØóÐó ,¾¨ÄÍÆÖõ ,¦ÅÙìÌõ ,§ÁÉ¢ 
 ,ÀÃÁ¡É ,§¾¸¦ÁøÄ¡ó ,¾ÊòÐ ,Å£íÌõ 
   À¡¾¦ÁøÄ¡õ ,¦ÅÊòÐÁ¢¸ô ,Òñ½¡í ,¸¡Ïõ 
 ,ºÃºã¼ý ,¦º¡È¢¸ÃôÀ¡ý ,À½õ§À¡ø ,§¾¡Ïõ 
 ºó¨¾Â¡§Á ,Å¢ó¨¾¦¸Îó ,¾ÊòÐ ,Å£íÌõ 
¿ÃÕÄ¸¢ ,Ä¢ó§¿¡öìÌ ,ÁÕó¾£Â¡§¾ 
 ¿ø§Ä¡¨Ãô ,ÀÆ¢ò¾Ìð¼í¸ýÁÁ¡§Á”. , 
 
In ,Agathiar ,Paripooranam ,400 ,it ,has ,been ,mentioned ,that ,diseases ,which ,are ,caused ,due ,to 
,sins ,committed ,in ,the ,previous ,birth ,will ,be ,cured ,only ,if ,Kanmam ,is ,expiated. 
Siddhar ,Agathiyar ,mentioned ,that ,Kanmam ,(Genetic , ,predisposition) ,is ,the ,main ,cause ,for 
,Kuttam ,in ,the ,text ,Kanma ,Kandam ,as ,follows: 
“§º÷ó¾ ,Ìð¼¦Á¡Î ,Ì¨È§¿¡ö¸û 
 §º¾¢§¸û ,ÁÄÃ¡¾ ,ÅÕõÀ ,¦¸¡ö¾ø , 
¾¡Ã¢ó¾ ,º£÷ ,¦ºóÐ ,Å¨¾¸û ,¦ºö¾ø 
 ¾¡ö ,¾ó¨¾ ,ÁÉÐ ,¦¿¡óÐ ,§Ã¡¸ó¾¡§É 
¾¡¦ÉýÈ ,¦¾öÅ×Õò ,¾¨ÉÂÆ¢ò¾ø 
 º¡÷Å¡É ,¦ÀÃ¢§Â¡÷¸û ,¾¨Áô ,ÀÆ¢ò¾ø 
¸¡¦ÉýÈ ,¿ó¾ÅÉõ ,âï¦ºÊ¸û ,¦Åð¼ø 




ä¦ÉýÈ ,×¼õ¦ÀøÄ¡õ ,¦Á¡ðÎ ,¦Á¡ð¼¡ 
 Ô¼ý ,¦ÅÙòÐ ,Ì¨È§Â¡Ô¾¢Ãï ,º¢óÐõ 
Å¡¦ÉýÈ ,¸ÕÁí¸û ,¾£÷ôÀ¾üÌ 
 Å¨Ã¦Â¡ýÚ ,¦º¡ø§Åý ,§¸û ,¿ó¾Åý¨Á§Â”. 
➢ Plucking ,the ,flower ,buds 
➢ Cruel ,to ,animals 
➢ Destroying ,statues ,of ,god 
➢ Abuse ,elderly ,people 
➢ Destroying ,forests ,and ,gardens. 
3a.1.5.SIGNS ,AND ,SYMPTOMS: 
The ,predominant ,symptoms ,are 
➢ Roughness ,of ,skin 
➢ Itching ,sensation 
➢ Anaesthesia , ,of ,the ,parts 
➢ Rapid ,growth ,and ,spread ,of ,ulcers. 
In ,Thirumoolar ,Vaithiyam 
“Å¢Â¡¾¢Ôû ,ãÅ¡Ú ,Å¢Çí¸¢Â ,Ìð¼í§¸û 
 ,ÍÂ¡¾¢ì ,¸¢Ãó¾¢ ,ÍÆø ,§Á¸ò¾¡ ,Ä¡Úõ 
 ,ÀÂ¡¾¢ ,ÁñÏÇô ,ÀÄÅñÊÉ¡ ,¦ÄðÎõ 
 ,¿¢Â¡¾¢ ,ÒØ¿¡Ä¡ö ,¿¢ýÈ¾¢ì ,Ìð¼§Á”. 
 
➢ Six ,types ,of ,skin ,diseases ,are ,caused ,by ,venereal ,disease 
➢ Eight ,types ,of ,skin ,diseases ,are ,caused ,by ,insect ,bites 
➢ Four ,types ,of ,skin ,diseases ,are ,caused ,by ,worm ,infestations. 
In ,Guru ,Naadi ,Nool  
“¸¢ÕÁ¢Â¡ø ,Åó¾ ,§¾¡¼õ ,¦ÀÕ¸×ñÎ  
 §¸ð¸¢ ,Ä¾ý ,À¢Ã¢×¾¨É ,¸¢ÃÁÁ¡¸ô 
 ÒØì¸Ê§À¡ø ,¸¡ÏÁÐ ,¸¢ÕÁ¢ ,Â¡§Ä 
 ,¦ºÕÁ¢ÅÕõ ,À×ò¾¢Ãí¸û ,¸¢ÕÁ¢ ,Â¡§Ä 
 §¾¸Á¾¢ø ,¦º¡È¢ìÌð¼õ ,¸¢ÕÁ¢ Â¡§Ä 
 ,ÐÕÁ¢ÅÕï ,Í§Ã¡½¢¾í ,¸¢ÕÁ¢ ,Â¡§Ä 
 , , , , , , , , , , , , , , , , , , , ÝðºÓ¼ý ,¸¢Ã¢¨ºôÀ¡ø ,¦¾¡Æ¢ø¦ºö ,Å£§Ã”. 






In ,the ,text ,Yugimuni ,800 
  “Å¢ÇõÀ§Å ,Á¢Ìó¾¯‰ ,½ó¾ý ,É¡Öõ  
 Á¢Ìó¾ ,º£¾Çò¾¡Ö ,ÁÆüº¢ ,Â¡Öõ 
ÅÇõÀ§Å ,Áó¾ò¾¡ø ,Å¡ó¾¢ ,Â¡Öõ 
 Á¸ò¾¡É ,¦Àñ§½¡Î ,ÁÕÅ ,Á¡Öõ 
¸¢ÇõÀ§Å ,¸¢§Äíº¸û ,Á¢Ì¾ ,Ä¡Öõ 
 ¦¸ÊÂ¡É ,×Ãì¸í¸Ç ,¨¼¾ ,Ä¡Öõ 
¾ÇõÀ§Å ,ÁÂ¢Õ¸ü¸û ,¾Å¢Î ,Áñ¸û 
 º¡¾ò¾¢ü ,ÀÕ¸Ä¡øÁ¢ìÌí ,Ì‰¼õ”. , 
  Excessive ,heat ,and ,cold, ,laziness, ,sleep ,in ,day ,time, ,sexual ,indulgence, ,robbery ,etc. 
,These ,habits ,are ,prominent ,among ,the ,factors ,which ,lower ,the ,immune ,mechanism ,of ,the 
,body ,(Udal ,vanmai) ,and ,make ,the ,body ,liable ,to ,disease. ,Added ,to ,the ,above ,excessive ,intake 
,of ,food ,items ,which ,are ,hard ,to ,digest, ,imbalanced ,diet, ,and ,vomiting ,due ,to ,indigestion, ,food 
,contaminated ,with ,stone ,and ,hair, ,chronic ,mental ,depression, ,intention ,to ,spoil ,others, ,greed, 
,abusing ,God ,and ,elderly ,people, ,neglecting ,orphans ,and ,beggars, ,cursing ,the ,elders ,would 
,also ,affect ,the ,body ,and ,mind ,disturbing ,the ,mechanism ,of ,the ,body. , 
3a.1.6.Triggering ,Factors ,of ,Kalanjagapadai ,: , 
❖ Seasonal ,variations 
❖ Stress ,and ,strain,Anxiety, ,Depression 
❖ Respiratory ,disorders 
❖ Allergic ,disorders 
❖ Tonsillitis ,(Lasuna ,thabitham) 




According ,to ,Thiru ,T.V. ,SambasivamPillai ,there ,are ,18 ,types ,of ,Kuttam, ,as ,listed ,below: 
1. ,Neer ,kuttam  - ,Leprosy ,with ,serous ,exudation , 
2. ,Venkuttam  - ,White ,Leprosy , 
3. ,Sori ,Kuttam  - ,Psoriasis , 
4. ,Karunkuttam  - ,Black ,Leprosy , 
5. ,Perumkuttam  , - ,True ,Leprosy , 
6. ,Senkuttam  - ,Macular ,Leprosy , 
7. ,Pori ,kuttam  - ,Leprosy ,with ,Granules , 
8. ,Viri ,kuttam ,  - ,Leprosy ,with ,Fissures , 
9. ,Yeri ,kuttam  - ,Leprosy ,with ,burning ,sensation , 
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10. ,Viral ,kurai ,kuttam , - ,Lepra ,mutilans , 
11. ,Sadai ,kuttam - ,Leprosy ,with ,confluent ,ulcers , 
12. ,Yaanai ,kuttam - ,Thick ,skinned ,Leprosy , 
13. ,Thimir ,kuttam - ,Anesthetic ,Leprosy , 
14. ,Virana ,kuttam - ,Ulcerated ,Leprosy , 
15. ,Kaai ,kuttam  - ,Nodular ,Leprosy , 
16. ,Azhi ,kuttam  - ,A ,form ,with ,sloughing ,ulcers , 
17. ,Kirumi ,kuttam - ,Leprosy ,with ,microbes , 
18. ,Aara ,kuttam  - ,Incurable ,Leprosy , 
 
According ,to ,by ,Dhanvanthri:  
"Å¡¾À¢ò¾î ,º¢§ÄüÀÉò¾¢ý ,Å¡¾§Ã¡¸ó ,¾¡¦ÉÉ¢Ûõ , 
¾£Ð ,Ìð¼§ÁØó ,¾£Õõ ,Ìð¼õ ,À¾¢¦É¡ýÚ 
§Á¡Ðí ,Ìð¼õ ,À¾¢¦ÉðÎ¼ý§È¡Â ,¨ÅÂ¢Ûü ,ÀÅÓõ 
§À¾ìÌ½ÓÅ¢Â¡¾¢Â¢ýÓýÀ¢ÈìÌõÌ½Ó ,Ó¨Ãô§À§É". 
 
1. Kabala ,Kuttam 
2. Sarmeega ,Kuttam 
3. Kideepa ,Kuttam , 
4. Mudhumba ,Kuttam , 
5. Visharchiga ,Kuttam , 
6. Mandalakira ,Kuttam , 
7. Aguvai ,Kuttam , 
8. Thathru ,Kuttam , 
9. Pundareegha ,Kuttam , 
10. Bama ,Kuttam , 
11. Kaghanandhi ,Kuttam , 
12. Sithma ,Kuttam , 
13. Vibadhiga ,Kuttam , 
14. Sadhariga ,Kuttam , 
15. Vispodaga ,Kuttam , 
16. Sarmathala ,Kuttam , 
17. Ven ,Kuttam , 
18. Alasa ,Kuttam 
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According ,to ,by ,Yugi ,Muni ,Vaidhya ,Chinthamani: 
In ,his ,Siddha ,literature ,the ,“Kuttam” ,has ,been ,classified ,into ,18 ,types, 
  ,"Óò¾¡Ìí ,Ìð¼ó¾¡ý ,À¾¢¦ÉðÎìÌõ 
  ÓÉ¢Â¡É ,ä¸¢¿¡ý ,¦º¡øÄì ,§¸Ç¡ö 
  , ,Òò¾¡Ìõ ,Òñ¼Ã£¸ ,Ìð¼ò ,§¾¡Î  
   ¦ÀÕ¸¢ýÈ ,Å¢ü§À¡¼¸ ,Ì‰¼ ,Á¡Ìõ 
  , , , , , , ,Àò¾¡Ìõ ,ÀÃÁÌ‰¼õ ,§¸ºÃ ,Ì‰¼õ 
   ÀÃ¢Å¡É ,¸÷½Ìð¼õ ,º¢ÌÁ ,Ìð¼õ 
  ¸¢ò¾¡Ìí ,¸¢Õ‰½Ìð¼ ,«×ÐõÀÃ ,Ìð¼õ 
   ¦¸ÊÂ¡É ,Áñ¼ÄÌð ,¼ÓÁ¡ ,¦Áý§É 
  Ìð¼Á¡õ ,ÀÃôÀÃ¢º ,Ìð¼ ,¦Á¡Î , 
   ÌÊÄÁ¡õ ,Å¢º÷îº£¸ ,Ìð¼ ,Á¡Ìõ 
  Åð¼Á¡õ ,¨ÅÂ¡¾¢ ,Ìð¼ ,§Á¡Î 
   ÁÕÅÄ¡í ,¸¢ËÀÌð¼ï ,º÷Á ,§¾Åõ 
  ¾¢ð¼Á¡ ,§¾ò¾¢Õì ,Ìð¼ ,§Á¡Î  
   º¢òÐÁ¡ ,Ìð¼ïº¡ ,¸¡ÚÌð¼õ 
  Ðð¼Á¡ï ,Í§Å¾Ìð¼ó ,¾ý§É¡ ,¦¼¡ì¸î 
   ÍÂõÀ¡É ,À¾¢¦ÉðÎ ,Ìð¼ ,Á¡î§º”. 
1. Pundareegam , - ,Padarthamarai 
2. Virpodagam , - ,Koppulaperunoi 
3. Bamam ,  - ,Siranguperunoi 
4. Gajasarmam , - ,Yaanaitholperunoi 
5. Karnam ,  - ,Kaadhuperunoi 
6. Sikuram ,  - ,Tholperunoi 
7. Krishnam ,  - ,Karuperunoi 
8. Avudhumbaram , - ,Athikkaiperunoi 
9. Mandalam ,  - ,Valayaperunoi 
10. Abarisam ,  - ,Valiperunoi 
11. Visharchigam , - ,Soriperunoi 
12. Vibhadhigam , - ,Sen ,kuttam 
13. Sarmathalam , - ,Tholvedippuperunoi 
14. Kidepam ,  - ,Pandritholperunoi 
15. Thethuru ,  - ,Thadippuperunoi 
16. Sithuma ,  - ,Naaperunoi 
17. Sadharu ,  - ,Puraiperunoi 
18. Suvedham ,  - ,Venkuttam 
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According ,to ,sage ,Yugi, ,Kuttam ,have ,been ,classified ,as ,7 ,types ,as ,per ,alteration ,of ,three 
,humors 
1) Vali ,kuttam 
2) Azhal ,kuttam 
3) Iyya ,kuttam 
4) Vali ,iyya ,kuttam 
5) Vali ,azhal ,kuttam , 
6) Azhal ,iyya ,kuttam 
7) Mukkutra ,kuttam 
According ,to ,sage ,Yugi, ,ten ,types ,of ,kuttam ,are ,curable , 
1) Virpodagam 
2) Bamam 
















8) Suvetham , 




3a.1.8.Clinical ,Features , 
Å¢ü§À¡¼¸ì ,Ìð¼õ7: 
“ÒÐ¨ÁÂ¡öî ,ºÃ£Ã¦ÁíÌó ,¾¢É×ñ ,¼¡Ìõ 
 ¦À¡Õ¦ÅÊÂ¡öò ,¾¢ì¦¸Éò¾£ì ,¦¸¡ØóÐ ,§À¡Ä 
 ,¦ÁÐ¨ÁÂ¡ö ,Å¢ð¦¼Ã¢Ôõ ,¿øÄÀ¡õÀ¢ý 
 Å¢„ôÀ¼õ ,§À¡ø ,¾ÊòÐ ,¦ÅÙôÒÁ¡Ìõ 
 ,ÍÐ¨ÁÂ¡öÁ¢¸ì ,¦º¡Ã¢Ôïº¢ÅôÒÁ¡Ìõ 
 àì¸¦Á¡Î ,ºïºÄÓõ ,Á¢¸ ,×ñ ,¼¡Ìõ 
 ,¸Ð¨ÁÂ¡ö ,§¾¡¦ÄøÄ¡ó ,¾ÊôÒñ¼¡Ìõ 
 ¸Éò¾ ,Å¢ü§À¡¼¸Á¡É ,Ìð¼ó¾¡§É”. 
 , , , , , , , , , , , , ,   ,-ä¸¢ ,ÓÉ¢ ,¨Åò¾¢Â ,º¢ó¾¡Á½¢ ,800, ,¦ºöÔû- ,498. 
 Characterized ,by ,elevated ,skin ,lesions ,with ,erythema ,and ,itching. ,Burning ,sensation 
,will ,be ,present. , ,These ,entities ,are ,associated ,with ,anxiety ,and ,despair. 
º¾¡Õ ,Ìð¼õ7: 
“º¢ò¾¡É¾ñÊôÀ¡ö ,Ãò¾Å÷½õ 
 ¦ºØõÀî¨º ,¦Åû¨ÇÂ¡öî ,º¢ÅôÒÁ¡Ìõ 
±ò¾¡ý ,¦ÅÃ¢ô§À¡Î ,¾¢É×Á¡Ìõ 
 ±Ç¢¾¡É ,§ºðÎÁÅ¡¾ò ,ÐüÀò¾¢ 
Àò¾¡É ,¸ÃÎ¸ðÊôÒñÏÁ¡Ìõ 
 À¡õÒ ,§¾¡ø ,§À¡üÈ¢¨ÃóÐÀÕòÐì¸¡Ïõ 
¦Åò¾¡É ,ãì§¸¡Î ,¸¡Ð ,¸ýÉõ 
  Á¢¸òÐÊôÀ¡ï ,º¾¡Õ ,Ì‰¼ó ,¾¡§É”.  
 , , , , , , , , , , , , , , , , , , , , , , , ,    , ,-ä¸¢ ,ÓÉ¢ ,¨Åò¾¢Â ,º¢ó¾¡Á½¢ ,800, ,¦ºöÔû- ,513.
 Characterized ,by ,skin ,lesions ,covered ,with ,silvery ,white ,scales, ,erythema, ,itching, 
,burning ,sensation ,and ,thickening ,of ,ears, ,cheeks ,and ,nose 
 
Clinical ,Features 
➢ The ,lesions ,are ,patches ,and ,macules ,which ,are ,red ,in ,colour ,with ,raised 
,margin , , ,and ,the ,lesions ,are ,covered ,by ,silvery, ,white ,and ,rough ,thick 
,scales. , 
➢ The ,patches ,are ,coin ,shaped ,over ,them. ,In ,some, ,the ,shape ,may ,be ,either 
,round ,or ,oval. 
➢ There ,are ,variations ,in ,the ,size ,and ,shape ,of ,patches ,according ,to ,the ,site. 
➢ The ,skin ,lesions ,occur ,all ,over ,body, ,commonly ,front ,of ,the ,knee ,and ,back 
,of ,the ,elbows ,affected 
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➢ Excessive ,scaling ,and ,generalized ,erythema ,develops ,all ,over ,the ,body. 
➢ In ,children ,this ,lesion ,may ,be ,like ,water ,drops ,and ,these ,may ,occur ,in ,scalp 
,and ,face. 
➢ Mild ,oozing ,will ,be ,present ,if ,flexure ,region ,(axilla, ,groin ,& ,infra 
,mammary ,regions) ,are ,involved ,in ,females. 
➢ One ,fourth ,of ,patients ,have ,nail ,involvement ,like ,pitting ,and ,dimpling ,in 
,nature 
➢ 7% ,of ,patients ,develop ,affection ,of ,joints ,as ,psoriatic ,arthropathy. 
3a.1.9.Prevalence ,of ,Kaalanjaga ,padai 
➢ 2% ,of ,population ,affected ,by ,psoriasis 
➢ 5-25 ,years ,is ,the ,commonest ,age ,group , 
➢ Remission ,and ,relapses ,occur 
➢ Females ,are ,commonly ,affected ,than ,males 
3a.1.10.Kalanjaga ,vaatham ,( ,Psoriatic ,Arthropathy ,): 
 Kalanjagapadai ,is ,often ,associated ,with ,painful ,joints ,known ,as ,“Kalanjaga 
,vaatham”. ,It ,may ,affect ,any ,joint. ,The ,most ,often ,affected ,joints ,are ,terminal ,inter-phalangeal 
,joints. ,In ,these ,cases, ,the ,affected ,fingers ,show ,nail ,changes. ,This ,combination ,is 
,termed“Psoriatic ,arthropathica”. 
Yugi ,muni ,describes ,the ,clinical ,features ,of ,Kaalanjaga ,vatham ,as ,follows: 
 “Å¡¾Á¡í ,¸¡ø¨¸Â¢ø ,ÌÃí¸¢ ,ÃñÎõ 
   ÅÕòÐ ,ºóÐÓÚì¸¢§Â ,Ì¨¼óÐ ,¦¿¡óÐ 
  ¿¡¾Á¡ ,¿¨¼¾¡Ûó ,¾¡ý¦¸¡¼¡Áø 
   ¿Ä¢óÐ§Á ,Ó¼Á¡¸¢ì ,¸ÃÎ ,¸ðÊî 
  §º¾Á¡ï ,º¼ó¾¡Û ,Á¢¸¦Å ,ÙòÐó 
   ¾¢É ,§Å¡Î ,º¢ÃíÌÁ¡öî ,§ºðÀ ,Á¡¸¢ì 
  , , , ,      , ,¸¡¾Á¡Â ,Õº¢¦Â¡Î ,ÁÂì¸ ,Á¡Ìõ 
   , , , , , ,¸Õ¾¢Â ,¸¡Ç¡ï ,º¸Á¡õ ,Å¡¾Á¡§Á”.- , , , , ,(¦ºöÔû- ,259) 
 The ,joints ,of ,fingers, ,feet, ,ankles, ,knees ,and ,sacroiliac ,are ,selectively ,affected ,and 
,these ,joints ,are ,painful. ,The ,deforming ,erosive ,arthritis ,targets ,fingers ,and ,toes. ,Marked 
,cartilage ,destruction ,and ,bony ,articulation ,results ,in ,loss ,of ,joint ,space ,and ,marked ,instability. 
,The ,whole ,body ,becomes ,pale ,(anaemic). ,Lesions ,of ,well-defined ,erythematous ,papules 






Karappan ,(Eczema): ,   
  Kollavae ,udambellam ,vedhuppaai ,nonthu 
   Kudainthumae ,migachsurandhu ,veekkamaagum 
  Villavae ,thaegamellaam ,punpol ,nonthu , , 
   Vediththumae ,punnagum ,viralgal ,santhu , 
  Mullavae ,mudangiyae ,narambu ,thaanum , , 
   Mazhikalpakka ,mikkaida ,migavu ,larnthu 
  Mallavae ,meniyadhu ,varandu ,kaanum , , 
   Vaadhamang ,karappaanran ,vanmai ,thaanae. 
        -Yugi ,muni 
➢ Itching ,is ,present ,in ,the ,patches. 
➢ Bleeds ,/ ,oozes ,on ,scratching 
Padarthamarai ,(Tinea ,infection):   
Koodumae ,thamarayin ,poovithalpol 
   Kuvindhidumae ,karupodu ,veluppumagum 
Thedumae ,sivappu ,pala ,vanna ,magundh 
   Thinavumiga ,vagiyae ,soriyum ,senneer 
Vadumae ,iyathinur ,pathi ,yagi 
   Varuthamiga ,vundaagi ,novumegum 
Podumae ,sareerangal ,mugangal ,kaalgal 
   Pundareega ,kuttathin ,pudhumai ,thanae. 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,- , ,Yugi ,muni 
➢ This ,is ,caused ,by ,kapha. 
➢ Patches ,are ,like ,lotus ,petals ,in ,the ,body. 
➢ Patches ,are ,black, ,white, ,red ,in ,colour. 
➢ Itching ,is ,present ,in ,the ,patches. 
➢ Bleeds ,/ ,oozes ,on ,scratching. 
➢ The ,discharge ,resembles ,rose ,water. 





3a.1.12.PATHOLOGY ,OF ,KALANJAGA ,PADAI 
The ,Kalanjagapadai ,affects ,the ,skin ,and ,mucous ,membrane. 
 
MUKKUTTRA ,VERUPADUGAL7 ,: 
"¾¡Ð ,Ó¨È¦Â ,¾É¢þ¨¼ ,Å¡¾Á¡õ 
§À¡ÐÚ ,À¢ý¸¨Ä ,Ò¸ýÈÐ ,À¢ò¾Á¡õ 
Á¡Ð ,ÍÆ¢Ó¨É ,ÅÆí¸¢Îõ ,³ÂÁ¡õ 
´Õ ,Ó¨È ,À¡÷òÐ ,¯½÷ó¾Å÷ ,º¢ò¾§Ã" 
- ,À¾¢¦½ñ ,º¢ò¾÷ ,¿¡Ê ,º¡Š¾¢Ãõ. 
 
 "Á¢¸¢Ûí ,Ì¨ÈÂ¢Ûõ ,§¿¡ö¦ºöÔõ ,á§Ä¡÷ 
 , , , , , ,       ÅÇ¢Ó¾Ä¡ ¦Åñ½¢Â ,ãýÚ" 
    -Saint ,Thiruvalluvar 
 
 , , , , , , , , , , ,Human ,body ,is ,influenced ,by ,three ,Thathus ,such ,as ,Vaatham, ,Pitham ,and ,Kabam. ,They 
,are ,responsible ,for ,normal ,physiological ,conditions ,of ,the ,body.The ,particular ,thodam 
,increase ,or ,decrease ,(Thannilai ,piralthal) ,then ,it ,influence ,the ,other ,thodam( ,vetrunilai 
,valarchi) ,and ,cause ,murkuri ,or ,premonitory ,symptoms ,in ,the ,localized ,area ,of ,the ,body ,and 
,later ,the ,typical ,signs ,and ,symptoms ,blows ,out. ,In ,the ,tertiary ,stage ,all ,the ,three ,thodams ,are 
,vitiated ,which ,is ,called ,mukkutram ,stage ,(sannipatham).This ,condition ,becomes ,incurable. 
,According ,to ,the ,text ,book ,Siddha ,Maruthuvam ,Sirappu ,in ,Kalanjagapadai, ,the ,following 
,Mukkutram ,are ,commonly ,affected, 
 
¯¼Ä¢ý ,²Ø ,¾¡Ðì¸Ùõ ,¦ÁÄ¢Å¨¼ó¾¡Öõ ,¦ÁÄ¢Å¨¼Â¡Å¢ð¼¡Öõ ,À¢ò¾ô 
,¦À¡Õð¸Ç¢ý ,¯½Å¡¾¢ ,§º÷ì¨¸Â¡ø ,«¾¢¸Ã¢òÐ ,À¢ò¾Á¡ÉÐ ,ºÁ¡Éò¨¾ ,«¨¼óÐ, 
,À¢ò¾õ,À¢ò¾Å¡¾õ,À¢ò¾¸Àõ,ÓìÌüÈõ, ,þ¨Å¸Ç¢ø ,¾É¢ò¾É¢Ôõ ,ÜðÎÈ×Á¡¸¢Â 
,ºõÀó¾í¸¨Çì ,¦¸¡ñÎ ,þÃò¾,þÃº ,¾¡Ðì¸¨Çì ,¦¸¡¾¢ì¸î ,¦ºöÐ, ,«îºÁ¡É ,Å¡Ô 
,À¢Ã§¸¡À¢òÐ ,À¢ò¾ ,¸Àí¸¨Ç ,¬í¸¡íÌ ,¦ºøÄ¡Ð ,¾ÎòÐ, ,«¾¢¸ ,º¢ò¾ ,À¢ò¾õ ,¬ÁòÐ¼ý 
,ÜÊ ,«ùÅ¡Áò¨¾ ,Å¢Ã¢ò¾¢ì¸î ,¦ºöÐõ ,º½¢ì¸î ,¦ºöÐõ, ,þÃò¾ ,¸À,ÁÄ,ºÄ, 
,¦¸Î¾¢¸¨Çì ,¦¸¡ñÎõ ,Ìð¼ ,§Ã¡¸õ ,¯ñ¼¡¸¢ýÈÐ. 
 





Table.3a.1.1.¸¡Ç¡ïº¸ôÀ¨¼Â¢ø ,ÓìÌüÈ ,ÌÈ¢Ì½í¸û ,: 
 




ÅÈðº¢ ±Ã¢îºø ¿£÷òÐÅõ 
¦ÅÊôÒ ÝÎ ÀÍ¨Á 
À¢ÇôÒ Òñ ¾ÊôÒ 
ÅÄ¢ ¦¸¡ôÒÇõ º£ú 
ÍÃÍÃôÒ º¢¨¾× «Ø¸ø 
¦º¾¢ø  ¸¢ÕÁ¢ ,¾¡À¢¾õ 
ÀÃÅø   
 
     
Vatham8 
1. Pranan ,  - ,Occasionally ,difficulty ,to ,breath ,in ,BA ,with ,KJP ,patients , 
2. Abanan  - ,Habitual ,Constipation 
3. Udhanan , , , , , , , , , , ,       , , , ,- ,Erythematous ,changes ,in ,the ,affected ,areas ,of ,skin 
4. Viyanan  - ,Dryness ,of ,the ,skin ,in ,the ,affected ,areas ,of ,skin 
5. Samanan  - ,Due ,to ,other ,vaayus, ,it ,is ,affected 
6. Kirukaran  - ,Loss ,of ,appetite 
7. Devathathan - ,Laziness, ,sleep ,disturbance , 
Pitham8 
 , ,1.Anarpitham , , , , , - ,Loss ,of ,appetite& ,In ,APD ,patient ,; ,acidity, ,burning , , , , , , , , , , , , , , , , ,
    , , , ,sensation ,of ,epigastric ,regionin ,very ,few ,cases 
2.Ranjaga ,pitham , - ,Erythematous ,changes ,in ,the ,affected ,areas ,of ,skin,Paleness ,
  , , , , , , , , , , , , , , , , , , , , , , , , ,           , ,of ,the ,conjunctiva ,and ,tongue 
3. ,Sadhaga ,pitham , - Difficulty ,to ,do ,the ,routine ,works ,and ,sluggishness 
 4.Prasaga ,pitham , - ,Dryness ,and ,roughness ,of ,skin , 
Kabam8 
 1.Tharpagam  - ,Burning ,sensation ,of ,eyes ,may ,be ,present 








 The ,structural ,components ,or ,the ,tissues ,components ,of ,the ,body ,are ,composed ,of 
,seven ,type ,of ,materials ,called , ,Udal ,thathukkal ,or ,Udal ,kattukal. ,It ,gives ,strength ,and 
,structure ,to ,our ,body. ,In ,Kalanjagapadai ,patients, ,the ,following ,Udal ,thathukkal ,are 
,commonly ,affected, 
 Saaram : ,Dryness, ,roughness, ,tiredness 
 Senneer : ,Erythematous ,patches ,present 
 Kozhuppu , : ,Synovial ,fluid ,secretion ,affected 
 Enbu  : ,Joint ,pain ,present ,in ,few ,cases , , , 
Natural ,ability ,- ,¯¼ø ,Åý¨Á8 ,: , 
"ÀÕ×¼Ä¢ý ,Åý¨Á§Â ,ÝìÌÁ ,¯¼Ä¢ý ,Åý¨Á"   
 
 ¯¼ø ,Åý¨Á ,±ýÀÐ ,¿õ ,ÁÉ¿Ä§É¡Î, ,¯¼ø ,ÅÄ¢×õ ,þ¨½ó¾¾¡Ìõ. ,¬ýÁ 
,¯¼Ä¢ý ,(ÁÉõ) ,ÅÇ÷º¢ìÌ ,¬¾¡ÃÁ¡ö ,þÕôÀÐ ,ŠàÄ ,¯¼Ä¢ý ,Åý¨Á¾¡ý. 
 
 ,“¯¼õÀ¢É¡ ,ÄýÈ¢ ,Ô½÷× ,¾¡É¢ø¨Ä 
 ,¯¼õÀ¢ ,É¡ÖýÉ¢Â§¾ ,Â¡õ 
 ,¯Â¢÷ìÌÚ¾¢ ,¦ÂøÄ¡ ,Ó¼õÀ¢ý ,ÀÂ§É 
 ,«Â÷ôÀ¢ñÈ¢ ,Â¡¾¢¨Â ,¿¡Î“ 
- ,´Ç¨ÅìÌÈû 
 
It ,is ,classified ,into ,3 ,types, ,they ,are 
Iyarkai ,Vanmai , , ,(Genetic) 
 Natural ,immunity ,of ,the ,body ,by ,birth. 
Seyarkai ,Vanmai ,(Acquired) , 
 Improving ,the ,health ,by ,intake ,of ,nutritious ,food ,materials ,and ,medicines. 
Kaala ,Vanmai ,( ,Related ,to ,age,climate,habitat) 
 Development ,of ,immunity ,according ,to ,age ,and ,the ,environment. , 
When ,the ,Udal ,vanmai ,is ,affected ,there ,may ,be ,possibilities ,of ,occurrence ,of 
,Kalanjagapadai. 
Iymporigal8 ,( ,Sense ,organ ,)  
 , , , , , , , , , , , , ,         In ,Kalanjagapadai, , 






Kanmenthriyam8 ,(Motor ,organ ,) 
 In ,Kalanjagapadai, 
  Kai, ,Kaal ,: ,Affected ,( ,Difficulty ,in ,using ,the ,limbs) 
   ,Eruvai , , , , , , ,: ,Affected ,( ,Constipation ,is ,seen ,) 
Kosam ,- , ,(Sheath) ,8 ,: 
 In ,Kalanjagapadai ,patients, ,the ,following ,Kosam ,are ,commonly ,affected, 
Annamaya ,Kosam , ,(Physical ,Sheath ,) , , , , ,: , ,Affected ,( ,loss ,of ,appetite ,and ,acidity 
,in , ,APD ,with ,KJP ,patients) 
Pranamaya ,Kosam ,(Respiratory ,Sheath) , ,: ,Affected ,( ,Difficulty ,to ,breath ,in ,BA 
,with , ,KJP ,patients ,) 
Manomaya ,Kosam , ,(Mental ,Sheath) , , , , , , ,: ,Affected ,( ,Stress) 
Seasonal ,variations1 ,: , 
Weather ,and ,environment ,changes ,that ,affect ,the ,health ,of ,the ,individual ,in ,each 
,Kaalam ,due ,to ,certain ,life ,style ,modifications. ,The ,Siddhars ,have ,classified ,the ,time ,scale ,of ,a 
,year ,into ,6 ,Kaalam ,it ,is ,known ,as ,six ,perum ,pozhuthu. 
Table.3a.1.2. ,Seasonal ,variations , 
Season ,(Perumpozhuthu) 
 
State ,of ,Thodam 
Ilavenil ,kaalam ,( ,Early ,summer ,season ,) 
Chithirai ,– ,Vaikasi ,(Mid ,April ,to ,Mid ,June) 
Kabam ,aggravated , 
Mudhuvenil ,kaalam ,(Latter ,summer ,season ,) 
Aani ,– ,Aadi ,(Mid ,June ,to ,Mid ,August) 
Vatham ,accumulated , 
Kabam ,mitigated 
Kaar ,kaalam ,(Early ,rainy ,season) 
Aavani ,– ,Purattasi ,(Mid ,august ,to ,Mid ,October ,) 
Vatham ,aggravated , 
Pitham ,accumulated 
Koothir ,kaalam ,(Late ,rainy ,season) 
Iypasi ,– ,Karthigai ,(Mid ,october ,to ,MidDecember) 
Pitham ,aggravated 
Vatham ,mitigated 
Munpani ,kaalam ,(Early ,winter ,season ,) 
Markazhi ,-Thai ,(Mid ,December ,to ,Mid , ,February) 
Pitham ,mitigated 
Pinpani ,kaalam(Late ,winter ,season) 
Masi ,-Panguni ,(Mid ,February ,to ,Mid ,April) 
Kabam ,accumulated , 
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Prevalence ,and ,the ,signs ,and ,symptoms ,of ,Kaalanjaga ,padai ,will ,aggravated ,in ,above 
,mentioned ,months ,due ,to ,seasonal ,changes ,according ,to ,the ,state ,of ,humor ,by ,certain ,life ,style 
,modifications ,and , ,maybe ,affected ,of ,kaala ,vanmai. 
 
3a.1.13.Piniyariyum ,muraimai ,(Diagnostic ,Methods) ,8 
 
"Á¾¢ò¾¢¼ü ,¸Õ¨Á ,Å¡öó¾ , 
Á¡ñÀÃ¢ ,¸¡Ã ,¦ÁøÄ¡õ 
Ð¾¢ò¾¢¼ ,×½÷ó¾¡ ,§ÉÛó 
   Ð¸ÇÈô ,À¢É¢Â¢ý ,Èý¨Á 
À¾¢ò¾¢¼ ,×½Ã¡ ,É¡¸¢ü 
   ÀÂÛÈ¡ ,É¡¸ ,Ä¡§É 
Å¢¾¢ò¾¢Î ,À¢½¢ò¾¢ ,Èò¨¾ 
Å¢ÇõÒÐ ,Ó¾ü¸ñ ,Áý§É¡" 
    - ,º¢¸¢îº¡ ,ÃòÉ ,¾£Àõ 
 
 Diagnostic ,methods ,in ,Siddha ,medicine ,are ,very ,unique ,and ,are ,solely ,dependent ,upon 
,the ,clinical ,acumen ,of ,the ,physician. 
o Poriyal ,aridhal ,(Understanding ,by ,the ,five ,organs ,of , , 
,perception,nose,tongue,eyes,skin,and ,the ,ears) 
o Pulanal ,aridhal ,(Understanding ,by ,the ,sense ,objects ,smell, ,taste, ,vision, 
,somatic ,sense ,and ,sound) 
o Vinaathal ,( ,Interrogation) 
 The ,physician ,using ,his ,organs ,of ,perception ,and ,senses ,examines ,the ,patient ,and 
,diagnosis ,the ,disease.Apart ,from ,this,an ,appropriate ,history ,taking ,also ,helpis ,one ,to ,diagnose 
,properly. ,However, ,it ,should ,be ,noted ,that ,the ,interrogation ,comes ,only ,finally ,after ,physical 
,examination. ,The ,diagnosis ,method ,id ,called ,“Envagai ,thervu , ,( ,Eight ,tools ,of ,diagnosis)” 
Envagai ,Thervugal ,(Eight ,tools ,of ,examination) ,8 ,are: 
  “¿¡ÊôÀÃ¢ºõ ,¿¡¿¢Èõ ,¦Á¡Æ¢Å¢Æ¢ 
 , , , , , , ,  , ÁÄõ ,ãò¾¢ÃÁ¢¨Å ,ÁÕòÐÅÃ¡Ô¾õ”. 
“«¸òÐÚ ,§¿¡¨Âì ,¸Ãò¾¡Á ,Ä¸õ§À¡ø 
 ÀÌò¾È¢Å£÷ ,¿¡Êô ,ÀÃ¢ºõ ,- ,¦¾¡Ìò¾¿¢Èõ 
 ¸ðÎÅ¨¸î ,¦º¡ø¦Á¡Æ¢¸ñ ,¸ñ¼ÁÄ ,ãò¾¢Ãõ¿¡ 
 ±ðÎÅ¨¸ ,Â¡ÖÁÈ¢ ,Å£÷"  
 




"§ÁÖ¨Ãò¾ ,¿¡Ê¦ÂíÌ ,§ÁÅ¢É¡ø ,¯ýÀ¡¸ 
 ãÄõ ,¸ÃãÄ ,ãÄ§Áø ,- ,áÄÇ§Å 
 ¾¢ñÊ ,¿¢ýÈ¡ø ,Å¡¾À¢ò¾ ,º¢§ÄðÎÁ¦ÁÉ ,ãýÈ¡Ìõ 
 ¾¡ñÊ ,¿¢ýÈ¡ø ,¬îºÃ¢Âó¾¡ý" 
- «¸ò¾¢Â÷ ,Á½¢ ,4000 
 
Pulse ,diagnosis ,is ,a ,quick, ,inexpensive, ,and ,non-invasive ,bedside ,diagnostic ,tool. 
,Normally ,the ,pulse ,is ,recorded ,in ,a ,radial ,artery ,in ,the ,right ,hand ,for ,the ,male, ,in ,the ,left ,hand 
,for ,the ,female ,by ,keeping ,the ,ring ,finer ,(vatham) ,,the ,middle ,finger ,( ,pitham ,) ,and ,the ,index 
,finger ,(kabam) ,over ,the ,artery ,after ,gently ,scrubbing ,the ,area. 
In ,Kalanjagapadai, ,the ,following ,types ,of ,Naadi ,could ,be ,felt. , 
They ,were, 
a) Pitha ,vatham 
b) Pitha ,kabam 
c) Vatha ,pitham 
d) Vaatha ,kabam 
e) Kaba ,pitham 
Sparism ,(Skin): 
 “¦Åõ¨Á ,Ì¨Èó¾¡Ö ,Á¢Ìó¾¡Ö ,Å¡¾À¢ò¾õ 
 ¾õ¨Á ,¿¢¨Ã¿¢¨ÃÂ¡öî ,º¡üÚÅ¡÷ ,- ,¦Åõ¨ÁÂýÈ¢ 
 º£¾Ó«ù ,Å¡È¡¸¢ø ,º¢§ÄðÎÁ ,¦Á¡ýÚ¦¾¡ó¾ 
  Á£¾Óõ«ù ,Å¡È¡Ì ,§Áø” 
    --«¸ò¾¢Â÷ ,Á½¢ ,4000 
  
 The ,physician ,must ,have ,ability ,to ,identify ,tactile ,sensation. ,Warmth ,indicates 
,Pitham, ,chillness ,kabamand ,dryness ,vatham. 
 
 In ,case ,of ,Kalanjagapadai, ,slightly ,raised ,well ,defined ,dry ,erythematous ,macules ,or 
,plaques, ,covered ,with ,white ,silvery ,scales,dryness, ,Burning ,sensation ,can ,be ,noticed ,in 
,affected ,areas. 
Naa ,(Tongue):    
“ÓûÇ¡ö ,¦ÅÊòÐì ,¸ÚòÐ¾¡ýÓý ,À¢ý ,¦ÅÙòÐò 
¾ûÇ¡¿£ ,Õñ§¼¡§º÷ó ,¾¡øÀºó¾¡ø ,- ,±øÄ¡õ 
¿ÎÅ¡õ ,ÀÄÀÄÅ¡õ ,¿üºýÉ¢ ,Óý§É¡ö 
 µÎ¿Ã¢ø ,¿¡¦Åý§È¡Ð” 
- «¸ò¾¢Â÷ ,Á½¢ ,4000 
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 A ,whitish ,tongue ,indicates ,Kabam ,imbalance ,and ,mucous ,accumulation. ,A ,red ,or 
,yellow ,green ,tongue ,indicates ,a ,Pitham ,imbalance ,, ,A ,Vatham ,imbalance ,is ,manifested ,by ,a 
,black ,to ,brown ,coloration ,on ,the ,tongue. , , , 
 In ,case ,of ,Kalanjagapadai ,abnormality ,of ,tongue ,like ,geographical ,tongue ,may ,be 
,noted. 
Niram ,(complexion): , 
"¯Ãò¾¸Úô ,À¡ýÅ¡¾ ,§Ã¡¸¢À¢ò¾ ,§Ã¡¸¢ 
«¨Ãò¾Áïº ,¨ÇìÌÇ¢ò§¾¡ý ,¬Å¡ý ,- ,þÃò¾õ 
ÌÇ¢ò¾ÅÛ ,Á¡Å¡ý ,¦¸¡Îõº¢§ÄòÐÁ ,§Ã¡¸¢ 
 ¦ÅÙò¾¢ÎÅ¡ý ,¦¾¡ó¾§Ã¡¸¢ ,§Â" 
    --«¸ò¾¢Â÷ ,Á½¢ ,4000 
 Vatham ,person’s ,skin ,black ,in ,colour ,; ,Pitham ,person’s ,skin ,either ,yellow ,or ,red ,in 
,colour, ,the ,person ,with ,whitish ,skin ,belongs ,to ,Kabam.The ,body ,temperament ,is 
,predominantly ,mixed ,in ,nature ,i.e ,Vatha ,kabam,Pitha ,vatham ,etc.The ,colour ,of ,the ,skin ,also 
,varies ,on ,mixer ,of ,thirithodam. 
 In ,case ,of ,Kalanjagapadai, ,Erythematous, ,hyperpigmented , ,patches ,with ,silvery 
,scales ,could ,be ,noticed ,at ,affected ,areas. 
Mozhi ,(Voice): , 
ÀÄ§Ã¡¸¢ ,Å¡÷ò¨¾ô ,ÀÄÅ¢¾Á¡õ ,Å¡¾ò 
¾¨Ä§Ã¡¸¢ ,Å¡÷ò¨¾î ,ºÁÁ¡Ìõ ,- ,¿¢¨Ä¸¼ó¾ 
À¢ò¾§Ã¡ ,¸¢ìÌ¯Â÷ó¾ ,§ÀîÍñ¼¡õ ,º¢§ÄðÎÁó¾¡ý 
 ºò¾õ® ,ÉÃÁ¡õ ,¾¡ý 
- «¸ò¾¢Â÷ ,Á½¢ ,4000 
 The ,normal ,speech ,indicates ,Vatham, ,a ,high ,pitched ,voice ,Pitham, ,and ,low ,pitched 
,voice ,like ,Kabam. 
 In ,case ,of ,kalanjagapadai ,high, ,low ,pitched ,voice ,and ,medium ,pitched ,voice ,were 
,observed. 
Vizhi ,(Eye): ` 
¸ñ¸ÚòÐ ,¿£§Ã¡Êø ,¸¡Ä¡õ ,¿ÎÅ¡¸¢ø 
¸ñÀºìÌõ ,¦º¡ìÌõ ,¸¨¼Â¡¸¢ø ,- ,¸ñÀ£¨Ç 
º¡Ê ,¦ÅÙìÌ§Á ,ºýÉ¢Å¡¾õ ,À¢ò¾Ó¦Áý 
 §È¡ÊÂ¸¡ ,Á¡¨Ä ,ÀºìÌõ 
-«¸ò¾¢Â÷ ,Á½¢ ,4000 
 A ,muddy ,conjunctiva ,indicates ,Vatham ,, ,yellowish ,or ,red ,– ,Pitham ,, ,pale ,– ,Kabam. 
 In ,case ,of ,Kalanjagapadai, ,no ,abnormality ,was ,seen ,in ,Vizhi. 
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Malam ,(Stool): , 
¸Úò¾ÁÄ ,Àó¾ÁÄí ,¸¡Ä¡Ìõ ,À¢ò¾õ 
º¢Úò¾Óð ,Ê½õ¦ºõ¨Á ,§ºÕõ ,-¦À¡Úò¦¾¡Õì¸¡ø 
º£¾ÁÄó ,¾¢ø¨ÄÔÁ¡õ ,§º÷ó¾ÀÄ ,§Ã¡¸¢Â¡õ 
 Á£¾ÁÄõ ,±ñ½¢ÈÓ ,§Á. 
-«¸ò¾¢Â÷ ,Á½¢ ,4000 
 Black ,coloured ,constipated ,stools ,indicated ,Vatham, ,yellowish ,or ,reddish ,with 
,diminished ,quantity ,and ,more ,heat ,indicated ,Pitham ,and ,it ,is ,whitish ,in ,Kabam. 
 In ,case ,of ,Kalanjagapadai, ,constipation ,was ,reported ,in ,some ,cases. 
Moothiram ,(Urine): , 
 In ,Siddha ,system,urine ,is ,a ,constituent ,of ,Pitha.It ,is ,a ,waste ,product ,of ,blood,which ,is 
,also ,a ,pitham ,constituent.It ,is ,the ,end ,product ,of ,various ,metabolic ,activities ,taking ,place ,in 
,our ,body.Metabolism ,itself ,is ,a ,normal ,function ,of ,pitham. ,Urine ,contains ,excess ,water ,and 
,dissolved ,waste ,materials ,filtered ,from ,the ,blood ,by ,the ,kidney. ,Normal ,urine ,contains ,excess 
,water, ,salt, ,minerals, ,urea ,from ,protein ,digestion, ,uric ,acid, ,creatinine ,from ,muscle 
,breakdown, ,hormone ,wastes, ,dead ,blood ,cells ,and ,toxins.So ,urine ,is ,an ,index ,of ,blood. ,Any 
,pathological ,changes ,in ,urine ,reflects ,the ,pathology ,of ,blood. ,Among ,various ,parameters ,of 
,urine ,analysis ,such ,as ,colour ,, ,smell, ,froth, ,specific ,gravity, ,and ,quantity ,/ ,deposits. , 
 “Therayar” ,one ,of ,the ,pioneer ,in ,Siddha ,pathology, ,classified ,the ,examination ,of 
,urine ,into ,two ,main ,categories. 
 1.Neerkuri , 
 2.Neikuri 
 "Åó¾ ,¿£÷ì¸Ã¢ ,±¨¼ ,Á½õ ,Ñ¨Ã ,±ïº¦Äý 
 ¨Èó¾¢ÂÖÇ¨Å ,Â¨ÈÌÐ ,Ó¨È§Â" 
 
Neerkkuri ,: 
In ,neerkuri ,various ,parameters ,of ,urine ,analysis ,such ,as 
 Niram ,   - ,Colour , 
 Edai ,   - ,Specific ,gravity , 
 Manam  - ,Smell  
 Nurai ,   - ,Froth 
 Enjal ,   - ,Quantity ,/ ,Deposits ,can ,be ,noted , 
Colour ,: 
 Normal ,  - ,Thurinji ,pazha ,niram ,(Citrus ,aurantium ,fruit) 
 Yellow ,,Red  - ,Hot ,food , 
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§¾¨ÃÂÃ¢ý ,¿£÷ìÌÈ¢ ,¦¿öìÌÈ¢ ,¿¢îºÂò¾¢üÌÃ¢Â ,¿£÷ ,þÄì¸½õ 
 
  ,"«ÕóÐÁ¡ ,È¢Ã¾Óõ ,«Å¢§Ã¡ ,¾Á¾¡ö 
  ,«·¸ø ,«Ä÷¾ø ,«¸¡Äçñ ,¾Å¢÷ó¾Æü 
  ,ÌüÈÇ ,ÅÕó¾¢ ,¯Èó¸¢ ,¨Å¸¨È , 
  ,¬Êì ,¸Äºò ,¾¡Å¢§Â ,¸¡Ð¦Àö 
  ,¦¾¡ÕÜ÷ò ,¾ì¸ÉÄì ,ÌðÀÎ ,¿£Ã¢ý , 
  ,¿¢ÈìÌÈ¢ ,¦¿öìÌÈ¢ ,¿¢ÕÁ¢ò¾ø ,¸¼§É" ,8 
§¿¡Ôü§È¡÷ìÌ ,§ÁüÀÊ ,Å¢¾¢Å¢Äì¸¡õ 
 
 "«ÕôÀ ,ÓüÈ¡÷ì ,¸ùÅ¢¾¢ ,Å¢Äì§¸" ,8 
 
 , , , , , , , , , , , , , ,Prior ,to ,the ,day ,of ,urine ,examination ,the ,patient ,is ,instructed ,to ,take ,a ,balanced ,diet. 
,The ,patient ,should ,have ,good ,sleep. ,After ,waking ,up ,in ,the ,morning, ,the ,first ,urine ,voided ,is 
,collected ,in ,a ,clear ,wide ,mouthed ,glass ,container ,and ,is ,subjected ,to ,analysis ,of ,“Neerkkuri” 
,within ,one ,and ,a ,half ,an ,hour.This ,rule ,exclude ,when ,and , ,emergency ,period ,severe ,condition 
,of ,disease ,condition. 
 In ,a ,Kalanjagapadai ,patients, ,Citrus ,aurantium ,fruit ,colour, ,wild ,citrus ,medica ,fruit 
,colour, ,Hey ,soaked ,rain ,water ,colour ,and ,Reddish ,yellow ,colour ,was ,noticed. , 
Neikkuri 
 The ,collected ,specimen ,(Urine) ,is ,kept ,open ,in ,a ,glass ,dish ,or ,china ,clay ,container. ,It 
,is ,to ,be ,examined ,under ,direct ,sunlight, ,without ,any ,shaking ,of ,the ,vessel. 
 , , , , , , , , , , , ,Then ,add ,one ,drop ,of ,gingelly ,oil ,in ,from ,1cm ,above ,the , ,urine ,specimen , ,without 
,disturbing ,the ,urinary ,specimen ,and ,the ,neikkuri ,was ,noted ,in ,direct ,sunlight ,and ,conclude ,the 
,diagnosis. 
Importance ,of ,Neikuri ,: 
✓ Findout ,the ,clearcut ,kuttram 
✓ Rule ,out ,the ,curable ,and ,incurable ,of ,disease 
✓ Assessment ,of ,prognosis 
 
¦¿öìÌÈ¢Â¢ø ,ÓìÌüÈ ,§ÅÚÀ¡Î¸û ,: 
Character ,of ,Vaathaneer 
Å¡¾õ ,: ,Å¡Ô ,+ ,¬¸¡Âõ ,( ,þ§ÄÍ ,) ,«ÕÅõ  
 “«Ã¦ÅÉ ,¿£ñÊÉ·§¾ ,Å¡¾õ” 
 When ,the ,oil ,drop ,spreads ,like ,a ,snake, ,it ,is ,called ,“Vaatha ,neer” 
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o ¯¼ÉÊ ,ÀÃÅø , 
o §Å¸Á¡É ,ÀÃÅø 
o ´Øí¸üÈ ,ÅÊÅõ , 
 
Character ,of ,Pithaneer 
 
À¢ò¾õ ,: ,¾£ ,- ,«Õ×ÕÅõ ,- ,(¿Î¿¢¨Ä) , 
 
“¬Æ¢ ,§À¡üÀÃÅ¢ý ,«·§¾ ,À¢ò¾õ” 
 When ,the ,oil ,drop ,spreads ,like ,a ,ring, ,it ,is ,called ,“Pitha ,neer” 
o º£Ã¡É ,§Å¸õ 
o ¯¼ÉÊ ,ÀÃÅø 
o Åð¼Á¡É ,ÀÃÅø , 
o ´Øí¸¡É ,ÅÊÅõ 
Character ,of ,Kabaneer 
¸Àõ ,: ,Áñ ,+ ,¿£÷ ,- ,¯ÕÅõ- ,(ÀÙ) 
 
“Óò¦¾¡òÐ ,¿¢ü¸¢ý ,¦Á¡Æ¢Å¦¾ý ,¸À§Á” 




Character ,of ,Thonthaneer 
 Snake ,in ,the ,ring, ,ring ,in ,the ,snake, ,snake ,in ,the ,pearl ,and ,ring ,in ,the ,pearl ,are ,the 
,characters ,of ,Thontha ,neer ,(mixed ,type). , 
 
¦¾¡ó¾ ,¿¢¨Ä ,: , 
 
¯¾¡Ã½Á¡¸, 
  1. ,¸ÀÅ¡¾õ ,: ,ÓòÐô§À¡ø ,¿£ñ¼ ,§¿ÃÁ¢ÕóÐ ,À¢ýÉ÷ ,´Øí¸üÈ ,ÅÊÅÁ¡¸ 
,Á¡Ú¾ø 
 
  2.À¢ò¾Å¡¾õ ,: ,º£Ã¡É ,Å¨ÇÂÁ¡¸ ,ÐÅí¸¢ ,´Øí¸üÈ ,ÅÊÅÁ¡¸ ,Á¡Ú¾ø. 
º¢¸¢î¨º ,Óý§ÉüÈõ ,«È¢¾ø ,: 
 
 º¢¸¢î¨º ,ÅÆí¸¢ ,§¿¡Â¢ý ,¾£Å¢Ãõ ,Ì¨ÈÔõ ,¦À¡ØÐ ,§Å¸õ ,Ì¨È¾ø,¦ÁøÄô 







§¾¨ÃÂ÷ ,¾É¢îº¢ÈôÒ ,: 
 
 ºøÄ¨¼ì ,¸ñ ,§À¡ýÈ ,¦¿öìÌÈ¢ ,¯ûÇ ,§¿¡ö ,¾£Ã¡Ð±É ,¿¢Ã¡¸Ã¢òÐÅ¢¼¡Áø 
,¸Àõ ,±É ,«ÏÌõ ,Ó¨È.8 
 
In ,Kalanjagapadai, ,the ,Neerkuri ,was ,manjal, ,sivappu ,majal ,and , ,Neikkuri ,was ,Vaatha ,neer, 
,Pitha ,neer ,and ,Kaba ,neer,Thondha ,neeer.  
CLINICAL ,APPLICATION ,OF ,MANIKADAI ,NOOL ,TECHNIQUE8 ,: 
Reference ,; ,Agathiyar ,Soodamani ,Kayaru ,Soothram 
Manikadai ,nool , ,is ,one ,among ,the ,tool ,of ,examination ,in ,siddha ,system ,to ,diagnose ,the 
,disease ,as ,well ,as ,to ,assess ,its ,prognosis. ,This ,unique ,method ,was ,revealed ,by ,siddhar , ,Agathiyr 
,to ,his ,disciple ,Vedhamamuni.The ,literary ,meaning ,of ,the ,terminology ,; 
 , , , , , , , , , , , , , ,Manikadai ,Nool ,= ,Mani ,+Kadai ,+ ,Nool 
 ,Mani ,= ,The ,protuberance ,of ,wrist; ,Kadai= ,The ,finger ,breadth; ,Nool; ,Thread , ,  
“Manikadai ,naalviral ,thalli ,vanmaiyaai 
Thanikidai ,kayaru ,pottalandhu ,paarakaiyil 
Kanithidum ,viralthanai ,kandu ,solavey 
Pinithidum ,noyigalai ,pirithuraikumey” 
-Agathiyar ,Soodamani ,Kayaru ,Soothiram 
 , , , , , , , ,    The ,circumference ,of ,the ,forearm ,of ,an ,individual ,at ,the ,region ,of ,4 ,finger ,breadth 
,proximal ,to ,the ,radial ,protuberance ,of ,wrist ,is ,measured ,by ,using ,a ,thread, ,which ,should ,be ,non 
,elastic. ,Then ,the ,length ,of ,the ,thread ,is ,converted ,in ,terms ,of ,finger ,breadth ,units ,(viral ,kadai ,) 
,of ,the ,concerned ,individual ,patient. 
PROCEDURE ,: , 
➢ The ,region ,of ,4 ,finger ,breadth ,proximal ,to ,the ,radial ,protuberance ,of ,wrist ,is 
,selected. 
➢ Using ,the ,thread ,the ,circumference ,of ,selection ,is ,taken 
➢ The ,length ,of ,the ,thread ,is ,converted ,in ,terms ,of ,finger ,breadth ,units ,( ,viral 
,kadai) 







PRECAUTION ,: , 
 Don’t ,use ,any ,elastic ,type ,of ,thread ,or ,twines ,which ,may ,lead ,to ,false ,reading 
 Avoid ,too ,much ,loose ,and ,tight ,during ,measuring ,the ,circumference ,of ,the 
,selected ,forearm. 
 The ,measurement ,should ,be ,converted ,into ,finger ,breadth ,units ,with ,the ,finger 
,breadth ,of ,concerned ,individual ,patient. 
 Don’t ,measure ,at ,the ,affected ,forearm ,like ,individuals ,suffering ,with 
,hemiplegia, ,fracture, ,deformity ,etc. 
ADVANTAGE ,OF ,MANIKADAINOOL ,: 
 Priceless ,procedure ,for ,arriving ,diagnosis 
 Time ,consumption ,is ,very ,less 
 Prognosis ,also ,can ,be ,confirmed , 
 Simple ,and ,painless ,procedure 
 No ,need ,of ,any ,specific ,skill ,in ,employing ,this ,technique. 
                    ±ð§¼Óì¸¡ø 
 
  "±ðÊÉ¢ø ,Óì¸¡ø ,¸¡½¢ø ,Â¢Ä¢ì¸¢Â ,×¼õÒ ,¸¡Âõ, , 
  ¦¾¡ðÊÂ ,Ìð¼õ§À¡§Ä ,º¢øÅ¢¼õ ,ÀÄ×ó ,§¾¡ýÚõ, 
  ÓðÊÂ ,ÅÂ¢üÈ¢Ûû§Ç ,Ó¨Ç§À¡§Ä ,Å¡Ô ,ÌòÐõ, 





                          ±ð¼¨Ã 
 
"Å¢ðÎ¼É¢ÕÁÖõ ,¦ÅÐôÒ ,§Á¦ÄøÄ¡õ 
  ¸¢ðÊÎï ,º¢¨ÄÔí ,¸¢Ãí¸¢ì ,¸¡Ï§Á" 




Pointedout ,of ,description ,of ,the ,stanza 
7 ,¾ , Head ,ache,Piles,Epistaxis,Kandamaalai. 
8 , , , , Loss ,of ,appetite,Bloating ,and ,upset ,of ,stomach,Fever 
8 ,¼ Body ,ache,Head ,ache,Sinusitis,TB,Hydrosis 
8 ,½ Fever, ,Cough ,and ,giddiness, ,Kudalvatha, ,Thathunattam, ,Skin ,diseases ,like 
,kuttam, ,Silanthi, ,Vettai ,and ,Sori 
8 ,¾ Fever, ,Skin ,diseases ,like ,kuttam,Piles,Eye ,disease,Sinusitis 
9 Pain ,Lumbar ,and ,thighs ,and ,difficulty ,in ,walk,Ear ,hearing ,problem 
9 ,¼ , Insomnia,Sinusitis,Buring ,sensation ,of ,eyes, ,Burning ,mituration 
9 ,½ Fever, ,Loss ,of ,appetite, ,Buring ,sensation ,of ,eyes,Swlling ,of ,whole ,body 
9 ,¾ Cough,Dryness,Fissure,Araiyaappu 
10 Pain ,in ,all ,over ,the ,body,Gastritis,Peptic ,ulcer 
11 Inflated ,of ,the ,body,only ,death ,is ,destiny. 
 
In ,case ,of ,Kalanjagapadai ,patient’smostly ,viral ,kadai ,was , ,8 ,¾ , ,, ,8 ,½ , ,finger ,breadth ,and 
,complaints ,of ,the ,patient ,was ,correlated ,with ,the ,description ,of ,the ,stanza, ,pointed ,out ,for ,8 ,¾ ,, 











3a.2.LINE ,OF ,TREATMENT 
 The ,treatment ,in ,Siddha ,medicine ,is ,aimed ,at ,maintaining ,the ,three ,dhoshams ,(life 
,constituents) ,and ,seven ,thathus ,(physical ,constituents) ,in ,equilibrium.Proper ,diet ,and ,regimen 
,of ,life ,including ,cleansing ,therapies ,are ,advised ,for ,a ,healthy ,living ,and ,to ,restore ,equilibrium 
,of ,dhoshams ,in ,the ,early ,stage ,of ,the ,disease. 
 
 “§¿¡ö¿¡Ê ,§¿¡öÓ¾ ,É¡Ê ,ÂÐ¾½¢ìÌõ 
 ,  ,Å¡ö¿¡Ê ,Å¡öôÀî ,¦ºÂø”. , 
    -¾¢ÕÅûÙÅ÷ 
 Thiruvalluvar ,says ,in ,“Thirukkural” ,about ,physician’s ,duty ,to ,study ,the ,disease, 
,study ,the ,cause, ,seek ,subsiding ,ways ,and ,do ,what ,is ,proper ,and ,effective. 
 “¯üÈÅý ,¾£÷ôÀ¡ý ,ÁÕóÐ¨Æî ,¦ºøÅ¡¦Éý 
 , ÈôÀÉ¡ü ,Üü§È ,ÁÕóÐ”. , 
      ,-¾¢ÕÅûÙÅ÷ 
 , , , , , , , , , , , ,In ,Siddha ,system ,of ,medicine, ,the ,main ,aim ,of ,the ,treatment ,is ,to ,cure ,Udalpini ,and 
,Manapini. ,Treatment ,is ,not ,only ,for ,perfect ,healing ,but ,also ,for ,prevention ,and ,rejuvenation. 
Line ,of ,treatment ,is ,as ,follows: 
• Neekam ,(Treatment) 
• Niraivu ,(Restoration) 
• Kaappu ,(Prevention) 






“Å¢§ÃºÉò¾¡ø ,Å¡¾õ ,¾¡Øõ 
 ,ÅÁÉò¾¡ø ,À¢ò¾õ ,¾¡Øõ 
 ,¿º¢Â ,«ïºÉò¾¡ø ,¸Àõ ,¾¡Øõ”. 
 ,“«È¢ó¾¢Îõ ,Å¡¾õ ,«¼íÌõ ,ÁÄò¾¢É¢ø”.9 
  
Detoxification ,is ,the ,first ,line ,of ,treatment ,used ,to ,restore ,the ,deranged ,dhoshams. , 
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First ,day ,: 
Agathiyar ,kulambu , ,with ,200mg ,with ,30ml ,leaf ,juice ,of ,Sangankuppi ,(Azima 
,tetracantha) ,quantity ,was ,administered ,at ,early ,morning ,as ,purgative ,(Kazhichal ,Medicine) 
,before ,starting ,the ,treatment ,for ,restore ,equilibrium ,of ,dhoshams. 
Second ,day ,: , 
 Oil ,bath ,with ,Arakku ,thylam , ,has ,taken ,at ,early ,morning. 
Third ,day ,onwards ,from , ,Sunday,Tuesday,Thursday ,for ,48 ,days ,: , 
 , , , , , ,ÁÕóÐñÏõ ,¸¡Äõ8 
“¸¡Ã¢ ,Ò¾õ ,¾¢í¸û ,¸Õ¾ ,ÁÕó¾¡¸¡Ð 
À¡Ã¢É¢ø ,Íí¸ý ,ÀÃ¢¸¡Ãõ- ,§¿ÃýÚ 
§¾ÃÌÕ ,§ºÔó¾¡ý ,¾£¾¢ø¨Ä ,±ýÚõ 
§ÀÃÕì¸ý ,¿ý¦ÈÉ§Å ,§ÀÍ" 
 , , , , , , , , , , , ,- ,¸ñÏº¡Á¢Âõ 
ÁÕóàðÞí¸¡Äõ1 , 
 ,   "«É¢Ä§¿¡ ,Â÷ì¸ºÉ ,Á¡¸¡Óý ,À¢ò¾ò 
 , ,    ,ÐÉ¢Â÷ì ,¸ºÉ¿Îò ,à¨Â- ,¦ÂÛ§¿¡Â÷ì 
 ,  , , , , ,  , , , , , ,      ¸¡¸¡Ãô ,À¢ýÛ ,ÁÕò¾¢Ö¨È ,ÂôÀ¢½¢Â¡ü 
 , , , , , , , , , , ,  º¡¸¡Ãô ,À¢ýÛÄ¸¢ü ,È¡ý" 
 
"Å¡¾ÁÄ¡Ð ,§ÁÉ¢ ,¦¸¼¡Ð ," ,8 
 
 Internal ,Medicine: ,Parangipattai ,Kudineer, ,three ,times ,a ,day ,before ,food. 
External ,Medicine: ,Sivappu ,thylam 
Pathiyam ,(Dietary ,Regimen): 
 , , , , , , , , , , ,In ,mild ,conditions ,of ,the ,disease, ,salt ,and ,tamarind ,can ,be ,taken ,in ,little ,quantities. ,When 
,the ,condition ,is ,severe, ,tamarind ,should ,be ,avoided ,and ,salt ,must ,be ,consumed ,after ,frying. 
 ,“Àò¾¢Âò¾¢É¡§É ,ÀÄÛñ¼¡Ìõ ,ÁÕóÐ 
 ,Àò¾¢Âí¸û ,§À¡É¡øÀÄý ,§À¡Ìõ ,Àò¾¢Âò¾¢ø 
 ,Àò¾¢Â§Á ,¦ÅüÈ¢ ,¾Õõ ,ÀñÊò÷ìÌ ,¬¾Ä¢É¡ø , 
 ,Àò¾¢Â§Á ,¯ò¾¢¦ÂýÚÀ¡ø” , 






  ,“¦ÀÕÌï ,§º¡Ç ,Á¢ÚíÌõ ,¦ÀÕõ¸õÒ 
 ,ÅÃÌ ,¸¡Õ¼ý ,Å¡¨ÆÂ¢ý ,¸¡¦Â¡Î 
 ,¯¨Ã¦¸¡û ,À¡¸ü ,¦¸Ç¢üÚÁ£ý ,¯ñÊÊø 
 ,Å¢Ã¢Å ,¾¡öì¸Ãô ,À¡ÛÁ¢Ìó¾§¾” , , , , , , , , , 
  , , , , , , , , , ,- ,À¾¡÷ò¾ ,Ì½ ,º¢ó¾¡Á½¢ 
 
“ÒÇ¢ÐÅ÷ ,Å¢ïÍ ,¸È¢Â¡÷ ,ÒÃ¢ìÌõ ,Å¡¾õ” , , 
 , , , , , , , , , , , , , , , , ,- ,À¾¡÷ò¾ ,Ì½ ,º¢ó¾¡Á½¢ 
Diet ,Restriction ,(Pathiyam)57 
➢ Fish, ,crab, ,prawn ,are ,some ,sea ,foods ,should ,be ,avoided. 
➢ Curd, ,Jaggery, ,oil, ,White ,gram ,should ,be ,avoided. 
➢ Non ,vegetarian ,diet ,should ,be ,avoided. 
➢ Alcohol ,beverages ,should ,be ,avoided. 
➢ Brinjal ,should ,be ,avoided. 
➢ In ,severe ,cases ,tamarind ,should ,be ,avoided. 
➢ Dietary ,taken ,salt ,in ,minimum ,quantities.  
3a.2.2.NIRAIVU ,( ,RESTORATION) ,1: 
 , , , , ,Substances ,used ,for ,neutralizing ,the ,three ,humors ,are: 
  "´ýÈ¢Â ,Å¡¾ ,À¢ò¾ ,¸ÀÁ¢¨ÅÔÂÃ¡ ,Åñ½õ 
  ¿ýÚÚ ,¸È¢¸¦ÇøÄ¡õ ,¿¡Ù§Á ,º¨ÁôÀÃ¡öóò ,§¾¡÷ 
  ¾¢ýÈ¢Î ,Á¢ÇÌ ,Áïºû ,º£Ã¸ ,ÓÂ÷ó¾ ,¸¡Âõ 
  ¦ÅýÈ¢ ,¦¸¡û ,Íì ,§¸¡§¼Äõ ,¦Åó¾¢Âõ ,¯ûÇ¢ ,§º÷ò§¾" 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,-À¾¡÷ò¾ ,Ì½ ,º¢ó¾¡Á½¢ 
The ,patients ,are ,well ,motivated. ,The ,nature ,and ,course ,of ,the ,disease ,is ,explained ,to 
,them, ,Life-style ,modification ,advised. 
Substances ,advised ,for ,Vaatha ,disease ,are: 
 “¦ºí¸Ø¿£÷ ,§¸¡¨¼ò ,§¾ýÁ¢ÇÌ ,¿ø¦Äñ¦½ö 
¾íÌ ,¦ÀÕí¸¡Âò ,¾Ø¾¡¨Æ ,- ,±í¦¸íÌõ 
¸ðÎ ,º¢Ú ,ÓòÐ ,¦¿ö ,§¸¡¾¢ø ,¯Ùó¾¢¨Å¸û 
Å¡ðÎ ,ÁÉ¢Äò¨¾ ,Á¾¢.” 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,-À¾¡÷ò¾ ,Ì½ ,º¢ó¾¡Á½¢ 
Honey ,collected ,during ,summer, ,pepper, ,gingely ,oil, ,asafoetida, ,castor ,oil ,and ,black 




 As ,per ,siddha ,system ,the ,aetiology ,of ,the ,diseases ,are ,various. ,The ,ultimate ,speciality 
,of ,siddha ,system ,is ,to ,prevent ,the ,diseases. 
 In ,the ,siddha ,classical ,text ,Pathartha ,guna ,chinthamani ,has ,given ,so ,many ,ideal 
,measures ,to ,prevent ,the ,diseases. ,These ,are ,given ,below 
  “¾¢ñ½ ,Á¢ÃñÎû§Ç ,º¢ì¸ ,Å¼ì¸¡Áü 
 , ,  , ,¦Àñ½¢ýÀ¡ ,¦Ä¡ý¨Èô ,¦ÀÕì¸¡Áø ,¯ñÏí¸¡ø 
   ,¿£÷ÍÕì¸¢ ,§Á¡÷¦ÀÕì¸¢ ,¦¿öÔÕì¸¢ ,ÔñÀÅ÷¾õ 
   §ÀÕ¨Ãì¸¢ü ,§À¡§Á ,À¢½¢” 
“¬Ú ,¾¢í¸ð ,¦¸¡Õ¾¼¨Å ,ÅÁÉÁÕó ,¾Â¢ø§Å¡õ 
 , ,«¼÷¿¡ýÌ ,Á¾¢ì¦¸¡Õ¸¡ü ,§À¾¢Ô¨È ,Ñ¸÷§Å¡õ 
 ,§¾ÚÁ¾¢ ,¦Â¡ýÈ¨Ãì§¸¡÷ ,¾Ã¿º¢Âõ ,¦ÀÚ§Å¡õ 
 , , ,¾¢í¸Ç¨Ãì ,¸¢ÃñÎ¾Ãï ,ºÅÃÅ¢Õô ,ÒÚ§Å¡õ 
Å£ÚºÐ÷ ,¿¡ð¦¸¡Õ¸¡ø ,¦¿öÓØì¨¸ò ,¾Å¢§Ã¡õ 
 , , ,Å¢Æ¢¸Ùì¸ï ,ºÉãýÚ ,¿¡ð¦¸¡Õ¸¡ ,Ä¢Î§Å¡õ 
             ¿¡Ú¸ó¾õ ,ÒðÀÁ¢¨Å ,¿Î¿¢º¢Â¢ý ,Ó¸§Ã¡õ  
   ¿ÁÉ¡÷ì¸¢í ,§¸Ð¸¨Å ,¿¡Á¢ÕìÌ ,Á¢¼ò§¾”.1 
  
 The ,Siddhar ,Theraiyar ,explains ,above ,lines ,are ,the ,rules ,to ,maintain ,healthy ,life ,and 
,prevent ,diseases. 
 
Karpa ,Marundhukal ,( ,Rejuvenative ,Drugs ,)3 ,: 
 “Kaya” ,means ,body ,and ,“Karpam” ,means ,“strong ,as ,stone” 
“Kayakarpam” , ,or ,“Kayakalpam” ,is ,one ,of ,the ,unique ,special ,therapeutic ,divisions ,in ,siddha 
,system ,of ,medicine ,advocated ,specially ,for , ,rejuvenation, ,decreasing ,morbidity ,and ,increasing 
,the ,life ,span. ,Thus ,this ,discipline ,details ,the ,methods ,and ,drugs ,used ,for ,longevity ,and 
,enhancement ,of ,innate ,health. , ,“Kayakarpam ,aims ,strongly ,on ,both ,physical ,and ,mental 






"«ïÍ¸ò¾¢ ,ÄÆ¢Â¡Áü ,¸¡Âó¾¡ý 
Á¢ïº¢Â ,¸üÀõ ,Å¢ÇõÀ¢§É¡õ ,áü¦ÈðÎò 
¾ïº ,ÓÈ§Å ,¾¡ý ,¾¢ýÉ ,Åø§Ä¡÷ìÌô 
ÀïÍ ,¿¨Ã ,§À¡ö ,À¾¢§¾¡í¸¢ ,Å¡úÅ¡§Ã" 
   -¾¢ÕãÄ÷ ,¨Åò¾¢Â ,ÀÌ¾¢ ,À¡¼ø:67 
In ,kalanjagapadai ,patients ,; ,advised , ,after ,clearance ,of ,kalanjagapadai’s ,symptoms , , ,to ,follow-
up ,the , , ,karpamarundhugal, , 
 Amukkaraa ,root ,(Withania ,somnifera) 
 Seenthil ,(Tinospora ,cordifolia) 
 Thetran ,kottai ,(Strychnos ,potatorum) 
 Ayajambira ,karpam ,( ,iron ,compound ,with ,lime ,juice) 
 Keezhanelli ,(Phyllanthus ,amaranthus ,) 
3a.2.4.KARPA ,YOGAM3 ,: 
The ,famous ,verses ,from ,Agathiyar ,Gnanam, ,a ,Siddha ,literature ,speaks ,about ,treating 
,the ,mind ,as ,follows; 
 “If ,the ,mind ,is ,good ,then ,no ,need ,of ,chanting 
  , ,If ,the ,mind ,is ,good ,then ,no ,need ,of ,breathing ,exercise 
 If ,the ,mind ,is ,good ,then ,no ,need ,of ,retention ,of ,inspired ,air 
 If ,the ,mind ,is ,good ,then ,body ,is ,good” ,3 , , , , , , , , , , , 
A ,Life ,free ,of ,ailments ,especially ,from ,life ,style ,disorders, ,a ,proper ,co-ordination ,over 
,the ,psychic ,stage, ,psychosomatic ,stage ,and ,organic ,stage ,towards ,the ,available ,holistic ,health 
,and ,Positive ,thinking ,are ,attained ,by ,Yogic ,practices. ,The ,integrated ,approach ,of ,Yoga ,therapy 
,(IAYT) ,is ,the ,need ,of ,the ,hour ,in ,maintaining ,sound ,physical, ,mental ,and ,social ,well ,being ,of 
,people ,globally.  
Globalization ,technological ,advancement ,intermixing ,of ,work ,culture, ,environment 
,changes, ,recessions ,and ,subsequent ,changes ,in ,the ,nature ,of ,work ,are ,in ,fast ,pace. ,Stress ,is 
,associated ,with ,everyone ,at ,workplace ,whether ,rich ,or ,poor, ,young ,or ,old, ,male ,or ,female ,and 
,no ,none ,is ,immune ,from ,it. ,Stress ,may ,be ,the ,biggest ,single ,cause ,for ,affect ,the ,mind ,in 
,kalanjagapadai ,patients. ,So ,regular ,practice ,yoga ,may ,help ,to ,manage ,of ,stress. 
Yoga ,is ,a ,subject ,of ,science ,of ,higher ,order, ,which ,carries ,in ,it ,the ,mystery ,of 
,conservation ,of ,health ,and ,transformation ,of ,life ,of ,complete ,expression ,of ,life ,is ,possible 
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,through ,Yoga. ,The ,concept ,of ,Ashtanga ,Yogam ,mentioned ,in ,Thirumandhiram, ,a ,Tamil 
,Siddha ,literature, ,have ,enormous ,contribution ,towards ,holistic ,health ,by ,practising ,Eight ,steps 
,of ,Yoga ,are ,outlined ,here. , 
➢ Iyamam ,(Purity ,of ,Mind ,) 
➢ Niyamam ,(Purity ,of ,Action) 
➢ Asanam ,(Posture) 
➢ Pranayamam ,(Breathing ,technique) 
➢ Prathyaharam ,(Controlling ,Sense) 
➢ Dharnai ,(Concentration) 
➢ Dhyanam ,(Meditation) 
➢ Samadhi ,(Contemplation) , 
 Skin ,is ,the ,reflex ,of ,mind ,and ,so ,we ,should ,treat ,not ,only ,the ,physical ,but ,also ,treat 
,mind ,and ,soul. ,There ,by ,patients ,are ,advised ,to ,do ,yogam ,practice. 
Asanas ,like,  
➢ Surya ,namaskaram ,(Sun ,salutation) 
➢ Padmasanam ,(Lotus ,position) 
➢ Nadi ,suddhi ,pranayamam ,( ,Alternate ,nostril ,breathing ,practice) 
➢ Paschimottanasanam ,( ,Forward ,bend ,pose) 
➢ Makarasanam ,(Crocodile ,pose) ,will ,be ,given ,for ,IPD ,patients ,and ,these ,are ,all 

















3b.1.ANATOMY ,AND ,PHYSIOLOGY ,OF ,SKIN ,9: 
3b.1.1.Anatomy ,of ,skin: 
The ,skin ,or ,integument ,is ,a ,protective ,covering ,of ,the ,body. ,The ,skin ,is ,the ,largest 
,organ ,of ,the ,body ,with ,a ,total ,area ,of ,about ,20 ,square ,feet. ,It ,is ,the ,dividing ,line ,between ,the 
,individual ,and ,his ,external ,environment. 
3b.1.2.Structure ,of ,skin: 
 
 
3b.1.1.Figure ,Structure ,of ,skin 
The ,skin ,varies ,in ,thickness ,from ,less ,than ,0.5mm ,to ,3 ,or ,even ,4mm. ,It ,consists ,of ,2 
,main ,parts- ,epidermis ,of ,ectodermal ,origin ,and ,an ,underlying ,dermis ,derived ,from ,the 






Structure ,of ,epidermis: , 
Epidermis ,is ,formed ,of ,stratified ,squamous ,epithelium ,and ,is ,non-vascular. ,Thickness ,is 
,between ,0.07mm ,and ,0.12mm. ,In ,soles ,and ,palms, ,it ,is ,very ,thick ,which ,ranges ,from ,0.8mm ,to 
,1.4mm. ,The ,downward ,projections ,of ,epidermis ,are ,referred ,as ,rete ,ridges. ,The ,colour ,of ,the 
,skin ,is ,mainly ,due ,to ,melanin, ,a ,pigment ,produced ,by ,special ,cells ,called ,melanocytes ,present 
,in ,the ,epidermis. 
There ,are ,five ,chief ,layers ,of ,epidermis. ,They ,are 
1. Stratum ,corneum , 
2. Stratum ,lucidum , 
3. Stratum ,granulosum 
4. Stratum ,spinosum 
5. Stratum ,germinativum 
Stratum ,corneum: 
This ,be ,the ,most ,superficial ,layer. ,This ,layer ,is ,exposed ,to ,the ,atmosphere. ,The ,cells ,in 
,this ,layer ,are ,non-nucleated ,and ,this ,layer ,consists ,of ,dead ,cells ,which ,are ,called ,corneocytes. 
,On ,application ,of ,intermittent ,mechanical ,pressure, ,this ,layer ,becomes ,thicker. ,This ,is ,thickest 
,on ,the ,palms ,and ,soles. ,This ,layer ,is ,very ,thin ,on ,the ,outer ,aspect ,of ,the ,lips ,and ,glans ,penis ,and 
,the ,eyes.The ,cytoplasm ,is ,flattened ,with , ,fibrous ,protein ,known ,as ,keratin.Apart ,from ,this, 
,these ,ceels ,also ,contain ,phopholipids ,and ,glycogen. 
Stratum ,lucidum: 
This ,layer ,lies ,superficial ,to ,stratum ,granulosum.It ,is ,made ,up ,of ,flattened ,epithelial 
,cells.As ,these ,cells ,exhibit ,shiny ,character.It ,is ,present ,only ,palm ,and ,sole. 
Stratum ,granulosum: 
It ,is ,a ,thin ,layer ,with ,2-5 ,rows ,of ,flattened ,rhomboid ,cells. ,This ,cells ,have ,keratohyaline 
,basophilic ,granules. ,Above ,the ,stratum ,malpighii ,and ,near ,the ,granular ,cell ,layer, ,odland 
,bodies ,are ,seen. ,The ,odland ,bodies ,take ,part ,in ,the ,barrier ,function ,of ,the ,epidermal 
,permeability. , 
Stratum ,spinosum ,(Stratum ,malpighi) ,: 
It ,is ,also ,known ,as ,prickle ,cell ,layer ,because ,the ,cells ,of ,this ,layer ,possess ,some ,spine 







The ,deepest ,portion ,of ,the ,epidermis ,is ,stratum ,germinativum. ,It ,is ,made ,up ,of 
,polygonal ,cells ,superficially ,and ,columnar ,cells ,in ,deeper ,parts. ,Since ,the ,entire ,dermis ,is 
,germinated ,from ,this ,layer, ,it ,is ,named ,as ,stratum ,germinativum. ,Trauma ,to ,this ,layer ,leads ,to 
,scar ,formation. ,Melanoblasts, ,melanocytes ,and ,Langerhans ,cells ,are ,present ,in ,this ,layer. 
Dentritic ,cells ,of ,epidermis ,(special ,epithelial ,cells): 
The ,epidermis ,contains ,3 ,types ,of ,specialized ,cells. ,They ,are 
a. The ,melanocytes 
b. The ,langerhans’ ,cells 
c. The ,Merker’s ,cell ,or ,touch ,cell. 
Epidermal ,appendages ,: 
 Sebaceous ,gland,sweat ,gland,hair, ,and ,nails ,are ,the ,epidermal ,appendages. 
Structure ,of ,dermis ,(cutis ,vera ,or ,corium) ,: 
The ,dermis ,is ,the ,inner ,layer ,of ,the ,skin ,which ,is ,rich ,in ,blood ,vessels, ,lymphatics ,and 
,nerves. ,and ,it ,is , ,composed ,of ,collagen ,fibers,fibroblasts,histeocytes. ,The ,collagen ,fibers 
,exhibit ,elastic ,property ,and ,are ,capble ,of ,holding ,water.The ,collagen ,fiber ,contain ,the ,enzyme 
,collagenase,which ,is ,responsible ,foe ,wound ,healing. 
Dermis ,has ,abundant ,collagen ,rich ,in ,fibroblasts. ,Collagen ,is ,a ,protein. ,It ,constitutes 
,about ,70% ,of ,dry ,weight ,of ,dermis. ,The ,thickness ,of ,dermis ,is ,1- ,3mm. ,Sensory ,end ,organs ,like 
,Pacinian ,and ,Meissner’s ,corpuscles, ,Ruffini ,corpuscles, ,end ,bulb ,of ,Krause ,are ,present ,in 
,dermis. , 
The ,dermis ,consists ,of ,two ,parts ,- , 
a. ,Superficial ,papillary ,dermis 
b. ,Reticular ,dermis 
A. ,The ,superficial ,papillary ,dermis , ,: 
 Dermal ,papillae ,are ,finger ,like ,projections ,arising ,from ,superficial ,papillary ,dermis.It ,is 
,extending ,from ,epidermis. ,This ,layer ,containg ,pigment ,cells ,known ,as ,chromotophores. 
B. ,Reticular ,dermis ,: 
 It ,is ,made ,up ,of ,reticular ,and ,elastic ,fibers.These ,fibers ,are ,found ,around ,the ,hair 
,bulbs,sweat ,glands, ,sebaceous ,glands.This ,layer ,contains ,mast ,cells,nerve 





3b.1.3.Physiology ,of ,skin: 
The ,skin ,performs ,a ,multitude ,of ,functions. ,They ,are 
a. Protection , 
b. Perception 
c. Regulation ,of ,body ,temperature , 
d. Secretory ,function ,and ,excretory ,function 
e. Absorption , 
f. Formation ,of ,vitamin ,D 
g. Storage ,function 
h. Respiratory ,function 
i. Acid ,base ,equilibrium 
j. Water ,balance 
k. Psychic ,function , 
Protection: 
The ,skin ,provides ,protection ,to ,the ,underlying ,parts ,against ,injury, ,infection, ,UV ,rays ,of 
,the ,sun. ,Nails ,are ,also ,protective ,adjunct ,of ,the ,skin. 
Perception ,: 
The ,skin ,is ,rich ,in ,nerves ,and ,various ,types ,of ,specialized ,sensory ,end ,organs. ,It 
,contains ,receptors ,which ,mediate ,the ,sensations ,of ,touch, ,pain, ,warmth ,and ,cold. 
Regulation ,of ,body ,temperature: 
Skin ,plays ,an ,important ,role ,in ,heat ,loss. ,The ,skin ,loses ,heat ,to ,the ,external ,environment 
,in ,3 ,ways: ,by ,conduction, ,radiation ,and ,evaporation. ,About ,90% ,of ,the ,total ,heat ,concentration 
,of ,the ,body ,is ,regulated ,by ,the ,skin. ,The ,sensory ,end ,organs ,of ,heat ,(organs ,of ,Ruffini) ,and ,cold 
,(end ,bulbs ,of ,Krause) ,also ,help ,in ,regulation ,of ,body ,temperature. 
Secretory ,function: 
The ,important ,glands ,present ,in ,skin ,are ,sweat ,glands ,and ,sebaceous ,glands. ,They 
,secrete ,sweat ,and ,sebum. ,Water, ,salt, ,lactic ,acid ,and ,product ,of ,nitrogen ,metabolism, ,drugs ,like 
,mercury, ,arsenic, ,and ,iodine ,etc.are ,excreted ,through ,skin. ,Sebum ,is ,composed ,of ,fatty ,acids, 
,cholesterol, ,alcohols ,etc. ,Fatty ,acids ,have ,a ,mild ,fungistatic ,activity. ,Sebum ,and ,sweat ,fight 
,against ,bacteria ,through ,certain ,fatty ,acids ,and ,enzymes. , 
Absorption: 
Intact ,skin ,absorbs ,substances ,dissolved ,in ,fatty ,solvents ,similar ,to ,vitamins ,and 
,hormones. ,Watery ,solutions ,are ,not ,absorbed. , 
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Respiratory ,function: , 
A ,small ,amount ,of ,gaseous ,exchange ,occurs ,through ,skin. ,Small ,amount ,of ,CO2 , , , ,is 
,eliminated ,along ,with ,sweat. ,Nitrogen ,and ,oxygen ,are ,reabsorbed. 
Acid ,base ,equilibrium: 
A ,fair ,amount ,of ,acid ,is ,excreted ,through ,sweat. ,Thus, ,it ,maintains ,acid ,base 
,equilibrium. 
Psychic ,function: 
Emotional ,status ,of ,a ,person ,is ,expressed ,through ,skin. ,For ,example ,; ,fear ,causes 
,blanching ,of ,skin ,and ,cold ,sweats. 
      
3b.2.PSORIASIS 
 
 , , , , , , , , , , , , ,The ,word ,psoriasis ,is ,derived ,from ,the ,Greek ,word ,“PSORA” ,meaning ,“Itch” ,or 
,“Rash”. ,It ,has ,been ,known ,since ,ancient ,times ,and ,was ,originally ,considered ,a ,type ,of ,leprosy, 
,It ,is ,one ,of ,the ,most ,common ,human ,skin ,diseases. 
3b.2.1.Definition: 
 Psoriasis ,is ,one ,of ,the ,commonest ,non-infectious, ,chronic,relapsing,papulo-
squamous , ,disorder ,characterized ,by ,erythematous, ,scaling, ,plaques ,of ,various ,sizes. ,The 
,lesions ,are ,usually ,covered ,by ,silvery ,white ,lamellar ,scales.10 
 Psoriasis ,affecting ,approximately ,2% ,of ,the ,population.Most ,scientific ,research ,refers 
,to , ,85-90% ,of ,patients ,affects ,by ,Psoriasis ,vulgaris. 
 The ,disease ,is ,usually ,manifested ,as ,raised, ,well-demarcated,erythematous ,oval 
,plaque ,with ,adherent ,silvary ,scales.The ,scales ,are ,a ,result ,of ,a ,hyperproliferative ,epidermis 
,with ,premature ,maturation ,of ,keratinocytes ,and ,incomplete ,cornification ,with ,retention ,of 
,nuclei ,in ,stratum ,corneum ,(Parakeratosis).The ,mitotic ,rate ,of ,the ,basal ,keratinocytes ,is 
,increased ,as ,compared ,with ,that ,in ,normal ,skin.As ,a ,result,the ,epidermis ,is ,thickened 
,(acanthosis),with ,elongated ,rete ,ridges: ,in ,combination ,with ,the ,dermal ,inflammatory 
,infiltrate,this ,contributes ,to ,the ,over ,all ,thickness ,of ,lesions,which ,can ,vary ,between ,thick ,and 
,thin ,plaque ,psoriasis ,and ,has ,been ,proposed ,as ,adistinctive ,trait. 
 The ,inflammatory ,infiltrate ,consist ,mainly ,of ,dendritic ,cells,macrophages,and ,T ,cells 
,in ,the ,dermis ,and ,neutrophils,with ,some ,T ,cells ,in ,epidermis.The ,redness ,of ,the ,lesion ,is ,due 






  Figure.3b.2.1. ,Difference ,between ,Normal ,skin ,and ,Psoriatic ,skin 
3b.2.2.Etiology58: 
The ,etiology ,of ,psoriasis ,isn't ,fully ,known, ,but ,it's ,thought ,to ,be ,associated ,to ,an 
,immune ,system. , 
 
3b.2.3.Exacerbating ,Factors: 
  ,Factors ,can ,be ,sub ,divided ,into, ,1) ,Local ,2) ,Systemic ,factors. 
Local ,factors: 
➢ Trauma: ,e.g. ,Physical ,electrical, ,chemical, ,surgical, ,skin ,injury ,or ,even ,too ,much 
,scratching ,can ,worsen ,or ,rapid ,localized ,psoriasis ,(Koebner ,reaction.). 
➢ Sunlight: ,Most ,patients ,commonly ,consider ,sunlight ,to ,be ,beneficial ,for ,their 
,psoriasis. ,Most ,report ,psoriasis ,severity ,is ,decrease ,during ,the ,summer ,months ,or 
,psseriods ,of ,increased ,sun ,exposure; ,however, ,a ,small ,minority ,get ,that ,their 
,symptoms ,are ,provoked ,by ,strong ,sunlight. 
 
Systemic ,factors: 
➢ Infection: ,Pharyngeal ,streptococcal ,infections ,have ,been ,shown ,to ,make ,guttate 
,psoriasis. ,Some ,proof ,suggests ,that ,subclinical ,streptococcal ,colonization ,(or 
,overgrowth) ,can ,be ,responsible ,for ,refractory ,plaque ,psoriasis. ,An ,increase ,in ,psoriasis 
,was ,noticed ,in ,HIV ,infected ,patients. 
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➢ Drugs: ,Some ,of ,the ,drugs ,cause ,of ,psoriasis. ,Lithium ,and ,withdrawal ,from 
,corticosteroids ,are ,commonly ,known ,to ,cause ,flares ,of ,disease. ,Beta-blockers, ,anti-
malarials,tetracyclines. ,and ,NSAIDs ,have ,also ,been ,implicated. 
➢ Psychogenic ,/ ,emotional ,factors: ,Many ,patients ,statement ,an ,increase ,in ,psoriasis 
,severity ,with ,mental ,stress. ,A ,clear ,cause-and-effect ,relationship ,between ,disease 
,exacerbation ,and ,stress ,has ,not ,been ,proven ,but, ,itching ,associated ,with ,increased 
,anxiety ,or ,depression ,may ,promote ,scratching. 
➢ Smoking: ,An ,increased ,risk ,factor ,of ,chronic ,plaque ,psoriasis ,exists ,in ,smokers. 
➢ Alcohol: ,Alcohol ,is ,worsen ,the ,severity ,of ,psoriasis. 
➢ Endocrine: ,Psoriasis ,severity ,has ,been ,noted ,to ,fluctuate ,with ,hormonal ,changes. 
,Disease ,incidence ,peak ,at ,puberty ,and ,for ,the ,period ,of ,menopause. ,Pregnant ,patients' 
,symptoms ,are ,more ,likely ,to ,improve ,than ,worsen. ,In ,difference, ,the ,disease ,is ,more 
,likely ,to ,flare ,in ,the ,postpartum ,period. 
3b.2.4.Triggering ,factors ,for ,psoriasis: 
 Weather 
Infections 
Injury ,to ,the ,skin 
Stress 
Smoking, 
 ,3b.2.5.PATHOGENISIS ,11: 
Role ,of ,genetic ,factors ,: 
There ,is ,considerable ,evidence ,that ,genetic ,factors ,play ,a ,key ,role ,in ,the ,development ,of 
,psoriasis. ,If ,only ,one ,parent ,has ,psoriasis, ,then ,the ,risk ,for ,the ,child ,developing ,psoriasis ,is 
,16%. ,It ,increases ,to ,a ,50% ,chance ,if ,both ,parents ,have ,psoriasis. ,Twin ,pair ,analysis ,has 
,revealed ,72% ,concordance ,among ,monozygotic ,twins ,compared ,to ,22% ,concordance ,among 
,dizygotic ,twins. , ,Due ,to ,genomic ,imprinting, ,men ,are ,more ,likely ,than ,women ,to ,transmit 
,psoriasis ,to ,the ,offspring. , ,Psoriasis ,has ,been ,associated ,with ,many ,(human ,leukocyte ,antigen) 
,HLA ,haplotypes. ,By ,using ,linkage ,analysis ,and ,genome-wide ,association ,studies, ,at ,least ,nine 
,candidate ,loci ,have ,been ,identified: ,6p ,(PSORS1), ,17q25 ,(PSORS2), ,4q34 ,(PSORS3), ,1q21 
,(PSORS4), ,3q21 ,(PSORS5), ,19p13 ,(PSORS6), ,1p32 ,(PSORS7), ,16q ,(PSORS8) ,and ,4q31 
,(PSORS9). ,A ,few ,non-major ,histocompatibility ,complex ,(MHC) ,susceptibility ,loci ,have ,also 
,been ,identified, ,but ,they ,may ,be ,of ,limited ,value ,in ,disease ,prediction ,as ,they ,confer ,a ,low ,risk 
,towards ,disease ,development. ,Recently, ,Chen ,et ,al. ,developed ,a ,psoriasis ,global ,genetic ,risk 
40 
 
,score ,(GRS) ,using ,ten ,single ,nucleotide ,polymorphism ,(SNP) ,previously ,confirmed ,psoriasis 
,susceptibility ,loci ,and ,observed ,that ,of ,the ,10 ,SNPs ,evaluated, ,the ,strongest ,signal ,was ,found ,at 
,the ,HLA-C ,locus ,at ,rs10484554, ,with ,a ,206% ,elevated ,risk ,of ,psoriasis. , ,They ,did ,not ,find ,any 
,association ,between ,weighted ,GRS ,(wGRS; ,which ,weights ,each ,risk ,allele ,by ,the ,logarithm 
,odds ,ratio) ,and ,psoriatic ,arthritis ,and ,a ,marginally ,significant ,association ,between ,wGRS ,and 
,guttate ,psoriasis. ,In ,a ,study ,from ,western ,India, ,Umapathy ,et ,al. ,showed ,a ,strong ,association ,of 
,HLA-A2, ,B8, ,and ,B17 ,antigens ,with ,psoriasis. , , 
Many ,authors ,classify ,psoriasis ,as ,a ,genetically ,complex ,disease ,as ,it ,shares ,features 
,like ,the ,pattern ,of ,inheritance, ,environmental ,influence ,and ,immune ,dysregulation ,with 
,diseases ,such ,as ,diabetes ,mellitus ,and ,Crohn's ,disease. ,One ,school ,of ,thought ,is ,that ,psoriasis 
,results ,from ,the ,interplay ,of ,multiple ,genes. ,The ,drawback ,of ,this ,hypothesis ,is ,that ,although 
,the ,psoriasis ,susceptibility ,genes ,are ,located ,in ,numerous ,loci ,throughout ,the ,genome, ,these 
,locations ,vary ,among ,different ,populations ,and ,families, ,and ,the ,results ,are ,difficult ,to 
,replicate. ,Goilhou ,et ,al. ,hypothesize ,that ,the ,same ,genes ,may ,be ,present ,at ,these ,different ,loci 
,as ,"jumping ,genes ,or ,retrotransposons". , ,This ,implies ,that ,a ,sequence ,may ,be ,present ,as 
,multiple ,copies ,in ,the ,human ,genome ,and ,the ,disease ,manifests ,when ,one ,or ,several ,copies ,are 
,activated. ,Human ,endogenous ,retroviruses ,(HERVs) ,may ,fit ,this ,criterion. ,HERVs ,are ,the 
,sequences ,in ,genome ,that ,were ,probably ,derived ,from ,the ,viruses ,many ,million ,years ,ago 
,which ,then ,integrated ,into ,the ,human ,genome ,and ,became ,its ,integral ,component ,during ,the 
,evolutionary ,process. ,These ,highly ,repetitive ,and ,moderately ,repetitive ,sequences ,are 
,transmitted ,as ,Mendelian ,genes ,and ,through ,retrotransposition. , 
Moreover, ,since ,these ,HERVs ,can ,be ,activated ,spontaneously ,during ,meiosis ,or ,by 
,environmental ,factors ,like ,UV ,radiation, ,they ,may ,account ,for ,the ,phenomenon ,of ,genomic 
,imprinting. 
PSORS1 ,is ,present ,in ,the ,HLA ,Class ,I ,region ,of ,chromosome ,6p ,and ,accounts ,for ,35-
50% ,of ,heritability ,of ,the ,disease. ,HLA-C-*06 ,is ,the ,most ,likely ,susceptibility ,gene ,in ,the 
,PSORS1 ,region ,and ,given ,its ,important ,role ,in ,antigenic ,presentation, ,the ,association ,reflects 
,the ,role ,of ,the ,adaptive ,immune ,response ,in ,psoriasis. ,The ,locus ,also ,harbours ,the 
,corneodesmosin ,(CDSN) ,gene, ,which ,encodes ,a ,protein ,expressed ,in ,differentiated 
,keratinocytes ,and ,is ,considered ,a ,genetic ,risk ,factor ,for ,psoriasis ,development. ,Since ,PSORS1 
,harbours ,both ,the ,CDSN ,gene ,and ,HLA-C-*06, ,it ,is ,quite ,possible ,that ,both ,adaptive ,immunity 
,and ,defective ,barrier ,function ,are ,involved ,in ,the ,pathogenesis ,of ,psoriasis. , ,enumerates ,the 
,various ,genetic ,loci ,that ,have ,been ,implicated ,in ,the ,pathogenesis ,of ,psoriasis. 
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Figure.3b.2.2. ,Genes ,involved ,in ,susceptibility ,to ,psoriasis. 
Significant ,associations ,have ,also ,been ,found ,in ,gene ,regions ,involving ,specific 
,inflammatory ,pathways, ,namely, ,IL-23 ,signaling ,(IL-23A, ,IL-12B ,and ,IL-23R), ,modulation ,of 
,Th2 ,immune ,responses ,(IL-4 ,and ,IL-13), ,and ,nuclear ,factor ,(NF) ,κB ,signaling. , ,Other 
,associations ,include ,epidermal ,defense ,genes, ,DEFB4 ,(copy ,number ,variation ,[CNV] ,of ,a 
,genomic ,segment ,on ,chromosome ,8p23.1 ,harboring ,a ,cluster ,of ,DEFB ,genes, ,encoding ,β-
defensins), ,and ,late ,cornified ,envelope ,proteins ,3B ,(LCE3B) ,and ,3C ,(LCE3C) ,(a ,CNV ,in ,the 
,PSORS4 ,region ,on ,chromosome ,1q21 ,encoding ,their ,deletion). ,These ,genes ,are ,expressed ,in 
,epithelial ,cells ,but ,not ,on ,immunocytes. ,Epistatic ,interactions ,involving ,HLA-C-*06, 
,endoplasmic ,reticulum ,aminopeptidase ,1 ,(which ,encodes ,a ,protease ,that ,has ,an ,important ,role 
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,in ,MHC ,class ,1 ,peptide ,processing) ,and ,LCE3C-LCE3B-del ,have ,also ,been ,documented. 
,Marrakchi ,et ,al. ,observed ,that ,homozygous ,missense ,mutation ,in ,the ,IL36RN ,gene ,on 
,chromosome ,2q13-q14.1, ,encoding ,for ,IL-36 ,receptor ,antagonist ,was ,associated ,with ,an 
,unregulated ,secretion ,of ,inflammatory ,cytokines ,and ,an , ,increased ,predisposition ,to ,develop 
,generalized ,pustular ,psoriasis. , 
The ,role ,of ,the ,NLR/CATERPILLAR ,(nucleotide ,binding ,domain) ,family ,of ,genes ,in ,psoriasis 
,has ,also ,been ,studied. ,These ,encode ,important ,mediators ,of ,innate ,immunity ,and ,are ,concerned 
,with ,maintaining ,epidermal ,barrier ,function ,and ,initiating ,pathogenic ,responses ,to 
,environmental ,microbes. , ,NLR ,genes ,have ,also ,been ,implicated ,in ,the ,causation ,of ,Crohn's 
,disease, ,Blau's ,syndrome, ,early ,onset ,sarcoidosis, ,familial ,cold ,urticaria, ,Muckle-Wells 
,syndrome ,and ,chronic ,infantile ,neurologic ,cutaneous ,syndrome. ,NLR ,products ,can ,be ,divided 
,into ,those ,with ,N-terminal ,coiled-coil ,structures ,and ,those ,with ,N-terminal ,Toll ,like ,receptors 
,(TLR)/IL-1 ,receptor ,domains. ,NLR ,gene ,products ,like ,Nod ,1, ,Nod ,2 ,and ,Ipaf ,proteins ,are 
,involved ,in ,intracellular ,recognition ,of ,bacterial ,components ,and ,regulation ,of ,chemokine 
,secretion ,and ,defensin ,release. , , 
Role ,of ,Adaptive ,and ,Innate ,immunity ,: 
Activated ,T ,cells ,are ,believed ,to ,be ,the ,primary ,modulators ,in ,the ,pathogenesis ,of ,psoriasis. 
,Disordered ,cellular ,immunity ,involving ,inflammatory ,cytokines ,(IL-1, ,IL-6, ,Tumour ,necrosis 
,factor-α ,[TNF-α]) ,and ,proinflammatory ,transcription ,factor ,(NF-κB, ,signal ,transduction ,and 
,transcription ,and ,AP-1) ,has ,also ,been ,implicated. , 
 Naïve ,T-cells ,can ,differentiate ,into ,any ,of ,the ,four ,types ,of ,inflammatory ,cells ,(viz. ,Th1, 
,Th2, ,Th17 ,or ,T ,regulatory ,cells) ,depending ,on ,the ,presence ,of ,TNF-α, ,TGF-β ,and ,IL-6. ,In ,the 
,presence ,of ,TGF-β ,and ,IL-6, ,naive ,T-cells ,transform ,into ,Th17 ,cells. , ,These ,activated ,cells 
,enter ,the ,circulation ,and ,extravasate ,through ,the ,endothelium ,to ,the ,sites ,of ,inflammation ,in 
,skin ,where ,they ,produce ,the ,Th1-Th2-Th17 ,imbalance. ,The ,role ,of ,the ,IL-23/Th17 ,pathway 
,has ,been ,intensely ,researched ,in ,recent ,years. ,IL-23, ,a ,heterodimer ,composed ,of ,p19 ,and ,p40 
,subunits, ,is ,produced ,by ,dendritic ,cells ,and ,macrophages. , ,It ,causes ,activation ,of ,Th17 ,cells ,to 
,produce ,IL-17 ,and ,IL-22. ,Psoriatic ,skin ,lesions ,contain ,high ,mRNA ,IL-23 ,levels ,compared ,to 
,normal ,skin. ,Th17 ,cells ,are ,CD4+ ,effector ,cells ,distinct ,from ,the ,classic ,Th1 ,and ,Th2 ,lineages 
,and ,are ,responsible ,for ,providing ,both ,innate ,and ,adaptive ,immunity ,against ,pathogens. ,IL-17 
,(also ,known ,as ,IL-17A) ,is ,part ,of ,a ,group ,of ,cytokines, ,called ,the ,IL-17 ,family, ,consisting ,of ,six 
,ligands ,(A ,to ,F), ,and ,with ,five ,receptor ,family ,members. ,IL-17 ,cytokines ,are ,probaby ,critical 
,for ,the ,pathogenesis ,of ,psoriasis. ,IL-17A ,and ,IL-17F ,are ,the ,predominant ,cytokines ,released ,by 
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,Th17 ,cells, ,but ,are ,also ,produced ,by ,γδ ,T ,cells, ,whereas ,IL-17C ,is ,produced ,by ,keratinocytes. 
,The ,effect ,of ,IL-17 ,cytokines ,is ,mediated ,via ,the ,adaptor ,protein ,connection ,to ,IκB ,kinase ,and 
,stress-activated ,protein ,kinases ,(CIKS)/Act1. ,This ,is ,confirmed ,by ,the ,association ,of ,psoriasis 
,with ,the ,gene ,encoding ,CIKS. ,IL-17A ,and ,IL-17F ,act ,on ,keratinocytes ,to ,stimulate ,the 
,production ,of ,β-defensins ,and ,antimicrobial ,peptides ,(AMPs), ,and ,chemokines ,such ,as ,IL-8, 
,CCL20 ,and ,CCL2. ,In ,addition, ,the ,IL-17 ,system ,may ,also ,play ,a ,role ,in ,antimicrobial ,defense 
,via ,maintenance ,of ,mucocutaneous ,immunity. ,Elevated ,levels ,of ,IL-17 ,result ,in ,an ,increase ,in 
,levels ,of ,pro-inflammatory ,cytokines ,like ,S-100, ,A7, ,β-defensins ,and ,lipocalin. ,In ,addition, 
,increased ,levels ,of ,β-defensins ,are ,associated ,with ,relative ,resistance ,to ,infections. ,Increased 
,levels ,of ,IL-17 ,also ,promote ,keratinocytes ,to ,produce ,CXC-chemokines ,and ,CCL-20, ,both ,of 
,which ,attract ,neutrophils ,to ,the ,site ,of ,inflammation. , ,Increased ,IL-22 ,levels ,lead ,to ,epidermal 
,acanthosis ,and ,abnormal ,keratinocyte ,differentiation. ,Ustekinumab, ,a ,monoclonal ,antibody 
,that ,inhibits ,the ,p40 ,subunit ,of ,IL-17, ,is ,effective ,in ,the ,treatment ,of ,psoriasis. ,Similarly, 
,Apilimod, ,an ,orally ,administered ,compound ,that ,selectively ,suppresses ,synthesis ,of ,IL-12 ,and 
,IL-23, ,leads ,to ,substantial ,improvement ,in ,psoriasis. , ,Analogous ,to ,psoriasis, ,the ,role ,of 
,Th17/IL-23 ,pathway ,has ,been ,investigated ,in ,psoriatic ,arthritis. ,However, ,a ,definite 
,involvement ,of ,Th17 ,cells ,and ,related ,cytokines ,in ,human ,arthritic ,disease ,remains ,to ,be 
,conclusively ,proven. ,Although ,initial ,studies ,with ,IL-17 ,antagonists ,and ,IL-23 ,monoclonal 
,antibodies ,have ,shown ,a ,favourable ,response ,in ,psoriatic ,arthritis, ,these ,results ,need ,to ,be 
,compared ,with ,TNF-α ,inhibitors. , 
Apart ,from ,Th-17 ,cells, ,the ,role ,of ,a ,new ,subtype ,of ,cells, ,Th-22 ,cells, ,is ,also ,considered 
,important ,in ,the ,pathogenesis ,of ,psoriasis. ,These ,cells, ,on ,activation ,by ,TNF-α, ,IL-6 ,and 
,CCL20, ,exclusively ,produce ,IL-22 ,and ,are ,involved ,in ,epidermal ,immunity ,and ,remodeling. 
,They ,express ,CCR10, ,CCR6 ,and ,CCR4 ,receptors ,on ,their ,surface. , ,Different ,dendritic ,cell 
,subsets ,might ,also ,regulate ,the ,Th17 ,versus ,Th22 ,activation ,with ,CD11C+ ,dermal ,DC's 
,promoting ,Th17 ,cells ,while ,epidermal ,Langerhans ,cells ,stimulate ,the ,Th22 ,cells. , 
Finally, ,angiogenic ,factors ,produced ,by ,epidermal ,keratinocytes ,are ,now ,recognized ,as ,drivers 
,of ,abnormal ,dermal ,vascular ,proliferation ,and ,angiogenesis.Levels ,of ,vascular ,endothelial 
,growth ,factor ,are ,raised ,in ,psoriatic ,plaque. 
The ,role ,of ,innate ,immune ,T ,cells ,and ,effector ,cells ,like ,γδ ,T ,cells ,and ,natural ,killer ,cells ,has 
,also ,been ,investigated. ,Cai ,et ,al. ,identified ,a ,new ,subset ,of ,γδ ,T ,cells ,in ,the ,dermis ,which, 
,unlike ,epidermal ,γδ ,T ,cells ,and ,conventional ,αβ ,T ,cells, ,express ,IL-23R, ,CCR6 ,and 
,transcriptional ,factor ,RORγt, ,and ,release ,IL-17. ,These ,act ,as ,the ,first ,line ,of ,defense ,against 
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,foreign ,pathogens ,and ,on ,activation, ,release ,mediators ,that ,promote ,and ,maintain 
,inflammation. ,Dermal ,γδ ,T ,cells ,are ,elevated ,in ,psoriasis ,plaques ,and ,may ,be ,important ,in ,the 
,pathogenesis ,of ,psoriasis ,due ,to ,their ,role ,in ,amplifying ,the ,adaptive ,immunity. ,Mabucchi ,et ,al. 
,showed ,that ,IL-23 ,failed ,to ,induce ,inflammation ,in ,T ,cell ,receptor ,(TCR) ,δ-deficient ,mice. 
,Laggner ,et ,al. ,found ,another ,novel ,Vγ9Vδ2 ,T ,cell ,subset, ,which ,expressed ,cutaneous 
,lymphocyte ,associated ,antigen, ,to ,be ,increased ,in ,psoriatic ,lesions ,but ,decreased ,in ,the 
,peripheral ,blood. ,Functional ,defects ,in ,regulatory ,T ,cells ,(T ,reg ,) ,have ,been ,found ,in ,psoriasis. 
,This ,may ,partly ,be ,due ,to ,the ,high ,levels ,of ,IL-6 ,in ,psoriatic ,lesions, ,which ,suppress ,T ,reg 
,activity ,and ,which ,in ,turn ,results ,in ,unopposed ,activity ,of ,pathogenic ,T ,cells. 
Role ,of ,impaired ,skin ,barrier ,in ,psoriasis ,:  
The ,hallmarks ,of ,psoriasis ,are ,hyperproliferation ,and ,abnormal ,differentiation ,of 
,epidermal ,keratinocytes, ,infiltration ,of ,T ,lymphocytes, ,and ,various ,endothelial ,vascular 
,changes ,in ,the ,dermal ,layer, ,such ,as ,angiogenesis, ,dilatation, ,and ,high ,endothelial ,venule 
,(HEV) ,formation. ,The ,skin ,acts ,as ,a ,two-way ,barrier ,to ,prevent ,the ,inward ,or ,outward ,passage 
,of ,water ,and ,electrolytes. ,The ,barrier ,is ,largely ,situated ,in ,the ,epidermis, ,isolated ,epidermis 
,being ,as ,impermeable ,as ,whole ,skin, ,whereas ,once ,the ,epidermis ,is ,removed ,the ,residual 
,dermis ,is ,almost ,completely ,permeable. ,The ,epidermal ,barrier ,is ,localized ,to ,the ,stratum 
,corneum. ,The ,barrier ,depends ,on ,both ,the ,cornified ,material ,of ,the ,keratinocytes ,and ,the 
,intercellular ,material, ,particularly ,lipids. ,A ,two-compartment ,model ,of ,the ,stratum ,corneum ,as 
,a ,barrier ,is ,currently ,accepted, ,in ,which ,protein-rich ,cells, ,the ,corneocytes, ,are ,embedded 
,within ,a ,continuous ,lipid-rich ,matrix. ,An ,intact ,stratum ,corneum ,prevents ,invasion ,of ,the ,skin 
,by ,normal ,skin ,flora ,or ,pathogenic ,microorganisms. , 
Minor ,injury ,in ,the ,skin ,and ,skin ,diseases ,can ,provide ,portals ,of ,entry ,to ,microorganisms, 
,particularly ,Streptococci ,or ,Staphylococci. ,AMPs, ,peptides ,present ,on ,the ,epidermis ,and ,its 
,appendages, ,act ,as ,the ,first ,line ,of ,immune ,defence. ,The ,two ,major ,groups ,of ,AMPs, ,defensins 
,and ,cathelicidins, ,provide ,a ,chemical ,barrier ,to ,infection ,where ,a ,physical ,barrier ,is ,absent ,or 
,limited. 
 Psoriasis ,is ,associated ,with ,epidermal ,defensin ,genes. ,Out ,of ,7 ,β-defensin ,genes, ,6 
,genes ,(except ,DEFB1 ,gene) ,are ,located ,on ,chromosome ,8p23.1 ,over ,a ,large ,repeat ,unit ,that ,can 
,vary ,in ,copy ,number. ,Case ,control ,studies ,have ,shown ,a ,significant ,association ,between 
,psoriasis ,and ,increased ,CNV ,of ,the ,β-defensin ,gene ,cluster. , ,Psoriatic ,lesions ,are ,characterized 
,by ,increased ,levels ,of ,hBD-2 ,β-defensin. ,While ,high ,defensin ,levels ,may ,account ,for ,the ,lower 
,incidence ,of ,skin ,infections ,in ,psoriatic ,plaques, ,they ,also ,possess ,potent ,proinflammatory 
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,activity. ,They ,may ,account ,for ,the ,KP ,as ,high ,β-defensin ,copy ,numbers ,increase ,the ,intensity 
,of ,inflammatory ,response ,to ,minor ,stimuli. ,Similarly, ,cathelicidin ,LL-37 ,is ,overexpressed ,in 
,inflamed ,skin ,in ,psoriasis, ,binds ,to ,extracellular ,self-DNA ,released ,from ,dying ,cells, ,and 
,converts ,self-DNA ,into ,a ,potent ,stimulus ,for ,plasmacytoid ,dendritic ,cells ,(pDCs). , 
,Subsequently, ,pDCs ,secrete ,type ,I ,interferons ,and ,trigger ,an ,auto-inflammatory ,cascade. 
 The ,abnormal ,keratinization ,in ,psoriasis ,is ,seen ,as ,an ,increased ,expression ,of ,early 
,differentiation ,markers ,such ,as ,CDSN ,and ,small ,proline ,rich ,proteins, ,cystatin ,A ,and 
,transglutaminase ,1, ,and ,decreased ,expression ,of ,late ,differentiation ,markers ,such ,as ,loricrin 
,and ,filaggrin. ,This ,leads ,to ,aberrant ,formation ,of ,the ,cornified ,envelope ,that ,in ,turn ,affects ,the 
,barrier ,capacity ,of ,the ,skin. ,This ,manifests ,as ,increased ,transepidermal ,water ,loss, ,which ,is 
,directly ,proportional ,to ,the ,clinical ,severity. ,The ,expression ,of ,aquaporins, ,a ,family ,of ,water 
,transporting ,proteins ,present ,in ,the ,plasma ,membrane ,of ,the ,stratum ,corneum ,and ,the ,stratum 
,spinosum, ,is ,decreased ,in ,lesional ,and ,perilesional ,skin ,in ,psoriasis. ,The ,LCE ,gene ,cluster, 
,which ,is ,composed ,of ,six ,groups ,(LCE ,1-6, ,with ,a ,total ,of ,18 ,members) ,is ,a ,part ,of ,the 
,epidermal ,differentiation ,complex. ,Its ,deletion ,has ,been ,strongly ,linked ,with 
,psoriasis.Deletions ,of ,LCE3B ,and ,LCE3C ,genes ,are ,present ,in ,60-70% ,of ,the ,general 
,population. ,The ,exact ,function ,of ,LCE3B ,and ,LCE3C ,genes ,is ,not ,known, ,but ,they ,are ,induced 
,after ,minor ,skin ,trauma ,such ,as ,tape ,stripping. ,de ,Cid ,et ,al. ,found ,significantly ,increased 
,expression ,of ,LCE3 ,genes ,and ,reduced ,expression ,of ,other ,LCE ,genes ,in ,psoriastic ,plaques. , ,de 
,Guzman ,Strong ,et ,al. ,found ,that ,loss ,of ,the ,32.4 ,kb ,region ,which ,functions ,as ,an ,epidermal 
,specific ,enhancer ,and ,is ,present ,adjacent ,to ,the ,LCE3B ,and ,LCE3C ,genes, ,may ,be ,the ,initiating 
,event ,in ,psoriasis. ,It ,has ,been ,speculated ,that ,deletions ,of ,LCE3B ,and ,LCE3C ,genes ,lead ,to 
,incomplete ,barrier ,repair ,after ,minor ,trauma, ,which ,in ,turn ,causes ,penetration ,of ,various 
,antigens ,and ,induces ,an ,inflammatory ,response. 
Interaction ,of ,damage ,associated ,molecular ,patterns ,(DAMP) ,and ,the ,pathogen ,associated 
,molecular ,patterns ,(PAMP) ,with ,their ,receptors, ,such ,as ,TLR ,and ,NOD ,like ,receptors, ,causes 
,the ,activation ,of ,keratinocytes ,and ,the ,epidermal ,innate ,immune ,system ,and ,thus, ,increased 
,secretion ,of ,antimicrobial ,proteins. ,This ,interaction ,between ,DAMP/PAMP ,with ,TLR/NOD 
,like ,receptors ,is ,also ,followed ,by ,liberation ,of ,inflammatory ,cytokines ,such ,as ,TNF-α, ,IL-8 ,and 
,IL-1β, ,all ,of ,which ,are ,potent ,chemoattractants. ,In ,patients ,who ,carry ,the ,psoriasis 
,susceptibility ,genes, ,such ,as ,HLA-C*06, ,LCE3B/LCE3C-del ,or ,defensin ,genes, ,exposure ,to 
,PAMP ,leads ,to ,a ,heightened ,inflammatory ,response ,and ,defective ,skin ,barrier ,repair ,with 
46 
 
,increased ,expression ,of ,keratins ,6 ,and ,17, ,and ,the ,LCE3 ,family. ,Aberrant ,skin ,repair ,allows ,a 
,sustained ,exposure ,to ,PAMPs ,which ,are ,engulfed ,by ,Langerhan ,cells ,and ,dendritic ,cells. 
 
Figure.3b.2.3.Pathogenesis ,of ,psoriasis 
 
Once ,the ,APCs ,engulf ,the ,inciting ,antigen, ,they ,migrate ,to ,the ,local ,lymph ,nodes ,where 
,they ,interact ,with ,naïve ,T-cells, ,resulting ,in ,T-cell ,activation. ,This ,process ,requires ,interaction 
,between ,the ,major ,histocompatibility ,complex ,antigens ,on ,APCs ,with ,the ,T-cell ,receptors. ,In 
,addition, ,costimulatory ,interactions ,between ,receptors ,and ,ligands ,on ,APCs ,and ,TCR ,are 
,important. ,These ,include ,interaction ,of ,lymphocyte ,function ,antigen ,(LFA)-3 ,and ,CD2; 
,between ,intercellular ,adhesion ,molecule-1 ,and ,LFA-1; ,and ,between ,B7 ,and ,CD28. ,[67] 
,Activation ,of ,such ,naïve ,T ,cells ,to ,pathogenic ,T ,cells ,is ,facilitated ,by ,the ,presence ,of 
,polymorphisms ,in ,IL-23 ,genes ,and ,HLA-C*06. ,Sustained ,activation ,of ,HLA-C*06 ,restricted 
,immunodominant ,epitopes ,could ,lead ,to ,antigen ,specific ,activation ,of ,CD8+ ,T ,cells, ,further 
,amplifying ,the ,production ,of ,TNF-α ,and ,IFN-γ, ,although ,such ,a ,subtype ,of ,T ,cells ,has ,not ,been 
,identified. ,Once ,the ,T ,cells ,are ,activated, ,both ,CD4+ ,and ,CD8+ ,T ,cells ,infiltrate ,the ,skin ,and 
,secrete ,Th1 ,and ,Th17 ,cytokines ,which ,activate ,the ,keratinocytes. ,Together ,with ,IL-1 ,and ,TNF-
α ,from ,keratinocytes, ,Th17 ,cytokines ,and ,IFN-γ ,increase ,expression ,of ,antimicrobial ,peptides 
,(AMPs). ,This ,leads ,to ,a ,vicious ,positive ,feedback ,cycle ,where ,initial ,activation ,of 
,keratinocytes ,promotes ,immune ,system ,activation, ,which ,in ,turn ,activates ,the ,keratinocytes 
,and ,is ,responsible ,for ,the ,chronic ,nature ,of ,the ,disease. ,Since ,Peroxisome ,proliferator ,activated 
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,receptors ,(PPAR) ,β/δ ,(PPAR ,β/δ), ,[one ,of ,three ,PPAR ,isoforms], ,is ,a ,key ,regulator ,of ,glucose 
,and ,lipid ,metabolism, ,its ,upregulation ,in ,psoriasis ,may ,partly ,explain ,the ,association ,with 
,metabolic ,syndrome. 
 
Figure.3b.2.4.Pathogenesis ,of ,psoriasis 
 
 










Signs ,and ,phenomenon: 
➢ With ,careful ,scratching, ,small ,silvery-white ,lamellar ,scales ,come ,off, ,more ,or ,less ,as 
,from ,a ,solidified ,candle ,strip ,(candle ,grease ,sign) , 
➢ Auspitz ,sign: ,Removal ,of ,this ,epithelial ,layer ,reveals ,punctuate ,bleeding ,because ,of ,a 
,lesion ,of ,the ,capillaries ,running ,out ,into ,the ,tips ,of ,the ,papillae. , 
➢ Koebners ,phenomenon: ,If ,the ,skin ,of ,a ,psoriatic ,patient ,is ,irritated ,(e.g. ,scratching) ,in 
,the ,phase ,of ,an ,acute ,episode ,of ,eruption, ,a ,new ,psoriatic ,focus ,is ,formed ,on ,the ,floor 
,of ,this ,epithelial ,lesion. 
3b.2.7.Clinical ,features ,Types58 ,: 
Plaque ,Psoriasis: 
 This ,is ,common ,type ,and ,its ,lesions ,are ,deeper ,pink ,in ,colour. , 
 As ,the ,plaques ,grow ,in ,size, ,they ,can ,merge ,to ,form ,annular ,(ring-shaped) ,and ,gyrate 
,(coined) ,forms. ,The ,most ,characteristic ,feature ,is ,silvery ,scale. ,The ,top ,scales ,lift ,away ,easily 
,but ,deeper ,scales ,stick ,together, ,and ,when ,removed, ,the ,exposed ,skin ,leaves ,punctuate 
,bleeding ,points. ,This ,is ,known ,as ,Auspitz ,sign. , 
Scalp ,psoriasis ,: 
 It ,is ,well-defined ,pale ,red ,plaques ,with ,a ,thick ,surface ,of ,silvery ,scales ,are ,seen. ,These 
,may ,become ,confluent ,and ,the ,entire ,scalp ,can ,be ,involved. 
Flexures ,psoriasis , 
 Psoriasis ,in ,flexures, ,especially ,under ,the ,breasts, ,and ,in ,the ,natal ,cleft ,and ,perineum 
,can ,appear ,different ,from ,plaques ,elsewhere. ,The ,scale ,is ,usually ,reduced ,or ,absent, ,leaving 
,shiny ,deep ,pink ,plaques, ,which ,may ,fissure ,in ,the ,depth ,of ,the ,skin ,crease. 
Palmar ,plantar ,psoriasis ,: , 
 Psoriasis ,can ,affect ,the ,hands ,and ,feet ,and ,can ,be ,difficult ,to ,distinguish ,from ,contact 
,dermatitis. ,The ,fissure ,occurs ,especially ,over ,the ,finger ,tips ,and ,heels, ,the ,lesion ,may ,very 
,painful ,and ,slow ,to ,heal. , 
Guttate ,Psoriasis: 
Guttate ,psoriasis ,occurs ,in ,2% ,of ,patients ,with ,psoriasis ,who ,are , ,usually ,younger ,than ,30 
,years, ,and ,is ,characterized ,by ,round ,1-to ,10-mm, ,salmon-pink ,papules ,(“dew-drops”) ,with ,a 
,fine ,white ,scale ,In ,many ,cases, ,it ,is ,preceded ,by ,a ,streptococcal ,throat ,(strep ,throat) ,or ,sinus 






 It ,is ,severe ,form ,of ,disease ,in ,which ,the ,lesions ,consist ,of ,small ,superficial ,pustules 
,which ,may ,appear ,on ,a ,plaque ,type ,of ,psoriais. 
Psoriasis ,erythroderma ,: 
 The ,psoriasis ,may ,extend ,to ,involve ,the ,entire ,body ,surface ,and ,present ,as ,generalized 
,redness ,and ,scaling ,all ,over ,the ,body ,with ,chills ,and ,rigors.  
Nails ,psoriasis ,: 
 The ,fingernails ,and ,toenails ,may ,show ,dystrophic ,changes ,of ,psoriasis. ,Pitting ,is ,the 
,commonest ,nail ,change, ,the ,whole ,of ,the ,nail ,may ,loosen ,and ,become ,raised ,from ,the ,nail 
,bed. , 
3b.2.8.Complications: 
 Complications ,of ,psoriasis ,may ,include ,the ,following: ,Secondary ,infections, ,Psoriatic 
,arthritis, ,possible ,increased ,risk ,of ,lymphoma, ,cardiovascular ,disease, ,ischemic ,heart ,disease, 
,and ,Mitral ,valve ,prolapse. ,Among ,these, ,Psoriatic ,arthritis ,is ,a ,major ,complication. 
Psoriasis ,Arthropathica: 
In ,a ,little ,fraction ,of ,psoriatic ,patients, ,there ,is ,involvement ,of ,the ,joints ,similar ,to 
,rheumatoid ,arthritis. ,The ,joints ,of ,the ,fingers, ,ankles, ,feet, ,knees ,and ,sacro-iliac ,are ,affected; 
,these ,joints ,are ,swollen ,and ,painful. ,The ,psoriatic ,eruption ,and ,the ,participation ,of ,the ,joints 
,may ,increase ,or ,decrease ,simultaneously. ,Nail ,changes ,are ,regularly ,present ,.Radiological 
,changes ,are ,osteoporosis ,followed ,by ,increased ,density, ,decreased ,joint ,space. 
 





Figure ,3b.2.6. ,Joints ,affected ,in ,Psoriatic ,arthritis 
 
3b.2.9.Diagnosis ,of ,psoriasis: 
 There ,are ,no ,laboratory ,tests ,which ,will ,positively ,identify ,psoriasis. ,The ,blood ,count, 
,Urine ,analysis, ,ESR ,and ,other ,hematologic ,chemical ,and ,serologic ,studies ,are ,within ,normal 
,limits ,in ,most ,cases ,of ,psoriasis. 
The ,diagnosis ,of ,psoriasis ,is ,based ,upon: 
1. Family ,history , 
2. Distribution ,-scalp, ,upper ,limb, ,lower ,limb, ,the ,front ,of ,the ,legs, ,front ,and ,back ,trunk 
,and ,nails. 
3. scaling 
4. The ,candle ,– ,grease ,sign. 
5. Auspitz ,sign ,(Complete ,removal ,of ,a ,scale ,produces ,pin-point ,bleeding) 
6. Koebner’s ,phenomenon , 
7. Little ,or ,no ,itching 
8. Previous ,attack 
9. Seasonal ,variations. 
3b.2.10.DIFFERENTIAL ,DIAGNOSIS58 
Nummular ,eczema 
 , Rounded, ,circular ,desquamative ,erythematous ,lesions ,covered ,with ,vesicles, ,crusts, 
,and ,scales, ,very ,itchy. ,Patients ,have ,whether ,atopic ,or ,allergic ,diathesis. ,Epicutaneous ,allergy 




Pityriasis ,rubra ,pilaris , 
 In ,typical ,cases ,follicular ,papules ,and ,infiltrating ,scales ,are ,observed ,as ,well ,as ,typical 
,hyperkeratosis. 
Lichen ,simplex ,chronic 
This ,disease ,shows ,dry ,and ,itchy ,oval ,plaques ,and ,resembles ,psoriasis ,as ,a ,shape ,but 
,not ,have ,silvery ,scales ,Auspitz ,and ,candle ,signs. ,And ,shows ,violaceous ,tint. 
Pityriasis ,alba , 
It ,shows ,a ,white ,plaque, ,like ,psoriasis ,but ,have ,not ,an ,erythema. ,It ,has ,been ,seen ,only 
,face. , ,Psoriasis ,usually ,affects ,more ,than ,one ,area ,of ,the ,body. ,Red ,skin ,covered ,with ,greasy-
looking ,white ,or ,yellowish ,scales. 































MODERN ,TREATMENT ,AVAILABLE ,FOR ,PSORIASIS12 
 




Topical corticosteroids are the most effective. Combination therapy 
with vitamin D and a corticosteroid was very effective.
Phototherapy
Phototherapy in the form 
of sunlight has long been used for 
psoriasis. The UVB lamps should 
have a timer that will turn off the 
lamp when the time ends. The 
amount of light used is determined 
by a person's skin type. Increased 
rates of cancer from treatment 
appear to be small. Psoralen and 
ultraviolet A phototherapy 
(PUVA) combines the oral or 
topical administration of psoralen 











 ,3c.1.INTERNAL ,MEDICINE 
 The ,Siddha ,system ,of ,medicine ,is ,32 ,forms ,of ,internal ,medicine ,were ,described ,in 
,Siddha ,text. ,Kudineer ,(Decoction) ,is ,the ,one ,form ,of ,internal ,medicine ,in ,which , ,powdered 
,plants ,or ,parts ,of ,plants ,added ,with ,specific ,quantity ,of ,water ,prescribed, ,be ,boiled , ,upto 
,1/4,1/8,1/16,1/24 ,th , ,of ,the ,initial ,quantity ,and ,taken ,after ,filtering ,it , ,or ,prepared ,in ,a ,specific 
,process ,if ,mentioned. ,Decoctions ,are ,water ,based ,extracts ,of ,herbal ,drugs ,which ,are ,easily 
,absorbed ,into ,the ,body ,and ,enter ,into ,the ,blood ,stream ,quickly ,which ,gives ,faster ,action ,than 
,other ,forms ,of ,medicine.( ,gets ,assimilated ,within ,an ,hour).The ,input ,water ,should ,be ,pure ,and 
,without ,hardness. ,Depending ,upon ,the ,characteristic ,feature ,of ,the ,ingredients ,they ,may ,be 
,made ,into ,separate ,pre-mix ,and ,blended ,together. ,They ,also ,should ,be ,used ,within ,three ,hours. 
3c.1.1.Chemical ,changes ,during ,the ,preparation ,of ,kudineer , ,: 
 The ,raw ,drug ,components ,when ,heated ,with ,water ,two ,types ,of ,changes ,are ,taking ,place 
,hydrolytic ,and ,pyrolitic ,changes.The ,hydrolytic ,changes ,include ,the ,conversion ,of ,esters ,into 
,alcohols ,and ,acid, ,rearrangement ,in ,the ,chemical ,structure ,of ,the ,components,better ,dispersion 
,in ,the ,water,removal ,of ,the ,volatile ,components ,with ,steam,imbibitions ,of ,the ,starchy ,materials 
,,decomposition ,of ,the ,proteins ,into ,peptides, ,is ,omerization ,and ,structural ,changes ,in ,the ,active 
,principles ,like ,carotenes,chlorophylls,vitamins,etc.In ,kudineerpreparation, ,tracing ,the 
,chemical ,changes ,of ,even ,the ,major ,components ,during ,heating ,is ,complicated ,problem. ,A 
,kudineer ,is ,a ,multi ,drug-multi ,component ,system. ,Hence ,changes ,can ,be ,multi-facial. ,Each 
,chemical ,changes ,is ,directly ,influenced ,by ,temperature/duration ,of ,heating/presence ,of 
,additives/other ,components/water/alkaline ,& ,acidic ,materials ,etc. , ,Isomerization ,, 
,decomposition, ,polymerization,etc ,can ,also ,take ,place ,depending ,upon ,the ,nature ,of ,heating. ,In 
,majority ,of ,kudineer ,preparations, ,the ,particle ,size ,of ,raw ,drug ,components ,has ,been ,specified 
,indirectly ,using ,the ,words ,crushed/ ,powdered ,/ ,pressed/etc. ,They ,may ,be , ,used ,as 
,powder,crushed ,products, ,heated ,and ,powdered ,materials ,/ ,pre-extracted ,solutions, 
,etc.Addition ,of ,components, ,duration ,of ,heating ,etc,. ,are ,also ,to ,be ,specific. ,The ,period ,of 








Trail ,drug ,:Parangipattai ,Kudineer ,- ,PPK , ,(Internal) 
 , , , , , , , , , , , , , , , , , , , , , ,Parangipattai ,Kudineer ,is ,one ,among ,the ,poly ,herbal ,formulation ,contains , ,10 
,ingredients ,which ,is ,mentioned ,in ,Siddha ,text ,book ,of , ,Pharmacopoeia ,of ,hospital ,of ,Indian 
,medicine. ,This ,drug ,used ,for ,all ,kind ,of ,skin ,diseases, ,insect ,bites,etc. , 
 , , , , , , , , , , , , , , , , , , , , , , ,The ,drug ,review ,of ,‘Parangipattai ,Kudineer’ ,is ,a ,poly ,herbal ,formulation ,gives , 
,evidence ,for ,its ,therapeutic ,action ,mentioned ,in ,literatures ,and ,research ,studies. 
3c.1.2.PROPERTIES ,OF ,TRIAL ,DRUGS ,15: 
1.Parangipattai ,: 
Botanical ,name : ,Smilax ,china.Linn 
Family   : ,Smilacaceae 
Organoleptic ,Characters: 
Taste  : , Sweet 
Potency : , Coolant , 
Division : , Sweet 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Thagam ,palavaathand ,thathunattam ,punpilavai 
megang ,kadikirandhi ,veelmooland ,– ,thegamudan 
kuttai ,pagandhamer ,kolvamanam ,pomparangip 
pattaiyinai ,yuchchariththup ,paar.” 
   - ,Agathiyar ,guna ,sinthamani 
2.Kadugu ,Rohini ,: 
Botanical ,name : , ,Picrorhiza ,kurroa.Royle 
Family   : , , ,Plantaginaceae , , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Bitter,Spicy 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Bitter 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Manthanj ,suramaiyam ,vayukarap ,paanaamanj 
sernthamalak ,kattu ,thirithodam-ponthapottup 
punvayiru ,noyivaipom ,porkodiye-pethiyundam 
thinkaduku ,rohinikkuth ,ther.” 
- Agathiyar ,guna ,sinthamani 
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3.Manjiti , ,: 
Botanical ,name : , ,Rubia , ,cordifolia.Linn 
Family   : , , ,Rubiaceae , , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Spicy, ,Bitter 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy 
4.Mara ,manjal ,: 
Botanical ,name : , ,Coscinium ,fenestratum.Colebr 
Family   : , , ,Menispermaceae , , , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Bitter 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Azhandrakana ,moolam ,arusi ,yudaney 
uzhandra ,kanachsuramum ,odunj-suzhandrulley 
veerusura ,mundhaniyum ,veesumara ,manjalukkuth 
theru ,mozhiyanamey ,seppu.” 
- Agathiyar ,guna ,sinthamani , 
5.Kadukkai ,: 
Botanical ,name : , ,Terminalia ,chebula.Retz 
Family   : , , ,Combretaceae , , , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Spicy 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Sweet , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Thaadai ,kazuththakki ,thalu ,kuriyividap 
peedai ,silipathamur ,pethimudam-aadaiyottaath 
thoolamidi ,punvaatha ,sonikaa ,malaiyiran 
daalamidi ,pomvarikkaa ,yaal.” 




Botanical ,name : , ,Terminalia ,bellerica.Roxb 
Family  : , , ,Combretaceae , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Astringent , 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Sweet , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Silanthividam ,kamiyappun ,seezhaana ,megang 
kalandhuvarum ,vathapithang ,kalo-dalarnthudalil 
undrikai ,veppa ,muthirapith ,thunkarakkun 
thandrikai ,kaiyileduth ,thaal. 
Aanipon ,menik ,kazhakum ,oliyumikum 
konikkol ,vathapiththak ,kolkaipom-thanikai 
kondavarkku ,megamarum ,koora ,anarraniyum 
kandavarkku ,vathampom ,kaan.” 
- Agathiyar ,guna ,sinthamani , 
7.Vasambu ,: 
Botanical ,name : , ,Acorus ,calamus.Linn 
Family  : , , ,Araceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Spicy , 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy , , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Pambaki ,nanjar ,puthappun ,valividapagang ,gunmam 
 ,   soombaa ,riraththapith ,thammuga ,naarramvan ,soolaisanni 
   veembaambai ,kaasam ,peeliganj ,silipatham ,veerirumal 
thaambaag ,kirumi ,ivaiyeegu ,maasiva ,sampinaiye” 







Botanical ,name : , ,Pimpinella ,anisum.Linn , 
Family  : , , ,Apiaceae , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Spicy ,,Sweet 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy , , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Yoninoi ,gunmam ,urutchaimand ,thamporumal 
penamuru ,kasam ,peeligamiraip-peenaurai 
serkindra ,vathamuponj ,seerperiya ,seeragaththal 
mookkuno ,yilai ,mozhi.” 
- Agathiyar ,guna ,sinthamani , 
9.Vembu ,: 
Botanical ,name : , ,Azhadirachta ,indica.A.Juss 
Family  : , , ,Meliaceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Bitter 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy , , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Kirumikutta ,mandhan ,keduvidanjsu ,rangal 
porumiyam ,soorikaiyin ,punkal ,– ,orumikka 
nimbath ,thilaiyirukka ,needulakil ,neengamal 
kambath ,thilaiyirukkak ,kaan.” 
- Agathiyar ,guna ,sinthamani , 
10.Seendhil ,: 
Botanical ,name : , ,Azhadirachta ,indica.A.Juss 
Family  : , , ,Meliaceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Bitter 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy , , 
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General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Seendhir ,kizhangkarunthath ,theebanamam ,megavagai 
ponthavuthi ,rappiththam ,pongusura-mandham 
athisaram ,veyyakanam ,aambalanoo ,yodey 
kathividamung ,kettuvidung ,kaan.” 
- Agathiyar ,guna ,sinthamani , 
 
 
Parangipattaikudineer ,is ,a ,polyherbal ,Siddha ,formulation ,containing ,10 ,ingredients ,of 
,plants ,origin ,their ,specific ,and ,individual ,locality ,names, ,action, ,phytochemistry ,and ,siddha 
,medicinal ,uses ,are ,tabulated ,below ,in ,Table. 
 
Table.3c..1.Information ,about ,ingredients , ,of ,Parangipattai ,kudineer16 
S.
No 
Botanical ,name , , , , , , 






Phytochemistry Action Medicinal 
,uses ,in 
,Siddha 
1. Smilax ,china.Linn Parangipattai 
,/China ,root 
Root Flavonoids, ,Saponins, 
,Sterols, ,Tannins, , , , , , , 








































































Fruit Ellargic ,Acid, ,Gallic 
,Acid,Tannins,Ethyl 























































Fissure ,in ,foot 

















3c.1.3.Pharmacological ,activity ,of ,herbs ,in ,Parangipattai ,Kudineer ,: 
 
The ,efficacy ,of ,all ,ingredients ,of , ,Parangipattai ,Kudineer ,was ,proved ,through ,the 
,following ,research ,studies. 
 
Smilax ,china.Linn ,: , 
Ethyl ,acetate ,fraction ,of ,Smilax ,china ,rhizome ,showed ,good ,anti-psoriatic ,activity ,in 
,the ,mouse ,tail ,test, ,anti-proliferent ,activity ,and ,nitric ,oxide ,inhibition ,assay. ,The ,plant ,Smilax 
,china ,rhizome ,possesses ,anti-psoriatic ,activity ,which ,is ,in ,agreement ,with ,its ,traditional ,use ,. 
,Smilax ,china ,has ,anti-inflammatory ,activity. ,Its ,decoction ,(90 ,and ,180 ,mg/kg; ,p.o) ,could 
,significantly ,inhibit ,inflammatory ,swelling ,on ,adjunctive ,arthritis ,mouse. ,The ,methanol ,extract 




The ,effect ,of ,an ,ethanolic ,extract ,of ,root ,of ,the ,Picrorhizakurroa.Roylewas ,studied ,on 
,delayed ,type ,hypersensitivity, ,humoral ,responses ,to ,sheep ,red ,blood ,cells, ,skin ,allograft 





Picrorhiza ,kurroa.Royle’s ,root ,has ,apocynin. ,Apocynin ,concentration ,dependently 
,inhibited ,the ,formation ,of ,thromboxane ,A2, ,where ,as ,the ,release ,of ,prostaglandins ,E2 ,and ,F2 
,was ,stimulated. ,Apocynin ,inhibited ,arachidonic ,acid ,induced ,aggregation ,of ,bovine ,platelets, 
,possibly ,through ,inhibition ,of ,thromboxane ,formation. ,The ,rhizome ,of ,Picrorhizais ,used ,to 
,treat ,inflammatory ,diseases ,as ,a ,traditional ,medication. 
Anti-diabetic ,activity: 
Extract ,of ,Picrorhiza ,was ,found ,to ,lower ,blood ,glucose ,in ,laboratory ,animals. ,Chronic 
,administration ,of ,the ,extract ,significantly ,reduced ,blood ,sugar ,in ,alloxan-induced ,diabetic ,rats 
,for ,10 ,days. ,The ,extract ,was ,also ,used ,to ,reduce ,the ,increased ,blood ,urea ,nitrogen ,and ,serum 
,lipid ,peroxides ,in ,alloxan-induced ,diabetic ,animals ,and ,to ,inhibit ,the ,body ,weight ,reduction 
,and ,leukopenia ,induced ,by ,alloxanadministration. 
In ,the ,streptozotocin ,induced ,diabetic ,rats, ,treated ,with ,a ,gavage ,of ,ethanol ,extraction ,of 
,Picrorhiza ,herbal ,formulation. ,It ,reduced ,NADPH ,- ,oxidase ,dependent ,superoxide ,generation 
,and ,decreased ,expression ,of ,malondialdehyde ,and ,advanced ,oxidation ,protein ,products ,in 
,diabetic ,kidney. ,So, ,extraction ,of ,Picrorhiza ,improves ,diabetic ,nephropathy ,through ,inhibition 
,of ,redox ,sensitive ,inflammation. 
Rubia ,cordifolia.Linn: 
Anti-Inflammatory ,Effect: , 
Rubia ,cordifolia, ,Linn. ,(Indian ,Manjishtha), ,was ,studied ,for ,the ,anti-inflammatory 
,effect ,in ,rats ,with ,carrageenan ,paw ,oedema 
Anti-bacterial ,Activity: 
 ,The ,anti-bacterial ,activity ,of ,the ,extracts ,of , ,rubia ,cordifolia ,root ,was ,significantly 
,active ,against ,B. ,subtilis ,and ,S. ,aureus ,compared ,with ,streptomycin ,and ,penicillin ,G ,used ,as 
,standards. 
Anti-proliferating ,Property: 
 ,Ethyl ,acetate ,fraction ,of ,the ,root ,of ,Rubia ,cordifolia.L ,inhibits ,keratinocyte 
,proliferation ,in ,vitro ,and ,promotes ,keratinocyte ,differentiation ,in ,vivo 
Anti-adipogenic ,activity ,of ,2-carbomethoxy-2, ,3-epoxy-3-prenyl-1, ,4-naphthoquinone 
,(CMEP-NQ) ,isolated ,from ,the ,roots ,of ,Rubia ,cordifolia.L., ,its ,effects ,on ,cell ,viability, 





Coscinium ,fenestratum.Colebr ,: 
immunomodulatory ,activity ,: 
The , ,assessment ,of ,immunomodulatory ,activity ,of ,ethanolic ,extract ,(Crude ,extract), 
,alkaloid ,fraction ,and ,non-alkaloid ,fraction ,of ,stem ,bark ,of ,Coscinium ,fenestratum ,was 
,carriedout ,by ,performing ,hemagglutinating ,antibody ,titer ,(H.A.) 
Anti-Depression: 
Coscinium ,fenestratum ,is ,a ,common ,medicinal ,plant ,widely ,used ,in ,the ,Indochina 
,region, ,but ,scientific ,data ,on ,its ,safety ,is ,very ,limited. ,Oral ,administration ,of ,plant ,alcoholic 
,extract ,at ,dosages ,of ,5, ,10 ,and ,20 ,mg/kg ,BW ,for ,14 ,days ,increased ,the ,rats ,body ,weight ,and 
,decreased ,the ,neuron ,density ,in ,the ,cerebral ,cortex, ,hippocampus ,and ,striatum. ,The ,plant 
,extract ,significantly ,increased ,stereotyped ,behavior ,in ,licking ,but ,did ,not ,cause ,anxiolytic 
activity, ,anti-depression, ,sensory ,motor ,co-ordination ,impairment ,and ,ataxia. 
Terminalia ,chebulla.Retz: 
Pharmacological ,investigations ,for ,antimutagenic, ,immunodulatory ,effect, 
,antibacterial, ,antifungal ,of ,different ,biological ,activities ,of ,Terminalia ,chebulain ,various ,in 
,vivo ,and ,in ,vitro ,test ,models ,have ,been ,carried ,out ,based ,on ,the ,presence ,of ,chemical 
,ingredients. ,The ,ethanolic ,extract ,of ,Terminalia ,chebulafruits ,possesses ,analgesic ,and ,anti- 
,inflammatory ,activities ,in ,mice ,and ,rats ,at ,the ,doses ,of ,250 ,mg/kg ,and ,500 ,mg/kg ,and, ,300 
,mg/kg ,respectively 
Terminalia ,bellerica.Roxb: 
Pharmacological ,activities ,such ,as ,anti-microbial, ,anti-oxidant,immumomodulatory, 
,anti-spasmodic ,of ,different ,biological ,activities ,of ,of ,Terminalia ,bellerica , ,in ,various ,in ,vivo 
,and ,in ,vitro ,test ,models ,have ,been ,carried ,out ,based ,on ,the ,presence ,of ,chemical ,ingredients 
Acorus ,calamus ,.Linn ,: , 
Anti-inflammatory: , 
Anti-inflammatory ,activity ,on ,keratinocyte ,hacat ,cells ,HaCaT ,cells ,induced ,the ,pro-
inflammatory ,cytokines, ,interleukin-8 ,(IL-8) ,and ,interleukin-6 ,(IL-6) ,expressions ,after 
treatment ,with ,polyI:C ,or ,PGN. ,ACL ,inhibited ,the ,expression ,of ,IL-8 ,and ,IL-6 ,RNA ,and 
,protein ,levels, ,and ,attenuated ,the ,activation ,of ,NF-ĸB ,and ,IRF3 ,after ,polyI:C ,treatment. ,ACL 
,also ,inhibited ,expression ,of ,IL-8 ,and ,activation ,of ,NF-ĸB ,following ,PGN ,induction. ,ACL 
,inhibits ,the ,production ,of ,pro-inflammatory ,cytokines ,through ,multiple ,mechanisms ,and ,may 




Anti-cellular ,and ,immunosuppressive ,properties ,: 
Modulation ,of ,immune ,response ,to ,alleviate ,disease ,has ,been ,of ,interest ,since ,long. 
,Plant ,extracts ,have ,been ,widely ,investigated ,for ,possible ,immunomodulatory ,properties. ,The 
,anti-cellular ,and ,immunomodulatory ,property ,of ,ethanolic ,extract ,ofAcorus ,calamus ,rhizome 
,has ,been ,evaluated. ,This ,extract ,inhibited ,proliferation ,of ,mitogen ,(phytohaemagglutinin; 
,PHA) ,and ,antigen(purified ,protein ,derivative; ,PPD)-stimulated ,human ,peripheral ,blood 
,mononuclear ,cells ,(PBMCs). ,In ,addition, ,A.calamusextract ,inhibited ,growth ,of ,several ,cell 
,lines ,of ,mouse ,and ,human ,origin. ,It ,also ,inhibited ,production ,of ,nitric ,oxide ,(NO), ,interleukin-
2 ,(IL-2) ,and ,tumor ,necrosis ,factor-a ,(TNF-a). ,Intra ,cytoplasmic ,interferon-gamma ,(IFN-
gamma) ,and ,expression ,of ,cell ,surface ,markers,CD16 ,and ,HLA-DR, ,on ,human ,PBMC, ,were 
,not ,affected ,on ,treatment ,with ,A. ,calamus ,extract ,but ,CD25 ,expression ,was ,down 
regulates. 
Pimpinella ,anisum.Linn: 
 Pharmacological ,properties ,of ,Pimpinella ,anisum ,such ,as ,antimicrobial, ,antifungal, 
,antiviral, ,antioxidant, ,and ,insecticidal ,effects ,have ,been ,reported ,of ,aniseeds 
Azhadirachta ,indica.A.Juss: 
The ,extracts ,showed ,potential ,antimicrobial ,activities ,against ,thirteen ,different ,strains 
,of ,microorganisms. ,Secondly, ,they ,were ,screened ,in ,vitro ,for ,cytotoxicity ,test ,by ,brine ,shrimp 
,lethality ,bioassay ,and ,results ,illustrated ,significant ,(p<0.05) ,cytotoxicity ,against 
,Artemiasalina. ,To ,test ,the ,analgesic ,properties ,of ,ethanol ,extract ,of ,Azadirachta ,indica, ,hot 
,plate ,and ,acetic ,acid ,induced ,writhing ,methods ,were ,used. ,At ,two ,different ,doses ,(250 ,and ,500 
,mg/kg ,body ,weight), ,the ,analgesic ,tests ,were ,performed ,on ,Swiss ,Albino ,mice. ,Also, ,the ,anti-
inflammatory ,tests ,were ,performed ,by ,carrageenan ,induced ,paw ,edema ,method ,on ,long ,Evans 
,rats ,at ,the ,two ,different ,doses ,of ,250 ,and ,500 ,mg/kg ,body ,weight ,using ,ethanol ,extract. ,Our 
,results ,indicated ,that ,Azadirachta ,indica ,possesses ,remarkable ,analgesic ,and ,anti-
inflammatory ,activity. 
Tinospora ,cordifolia.Miers: 
 Tinospora ,cordifolia ,has ,an ,importance ,in ,traditional ,medicine ,used ,for ,ages ,in ,the 
,treatment ,of ,fever, ,jaundice, ,chronic ,diarrhea, ,cancer, ,dysentery, ,bone ,fracture, ,pain, ,asthma, 
,skin ,disease, ,poisonous ,insect ,bite, ,snake ,bite, ,eye ,disorders. ,Pharmacological ,activities ,such ,as 
,antimicrobial, ,antioxidant, ,immumomodulatory,antispasmodic ,of ,different ,biological 
,activities ,of ,Tinospora ,cordifolia , ,in ,various ,in ,vivo ,and ,in ,vitro ,test ,models ,have ,been ,carried 
,out ,based ,on ,the ,presence ,of ,chemical ,ingredients 
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 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,3c.2.EXTERNAL ,MEDICINE 
The ,Siddha ,system ,of ,medicine ,is ,32 ,forms ,of ,external ,medicine ,were ,described ,in 
,Siddha ,text. ,Medicated ,oils ,are ,prepared ,by ,extracting ,drug ,substances ,in ,oil. ,Shelf ,life ,of 
,medicated ,oil ,is ,one ,year. ,Apart ,from ,vegetable ,oil ,animal ,fats ,are ,also ,used. 
In ,thylams, ,the ,medicinal ,principles ,of ,the ,raw ,drugs ,are ,directly ,or ,indirectly ,dissolved 
,in ,the ,oils.Cleanliness, ,purity ,of ,the ,drugs, ,good ,storage ,conditions, ,free ,from ,microbial ,and 
,other ,contaminations ,are ,the ,pre-conditions ,to ,be ,satisfied ,in ,the ,preparation ,of ,the ,thylams ,for 
,maintaining ,the ,quality ,of ,the ,oil, ,otherwise ,the ,peroxide ,formation, ,rancidity ,and ,hydrolytic 
,degradation ,will ,result ,in ,thylams. ,There ,are ,two ,general ,methods ,for ,the ,preparation ,of ,the 
,thylams ,either ,by ,directly ,heating ,the ,oil ,with ,raw ,drugs ,after ,proper ,grinding ,or ,extracting ,the 
,active ,principles ,of ,the ,drugs ,with ,water ,or ,milk ,and ,then ,from ,that, ,the ,thylam ,is ,prepared.In 
,the ,first ,method ,the ,active ,principles ,of ,the ,drug ,get ,dissolved ,in ,the ,oil ,and ,it ,is ,absorbed ,either 
,externally ,or ,internally ,depending ,upon ,its ,application. ,In ,the ,second ,method, ,all ,the ,required 
,heat ,and ,hydrolytic ,changes ,will ,be ,taking ,place ,when ,the ,raw ,drugs ,are ,extracted ,as ,kudineer 
,and ,from ,that ,concentrate; ,the ,active ,principles ,get ,dissolved ,into ,the ,oil14. 
Trail ,drug ,:Sivappu ,thylam ,(External) 
 , , , , , , , , , , , , ,Sivappu ,thylam ,is ,one ,among ,the ,poly ,herbal ,formulation ,contains , ,8 ,ingredients ,which 
,is ,mentioned ,in ,siddha ,text ,book ,of , ,Pharmacopoeia ,of ,hospital ,of ,Indian ,medicine. ,This ,drug 
,used ,for ,all ,kind ,of ,skin ,diseases. ,The ,drug ,review ,of ,‘Sivappu ,thylam’ ,, ,is ,a ,poly ,herbal 
,formulation ,gives , ,evidence ,for ,its ,therapeutic ,action ,mentioned ,in ,literatures ,and ,research 
,studies. 
3c.2.1.PROPERTIES ,OF ,TRIAL ,DRUGS ,15: 
1.Pungan ,Ver ,: , 
Botanical ,name : , ,Pongamia ,pinnata ,Pierre 
Family   : , , ,Fabaceae , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Bitter, ,Astringent 
Potency  , , , , , , , , , , ,: , ,Hot 








General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Punginvidhai ,karkirandhi ,punkarappan ,kathezhuchchi 
Angasanni ,kannoykkum ,aambethi-yungkattum 
Kaatuppung ,kin ,vithaikku ,kandathey ,marsorimeip 
Poottuppang ,kinvaayvum ,pom.” 
- Agathiyar ,guna ,sinthamani 
2.Manjiti , ,: 
Botanical ,name : , ,Rubia , ,cordifolia.Linn 
Family   : , , ,Rubiaceae , , 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Spicy, ,Bitter 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy 
3. ,Nannari ,: , 
Botanical ,name : , ,Hemidesmus ,indicus ,R.Br , 
Family   : ,Asclepiadaceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Sweet, ,Bitter 
Potency  , , , , , , , , , , ,: , ,Coolant , 
Division  , , , , , , , , , , ,: , ,Sweet 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Salathodam ,piththamathi ,thaagam ,uzhalai 
Salameru ,seethaminnaar ,thanjoo-dulagamathir 
Sonnamathu ,megam ,pun ,suramivaiye ,laamozhikkum 
Menmathura ,nannari ,ver.” 
-Therayar ,gunavagadam , , , , , , , 
4. ,Manjal ,Mezhugu ,( ,Cera ,wax ,) ,: , , , , , , , , , , , , , , , , , , , , , , , , , 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Araipakka ,vatha ,mathaippaiya ,moothai 
Kuraivindhi ,thazhnoy ,thelkooli-karaiyaip 
Puzhukedukka ,vangamuru ,punnidippun ,deeppun 
Mezhugedukka ,vaangalu ,mei.” 






6. Vellai ,Kungiliyam.: , , , , , , , , , , , , , , , , , , , , , , , , , 
Botanical ,name : , ,Vateria ,indica ,Linn 
Family   : ,Dipterocarpaceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Bitter 
Potency  , , , , , , , , , , ,: , ,Hot 
Division  , , , , , , , , , , ,: , ,Spicy 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Vellai ,yaliththa ,virananaa ,pikkamalath 
Thollaivira ,nammegandh ,thorrukinum- ,ulley 
Varuvarasanaimerpun ,varinunj ,suvethach , 
saruvarasa ,merpazhiyaich ,chaarru.” 
-Therayar ,gunavagadam 
6. ,Chevvallikkodi ,: , , 
Botanical ,name : , ,Dioscorea ,purpurea , , , , , , , , , , , 
Family   : ,Dioscoreaceae 
Organoleptic ,Characters ,: 
Taste   , , , , , , , , , , ,: , ,Sweet 
Potency  , , , , , , , , , , ,: , ,Coolant , 
Division  , , , , , , , , , , ,: , ,Sweet 
General ,Properties ,: , , , , , , , , , , , , , , , , , , , , , , 
“sevvalli ,yinkodikkuch ,sediththa ,kuttamodu 
Kavvu ,kurainoyi ,karappanum-ivvulakil 
Maaney ,! ,kudalvatham ,valla ,vaduvanudan 
Aanaparu ,moolamumpom ,aay.” 
- ,Agathiyar ,guna ,sinthamani 
7. ,Surul ,Pattai ,: , , , , , , , , , , , , , , , , , , , , , , , , , 
Botanical ,name : , ,Cinnamomum ,verum.Juss 
Family   : ,Lauraceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Spicy, ,Sweet 
Potency  , , , , , , , , , , ,: , ,Coolant ,,Hot 





General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Thathunattam ,pethi ,saruvavisam ,aagiyanoyi 
Poothakira ,kanjsilandhip ,poochchividanj-saathividam 
Aattumiraip ,podirumal ,aagiyanoyik ,koottamara 
Oatttumila ,vangath ,thuri.” 
- ,Agathiyar ,guna ,sinthamani 
8. ,Coconut ,Oil , ,: , , , , , , , , 
Botanical ,name : , ,Cocos ,nucifera ,Linn , 
Family   : ,Arecaceae 
Organoleptic ,Characters: 
Taste   , , , , , , , , , , ,: , ,Sweet 
Potency  , , , , , , , , , , ,: , ,Coolant , 
Division  , , , , , , , , , , ,: , ,Sweet 
 
General ,Properties: , , , , , , , , , , , , , , , , , , , , , , 
“Thengayi ,neyyathanaar ,riyaal ,varupunpom , 
Paangaakak ,koondhar ,padandheru-neengadha 
Palladiyin ,noyum ,padatha ,maraisirangum 
Allarap ,pomen ,rari.” 
- ,Agathiyar ,guna ,sinthamani 
 





,name , , , , , , , , , , , , , , , , , , , , 















































Root Glucose ,hemidesmol, 
,2hydroxy-4-methoxy 
,benzaldehyde, ,glucoside, 












4. Manjal ,mezhugu 
, , 
Cera ,wax Wax Cerotic ,Acid 
Myricin 



















,Dioscorea , , , 
,alata , 



































3c.2.2.Pharmacological ,activity ,of ,herbs ,in ,Sivappu ,thylam ,: 
The ,efficacy ,of ,all ,ingredients ,of , ,Sivappu ,thylam ,was ,proved ,through ,the ,following 
,research ,studies. 
1.Pongamia ,pinnata ,Pierre19 ,: 
The ,plant ,shows ,the ,presence ,of ,many ,chemical ,constituents ,like ,alkaloids, ,tannins, 
,steroids, ,glycosides, ,demethoxy-kanugin, ,glabrin, ,kanugin, ,karangin, ,ﬂavonoids ,and ,ﬁxed ,oils 
,which ,are ,responsible ,for ,varied ,pharmacological ,and ,medicinal ,properties ,like ,Anti-
inﬂammatory ,activity, ,Anti-pyretic ,action,Anti-microbial ,activity,Anti-diarrhoeal ,action, ,Anti-
viral ,activity, ,Anti-hepato-protective ,activity, ,Anti-ﬁlarial ,activity, ,Dyspepsia, ,Gonorrhea, 
,Leprosy, ,Anti-hyperglycemic ,activity, ,Antilipidperoxidative ,activity, ,Anti-hyperammonemic 




2.Rubia ,cordifolia.Linn ,16: 
Anti-Inflammatory ,Effect: , 
Rubia ,cordifolia, ,Linn. ,(Indian ,Manjishtha), ,was ,studied ,for ,the ,anti-inflammatory 
,effect ,in ,rats ,with ,carrageenan ,paw ,oedema 
Antibacterial ,Activity: 
 ,The ,antibacterial ,activity ,of ,the ,extracts ,of , ,Rubia ,cordifolia ,root ,was ,significantly 
,active ,against ,B. ,subtilis ,and ,S. ,aureus ,compared ,with ,streptomycin ,and ,penicillin ,G ,used ,as 
,standards. 
Anti-proliferating ,Property: 
 ,Ethyl ,acetate ,fraction ,of ,the ,root ,of ,Rubia ,cordifolia.L ,inhibits ,keratinocyte 
,proliferation ,in ,vitro ,and ,promotes ,keratinocyte ,differentiation ,in ,vivo 
Anti-adipogenic ,activity ,of ,2-carbomethoxy-2, ,3-epoxy-3-prenyl-1, ,4-naphthoquinone 
,(CMEP-NQ) ,isolated ,from ,the ,roots ,of ,Rubia ,cordifolia.L., ,its ,effects ,on ,cell ,viability, 
,apoptosis, ,and ,adipogenesis ,in ,3T3-L1 ,preadipocytes ,were ,investigated. 
3.Hemidesmus ,indicus ,R.Br , ,: 
Anti-inflammatory ,activity20 ,: 
Ethyl ,acetate ,root ,extract ,of ,HI ,exhibited ,anti-inflammatory ,activity ,in ,acute ,and 
,subacute ,inflammation ,evident ,from ,the ,significant ,inhibition ,of ,inflammation ,caused ,by 
,carrageenan, ,bradykinin, ,S-hydroxy ,tryptamine ,in ,rats. ,The ,extract ,was ,less ,active ,than 
,phenylbutazone. ,HI ,root ,aqueous ,extract ,showed ,sufficient ,anti-inflammatory ,activity 
,compared ,to ,diclofenac ,sodium ,gel 
Anti-cancerous ,activity21 ,: 
Roots ,of ,HI ,exhibit ,protective ,activity ,against ,hepatocarcinogenesis ,and ,other ,cancers 
Anti-arthritic ,activity ,22 , 
HI ,root ,display ,protective ,activity ,against ,arthritis, ,probably ,assigned ,by ,the ,presence ,of 
,terpenes, ,sterols, ,and ,phenolic ,compounds ,in ,hydroalcoholic ,root ,extract ,and ,ethyl ,acetate 
,fraction. ,These ,fractions ,showed ,higher ,anti-arthritic ,activity ,than ,chloroform ,and ,residual 
,fraction 
4.Manjal ,mezhugu , , ,(Cera ,wax ,)23 ,: 
Yellow ,Wax. ,A ,peculiar, ,concrete ,substance, ,preparedby ,ApismellificaLinne.Ethanol ,extracts 
,of ,propolis ,(EEP) ,have ,shown , ,antibacterial ,activities. ,Therefore, ,propolis ,might ,be ,useful ,as 
,antibacterial ,especially ,against ,Bacillus ,subtilis, ,MRSA, ,Micrococcus, ,Escherichia ,coli, 
,Pseudomonas ,aeruginosa ,and ,Proteus ,vulgaris. 
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5.Vateria ,indicaLinn24 ,: 
Vateria ,indica ,Linn. ,resin ,extract ,possess ,significant ,Anti-inflammatory, ,Anti-ulcer. 
6.Dioscorea ,purpurea/ ,Dioscorea ,alata25 ,: 
Antioxidant ,Activity ,and ,Anti-bacterial ,activity ,: 
Extract ,of ,D. ,alata ,exerts ,antioxidant ,and ,antibacterial ,activities. ,Antioxidant ,activity 
,investigated ,by ,DPPH ,free ,radical ,scavenging ,assay, ,the ,IC50 ,value ,of ,plant ,extract ,was 
,24.99µg/mL. ,Significant ,absorption ,of ,extract ,(1.317 ,of ,1mg/mL) ,showed ,the ,ferric ,reducing 
,activity. ,Extract ,showed ,significant ,zone ,of ,inhibition ,in ,antibacterial ,activity ,test. ,The 
,presence ,of ,myricetin ,along ,with ,other ,detected ,polyphenols ,might ,contribute ,to ,antioxidant 
,and ,antibacterial ,activities. , 
7.Cinnamomum ,verum.Juss26 
Antimicrobial ,: 
 Cinnamomum ,extract ,and ,oil ,possess ,various ,antimicrobial ,activities ,against ,several 
,bacteria ,and ,fungi ,etc,. , 
8.Cocos ,nucifera ,Linn27 ,: 
Anti-inﬂammatory ,: 
A ,study ,using ,animal ,models ,of ,inﬂammation ,(formalin ,test ,and ,subcutaneous ,air ,pouch 
,model) ,showed ,that ,aqueous ,crude ,extracts ,of ,C. ,nucifera ,var. ,typica ,(50, ,or ,100 ,mg/kg) 
,signiﬁcantly ,inhibited ,(Po0.05) ,the ,time ,that ,animals ,spent ,licking ,their ,formalin-injected ,paws 
,and ,reduced ,inﬂammation ,induced ,by ,subcutaneous ,carrageenan ,injection ,by ,reducing ,cell 






















The ,famous ,verses ,from ,Agathiyar ,Gnanam, ,a ,Siddha ,literature ,speaks ,about ,treating 
,the ,mind ,as ,follows; 
 “If ,the ,mind ,is ,good ,then ,no ,need ,of ,chanting 
  , ,If ,the ,mind ,is ,good ,then ,no ,need ,of ,breathing ,exercise 
 If ,the ,mind ,is ,good ,then ,no ,need ,of ,retention ,of ,inspired ,air 
 If ,the ,mind ,is ,good ,the ,body ,is ,good” , , , , , , , , , , , 
A ,Life ,free ,of ,ailments ,especially ,from ,life ,style ,disorders, ,a ,proper ,co-ordination ,over 
,the ,psychic ,stage, ,psychosomatic ,stage ,and ,organic ,stage ,towards ,the ,available ,holistic ,health 
,and ,Positive ,thinking ,are ,attained ,by ,Yogic ,practices. ,The ,integrated ,approach ,of ,Yoga ,therapy 
,(IAYT) ,is ,the ,need ,of ,the ,hour ,in ,maintaining ,sound ,physical, ,mental ,and ,social ,well ,being ,of 
,people ,globally.  
 
The ,concept ,of ,Ashtanga ,Yogam ,mentioned ,in ,Thirumandhiram, ,a ,Tamil ,Siddha ,literature, 
,have ,enormous ,contribution ,towards ,holistic ,health ,by ,practising ,Eight ,steps ,of ,Yoga ,are 
,outlined ,here. , 
“Iyama ,niyamam ,ennilaa ,aadhanam 
Nayamuru ,pranaayaamam ,prathiyaagaram 
Sayamuru ,dhaaranai ,dhiyanam ,samadhi 
Ayamurum ,attangam ,aavadhu ,mamae” 
-Tamil ,moovayiram 
➢ Iyamam ,(Purity ,of ,Mind ,) 
➢ Niyamam ,(Purity ,of ,Action) 
➢ Asanam ,(Posture) 
➢ Pranayamam ,(Breathing ,technique) 
➢ Prathyaharam ,(Controlling ,Sense) 
➢ Dharnai ,(Concentrating ,Mind) 
➢ Dhyanam ,(Continuous ,Contemplation) 




3d.2.In ,Agathiyar ,Maamunivar ,Paripooram ,1200 ,28: 
Attangam ,: ,8 
 “Kaanavey ,attanga ,mettuk ,kezhu 
  ,---------------------- ,Kaaviyaththai ,kanduthaerey” ,Verse ,no ,: ,1121 
Iyamam ,: ,11 
 “Thaerappaa ,thaerndhumanang ,kandukozhzha 
  ,--------------------- ,Naemamadhaith ,thiramaaikkaney” ,Verse ,no ,: ,1122, ,1123 
Naemam ,: ,10 
 “Kaanavey ,naemamadhu ,eeranjappaa 
  ,--------------------- ,Sugamaga ,naemavagai ,paththunjsithey” Verse ,no ,: ,1124  
Aasanam ,: ,9 
 “Siththamudan ,naemavagai ,paththukkandu ,----------- 
  ,Veththyuzhzha ,aasandhaa ,nonbadhappa ,----------------- 
  ,Karpoora ,theebam ,paarey” Verse ,no ,: ,1125-1126 
Prathiyagaram ,: ,6 
 “Muththiyudan ,sivayogath ,thirundhu ,kondu 
  ,---------------------------- ,aaruvagai ,prathiyagaram ,paarey” ,Verse ,no ,: ,1128  
Thaaranai ,: ,6 
 “Paaradaa ,thaaranaithaa ,naaru ,vagaithannai , 
  ,--------------------------- ,naruvagai ,thaaranaithan ,paarey” ,Verse ,no ,: ,1129 
Dhiyanam ,: ,10 
 “Paarappa ,aaruvagai ,thaaranaiyin ,nindru 
  ,Pathivaana ,athiyanavagai ,paththung ,kezhu 
  ,------------------------------------ ,vagaiyai ,kezhey” ,Verse ,no ,: ,1130 ,– ,1131 
Samathi ,5: 
 “Kezhappaa ,samadhiyanju ,nandraai ,solven , 
  ,Kirubaiyuzhzha ,thathvalaya ,samadhiyondru , 
  ,------------------------- ,sagalasiththu ,maadalamey” ,Verse ,no ,: ,1132 ,– ,1133 
The ,above ,verses ,are ,describes ,about ,Attangayogam ,& ,its ,divisions, ,subdivisions. 
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3d.3.The ,role ,of ,psychoneuroimmunology29 
Psychodermatology ,is ,a ,relatively ,new ,discipline ,in ,psychosomatic ,medicine. ,It ,is ,the 
,interaction ,between ,mind ,and ,skin. ,The ,two ,disciplines ,are ,interconnected ,at ,the ,embryonal 
,level ,through ,ectoderm. ,There ,is ,a ,complex ,interplay ,between ,skin ,and ,the ,neuroendocrine ,and 
,immune ,systems. ,Skin ,responds ,to ,both ,endogenous ,and ,exogenous ,stimuli. ,It ,senses ,and 
,integrates ,environmental ,cues ,and ,transmits. 
Stress ,activates ,2 ,major ,neuronal ,pathways: ,the ,hypothalamic-pituitary-adrenal ,axis 
,and ,the ,sympathetic ,nervous ,system. ,The ,identification ,of ,external ,stress ,by ,the ,brain ,results ,in 
,activation ,of ,the ,paraventricular ,nucleus ,of ,the ,hypothalamus ,and ,locus ,ceruleus. 
,Corticotropin-releasing ,factor ,is ,secreted ,from ,the ,hypothalamus ,and ,transported ,through 
,portal ,circulation ,to ,the ,pituitary, ,where ,it ,induces ,the ,release ,of ,adrenocorticotropic ,hormone 
,from ,the ,anterior ,pituitary ,to ,the ,general ,circulation. ,This ,results ,in ,the ,secretion ,of 
,glucocorticoids ,and ,catecholamines ,from ,the ,adrenal ,gland. 
Cortisol ,acts ,as ,negative ,feedback ,on ,the ,hypothalamus ,and ,inhibits ,the ,further ,release 
,of ,corticotropin-releasing ,factor. ,The ,cells ,of ,the ,locus ,ceruleus ,activate ,the ,sympathetic 
,system, ,which ,results ,in ,the ,secretion ,of ,epinephrine ,and ,norepinephrine. 
Both ,catecholamines ,and ,cortisol ,have ,potent ,effects ,on ,the ,immune ,system. ,They 
,modulate ,antigen-presenting ,cells ,and ,macrophages ,and ,inhibit ,their ,activity ,and ,the 
,production ,of ,interleukin ,(IL)-12 ,and ,IL-18. ,They ,also ,mediate ,the ,differentiation ,of ,naive ,T-
helper ,(TH) ,cells ,toward ,TH2, ,to ,the ,detriment ,of ,the ,development ,of ,TH1. ,This ,tilts ,the 
,balance ,toward ,humoral ,immunity ,and ,activates ,B ,cells, ,mast ,cells, ,and ,eosinophils, ,with ,a 
,consequent ,increase ,in ,allergic ,inflammatory ,response. ,Nerve ,terminals ,in ,cutaneous ,sensory 
,nerves ,release ,neuropeptides, ,such ,as ,calcitonin ,gene-related ,peptide ,and ,substance ,P, ,which 






Figure.5a.1.The ,role ,of ,psychoneuroimmunology 




Skin ,is ,the ,reflex ,of ,mind ,and ,so ,we ,should ,treat ,not ,only ,the ,physical ,but ,also ,treat ,mind ,and 
,soul. ,There ,by ,patients ,are ,advised ,to ,do ,yogam ,practice. 
Asanas ,like,  
➢ Yogam ,therapy ,(Agathavam ,Ettu) 
➢ Surya ,namaskaram ,(Sun ,salutation) 
➢ Padmasanam ,(Lotus ,position) 
➢ Nadi ,suddhi ,pranayamam ,( ,Alternate ,nostril ,breathing ,practice) 
➢ Paschimottanasanam ,( ,Forward ,bend ,pose) 
➢ Makarasanam ,(Crocodile ,pose) ,will ,be ,given ,for ,IPD ,patients ,and ,these ,are ,all 








Surya” ,means ,sun ,and ,“Namaskar” ,Means ,Salutation. ,Suryanamaskar ,is ,the ,complete ,body 
,workout. ,It ,is ,Very ,effective ,in ,weight ,loss ,program. ,Only ,in ,Suryanamaskar ,(Sun 
,Salutation), ,there ,are ,12 ,different ,yoga ,poses ,which ,give ,total ,exercise ,to ,the ,whole ,body. ,By 
,practicing ,the ,sun ,salutation ,regularly, ,we ,can ,become ,active ,and ,strong ,in ,our ,whole ,life. 
Morning ,is ,the ,best ,time ,to ,practice ,Suryanamskar ,(Sun ,Salutation). ,But ,don’t ,eat ,anything 
,for ,5 ,hours ,prior ,to ,Surya ,Namaskar 
Steps ,for ,Surya ,Namaskaram ,: 
Surya ,Namaskar ,(Sun ,Salutation) ,is ,the ,combination ,of ,12 ,different ,asanas ,(Yoga ,poses). 
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1. Pranamasanam ,: ,Stand ,straight ,and ,erect ,in ,such ,a ,way ,that ,your ,face ,is ,in ,the 
,direction ,of ,the ,sun. ,Both ,feet ,should ,be ,touching ,each ,other. ,Bring ,your ,hands ,close 
,to ,your ,chest ,by ,touching ,palm ,to ,palm ,called ,Namaskar ,( ,Salutation). 
2. Hastauttanasanam ,: ,Take ,a ,deep ,breath ,and ,raise ,your ,hand ,in ,upward ,direction. 
3. Padahastasanam: ,Now ,breathe ,out ,slowly ,and ,bend ,forward. ,Hands ,should ,be ,lined 
,with ,your ,feet ,and ,head ,touching ,your ,knees. 
4. Ashwa ,Sanchalanasanam ,:Inhale ,slowly ,and ,extend ,the ,right ,leg ,back ,and ,drop ,the 
,knee ,to ,the ,ground. ,Bend ,the ,left ,knee ,and ,hands ,should ,be ,firm ,with ,the ,ground. 
5. Parvatasanam ,: ,During ,exhaling ,bring ,the ,right ,leg ,back ,to ,join ,the ,left ,leg. ,Raise 
,your ,buttocks ,upwards ,forming ,a ,triangle. 
6. ,Ashtanga ,namaskaram ,:Exhale ,until ,your ,feet, ,knees, ,hands, ,chest, ,forehead 
,touches ,the ,ground. ,Hold ,the ,breath. 
7. ,Bujangasanam ,:On ,inhaling ,raise ,your ,head ,in ,an ,upward ,direction ,and ,bend ,in 
,the ,backward ,direction ,as ,much ,you ,can. ,It ,is ,called ,Bhujagasana ,pose. 
8. ,Parvatasanam ,:Now ,exhale ,slowly ,and ,make ,an ,upward ,arc , 
9 ,.Ashwa ,Sanchalanasanam ,: ,Inhale ,slowly ,and ,extend ,the ,right ,leg ,back ,and ,drop 
,the ,knee ,to ,the ,ground. ,Bend ,the ,left ,knee ,and ,hands ,should ,be ,firm ,with ,the ,ground. 
10.Padahastasanam ,: , , ,Now ,breathe ,out ,slowly ,and ,bend ,forward. ,Hands ,should ,be 
,lined ,with ,your ,feet ,and ,head ,touching ,your ,knees. 
11.Hastauttanasanam ,: ,Take ,a ,deep ,breath ,and ,raise ,your ,hand ,in ,upward ,direction. 
12.Pranamasanam ,: ,Stand ,straight ,and ,erect ,in ,such ,a ,way ,that ,your ,face ,is ,in ,the 
,direction ,of ,the ,sun. ,Both ,feet ,should ,be ,touching ,each ,other. ,Bring ,your ,hands ,close 
,to ,your ,chest ,by ,touching ,palm ,to ,palm ,called ,Namaskar ,( ,Salutation). 
Benefits ,of ,Surya ,Namaskar ,(Sun ,Salutation) ,: 
➢ Effective ,in ,weight ,loss. 
➢ Improved ,digestion ,and ,appetite. 
➢ Cures ,constipation. 
➢ Increases ,body ,flexibility. 
➢ Helps ,to ,Reduce ,stress ,and ,stay ,calm. 
➢ It ,strengthens ,the ,arms, ,back, ,shoulders ,and ,legs, ,hips, ,quads ,and ,calves. 
➢ It ,gives ,physical ,and ,mental ,strength. 




➢ Pregnant ,women ,should ,not ,practice ,Suryanamaskar. 
➢ Those ,suffering ,from ,high ,blood ,pressure ,and ,hernia ,should ,not ,practice 
,Suryanamaskar. 
➢ During ,menses, ,women ,should ,avoid ,Suryanamaskar. 
➢ Those ,suffering ,from ,back ,pain ,should ,take ,expert ,guidance. ,All ,asana 
,should ,perform ,under ,expert ,guidance. 
3d.5.Padmasanam ,Yoga ,(Lotus ,Pose)31 ,: 
In ,Sanskrit, ,“Padmam” ,means ,lotus. ,Hence ,padmasana ,is ,called ,the ,lotus ,pose. , 
 
 
Figure.5a.3. ,Padmasanam ,Yoga 
 
Padmasana ,Yoga ,Steps: 
 
Padmasana ,is ,quite ,a ,difficult ,asana. ,Hence ,it ,is ,ideal ,to ,perform ,few ,preparatory ,asanas ,like 
,Pigeon ,pose ,or ,Butterfly ,pose ,before ,performing ,this ,asana. 
1. ,Begin ,by ,sitting ,in ,a ,cross-legged ,posture ,with ,right ,leg ,crossed ,over ,your ,left. ,Ensure ,that 
,your ,hips ,are ,higher ,than ,your ,knees. 
2. ,Taking ,the ,assistance ,of ,your ,hands, ,bring ,your ,right ,foot ,onto ,the ,left ,thigh ,such ,that ,the ,hell 
,touches ,the ,hip ,joint. 
3. ,Now ,turn ,the ,sole ,of ,your ,foot ,up, ,lengthening ,through ,your ,ankle. 
4. ,Once ,you ,are ,comfortable ,in ,this ,position, ,bring ,your ,left ,foot ,onto ,the ,right ,thigh ,with ,the 
,heel ,touching ,the ,hip ,joint, ,sole ,turned ,up. 
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5. ,Gently ,press ,down ,your ,ankles ,to ,your ,thighs. ,Now ,extend ,from ,the ,base ,of ,the ,perineum, ,all 
,the ,way ,up ,the ,length ,of ,the ,spine, ,with ,full ,energy ,in ,one ,go. 
6. ,Now ,place ,your ,hands ,on ,the ,knees. ,And ,bring ,your ,fingers ,to ,Sin ,mudra, ,i.e, ,with ,the ,thumbs 
,and ,index ,finger ,forming ,a ,circle ,and ,the ,rest ,of ,the ,fingers ,extended ,out. 
7. ,Remain ,in ,this ,position ,for ,a ,period ,of ,time, ,taking ,deep ,breaths, ,as ,many ,as ,possible. 
8. ,In ,case, ,you ,experience ,any ,difficulty ,or ,numbing ,sensation, ,go ,back ,to ,the ,original ,position 
,immediately. 
9. ,While ,practising, ,remember ,to ,alternate ,the ,lead ,leg ,every ,time ,you ,come ,to ,this ,pose. 
 
Padmasana ,(Lotus ,Pose) ,Benefits: 
 
➢ Padmasana ,yoga ,is ,quoted ,as ,the ,“destroyer ,of ,all ,diseases” ,in ,traditional ,texts. 
➢ Helps ,to ,Reduce ,stress ,and ,stay ,calm. 
➢ Help ,to ,stretch ,the ,spine,knees ,and ,ankles. 
Precautions ,For ,Padmasana ,(Yoga ,Lotus ,Pose): 
 
➢ Knee ,injury ,or ,ankle ,injury. 
 
3d.6.Nadi ,sudhi , ,Pranayamam( ,Breathing ,techniques)32 ,: 
 
Pranayamam ,( ,Mochu ,Payirchi) 
Pranayamam ,means ,Controlling ,the ,Prama ,or ,breathe ,. ,“prana” ,+ ,“ayama” ,• ,Prana ,= ,pra 
,(prefix) ,+ ,an ,(to ,breathe, ,to ,live) ,• ,“prana” ,is ,life‐force, ,the ,cosmic ,vital ,energy ,• ,“ayama” 
,means ,to ,stretch, ,expand, ,control ,• ,Pranayama ,is ,to ,expand ,and ,control ,prana ,• ,Breath ,is ,a ,gross 
,manifestation ,of ,prana, ,usually , ,equated ,with ,prana ,equated ,with ,prana ,• ,Breathing ,techniques 
,help ,control ,prana ,in , ,different ,waysywe ,may ,not ,be ,able ,to ,control ,it ,right ,away,but ,bybeing 
,able ,to ,monitor ,your ,breath ,,you ,can ,literally ,place ,your ,life ,in ,your ,own ,hands. 
If ,u ,take ,in ,21,600 ,breaths ,a ,day ,on ,average ,,you ,could ,live ,for120 ,years.if ,u ,breathe ,at ,a 
,faster ,pace,your ,lifespan ,is ,shortened. ,When ,you ,lessen ,the ,number ,of ,inhalations,your ,life 
,spans ,increasese.breath ,goes ,out ,for ,12 ,inches ,and ,goes ,in ,only ,8 ,inches-4 ,inches ,is ,ordinarily , 
,wasted.while ,eating ,18 ,inches ,,walking ,24 ,inches,running ,-42 ,inches,During ,intercourse ,and 
,sleeping ,-50t060 ,inches ,are ,wasted.so ,our ,life ,will ,be ,less ,than ,120 ,years. 
The ,practice ,of , ,Pranayama , ,varies ,from ,person ,to ,person. 
Nadi ,sudhi: ,The ,breath ,taken ,by ,the ,left ,nostril ,is ,known ,as ,Idaikalai ,and ,the ,breath ,taken ,by ,the 
,right ,nostril ,is ,known ,as ,Pingalai. ,Left ,nostril ,breath ,is ,cooling ,and ,Right ,nostril ,breath ,is ,heat. 
,If ,we ,concentrate ,our ,breath, ,it ,flow ,any ,one ,side ,of ,the ,nostril, ,at ,that ,time ,other ,nostril ,won’t 
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,take ,breath. ,After ,sometime ,the ,next ,nostril ,will ,take ,breath ,and ,the ,other ,wont. ,Sometimes 
,both ,of ,the ,nostrils ,will ,take ,breath, ,which ,is ,the ,symptom ,the ,breath ,will ,going ,to ,change ,to ,any 
,one ,nostril. ,Thus ,our ,body ,heat ,will ,be ,spontaneously ,balanced ,by ,these ,alternate ,nostril 
,breathing. 
 




1. Sit ,in ,Padmasana 
2. Keep ,the ,spine ,erect ,and ,your ,head ,and ,neck ,straight 
3. Your ,eyes ,should ,be ,closed 
4. Relax ,the ,muscles ,of ,the ,body ,and ,become ,aware ,of ,your ,breath 
5. At ,no ,point ,during ,the ,exercise ,should ,the ,breath ,be ,controlled ,or ,forced 
6. If ,you ,find ,the ,Padmasana ,pose ,difficult ,to ,maintain, ,you ,can ,practice ,Nadi ,Suddhi 
,breathing ,seated ,on ,a ,chairi ,It ,is ,important ,to ,make ,sure ,that ,your ,feet ,are ,on ,the ,floor ,and 
,your ,back ,is ,straight ,throughout ,the ,time ,you ,are ,in ,this ,posturer 
7. With ,one ,hand, ,let ,your ,fingers ,stretch ,and ,bend ,your ,index ,and ,your ,middle ,fingers ,and 
,place ,them ,on ,the ,palm ,of ,your ,handn 
8. Place ,the ,thumb ,on ,one ,nostril ,and ,the ,tip ,of ,the ,ring ,finger ,against ,the ,other ,nostrili 
9. The ,thumb ,and ,ring ,finger ,will ,be ,used ,to ,close ,alternate ,nostrils ,as ,you ,breatheh 
10. Begin ,the ,exercise ,by ,blocking ,your ,left ,side ,nostril ,and ,breathe ,out ,with ,your ,right ,nostrili 
11. Continue ,to ,block ,your ,left ,nostril ,and ,breathe ,in ,using ,your ,right ,nostrili 
12. Open ,your ,left ,nostril ,as ,you ,simultaneously ,cover ,and ,block ,your ,right ,nostrili ,Breathe ,out 
,slowly ,using ,the ,open ,left ,nostrili 
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13. Once ,this ,is ,done ,go ,ahead ,and ,breathe ,in ,with ,your ,left ,nostril ,that ,is ,opene 
14. Close ,the ,left ,nostril ,and ,let ,the ,air ,move ,out ,through ,your ,right ,nostril ,that ,you ,now ,leave 
,opene 
15. This ,is ,considered ,one ,cyclel ,The ,breathing ,should ,be ,slow ,and ,rhythmici 
16. Continue ,breathing ,this ,way ,by ,opening ,and ,closing ,left ,and ,right ,nostrils ,and ,complete ,ten 
,cycles ,to ,begin ,witht 
17. As ,you ,advance ,in ,your ,practice, ,you ,can ,increase ,the ,duration ,of ,each ,cycle ,and ,the 
,number ,of ,repetitionsn 
As ,a ,beginner, ,Nadi ,Suddhi ,pranayama ,can ,take ,a ,great ,deal ,of ,practice ,and ,concentration ,to 
,mastere ,Try ,and ,focus ,on ,the ,breath ,to ,prevent ,the ,mind ,from ,wanderingn. 
 
Duration: 
Ideally, ,at ,least ,18 ,to ,30 ,rounds ,of ,Alternate ,Nostril ,breathing ,should ,be ,performed ,to ,maximize 
,the ,benefits. 
Benefits 
➢ As ,pure ,oxygenated ,air ,is ,breathed ,into ,the ,lungs ,with ,each ,cycle, ,the ,blood ,gets 
,purified ,and ,circulation ,improvese 
➢ This ,pranayama ,helps ,strengthen ,the ,lungs ,and ,increases ,overall ,lung ,capacity. 
➢ As ,circulation ,improves, ,energy ,levels ,also ,increases 
➢ Nadi ,Suddhi ,pranayama ,can ,help ,with ,weight ,loss ,as ,it ,increases ,the ,rate ,of 
,metabolisms. 
➢ It ,helps ,calm ,the ,nervous ,systeme 
➢ Regular ,practice ,helps ,reduce ,stresss 
➢ It ,can ,improve ,mental ,healtht 
➢ Alternate ,Nostril ,breathing ,can ,help ,remove ,excess ,body ,heata 
➢ It ,can ,help ,improve ,appetitet 
➢ Alternate ,Nostril ,breathing ,can ,help ,reduce ,body ,odoro 




➢ The ,effects ,of ,pranayama ,breathing ,on ,the ,organs ,are ,almost ,instantaneousu 
,Therefore ,it ,is ,extremely ,important, ,to ,practice ,pranayama ,breathing ,exercises ,only 




➢ There ,should ,be ,no ,forced ,or ,strained ,breathing ,during ,the ,exercise, ,as ,this ,can ,prove 
,harmful ,to ,the ,body. 
 
➢ If ,during ,the ,exercise, ,you ,feel ,your ,body ,shaking ,involuntarily ,or ,that ,your ,muscles 
,have ,become ,tense, ,stop ,the ,exercise ,and ,breathe ,normallyl 
➢ If ,you ,suffer ,from ,high ,blood ,pressure, ,you ,should ,avoid ,Alternate ,Nostril 
,breathing. 
 
3d.7.Paschimottanasanam ,(Seated ,Forward ,Bend ,pose) ,33: 
 
Paschimottanasana ,is ,the ,Sanskrit ,word. ,“Paschima” ,means ,your ,“back” ,and 
,“Uttana” ,means ,“stretching“. ,It ,is ,also ,known ,as ,seated ,forward ,bend ,pose. ,This ,asana 






➢ It ,acts ,as ,a ,stress ,reliever. 
➢ Reduces ,fatty ,deposits ,in ,the ,abdomen. 
➢ Remove ,anxiety, ,anger, ,and ,irritability. 
➢ Calms ,the ,mind. 
➢ Stretches ,the ,spine ,and ,brings ,flexibility. 
➢ Good ,for ,constipation ,and ,digestive ,disorder. 
➢ Regular ,practice ,cure ,impotency ,and ,enhance ,the ,sexual ,power. 
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➢ Tones ,the ,abdominal-pelvic ,organs. 
➢ Balance ,the ,menstrual ,cycles. 
➢ This ,asana ,is ,recommended ,especially ,for ,women ,after ,delivery. 
Steps ,: 
Sit ,down ,straight ,with ,your ,legs ,together ,by ,stretching ,in ,front ,of ,you. , ,keep ,your ,head 
,neck ,and ,spine ,erect. 
1. Place ,the ,palms ,on ,your ,respective ,knees. 
2. Now ,bend ,your ,head ,and ,trunk ,slowly ,forward ,to ,catch ,the ,toes ,with ,the ,thumb, ,index ,and 
,middle ,fingers ,without ,bending ,knees. 
3. Take ,a ,deep ,breath ,and ,exhale ,slowly. ,Try ,to ,touch ,your ,head ,to ,your ,both ,knees. 
4. Bend ,the ,arm ,and ,try ,to ,touch ,the ,elbow ,on ,the ,floor. 
5. Exhale ,completely ,and ,holding ,out ,your ,breath ,stay ,in ,this ,posture ,for ,a ,few ,seconds. 
6. After ,few ,seconds ,slowly ,return ,to ,your ,starting ,position. 
7. breathe ,normally. 
8. Repeat ,this ,for ,3-4 ,times. 
Precautions ,: 
➢ Pregnant ,women ,should ,not ,practice ,Paschimottanasana. 
➢ A ,person ,suffering ,from ,slip ,disc ,or ,sciatica ,problem, ,asthma ,should ,avoid 
,Paschimottanasana. 






















1. First, ,lie ,down ,on ,your ,stomach ,and ,stretch ,your ,hands ,forward. 
2. Before ,going ,to ,next ,steps, ,breathe ,normally ,for ,few ,seconds ,to ,let ,your ,body ,relax. 
3. Now ,while ,inhaling ,raise ,your ,upper ,body ,up ,as ,shown ,in ,above ,image. 
4. Place ,your ,chin ,in ,your ,palms ,and ,keep ,breathing ,deeply. 
5. Hold ,this ,position ,for ,few ,minutes. 
6. Now ,while ,exhaling ,release ,your ,pose. ,Remove ,your ,palms ,and ,bring ,down ,your 
,shoulders ,and ,chin ,on ,the ,ground. 
7. Repeat ,this ,for ,few ,more ,times. 
Benefits 
➢ It ,is ,an ,excellent ,yoga ,exercise ,for ,relieving ,back ,pain. 
➢ Effective ,to ,reduce ,stress, ,anxiety, ,and ,depression. 
➢ Improves ,blood ,circulation. 
➢ Much ,effective ,to ,prevent ,constipation ,and ,indigestion. 
➢ Beneficial ,in ,the ,treatment ,of ,high ,blood ,pressure ,and ,heart ,disease. 
➢ Stretches ,your ,spine ,and ,brings ,flexibility. 
Precautions 
➢ Those ,who ,are ,suffering ,from ,serious ,back ,pain, ,neck ,and ,beck ,injuries ,should ,not 
,practice. 





4.MATERIALS ,AND ,METHODS 
4.1.METHODOLOGY ,: , 
 , , , , , , , , , , , , , , ,STUDY ,TYPE , , , , , , , , , , ,: , , , ,A ,preclinical ,and ,clinical ,study. 
 , , , , , , , , , , , , , , ,STUDY ,DESIGN , , , , , , , 
 , , , , , , , , , , , , , , ,Study ,Place , , , , , , , , , , , , , , , ,: , , ,,OPD ,and ,IPD ,of ,Ayothidoss ,Pandithar ,Hospital, , 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,       National ,Institute ,of ,Siddha, 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,       ,Tambaram ,Sanatorium, ,Chennai ,- ,47. , 
 , , , , , , , , , , , , , , ,Study ,Period , , , , , , , , , , , , , ,: , , , ,18 ,Months 
 , , , , , , , , , , , , , , ,Year , , , , , , , , , , , , , , , , , , , , , , , , ,       , , ,: , , , ,2016-2019. 
 , , , , , , , , , , , , , , ,Sample ,Size , , , , , , , , , , , , , , , , ,: , , , ,40 ,patients , ,(20 ,Patients ,in ,OPD ,and ,20 ,Patients ,in ,IPD) 
 
4.2.TRAIL ,DRUG ,: 
 , ,Internal ,Medicine , , , , , , , , , , , , , , , , , , , , , , , , ,              ,: , Parangipattai ,kudineer ,(PPK)35 
Dosage   : ,30 ,ml ,, ,Three ,times ,a ,day ,(Before ,food) 
Duration ,of ,Treatment : , ,4 ,8 ,days 
Reference   : , ,Pharmacopoeia ,of ,hospital ,of ,Indian ,medicine 
Page ,.No   : , ,3 
Edition   : , ,2nd ,edition ,1995 
Edited ,& ,Publish ,by , , , , , , , , , , ,        , ,: , Directorate ,of ,Indian ,medicine ,& ,Homeopathy. 
 , ,External ,Medicine , , , , , , , , , , , , , , , , , , , , , , , ,              , ,: ,Sivappu ,Thylam36 
Reference   : ,Pharmacopoeia ,of ,hospital ,of ,Indian ,medicine 
Page.No   : ,33  
Edition   : ,2nd ,edition ,1995 
Dosage   : ,Required ,quantity , ,(Local ,application) 
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4.3..Standard ,Operating ,Procedure: 
Source ,of ,raw ,drugs: 
The ,required ,raw ,drugs ,for ,the ,trial ,medicine , ,purchased ,from ,a ,well ,reputed ,country 
,raw ,drug ,shop ,and ,drugs ,was ,authenticate ,by ,the ,competent ,authority ,Medicinal ,Botany ,and 
,CCRS. ,After ,that ,the ,raw ,drugs ,was ,purified ,separately ,then ,the ,trial ,drugs ,prepared ,in 
,Gunapadam ,laboratory ,of ,National ,Institute ,of ,Siddha. 
  
4.4.1..INTERNAL ,DRUG: ,PARANGIPATTAI , ,KUDINEER 
Ingredients: 
1.Parangipattai ,(Smilax ,chin. ,Linn.)  , , , , , , , , , ,---1.000kg 
2.Kadugu ,Rohini ,(Picrorhiza ,kurroa.Royle ,) , , , , , , , ,---1.000kg 
3.Manjitti ,(Rubia ,cordifolia.Linn.)   , , , , , ,---1.000kg 
4.Mara ,Manjal ,(Coscinium ,fenestratum.Colebr.)---1.000kg 
5.Kadukkai ,(Terminalia ,chebula.Retz.)  , , , , , ,---1.000kg 
6.Thandrikai ,(Terminalia ,bellarica.Roxb)  , , , , , ,---1.000kg 
7.Vasambu ,(Acorus ,calamus.Linn.)   , , , , , ,---1.000kg 
8.Sombu ,(Pimpinella ,anisum.Linn)   , , , , ,---1.000kg 
9.Veppampattai ,(Azadirachta ,indica.A.Juss) , , , , ,---1.000kg  













Figure.4.1..Image ,of ,ingredients ,of ,Parangipattai ,Kudineer 
1.  ,2.  3.  
4 5.  
6 7. 8. 9
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1.Smilax ,china.Linn ,2.Picrorhiza ,kurroa.Royle ,3.Rubia ,cordifolia.Linn 
4.Coscinium ,fenestratum.Colebr ,5.Terminalia ,chebula.Retz ,6.Terminalia ,bellerica.Roxb 






4.4.2..METHOD ,OF ,PURIFICATION ,OF ,RAW ,DRUGS: , , 
 , , , , , ,
 
1. Parangipattai ,(Smilax ,china ,Linn.) 
It ,should ,be ,cleaned ,with ,white ,cloth ,then , ,the ,outer ,layer ,of ,parangipattai ,root ,bark ,to 
,be ,peeled ,out.(Ref: ,Sigicharathina ,theebam:28) , , , , 
2. Kadugu ,Rohini ,(Picrorhiza ,kurroa.Royle. ,)  
 It ,should ,be ,soaked ,in ,the ,neemleaf , ,juice , ,for ,3 ,hours ,and ,it ,should ,be ,dried ,under 
,sunlight.(Ref: ,Sigicharathina ,theebam:30) 
3. Manjitti ,(Rubia ,cordifolia.Linn.) , , 
It , ,should ,be ,dried ,under , ,sunlight.(Ref: ,Sigicharathina ,theebam:30) , , , , , 
4. Mara ,Manjal ,(Coscinium ,fenestratum.Colebr) , 
  ,The ,outer ,skin ,should ,be ,removed.(Ref: ,Sigicharathina ,theebam:29) , , , , , 
5. Kadukkai( ,Terminalia ,chebula.Retz) , , , 
 ,The ,seed ,removed ,and ,rinds ,alone ,to ,be ,used ,for ,preparation.(Ref:Sigicharathina 
theebam:30) , , , , , 
6. Thandrikai( ,Terminalia ,bellarica.Roxb) , , , 
 , , , , , , , ,The ,seed ,removed ,and ,rinds ,alone ,to ,be ,used ,for ,preparation.(Ref: ,Sigicharathina 
,theebam:30) , , , 
7. Vasambu( ,Acorus ,calamus.Linn) , , , 
 , , , , ,, ,It ,should ,be ,cleaned ,with ,white ,cloth ,then , ,the ,outer ,layer ,of ,vasambu ,root ,bark ,to ,be 
,peeled ,out ,(Ref: ,Sigicharathina ,theebam:30) , , , , 
8. Sombu ,( ,Foeniculum ,vulgare.Linn) , , , 
 , , , ,      ,It ,should ,be ,dried ,for ,six ,hours ,under ,sunlight. , ,(Ref: ,Sigicharathina ,theebam:29) 
9. Veppampattai( ,Azadirachta ,indica ,.A.Juss.) , , , 
 , , , , , , ,It ,should ,be ,cleaned ,with ,white ,cloth ,then , ,the ,outer ,layer ,of ,veppampattai’s ,bark ,to ,be 
,peeled ,out.(Ref: ,Sigicharathina ,theebam:28) , , , 
10. Seendhil( ,Tinospora ,cordifolia ,.Miers.) 






4.4.3.METHOD ,OF ,PREPARATION: , 
 ,All ,the ,drugs ,was ,purified ,and ,crushed ,into ,coarse ,powder. , ,Then ,adding ,8 ,times ,of ,water ,with 
,the ,coarse ,powder ,before ,boiling. ,Preparing ,the ,decoction ,by ,reduced , ,it ,into ,1/8. , 
 
Figure.4.2..Image ,of ,Pepared ,PPK 
4.4.4.Dosage             : ,30ml ,, ,Three ,times ,a ,day ,(Before ,food). 
4.4.5...Route ,of ,administration , , , , , , ,: ,Per ,oral 
4.4.6...Duration ,of ,Treatment , , , , , , , , ,: ,48 ,days. 









4.5.EXTERNAL ,MEDICINE: , ,SIVAPPU , ,THYLAM 
4.5.1.Ingredients ,of ,Sivappu , ,thylam ,: 
1. ,Pungan ,Ver ,(Pongamia ,pinnata ,Pierre.) , , , , , , , , ,-- ,4kg , , 
2. ,Manjitti ,(Rubia ,cordifolia ,Linn.) , , , , , , , , , , , , , , , , , ,      , , ,-- ,62.5gm , , 
3. ,Nannari ,(Hemidesmus ,indicus ,R.Br.) , , , , , , , , , , , , , ,-- ,62.5gm , 
 ,4. ,Manjal ,Mezhugu ,(Cera ,wax) , , , , , , , , , , , , , , , , , , , , , , , , ,     , -- ,62.5gm , , 
5. ,Vellai ,Kungiliyam ,(Vateria ,indica ,Linn.) , , , ,  , ,-- ,62.5gm , , 
6. ,Chevvallikkodi ,(Dioscorea ,purpurea) , , , , , , , , , , , ,-- ,20gm , , 
7. ,Surul ,Pattai ,(Cinnamomum ,verum.Juss.) , , , , , ,-- ,30gm , , 
8. ,Coconut ,Oil ,(Cocos ,nucifera ,Linn.) , , , , , , , , , , ,         , ,-- ,1 ,Lr , 





















4.5.2.METHOD ,OF ,PREPARATION ,: , 
 , , , , , , , , , , , , ,The ,Manjitti, ,Nannari, ,Chevvallikodi, ,PunganVer ,and ,adding ,8 ,times ,of ,water ,then 
,boiled. ,Prepare ,the ,decoction ,by ,reduced ,it ,into ,1/8.Then ,equal ,quantity ,of ,oil ,should ,be ,mixed 
,with ,the ,decoction ,and ,again ,to ,be ,boil.The ,yellow ,wax ,should ,be ,cut ,into ,pieces ,and ,added 
,them ,into ,the ,melted ,thick ,consistency. ,After ,melting, ,it ,will ,be ,taken ,from ,the ,oven ,in ,the 
,texture ,of ,sand. , ,Then ,the ,pulverized ,Surulpattai ,(lavangapattai) ,added ,into ,it ,and ,stirr 
,well.Then ,filter ,and ,keep ,it ,for ,use. 
 
 
Figure.4.4.Image ,of ,Pepared ,Sivappu ,thylam 
 
4.5.3.Dosage     : ,Required ,quantity , ,(Local ,application) 
4.5.4.Duration ,of ,Treatment  : ,48 ,days. 
4.5.5.Indications                      : ,All ,skin ,diseases. , 
4.5.6.Drug ,Storage: 
The ,trial ,drug ,Parangipattai ,Kudineer ,powder ,is ,stored ,in ,clean ,and ,dry ,container. 
,Sivappu ,Thylam ,is ,stored ,in ,clean ,and ,dry ,narrow ,mouthed ,bottles. 
4.6.Dispensing: 
The ,Parangipattai ,Kudineer ,powder ,10gram/time ,is ,given ,in ,packets ,and ,Sivappu 
,Thylam ,quantity ,sufficient ,is ,given ,in ,bottles. 
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4.7.ANALYTICAL ,SPECIFICATION ,FOR ,CHOORANAM 
4.7a.PHYSIOCHEMICAL ,ANALYSIS41,42 ,: , 
4.7a.1.Loss ,On ,Drying: 
 An ,accurately ,weighed ,2g ,of ,parangipattai ,kudineer ,chooranam ,formulation ,was ,taken 
,in ,a ,tarred ,glass ,bottle. ,The ,crude ,drug ,was ,heated ,at ,1050 ,C ,for ,6 ,hours ,in ,an ,oven ,till ,a ,constant 
,weight. ,The ,percentage ,moisture ,content ,of ,the ,sample ,was ,calculated ,with ,reference ,to ,the 
,shade ,dried ,material. 
4.7a.2. ,Determination ,of ,total ,ash: 
 Weighed ,accurately ,2g ,of ,parangipattai ,kudineer ,chooranam ,formulation ,was ,added ,in 
,crucible ,at ,a ,temperature ,6000 ,C ,in ,a ,muffle ,furnace ,till ,carbon ,free ,ash ,was ,obtained. ,It ,was 
,calculated ,with ,reference ,to ,the ,air ,dried ,drug. 
4.7a.3. ,Determination ,of ,acid ,insoluble ,ash: 
 Ash ,above ,obtained, ,was ,boiled ,for ,5 ,min ,with ,25ml ,of ,1 ,M ,hydrochloride ,and ,filtered 
,using ,an ,ash ,less ,filter ,paper. ,Insoluble ,matter ,retained ,on ,filter ,paper ,was ,washed ,with ,hot 
,water ,and ,filter ,paper ,was ,burnt ,to ,a ,constant ,weight ,in ,a ,muffle ,furnace. ,The ,percentage ,of ,acid 
,insoluble ,as ,was ,calculated ,with ,reference ,to ,the ,air ,dried ,drug. 
4.7a.4. ,Determination ,of ,water ,soluble ,ash: 
 Total ,ash ,1g ,was ,boiled ,for ,5min ,with ,25ml ,water ,and ,insoluble ,matter ,collected ,on ,an 
,ash ,less ,filter ,paper ,was ,washed ,with ,hot ,water ,and ,ignited ,for ,15min ,at ,a ,temperature ,not 
,exceeding ,4500 ,C ,in ,amuffle ,furnace. ,The ,amount ,of ,soluble ,ash ,is ,determined ,by ,drying ,the 
,filtrate. 
4.7a.5. ,Determination ,of ,water ,soluble ,extractive: 
  ,5gm ,of ,air ,dried ,drug, ,coarsely ,powered ,parangipattai ,kudineer ,chooranam ,was 
,macerated ,with ,100ml ,of ,distilled ,water ,in ,a ,closed ,flask ,for ,twenty-four ,hours, ,shaking 
,frequently. ,Solution ,was ,filtered ,and ,25ml ,of ,filtered ,and ,25ml ,of ,filtrated ,was ,evaporated ,in ,a 
,tarred ,flat ,bottom ,shallow ,dish, ,further ,dried ,at ,1000 ,C ,and ,weighted. ,The ,percentage ,of ,water 
,soluble ,extractive ,was ,calculated ,with ,references ,to ,the ,sir ,dried ,drugs. 
4.7a.6. ,Determination ,of ,alcohol ,soluble ,extractive: 
 2.5gm ,of ,air ,dried ,drugs, ,coarsely ,powdered ,parangipattai ,kudineer ,chooranam ,was 
,macerated ,with50ml. ,The ,alcohol ,in ,closed ,flak ,for ,24 ,hrs. ,With ,frequent ,shaking, ,it ,was 
,filtered ,rapidly ,taking ,precaution ,against ,loss ,of ,alcohol. ,10ml ,of ,filtrate ,was ,then ,evaporated ,in 
,a ,tarred ,flat ,bottom ,shallow ,dish, ,dried ,at ,1000 ,C ,and ,weighted. ,The ,percentage ,of ,alcohol 
,soluble ,extractive ,was ,calculated ,with ,reference ,to ,air ,dried ,drug. , 
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4.7a.7.Determination ,of ,pH 
About ,5 ,g ,of ,test ,sample ,will ,be ,dissolved ,in ,25ml ,of ,distilled ,water ,and ,filtered ,the 
,resultant ,solution ,is ,allowed ,to ,stand ,for ,30 ,mins ,and ,the ,subjected ,to ,pH ,evaluation 
4.7a.8.Particle ,Size ,Determination ,37,38 ,: , 
       Particle ,Size ,for ,the ,Test ,Sample- ,PKC ,determined ,by ,Electron ,Microscopic ,Observation. 
4.7a.9.Microbiological ,contaminant ,study ,:  
Sterility ,test ,by ,pour ,plate ,method ,: 
Objective , 
The ,pour ,plate ,techniques ,were ,adopted ,to ,determine ,the ,sterility ,of ,the ,product. 
,Contaminated ,/ ,un ,sterile ,sample ,(formulation) ,when ,come ,in ,contact ,with ,the ,nutrition ,rich 
,medium ,it ,promotes ,the ,growth ,of ,the ,organism ,and ,after ,stipulated ,period ,of ,incubation ,the 
,growth ,of ,the ,organism ,was ,identified ,by ,characteristic ,pattern ,of ,colonies. ,The ,colonies ,are 
,referred ,to ,as ,Colony ,Forming ,Units ,(CFUs). , , 
Methodology 
Test ,sample ,was ,admixed ,with ,sterile ,distilled ,water ,and ,the ,mixture ,were ,been ,used ,for 
,the ,sterility ,evaluation. ,About ,1ml ,of ,the ,test ,sample ,was ,inoculated ,in ,sterile ,petri ,dish ,to 
,which ,about ,15 ,mL ,of ,molten ,agar ,45oC ,were ,added. ,Agar ,and ,sample ,were ,mixed ,thoroughly 
,by ,tilting ,and ,swirling ,the ,dish. ,Agar ,was ,allowed ,to ,completely ,gel ,without ,disturbing ,it. 
,(about ,10 ,minutes). ,Plates ,were ,then ,inverted ,and ,incubated ,at ,37o ,C ,for ,24-48 ,hours. ,Grown 
,colonies ,of ,organism ,was ,then ,counted ,and ,calculated ,for ,CFU. 
4.7a.10.TLC ,& ,HPTLC ,analysis ,of ,aqueousextract ,of ,Parangipattai ,Kudineer 
,Chooranam ,(PKC)39: 
TLC ,Analysis 
Test ,sample ,was ,subjected ,to ,thin ,layer ,chromatography ,(TLC) ,as ,per ,conventional ,one 
,dimensional ,ascending ,method ,using ,silica ,gel ,60F254, ,7X6 ,cm ,(Merck) ,were ,cut ,with 
,ordinary ,household ,scissors. ,Plate ,markings ,were ,made ,with ,soft ,pencil. ,Micro ,pipette ,were 
,used ,to ,spot ,the ,sample ,for ,TLC ,applied ,sample ,volume ,10-micro ,liter ,by ,using ,pipette ,at 
,distance ,of ,1 ,cm ,at ,5 ,tracks. ,In ,the ,twin ,trough ,chamber ,with ,the ,specified ,solvent ,system ,After 
,the ,run ,plates ,are ,dried ,and ,was ,observed ,using ,visible ,light ,Short-wave ,UV ,light ,254nm ,and 






High ,Performance ,Thin ,Layer ,Chromatography ,Analysis40 
HPTLC ,method ,is ,a ,modern ,sophisticated ,and ,automated ,separation ,technique ,derived 
,from ,TLC. ,Pre-coated ,HPTLC ,graded ,plates ,and ,auto ,sampler ,was ,used ,to ,achieve ,precision, 
,sensitive, ,significant ,separation ,both ,qualitatively ,and ,quantitatively. ,High ,performance ,thin 
,layer ,chromatography ,(HPTLC) ,is ,a ,valuable ,quality ,assessment ,tool ,for ,the ,evaluation ,of 
,botanical ,materials ,efficiently ,and ,cost ,effectively. ,HPTLC ,method ,offers ,high ,degree ,of 
,selectivity, ,sensitivity ,and ,rapidity ,combined ,with ,single-step ,sample ,preparation. ,Thus ,this 
,method ,can ,be ,conveniently ,adopted ,for ,routine ,quality ,control ,analysis. ,It ,provides 
,chromatographic ,fingerprint ,of ,phytochemicals ,which ,is ,suitable ,for ,confirming ,the ,identity 
,and ,purity ,of ,phytotherapeutics. , 
Chromatogram ,Development 
It ,was ,carried ,out ,in ,CAMAG ,Twin ,Trough ,chambers. ,Sample ,elution ,was ,carried ,out 
,according ,to ,the ,adsorption ,capability ,of ,the ,component ,to ,be ,analyzed. ,After ,elution, ,plates 
,were ,taken ,out ,of ,the ,chamber ,and ,dried. 
Scanning 
Plates ,were ,scanned ,under ,UV ,at ,366nm. ,The ,data ,obtained ,from ,scanning ,were ,brought 
,into ,integration ,through ,CAMAG ,software. ,Chromatographic ,finger ,print ,was ,developed ,for 
,the ,detection ,of ,phytoconstituents ,present ,in ,each ,sample ,and ,their ,respective ,Rf ,values ,were 
,tabulated. 
 
7a.1.11.Heavy ,Metal ,Analysis ,by ,AAS41,42 
Standard: ,Hg, ,As, ,Pb ,and ,Cd ,– ,Sigma 
Methodology 
Atomic ,Absorption ,Spectrometry ,(AAS) ,is ,a ,very ,common ,and ,reliable ,technique 
,for ,detecting ,metals ,and ,metalloids ,in ,environmental ,samples. ,The ,total ,heavy ,metal 
,content ,of ,the ,sample ,was ,performed ,by ,Atomic ,Absorption ,Spectrometry ,(AAS) ,Model 
,AA ,240 ,Series. ,In ,order ,to ,determination ,the ,heavy ,metals ,such ,as ,mercury, ,arsenic, ,lead 
,and ,cadmium ,concentrations ,in ,the ,testitem. 
Sample ,Digestion 
Test ,sample ,was ,digested ,with ,1mol/L ,HCl ,for ,determination ,of ,arsenic ,and 
,mercury. ,Similarly ,for ,the ,determination ,of ,lead ,and ,cadmium ,the ,sample ,were 




As ,& ,Hg- ,100 ,ppm ,sample ,in 
,1mol/L ,HCl ,Cd ,& ,Pb- ,100 
,ppm ,sample ,in ,1mol/L 
,HNO3 
4.7a.11..Pesiticide ,Residue41,42 ,: , 
Extraction , 
 Test ,sample ,were ,extracted ,with ,100ml ,of ,acetone ,and ,followed ,by ,homogenization ,for 
,brief ,period ,.Further ,filtration ,was ,allowed ,and ,subsequent ,addition ,of ,acetone ,to ,the ,test 
,mixture. ,Heating ,of ,test ,sample ,was ,performed ,using ,a ,rotary ,evaporator ,at ,a ,temperature ,not 
,exceeding ,40ºC ,until ,the ,solvent ,has ,almost ,completely ,evaporated. ,To ,the ,residue ,add ,a ,few 
,millimetres ,of ,toluene ,R ,and ,heat ,again ,until ,the ,acetone ,is ,completely ,removed. ,Resultant 
,residue ,will ,be ,dissolved ,using ,toluene ,and ,filtered ,through ,membrane ,filter. 
4.7a .12.Test ,for ,Specific ,Pathogen41,42 
Methodology 
One ,part ,of ,the ,test ,sample ,was ,dissolved ,in ,9 ,mL ,of ,sterile ,distilled ,water ,and ,the ,test 
,sample ,was ,directly ,inoculated ,in ,to ,the ,specific ,pathogen ,medium ,(EMB, ,DCC, ,Mannitol 
,,Cetrimide) ,by ,pour ,plate ,method. ,The ,plates ,were ,incubated ,at ,37oC ,for ,24 ,- ,72h ,for 
,observation. ,Presence ,of ,specific ,pathogen ,identified ,by ,their ,characteristic ,colour ,with ,respect 
,to ,pattern ,of ,colony ,formation ,in ,each ,differential ,media. 
Detail ,of ,Specific ,Medium ,and ,their ,abbreviation 
Organism Abbreviation Medium , 
E-coli EC EMB ,Agar 
Salmonella SA Deoxycholate ,agar 
Staphylococcus ,Aureus ST Mannitol ,salt ,agar 























Standard ,samples ,was ,dissolved ,in ,a ,mixture ,of ,chloroform ,and ,acetonitrile ,(9.8 ,: ,0.2) 
,to ,obtain ,a ,solution ,having ,concentrations ,of ,0.5 ,µg ,per ,ml ,each ,of ,aflatoxin ,B1 ,and ,aflatoxin 
,G1 ,and ,0.1 ,µg ,per ,ml ,each ,of ,aflatoxin ,B2 ,and ,aflatoxin ,G2. 
Test ,solution: ,Concentration ,1 ,µg ,per ,ml 
Procedure 
Standard ,aflatoxin ,was ,applied ,on ,to ,the ,surface ,to ,pre ,coated ,TLC ,plate ,in ,the ,volume ,of ,2.5 
,µL, ,5µL, ,7.5 ,µL ,and ,10 ,µL. ,Similarly ,the ,test ,sample ,was ,placed ,and ,Allow ,the ,spots ,to ,dry ,and 
,develop ,the ,chromatogram ,in ,an ,unsaturated ,chamber ,containing ,a ,solvent ,system ,consisting ,of ,a 
,mixture ,of ,chloroform, ,acetone ,and ,isopropyl ,alcohol ,(85 ,: ,10 ,: ,5) ,until ,the ,solvent ,front ,has ,moved ,not 
,less ,than ,15 ,cm ,from ,the ,origin. ,Remove ,the ,plate ,from ,the ,developing ,chamber, ,mark ,the ,solvent ,from 
,and ,allow ,the ,plate ,to ,air-dry. ,Locate ,the ,spots ,on ,the ,plate ,by ,examination ,under ,UV ,light ,at ,365nm. 
4.7b.Chemical ,Method ,Of ,Testing: 
4.7b.1. ,Phytochemical ,Analysis: , , 
The ,following ,preliminary ,phytochemical ,investigations ,of ,extract ,were ,performed ,by 
,the ,standard ,methods ,(Harborne, ,1973; ,Markham, ,1982; ,Kokate, ,1994). 
PRELIMINARY ,PHYTOCHEMICAL ,SCREENING ,-PPK , 
The ,preliminary ,photochemical ,screening ,test ,was ,carried ,out ,for ,each ,extracts ,of ,parangipattai 
,kudineer ,chooranam ,as ,per ,the ,standard ,procedure. 
4.7b.1.1. ,Detection ,of ,alkaloids: 
Extracts ,were ,dissolved ,individually ,in ,dilute ,hydrochloride ,acid ,and ,filtered , 
a) Mayer’s ,test: ,Filter’s ,were ,treated ,with ,Mayer’s ,reagent ,(potassium ,mercuric ,iodide). 
,Formation ,of ,a ,yellow ,coloured ,precipitate ,indicates ,the ,presence ,of ,alkaloids. 
b) Wager’s ,test: ,Filter’s ,were ,treated ,with ,wager’s ,reagent ,(Iodine ,in ,Potassium ,Iodine). 
,Formation ,of ,brown/reddish ,precipitate ,indicates ,the ,presence ,of ,alkaloids. 
c) Dragendroff’s ,test: ,Filter’s ,were ,treated ,with ,Dragendroff’s ,reagent ,(solution ,of 




d) Hager’s ,test: ,Filter’s ,were ,treated ,with ,Hager’s ,reagent ,(saturated ,picric ,acid ,solution). 
,Presence ,of ,alkaloids ,confirmed ,by ,the ,formation ,of ,yellow ,colored ,precipitate. 
4.7b.1.2. ,Detection ,of ,carbohydrates: 
Extracts ,were ,dissolved ,individually ,in ,5 ,ml ,distilled ,water ,and ,filtered. ,The ,filtrates ,were ,used 
,to ,test ,for ,the ,presence ,of ,carbohydrates. 
a) Molisch’s ,test: , 
To ,2 ,ml ,of ,plant ,sample ,extract, ,two ,drops ,of ,alcoholic ,solution ,of ,- ,naphthol ,are ,added. ,The 
,mixture ,is ,shaken ,well ,and ,a ,few ,drops ,of ,concentrated ,sulphuric ,acid ,is ,added ,slowly ,along 
,the ,sided ,of ,test ,tube. ,A ,violet ,ring ,indicates ,the ,presence ,of ,carbohydrates. 
b) Benedict’s ,test: 
Filtrates ,were ,treated ,with ,Benedict’s ,reagent ,and ,the ,heated ,gently. ,Orange ,red ,precipitate 
,indicates ,the ,presence ,of ,reducing ,sugars. 
4.7b.1.3. ,Detection ,of ,glycoside: 
Extract ,were ,hydrolyzed ,with ,dil.HCL, ,and ,then ,subjected ,to ,test ,for ,glycoside. 
a) Modified ,borntrager’s ,test: ,Extract ,were ,treated ,with ,ferric ,chloride ,solution ,and 
,immersed ,in ,boiling ,water ,for ,about ,5 ,minutes ,. ,The ,mixture ,was ,cooled ,and ,extracted 
,with ,equal ,volumes ,of ,benzene. ,The ,benzene ,layer ,was ,separated ,and ,treated ,with 
,ammonia ,solution. ,Formation ,of ,rose-pink ,color ,in ,the ,ammonical ,layer ,indicates ,the 
,presence ,of ,anthranol ,glycosides. 
b) Cardiac ,glycoside ,(keller ,-killiani ,test):Extract ,was ,shaken ,with ,distilled ,water ,(5 ,ml), 
,To ,this ,, ,glacial ,acetic ,acid ,(2ml) ,containing ,a ,few ,drops ,of ,ferric ,chloride ,was ,added, 
,followed ,by ,H2SO4 ,(1 ,ml) ,along ,the ,side ,of ,the ,test ,tube. ,The ,formation ,of ,brown ,ring 
,at ,the ,interface ,gives ,indication ,for ,cardiac ,glycoside ,and ,a ,violet ,ring ,may ,appear 
,below ,the ,brown ,ring. 
4.7b.1.4. ,Detection ,of ,saponins: 
a) Froth ,test: ,Extracts ,were ,diluted ,with ,distilled ,water ,to ,20ml ,and ,this ,was ,shaken ,in ,a 
,graduated ,cylinder ,for ,15 ,minutes. ,Formation ,of ,1 ,cm ,layer ,of ,foam ,indicates ,the 
,presence ,of ,saponins. 
b) Foam ,test: ,0.5gm ,of ,extract ,was ,shaken ,with ,2ml ,of ,water. ,If ,foam ,produced ,persists 




4.7b.1.5.Detection ,of ,phytosterols: 
a) Salkowski.s ,test: ,Extract ,were ,treated ,with ,chloroform ,and ,filtered. ,The 
,filtrates ,were ,treated ,with ,few ,drops ,of ,conc. ,sulphuric ,acid, ,shaken ,and ,allowed 
,to ,stand. ,Appearance ,of ,golden ,yellow ,colour ,indicates ,the ,presence ,of 
,triterpenes. 
4.7b.1.6. ,Detection ,of ,phenols ,ferric ,chloride ,test: 
 ,Extracts ,were ,treated ,with ,3-4 ,drops ,of ,ferric ,chloride ,solution. ,Formation ,of ,bluish ,black 
,colour ,indicates ,the ,presence ,of ,phenols. 
4.7b.1.7. ,Detection ,of ,tannins ,gelatin ,test: 
The ,extract ,is ,dissolved ,in ,5 ,ml ,of ,distilled ,water ,and ,2 ,ml ,of ,1% ,soluti0on ,of ,gelatine 
,containing ,10% ,Nacl ,is ,added ,to ,it. ,White ,precipitate ,indicates ,the ,presence ,of ,phenolic 
,compounds. 
4.7b.1.8. ,Detection ,of ,Flavanoids: 
a) Alkaline ,reagent ,test: ,Extracts ,were ,treated ,with ,few ,drops ,of ,sodium 
,hydroxide ,solution. ,Formation ,of ,intense ,yellow ,color, ,which ,becomes 
,colourless ,on ,addition ,of ,dilute ,acid, ,indicates ,the ,presence ,of ,flavanoids. 
b) Lead ,acetate ,test: ,Extract ,were ,treated ,with ,few ,drops ,of ,lead ,acetate ,solution 
,of ,yellow ,color ,precipitate ,indicates ,the ,presence ,of ,flavanoids. 
4.7b.1.9. ,Detection ,of ,proteins ,and ,amino ,acid: 
a) Xanthoproteic ,test: ,The ,extracts ,were ,treated ,with ,few ,drops ,of ,conc. ,Nitric ,acid. 
,Formation ,of ,yellow ,color ,indicates ,the ,presence ,of ,proteins. 
b) Ninhydrin ,test: ,To ,the ,extract, ,0.25% ,w/v ,ninhydrin ,reagent ,was ,added ,and ,boiled ,for 
,few ,minutes. ,Formation ,of ,blue ,colour ,indicates ,the ,presence ,of ,amino ,acids. 
4.7b.1.10. ,Detection ,of ,diterpenes ,copper ,acetate ,test: 
Extracts ,were ,dissolved ,in ,water ,and ,treated ,with ,3-4 ,drops ,of ,copper ,acetate ,solution. 
,Formation ,of ,emerald ,green ,color ,indicated ,the ,presence ,of ,diterpenes. 
4.7b.1.11. ,Gum ,and ,Mucilage: 
To ,1 ,ml ,of ,extract ,add ,2.5ml ,of ,absolute ,alcohol ,and ,stirring ,constantly. ,Then ,the ,precipitate 
,was ,dried ,in ,air ,and ,examine ,for ,its ,swelling ,properties. ,Swelling ,was ,observed ,that ,will 




4.7b.1.12. ,Test ,for ,fixed ,oils ,and ,fats: 
a) Spot ,test: ,A ,small ,quantity ,of ,extract ,is ,pressed ,between ,two ,filter ,paper. ,Oil ,stain ,on 
,the ,paper ,indicates ,the ,presence ,of ,fixed ,oils. 
4.7b.1.13. ,Test ,for ,quinones: 
Extract ,was ,treated ,with ,sodium ,hydroxide ,blue ,or ,red ,precipitate ,indicates ,the ,presence 
,of ,quinines. 
 The ,preliminary ,phytochemical ,studies ,of ,aqueous ,extract ,of ,parangipattai ,kudineer 
,chooranam ,were ,done ,using ,standard ,procedures. , 
4.7b.2.CHEMICAL ,ANALYSIS ,: 
S.No EXPERIMENT OBSERVATION 
1. Appearance ,of ,sample Dark ,brown ,in 
colour 
2. Test ,for ,Silicate: 
a. A ,little ,(500mg) ,of ,the ,sample ,is ,shaken ,well ,with 
,distilledwater. 
b. A ,little(500mg) ,of ,the ,sampleis 




3. Action ,of ,Heat: 
A ,small ,amount ,(500mg) ,of ,the ,sample ,is ,taken ,in ,a ,dry ,test 






4. Ash ,Test: ,A ,filter ,paper ,is ,soaked ,in ,a ,mixture ,of ,sample ,and 
,dil. ,cobalt ,nitrate ,solution ,and ,introduced ,into ,the ,Bunsen 
,flame ,and ,ignited. 
 











Test ,For ,Acid ,Radicals 
S.No EXPERIMENT OBSERVATION 
1. Test ,For ,Sulphate: 
 
2ml ,of ,the ,above-prepared ,extract ,was ,taken ,in ,a 
,test ,tube ,and ,2ml ,of ,4% ,dil. ,ammonium ,oxalate 
,solution ,was ,added. 
 
No ,Cloudy ,appearance 
2. Test ,For ,Chloride: 
 
2ml ,of ,the ,above-prepared ,extracts ,was ,added 
,with ,2ml ,of ,dil-HNO3 ,until ,the ,effervescence 
,ceases ,off. ,Then ,2 ,ml ,of ,silver ,nitrate ,solution ,was 
,added. 
 
Presence ,of ,Cloudy 
,appearance 
3. Test ,For ,Phosphate: 
 
2ml ,of ,the ,extract ,was ,treated ,with ,2ml ,of 
,con.HNo3 ,and ,2ml ,of ,dil. ,ammonium ,molybdate 
,solution. 
Cloudy ,Yellow ,appearance 
,present 
4. Test ,For ,Carbonate: 
 
2ml ,of ,the ,extract ,was ,treated ,with ,2mldil. 
,magnesium ,sulfate ,solution 
Presence ,of ,Cloudy 
,appearance 
5. Test ,For ,Sulphide: 
 
1gm ,of ,the ,substance ,was ,treated ,with ,2ml ,of ,the 
,con.HCL 
 
Rotten ,Egg ,Smelling ,gas ,was 
,not ,evolved 
6. Test ,For ,Fluoride ,& ,Oxalate: 
 
2ml ,of ,the ,extract ,was ,added ,with ,2ml ,of ,dil. 
,Acetic ,acid ,and ,2ml ,dil. ,calcium ,chloride ,solution 
,and ,heated. 
 







 , ,8. 
Test ,For ,Nitrite: 
3drops ,of ,the ,extract ,was ,placed ,on ,a ,filter ,paper, ,on 
,that-2 ,drops ,of ,dil. ,acetic ,acid ,and ,2 ,drops ,of ,dil. 
,Benzidine ,solution ,was ,placed. , 
Test ,for ,Borate: 
2 ,pinches ,of ,the ,substance ,is ,made ,into ,paste ,by 
,using ,sulphuric ,acid ,and ,alcohol ,(95%) ,and 
,introduced ,into ,the ,blue ,flame 
 , 












Test ,For ,Basic ,Radicals 
 
4. Test ,For ,Iron: 
 
a. To ,the ,2ml ,of ,extract ,add ,2ml ,of ,dil. ,ammoniumsolution 
b. To ,the ,2ml ,of ,extract, ,2ml ,thiocyanate ,solution ,and ,2ml ,of 
,con ,HNo3 ,isadded 
 
 




5. Test ,For ,Zinc: 
In ,2ml ,of ,the ,extract ,dil. ,sodium ,hydroxide ,solution ,was 




White ,precipitate ,was 
,not ,formed 
6. Test ,For ,Calcium: 
2ml ,of ,the ,extract ,was ,added ,with ,2ml ,of ,4% ,dil. ,ammonium 
,oxalate ,solution 
No ,Cloudy ,appearance 
,and ,white ,preciptitate 
,is ,obtained , 
1. Test ,For ,Lead: 
 





,was ,not ,obtained. 
2. Test ,For ,Copper: 
 
One ,pinch ,(50mg) ,of ,substance ,was ,made ,into ,a ,paste ,with ,con. 




The ,blue ,colour 
,precipitate ,formed. 
3. Test ,For ,Aluminium: 
 
In the 2ml of extract dil. sodium ,hydroxide ,was 
,added ,in ,5 ,drops ,toexcess. 
 




7. Test ,For ,Ammonium: 
 
In ,2ml ,of ,extract ,1 ,ml ,of ,Nessler's ,reagent ,and ,excess ,of ,dil. 
















Test ,For ,Potassium: 
 
A ,pinch ,(25mg) ,of ,substance ,was ,treated ,with ,2ml ,of ,dil. ,sodium 
,nitrite ,solution ,and ,then ,treated ,with ,2ml ,of ,dil. ,cobalt ,nitrate ,in 






 ,9 Test ,For ,Sodium: 
 
2 ,pinches ,(50mg) ,of ,the ,substance ,was ,made ,into ,a ,paste ,by 




10 Test ,For ,Mercury: 
 





11 Test ,For ,Arsenic: 
 

















1. Test ,For ,Starch: 
 
2ml ,of ,extract ,was ,treated ,with ,weak ,dil. ,iodine ,solution 
No ,Blue ,colour 
,developed 
2. Test ,For ,Reducing ,Sugar: 
 
5ml ,of ,Benedict's ,qualitative ,solution ,was ,taken ,in ,a ,test ,tube 
,and ,allowed ,to ,boil ,for ,2minutesandadded8to10dropsofthe 
extract ,and ,again ,boil ,it ,for ,2 ,minutes. 
 
The ,was ,no ,specific 
,change ,in ,colour 
3. Test ,For ,The ,Alkaloids: 
 
a) 2ml ,of ,the ,extract ,is ,treated ,with ,2ml ,of ,dil. ,Potassium 
,iodide ,solution. 
b) 2ml ,of ,the ,extract ,is ,treated ,with ,2ml ,of ,dil. ,picricacid. 
 
Reddish ,brown 
,precipitation ,not ,formed 
Yellow ,precipitation 
,formed 
 ,4. Test ,For ,Tannic ,Acid: 
 
2ml ,of ,the ,extract ,was ,treated ,with ,2ml ,of ,dil. ,ferric ,chloride 
,solution 
Black ,precipitate ,not 
,formed 
5. Test ,For ,Amino ,Acid: 
2 ,drops ,of ,the ,extract ,were ,placed ,on ,a ,filter ,paper ,and ,dried 
,well, ,and ,then ,20ml ,of ,Biuret ,reagent ,was ,added ,to ,it. 
Violet ,colour ,not 
,developed 
6. Test ,for ,Type ,of ,Compound: 
2 ,ml ,of ,the ,extract ,is ,treated ,with ,2 ,ml ,of ,ferric ,chloride 
,solution 




4.7c.PHARMACOLOGICAL ,SCREENING ,OF ,PARANGIPATTAI ,KUDINEER 
,CHOORANAM ,: 
4.7c.1.In-vitro ,Anti-Inflammatory ,Activity ,by ,Protein ,(Albumin) ,denaturation ,Assay44,45 
Albumin ,Denaturation ,Assay ,Procedure 
In-vitro ,anti-inflammatory ,activity ,PKC ,was ,studied ,using ,albumin ,denaturation 
,technique. ,The ,reaction ,mixture ,consisted ,of ,bovine ,serum ,albumin ,(5% ,aqueous ,solution) ,and 
,test ,sample ,PKC ,at ,varying ,concentration ,ranges ,from ,100 ,to ,500 ,µg/ml ,and ,standard 
,Diclofenac ,sodium ,at ,the ,concentration ,of ,100 ,µg ,/ml ,of ,final ,volume. ,pH ,was ,adjusted ,by 
,using ,a ,small ,amount ,of ,1N ,Hydrochloric ,acid. ,The ,samples ,were ,incubated ,at ,37°C ,for ,20 ,min 
,and ,then ,heated ,at ,57°C ,for ,3 ,min. ,After ,cooling ,the ,sample, ,2.5 ,ml ,of ,phosphate ,buffer ,solution 
,was ,added ,into ,each ,test ,tube. ,Turbidity ,developed ,was ,measured ,spectrophotometrically ,at 
,660 ,nm, ,for ,control ,distilled ,water ,was ,used ,instead ,of ,test ,sample ,while ,product ,control ,tests 
,lacked ,bovine ,serum ,albumin. ,The ,experiment ,was ,performed ,in ,triplicate. 
 
The ,Percentage ,protection ,from ,denaturation ,is ,calculated ,by ,using ,the ,formulae 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,  
 
4.7c.2.In ,vitro ,Immunomodulatory ,Activity ,of ,Siddha ,formulation , ,Parangipattai 
,Kudineer ,Chooranam ,(PKC) ,in ,RAW ,Macrophage ,Cell ,line46,47 ,: 
Immunomodulatory ,activity , ,Materials ,and ,Methods 
For ,anti-proliferative ,studies, ,serial ,dilutions ,of ,test ,formulation ,(50, ,100 ,and ,200 
,μg/ml) ,were ,prepared. , 
Culture: ,Macrophage ,cell ,line ,RAW ,264.7 
Cell ,culture, ,measurement ,of ,cell ,viability , 
Macrophage ,cell ,line ,RAW ,264.7 ,was ,obtained ,from ,National ,Center ,for ,Cell ,Science 
,(Pune, ,India) ,and ,cultured ,in ,DMEM ,supplemented ,with ,fetal ,bovine ,serum ,(10%) ,containing 
,penicillin-streptomycin ,(10%) ,at ,37°C ,in ,a ,humidified ,atmosphere ,containing ,5% ,CO2. ,Cells 
,were ,plated ,at ,a ,density ,of ,1 ,× ,104 ,cells/well ,in ,25 ,or ,75 ,cm2 ,flasks, ,or ,in ,96-well ,plate 
,overnight. ,RAW ,264.7 ,were ,grown ,to ,60% ,confluence ,followed ,by ,activation ,with ,1 ,µL 
,lipopolysaccharide ,(LPS) ,(1µg/mL). ,LPS ,stimulated ,RAW ,cells ,were ,exposed ,with ,different 
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,concentration ,(50, ,100,200 ,µg/mL) ,of ,the ,test ,sample ,and ,incubated ,for ,24 ,hours. , ,After ,24 
,hours ,of ,incubation, ,the ,cells ,were ,digested ,and ,centrifugation ,was ,done ,at ,6000 ,rpm ,for ,10 
,minutes. ,Supernatant ,was ,discarded ,and ,cells ,were ,then ,resuspended ,in ,200µl ,of ,cell ,lysis 
,buffer ,(0.1M ,TrisHCl, ,0.25M ,EDTA, ,2M ,NaCl, ,0.5 ,% ,Triton ,x-100). , ,The ,samples ,were ,then 
,kept ,at ,4oC ,for ,20 ,minutes. ,After ,incubation, ,the ,Immunomodulatory ,response ,was ,performed 
,by ,estimating ,nitrite ,levels ,in ,the ,cell ,lysate. 
Estimation ,of ,Cellular ,Nitrite ,Levels , 
The ,level ,of ,nitrite ,level ,was ,estimated ,by ,the ,method ,of ,Lee ,et ,al. ,(Lepoivre ,et. ,al. ,1990) 
,To ,0.5 ,mL ,of ,cell ,lysate, ,0.1 ,mL ,of ,sulphosalicylic ,acid ,was ,added ,and ,vortexed ,well ,for ,30 
,minutes. ,The ,samples ,were ,then ,centrifuged ,at ,5,000 ,rpm ,for ,15 ,minutes. ,The ,protein-free 
,supernatant ,was ,used ,for ,the ,estimation ,of ,nitrite ,levels. ,To ,200 ,μL ,of ,the ,supernatant, ,30 ,μL ,of 
,10% ,NaOH ,was ,added, ,followed ,by ,300 ,μL ,of ,Tris-HCl ,buffer ,and ,mixed ,well. ,To ,this, ,530 ,μL 
,of ,Griess ,reagent ,was ,added ,and ,incubated ,in ,the ,dark ,for ,10–15 ,minutes, ,and ,the ,absorbance 
,was ,read ,at ,540 ,nm ,against ,a ,Griess ,reagent ,blank. ,Sodium ,nitrite ,solution ,was ,used ,as ,the 
,standard. ,The ,amount ,of ,nitrite ,present ,in ,the ,samples ,was ,estimated ,from ,the ,standard ,curves 
,obtained. , 
 
4.7c.3.In ,vitro ,Anti-proliferative ,Activity ,of ,Siddha ,formulation ,Parangipattai ,Kudineer 
,Chooranam ,(PKC) ,in ,HaCaT ,cell ,line ,using ,MTT ,assay48,49 ,: 
Anti-proliferative ,activity 
 The ,In ,Vitro ,determinations ,of ,anti-proliferative ,effects ,of ,the ,test ,formulation ,have 
,been ,performed ,by ,counting ,viable ,cells ,after ,staining ,with ,a ,vital ,dye. ,The ,MTT ,system ,is ,a 
,means ,of ,measuring ,the ,activity ,of ,living ,cells ,via ,mitochondrial ,dehydrogenases. ,The ,MTT 
,method ,is ,simple, ,accurate ,and ,yields ,reproducible ,results. ,The ,key ,component ,is ,(3-[4, ,5-
dimethylthiazol-2-yl]-2, ,5-diphenyl ,tetrazolium ,bromide) ,or ,MTT, ,is ,a ,water ,soluble 
,tetrazolium ,salt ,upon ,incubation ,MTT ,is ,converted ,to ,an ,insoluble ,purple ,formazan ,by ,cleavage 
,of ,the ,tetrazolium ,ring ,by ,mitochondrial ,dehydrogenase ,enzymes ,of ,viable ,cells. ,The ,resulting 
,colored , ,solution ,is ,spectrophotometrically ,measured. ,An ,increase ,or ,decrease ,in ,cell ,number 
,results ,in ,a ,concomitant ,change ,in ,the ,amount ,of ,formazan ,formed, ,indicating ,the ,degree ,of 






Preparation ,of ,test ,solutions 
For ,anti-proliferative ,studies, ,serial ,dilutions ,of ,test ,formulation ,(10, ,50, ,100, ,150, ,200 
,and ,250 ,μg/ml) ,were ,prepared. , 
HaCat ,Cell ,culture ,and ,media 
HaCaT ,cell ,lines ,were ,procured ,from ,NCCS, ,stock ,cells ,was ,cultured ,in ,DMEM 
,medium ,supplemented ,0.07 mM ,Ca2+,10% ,heat-inactivated ,fetal ,bovine ,serum, ,glutamine 
,(2 mM), ,penicillin ,(100 U⁄ml), ,and ,streptomycin ,(100 mg⁄ml) ,in ,an ,humidified ,atmosphere ,of 
,5% ,CO2 ,at ,37
oC ,until ,confluent. ,The ,cell ,was ,dissociated ,with ,TPVG ,solution ,(0.2 ,% ,trypsin, 
,0.02 ,% ,EDTA, ,0.05 ,% ,glucose ,in ,PBS). ,The ,viability ,of ,the ,cells ,are ,checked, ,centrifuged ,and 
,was ,seeded ,in ,a ,96 ,well ,plate ,and ,incubated ,for ,24hrs ,– ,7 ,days ,at ,37oC, , ,5% ,CO2 ,incubator. , 
Anti- ,proliferation ,assay , 
For ,anti- ,proliferation ,assay, ,1.25 ,x ,104 ,HaCaT ,cells, ,were ,seeded ,per ,well ,in ,96-well 
,culture ,plates ,and ,incubated ,overnight. ,Growth ,medium ,was ,then ,substituted ,with ,fresh 
,medium ,supplemented ,with ,tested ,compounds ,at ,appropriate ,concentrations. ,Following 
,incubation ,for ,24 ,and ,48 ,hours ,till ,7 ,-days ,(to ,test ,cell ,proliferation), ,medium ,was ,substituted 
,with ,MTT ,solution ,and ,after ,a ,2-hour ,incubation ,at ,37°C ,the ,formazan ,product ,was ,dissolved 
,and ,absorbance ,was ,read ,at ,570 ,nm ,using ,microplate ,reader. ,The ,optical ,density ,of ,formazan 
,formed ,in ,the ,control ,and ,test ,drug ,treated ,wells ,was ,taken ,as ,a ,measure ,of ,cell ,viability. ,IC50 
,was ,calculated ,from ,dose-response ,curves. 
 
 
4.7c.4.Docking ,analysis ,50,51,52,53: 
Objective: 
 , Binding ,of ,lead/ ,drug ,with ,these ,core ,amino ,acids ,by ,forming ,hydrogen ,bond ,will 
,hinders ,the ,functions ,of ,TNF-α, ,IL-6 ,and ,Nitric ,oxide ,synthase, ,since ,these ,are ,the ,core 
,cytokines ,involved ,in ,mediating ,the ,immune ,system. ,Thereby ,lead ,molecules ,which ,halts ,the 








Name ,of ,the ,formulation , , ,: ,Parangipattai ,Kudineer ,Chooranam ,(PKC) 
 
List ,of ,herbs ,present ,in ,the ,formulation 
1.Parangi ,pattai ,(Simlax ,Chin ,Linn) 
2.Kadugu ,Rohini ,(Picrorhiza ,kurroa) 
3.Manjitti ,(Rubia ,Cordifolia) 
4. ,Mara ,Manjal ,(Coscinium ,fenestratum) 
5.Kadukkai ,(Terminalia ,Chebula) 
6.Thandrikai ,(Terminalia ,Bellarica) 
7.Vasambu ,(Acorus ,Calamus) 
8.Sombu ,(Pimpinella ,Anisum) 
9.Veppampattai ,(Azardirachta ,Indica) 
10.Seendhil ,(Tinospora ,Cordifolia) 
 
 
List ,of ,Phytocomponents ,Selected ,for ,docking 
 
Herbs Phyto ,components References 
1.Parangi ,pattai ,(Simlax 
,Chin ,Linn) 
Protocatechuic ,acid, 






















 Docking ,calculations ,were ,carried ,out ,using ,Auto ,Dock ,4. ,Gasteiger ,partial ,charges 
,were ,added ,to ,the ,ligand ,atoms. ,Non-polar ,hydrogen ,atoms ,were ,merged, ,and ,rotatable ,bonds 
,were ,defined. ,Docking ,calculations ,were ,carried ,out ,for ,the ,compounds ,retrieved ,such ,as , 
,Anisaldehyde ,, ,Berberine, ,Kaempferol, ,Protocatechuic ,acid, ,Nimbolide, ,Picein ,and ,their 
,respective ,standard ,Tacrolimus , ,against ,target ,protein ,model. ,Essential ,hydrogen ,atoms, 
,Kollman ,united ,atom ,type ,charges, ,and ,solvation ,parameters ,were ,added ,with ,the ,aid ,of ,Auto 
,Dock ,tools ,(Morris, ,Goodsell ,et ,al., ,1998). ,Affinity ,(grid) ,maps ,of ,×× ,Å ,grid ,points ,and ,0.375 
,Å ,spacing ,were ,generated ,using ,the ,Autogrid ,program ,(Morris, ,Goodsell ,et ,al., ,1998). ,Auto 
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,Dock ,parameter ,set- ,and ,distance-dependent ,dielectric ,functions ,were ,used ,in ,the ,calculation ,of 
,the ,van ,der ,Waals ,and ,the ,electrostatic ,terms, ,respectively. ,Docking ,stimulations ,were 
,performed ,using ,the ,Lamarckian ,genetic ,algorithm ,(LGA) ,and ,the ,Solis ,& ,Wets ,local ,search 
,method ,(Solis ,and ,Wets, ,1981). ,Initial ,position, ,orientation, ,and ,torsions ,of ,the ,ligand 
,molecules ,were ,set ,randomly. ,All ,rotatable ,torsions ,were ,released ,during ,docking. ,Each 
,docking ,experiment ,was ,derived ,from ,2 ,different ,runs ,that ,were ,set ,to ,terminate ,after ,a 
,maximum ,of ,250000 ,energy ,evaluations. ,The ,population ,size ,was ,set ,to ,150. ,During ,the ,search, 
,a ,translational ,step ,of ,0.2 ,Å, ,and ,quaternion ,and ,torsion ,steps ,of ,5 ,were ,applied. 
 
4.7d.Sivappu ,Thylam , ,: , 
7d.1.In-vitro ,Anti-Inflammatory ,Activity ,by ,Protein ,(Albumin) ,denaturation ,Assay54,55 
Albumin ,Denaturation ,Assay ,Procedure 
In-vitro ,anti-inflammatory ,activity ,ST ,was ,studied ,using ,albumin ,denaturation 
,technique. ,The ,reaction ,mixture ,consisted ,of ,bovine ,serum ,albumin ,(5% ,aqueous ,solution) ,and 
,test ,sample ,ST ,at ,varying ,concentration ,ranges ,from ,100 ,to ,500 ,µg/ml ,and ,standard ,Diclofenac 
,sodium ,at ,the ,concentration ,of100 ,µg ,/ml ,of ,final ,volume. ,pH ,was ,adjusted ,by ,using ,a ,small 
,amount ,of ,1N ,Hydrochloric ,acid. ,The ,samples ,were ,incubated ,at ,37°C ,for ,20 ,min ,and ,then 
,heated ,at ,57°C ,for ,3 ,min. ,After ,cooling ,the ,sample, ,2.5 ,ml ,of ,phosphate ,buffer ,solution ,was 
,added ,into ,each ,test ,tube. ,Turbidity ,developed ,was ,measured ,spectrophotometrically ,at ,660 
,nm, ,for ,control ,distilled ,water ,was ,used ,instead ,of ,test ,sample ,while ,product ,control ,tests ,lacked 
,bovine ,serum ,albumin. ,The ,experiment ,was ,performed ,in ,triplicate. 













 The ,acute ,and ,subacute ,toxicity ,studies ,on ,animals ,were ,conducted ,at ,animal ,house, 
,National ,Institute ,of ,Siddha ,( ,Reg.no ,: ,1248/GO/RE/2009/CPCSEA ,),Chennai-47. ,(IAEC 
,NO:NIS ,/ ,IAEC ,VI ,/ ,2404 ,/ ,2018 ,/09 ,). 
ACUTE ,AND ,SUBACUTE , ,TOXICITY ,STUDY ,: 
Objective ,: 
The ,“Acute ,oral ,Toxicity ,Study ,of , ,“Parangipattai ,Kudineer” ,on , ,Wistar ,albino ,rats 
,was ,to ,evaluated ,the ,toxicological ,studies ,of ,the ,drug ,as ,per ,guideline ,and ,IAEC ,guidance. , 
Test ,Guideline ,Followed: 
 Acute ,toxicity ,study ,was ,conducted ,as ,per ,OECD- ,423 ,Guideline ,with ,slight 
,modification. 
4.e.1.ACUTE ,TOXICITY ,STUDY ,: , 
4.e.1.1.Materials ,and ,Methods: 
 The ,acute ,toxicity ,study ,was ,conducted ,on ,8-12 ,weeks ,old ,Albino ,rats ,of ,female ,sex 
,weighing ,140-160g ,. ,These ,animals ,were ,selected ,because ,literature ,surveys ,of ,conventional 
,LD50 ,tests ,show ,that, ,although ,there ,is ,little ,difference ,in ,sensitivity ,between ,the ,sexes, ,in ,those 
,cases ,where ,differences ,are ,observed ,females ,are ,generally ,slightly ,more ,sensitive ,.The ,body 
,weight ,range ,should ,be ,within ,± ,20% ,of ,the ,mean ,body ,weight ,at ,the ,time ,of ,Randomization 
,and ,grouping ,for ,acute ,and ,subacute ,toxicity ,study.The ,rats ,were ,purchased ,from ,The 
,Tamilnadu ,Veterinary ,and ,animal ,sciences ,university, ,Madhavaram ,milk ,colony ,,Chennai ,and 
,housed ,in ,standard ,laboratory ,condition ,in ,Polypropylene ,cages, ,provided ,with ,Rodent ,pelleted 
,feed,Ro ,purified ,water ,ad ,libitum. 
4.e.1.2.Acclimatization: 
The ,animals ,were ,selected ,after ,veterinary ,examination ,by ,the ,veterinarian; ,selected ,rats 
,were ,kept ,under ,acclimatization ,for ,a ,week. 
4.e.1.3.Randomization ,& ,grouping: 
 After ,acclimatization, ,Rats ,were ,randomized ,as ,control ,and ,PPK ,treated ,group ,as 
,followed, , 
Acute ,toxicity ,study-14 ,days ,(OECD ,Guidelines ,- ,423) 
Groups No. ,of ,Rat 
Group ,I ,: ,Test ,drug ,(PPK)-2000mg/kg ,b.wt 6F ,(3F+3F) 
*PPK-Parangipattai ,Kudineer 





Animals ,were ,housed ,with ,appropriate ,identification ,by ,colouring ,the ,fur ,with ,picric 
,acid ,solution ,prepared ,in ,water ,and ,with ,cage ,cards. 
4.e .1.5.Husbandry: 
Housingand ,Environmental ,conditions: 
Animals ,were ,housed ,in ,1 ,groups ,(2/cage) ,in ,polypropylene ,cages ,in ,a ,well ,ventilated 
,room ,under ,a ,temperature ,of ,22 ,± ,3°C ,and ,30 ,- ,70% ,relative ,humidity, ,with ,a ,12-hr ,light/dark 
,artificial ,light ,cycle. , ,.Paddy ,husk ,was ,used ,as ,bedding. ,Each ,cage ,contained ,a ,maximum ,of ,3 
,rats. ,The ,cages ,corresponding ,to ,each ,experimental ,group ,were ,distributed ,on ,racks ,in ,such ,a 
,manner ,that ,outside ,factors, ,such ,as ,environmental ,conditions, ,were ,balanced ,as ,far ,as ,possible. 
Feed ,& ,feeding ,schedule: 
Feed ,was ,provided ,from ,‘National ,institute ,of ,Siddha ,animal ,house, ,Chennai. ,The 
,animals ,had ,free ,access. , 
Water: 
The ,water ,was ,offered ,ad ,libitum ,in ,bottles. ,This ,was ,periodically ,analysed ,to ,detect ,the 
,presence ,of ,possible ,contaminants. 
4.e.1.6.Doses: 
Following ,the ,fasting ,period, ,the ,animals ,were ,weighed ,and ,then ,PPK ,was ,administered 
,orally ,as ,single ,dose ,using ,a ,needle ,fitted ,onto ,a ,disposable ,syringe ,of ,approximate ,size. 
The ,drug ,was ,administered ,at ,2gms/kg ,b.wt ,as ,a ,single ,dose. ,After ,administration 
,period, ,all ,animals ,were ,observed ,for ,14 ,days. 
4.e .1.7.Administration: 
The ,test ,item ,was ,administered ,orally ,to ,each ,female ,Wister ,rats ,as ,single ,dose ,using ,a 
,needle ,fitted ,onto ,a ,disposable ,syringe ,of ,appropriate ,size. , 
4.e.1.8.Observation ,period: 
After ,drug ,administration ,observations ,were ,started ,to ,be ,recorded ,at ,the ,½ ,hr, ,1hour, 
,2hours, ,4hours ,on ,day ,one ,of ,dosing ,and ,twice ,daily ,after ,that ,for ,the ,next ,13 ,consecutive ,days. 
,At ,the ,14th ,day, ,sensory ,reactivity ,to ,stimuli ,of ,different ,types ,was ,conducted. ,Auditory ,stimuli 
,responses ,were ,measured ,by ,clicker ,sound ,from ,approximately ,30 ,cm ,to ,the ,rats; ,visual ,stimuli 
,response ,were ,measured ,with ,the ,help ,of ,shining ,pen ,light ,in ,the ,eye ,of ,rats ,and ,placing ,a ,blunt 
,object ,near ,to ,the ,eye ,of ,rats. ,Response ,to ,proprioceptive ,stimuli ,was ,measured ,by ,placing 
,anterior/dorsal ,surface ,of ,animals ,paw ,to ,the ,table ,edge. ,The ,responses ,of ,reactions ,for ,these 
,three ,exercises ,were ,normal ,in ,animals ,belonging ,to ,both ,the ,controls ,as ,well ,as ,drug ,treatment 
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,dose ,groups. ,On ,day ,15, ,the ,overnight ,fasted ,animals ,(water ,allowed ,ad ,libitum) ,were 
,sacrificed ,and ,examine ,for ,gross ,pathological ,changes ,in ,the ,major ,internal ,organs. 
4.e.1.9.Body ,Weight: 
Individual ,weights ,of ,animals ,were ,determined ,before ,PPK ,administration, ,weekly 
,thereafter ,and ,at ,14 ,days. 
4.e.1.10.Food ,Consumption: 
 ,The ,quantity ,of ,feed ,was ,accessible ,based ,on ,the ,requirement ,to ,the ,group ,of ,animal 
,housed ,in ,each ,cage ,(3 ,rats). ,The ,leftover ,of ,the ,feed ,was ,calculated ,weekly ,once. ,The ,feed 
,consumed ,/3 ,animals ,/cage ,/week ,were ,calculated ,by ,subtraction ,of ,left ,over ,from ,total ,quantity 
,of ,feed ,offered ,during ,that ,week. 
4.e.1.11.Sacrifice ,and ,macroscopic ,examination: 
At ,the ,end ,of ,study ,period, ,the ,overnight ,fasted ,(water ,ad ,libitum) ,animals ,were 
,anaesthetized ,with ,ketamine, ,the ,animals ,in ,control ,and ,PPK ,treated ,group ,were ,sacrificed ,on 
,15th ,day ,and ,gross ,pathological ,changes ,were ,observed ,in ,the ,experimental ,animals. 
Statistical ,analysis: 
Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical ,significance ,(p) ,calculated ,by ,one ,way 
,ANOVA ,followed ,by ,Dunnett’s. ,P< ,0.05 ,considered ,as ,significant ,by ,comparing ,treated ,group 
,with ,control ,group ,using ,Graph ,Pad ,Prism ,4.0. , , 
 
4.e.2.SUBACUTE ,TOXICITY ,STUDY: 
4.e.2.1.Objective: 
Sub ,Acute ,toxicity ,study ,was ,conducted ,as ,per ,OECD-407Guideline. ,Animals ,should 
,be ,observed ,for ,28 ,days ,during ,the ,PPK ,administration. ,Sub ,acute ,study ,give ,information ,on ,the 
,health ,hazard ,likely ,to ,arise ,from ,frequent ,exposure ,over ,a ,relatively ,period ,of ,28 ,days. 
4.e.2.2.Test ,Guideline ,Followed 
  , , , , , ,OECD ,407 ,Method ,- ,Sub-Acute ,Toxic ,Class ,Method ,(Repeated ,Dose ,28-Day ,Oral 
,Toxicity ,Study ,in ,Rats). 
4.e.2.3.Good ,Laboratory ,Practices 
The ,study ,was ,conducted ,following ,the ,principles ,of ,good ,Laboratory ,Practice ,as ,set ,for 
,the ,Principles ,of ,Good ,Laboratory ,Practice, ,OECD, ,1998. 
4.e .2.4. ,Staff ,safety 
Personnel ,handling ,the ,test ,item ,were ,worn ,appropriate ,shielding ,clothing ,to ,avoid 
,inhalation, ,Skin ,contact ,with ,the ,test ,item. 
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4.e.2.5.Materials ,and ,methods 
Detail ,of ,subacute ,test ,: , 
 Young ,adult ,Wister ,albino ,rats ,of ,8-12 ,weeks ,old ,weighing ,140-160 ,gms ,of ,both ,the ,sex 
,was ,used ,for ,this ,study. ,The ,body ,weight ,range ,should ,be ,within ,± ,20% ,of ,the ,mean ,body 
,weight ,at ,the ,time ,of ,Randomization ,and ,grouping. ,Animals ,were ,housed ,in ,four ,groups 
,(4/cage/sex) ,in ,polypropylene ,cages ,in ,a ,well ,ventilated ,room ,under ,a ,temperature ,of ,22 ,± ,3°C 
,and ,30 ,- ,70% ,relative ,humidity, ,with ,a ,12-hr ,light/dark ,artificial ,light ,cycle. , ,The ,rats ,were 
,purchased ,from ,The ,Tamilnadu ,Veterinary ,and ,animal ,sciences ,university, ,Madhavaram ,milk 
,colony ,,Chennai ,and ,housed ,in ,standard ,laboratory ,condition ,in ,Polypropylene ,cages, ,provided 
,with ,Rodent ,pelleted ,feed,Ro ,purified ,water ,ad ,libitum.. 
4.e 2.6.Acclimatization 
The ,animals ,were ,selected ,after ,veterinary ,examination ,by ,the ,veterinarian. ,All ,the 
,selected ,animals ,were ,kept ,under ,acclimatization ,for ,a ,week. 
4.e.2.7.Randomization ,& ,grouping: 
One ,day ,before ,the ,initiation ,of ,treatment ,(last ,day ,of ,acclimatization), ,the ,selected 
,animals ,were ,randomly ,grouped ,into ,four ,different ,groups ,containing ,5 ,male ,animals ,and ,5 
,female ,animals ,per ,group. , 
4.e .2.8.Numbering ,and ,Identification: 
Animals ,were ,housed ,with ,appropriate ,identification ,by ,colouring ,the ,fur ,with ,picric 
,acid ,solution ,prepared ,in ,water ,and ,with ,cage ,cards. 
The ,group , ,no., ,cage ,no., ,sex ,of ,the ,animal ,and ,animal ,no. ,were ,identified , ,as 



















The ,Wister ,albino ,rats ,were ,housed ,in ,standard ,polypropylene ,cages ,with ,stainless ,steel 
,top ,grill. ,Paddy ,husk ,was ,used ,for ,bedding. ,The ,paddy ,husk ,was ,changed ,at ,least ,two ,times ,in ,a 
,week. 
Environmental ,conditions: 
The ,animals ,were ,kept ,in ,a ,fresh ,environment ,with ,12 ,hr ,light ,and ,12 ,hr ,dark ,cycles. ,The 
,air ,was ,conditioned ,at ,22 ,± ,30C ,and ,the ,relative ,humidity ,was ,maintained ,between ,30-70% ,with 
,exhaust ,facility. ,The ,cages ,corresponding ,to ,each ,experimental ,group ,were ,kept ,on ,racks ,in 
















4 IILOW ,DOSE 
Female 
H,B,T,HB,BT Female 




6 IIIMID ,DOSE , 
Female 
H,B,T,HB,BT Female 









Feed ,& ,feeding ,schedule: 
Feed ,was ,provided ,from ,‘National ,institute ,of ,Siddha ,animal ,house, ,Chennai. ,The 
,animals ,had ,free ,accessto ,feed ,of ,standard ,composition ,containing ,all ,macro ,and ,micro 
,nutrients. , 
Water: 
The ,water ,was ,offered ,adlibitum ,in ,bottles. ,There ,was ,analysed ,at ,regular ,intervals ,to 
,detect ,the ,presence ,of ,possible ,contaminants. 
4.e.2.10.Doses: 
 The ,doses ,for ,the ,study ,were ,selected ,based ,on ,acute ,toxicity ,study. ,Following ,the 
,period ,of ,fasting, ,the ,animals ,were ,weighed ,and ,then ,test ,drug ,was ,administered ,orally ,as ,single 
,dose ,using ,a ,needle ,fitted ,on ,to ,a ,disposable ,syringe ,of ,approximate ,size ,at ,the ,following 
,different ,doses. 
 
Table ,. 4.e.2. ,Dose ,level ,in ,subacute ,toxicity ,study 
 
*1x=9ml 
Kudineer ,will ,be ,condensed ,to ,2ml 
The ,test ,item ,was ,administered ,for ,a ,period ,of ,28 ,days. ,All ,animals ,in ,group ,I ,to ,IV 










Dose ,To ,Animals 
(mg/kg ,body-weight/day) 
 
Number ,of ,Animals 
Group-1 Control ,(Distilled ,Water). 
10 ,ml/kg ,bw 
10 ,(5male ,and ,5 ,female) 
Group-II Low ,dose ,of ,PPK ,9mg/kg. 10 ,(5male ,and ,5 ,female) 
 
Group-III Mid , ,dose , ,of , ,PPK ,18mg/kg 10 ,(5male ,and ,5 ,female) 




The ,test ,item ,was ,administered ,orally ,to ,each , , ,rat ,as ,single ,dose ,using ,a ,needle ,fitted 
,onto ,a ,disposable ,syringe ,of ,appropriate ,size ,at ,the ,following ,different ,doses. ,The ,concentration 
,was ,adjusted ,according ,to ,its ,body ,weight; ,the ,volume ,not ,exceeding ,10 ,ml/kg ,body ,weight. 
,Variability ,in ,test ,volume ,was ,minimized ,by ,adjusting ,the ,concentration ,to ,make ,sure ,a 
,constant ,volume ,at ,all ,dose ,levels. 
4.e .2.12.Observations: 
The ,observations ,included ,but ,were ,not ,restricted ,to ,changes ,in ,skin ,and ,the ,eyes ,and 
,mucous ,membranes ,and ,in ,the ,respiratory, ,circulatory, ,central ,and ,autonomous ,nervous ,systems 
,and ,behaviour. 
8.2.13.Clinical ,signs ,of ,toxicity: 
 , , , , , , , , , , , , , ,All ,the ,rats ,were ,observed ,at ,least ,two ,times ,daily ,with ,the ,purpose ,of ,recording ,any 
,symptoms ,of ,ill- ,health ,or ,behavioural ,changes ,and ,clinical ,signs ,of ,toxicity ,daily ,for ,28 ,days 
,for ,animals ,in ,group ,I ,to ,IV. 
4.e.2.14.Food ,intake: 
A ,measured ,amount ,of ,feed ,was ,kept ,in ,the ,cages ,and ,then ,after ,24 ,hrs ,the ,left ,out 
,amount ,of ,feed ,was ,measured ,to ,calculate ,the ,amount ,of ,food ,consumed ,by ,the ,rats. 
4.e.2.15.Water ,intake: 
Water ,intake ,was ,observed ,by ,visual ,observation ,during ,the ,Study. ,In ,addition, ,the 
,water ,consumption ,in ,each ,cage ,was ,observed ,daily ,for ,a ,period ,of ,28 ,days. 
4.e.2.16.Bodyweight: 
 The ,body ,weight ,of ,rats ,were ,recorded ,one ,week ,before ,the ,start ,of ,treatment, ,and 
,during ,the ,course ,of ,the ,treatment ,on ,day ,one, ,7th, ,14th, ,21st ,and ,28th ,days ,(day ,of ,sacrifice). 
,The ,mean ,weights ,for ,all ,groups ,and ,sexes ,were ,calculated ,from ,the ,individual ,weights. 
4.e.2.17.Pre-terminal ,deaths: 
 All ,rats ,were ,observed ,twice ,daily ,for ,any ,pre ,terminal ,deaths. 
4.e.2.18.Blood ,Collection: 
Blood ,was ,collected ,through ,abdominal ,aorta , ,from ,all ,the ,animals ,of ,four ,groups ,on 
,28th ,day. ,The ,blood ,was ,collected ,in ,tubes ,containing ,as ,an ,anticoagulant ,(Heparin/EDTA). 







 , ,During ,the ,4th ,week ,of ,treatment, ,blood ,were ,withdrawn ,from ,abdominal ,aorta ,of , 
,animals ,from ,each ,group, ,under ,ketamine ,anaesthesia ,.The ,blood ,samples ,are ,used ,to ,evaluate 
,Haematological ,parameters ,like ,RBC, ,WBC, ,and ,platelets ,etc….. ,The ,collected ,blood ,samples 
,also ,centrifuged ,10000 ,rpm ,in ,10 ,minutes ,to ,separate ,the ,serum. ,The ,separated ,serum ,used ,to 
,evaluate ,biochemical ,parameters ,like ,SGOT, ,SGPT, ,ALP ,and ,BILIRUBIN ,etc……...  
Hematology , 
The ,following ,hematological ,parameters ,were ,analysed ,(Autoanalyzer) , 
Hb   : ,Hemoglobin ,(g ,%) , 
PCV ,   : ,Packed ,Cell ,Volume 
WBC   : ,White ,Blood ,Corpuscles ,(x103/cmm) , 
RBC   : ,Red ,Blood ,Corpuscles ,(x106/cmm) , 
Blood ,Platelet ,count ,(x103/cmm) , 
Differential ,WBC ,count: , 
Clinical ,Biochemistry: , 
The ,following ,clinical ,Bio ,parameters ,were ,analyzed ,using ,Auto ,analyzer , 
Total ,serum ,protein ,(g/dl) , 
ALT/SGPT  : , Alanine ,amino ,transferase ,(U/L) , 
AST/SGOT  : , Aspartate ,amino ,transferase ,(U/L) , 
ALP ,   : , Alkaline ,serum ,phosphatase ,(U/L) , 
CHL ,   : , Cholesterol ,(mg/dL) , 
TG ,   : , Triglyceride 
 
4.e.2.20.Sacrifice ,and ,macroscopic ,examination 
At ,the ,end ,of ,study ,period, ,the ,overnight ,fasted ,(water ,ad ,libitum) ,animals ,were 
,anaesthetized ,with ,ketamine, ,blood ,samples ,were ,collected ,from ,abdominal ,aorta. ,After ,blood 
,collection, ,the ,animals ,in ,group ,1 ,to ,4 ,were ,sacrificed ,on ,29th ,day. , 
4.e.2.21.Organ ,weights: 
 , , , , , , , , , , , ,After ,the ,macroscopic ,examination ,the ,following ,organs ,were ,weighed ,after ,separating 






4.e.22. ,Histopathology:  
 The ,target ,organs ,from ,control ,and ,drug ,treated ,animals ,were ,preserved ,in ,10 ,% 
,buffered ,neutral ,formalin ,for ,histopathological ,examination.Control ,and ,highest ,dose ,animals 
,will ,be ,initially ,subjected ,to ,histopathological ,invstigaion. ,If ,any ,abnormality ,was ,found ,in ,the 
,highest ,dose ,group, ,then ,the ,low ,and ,mid ,group ,will ,also ,be ,examined. ,All ,deviations ,from 
,normal ,histology ,were ,recorded ,and ,compared ,with ,corresponding ,controls. 
Statistical ,analysis: 
Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical ,significance ,(p) ,calculated ,by ,one ,way 
,ANOVA ,followed ,by ,Dunnett’s. ,P< ,0.05 ,considered ,as ,significant ,by ,comparing ,treated ,group 
,with ,control ,group ,using ,Graph ,Pad ,Prism ,4.0. , 
 
PATIENTS ,AND ,CLINICAL ,METHODS 
4f.CLINICAL ,STUDY: 
4f.1.Clinical ,trial ,Approval ,& ,Registration: 
The ,Clinical ,trial ,was ,approved ,by ,the ,Institutional ,Ethics ,Committee ,(IEC) ,of ,National 
,Institute ,of ,Siddha, ,Chennai ,47 ,(NIS/13-IEC/2017-1-08/22-11-2017) ,and ,further ,registered ,in 
,Clinical ,Trial ,Registry ,of ,India ,(CTRI). 
4f.2.Study ,Centre: 
Clinical ,study ,was ,conducted ,at ,AyothidossPandither ,Siddha ,Hospital, ,National 
,Institute ,of ,Siddha ,(NIS), ,Tambaram ,Sanatorium, ,Chennai ,- ,47. ,Necessary ,permission ,was 
,obtained ,from ,the ,Administrative ,head ,to ,conduct ,the ,study. , 
4f.3.Study ,Population: 
For ,Open ,Clinical ,trial, ,patients ,who ,were ,attending ,the ,OPD ,of ,NIS ,were ,inducted ,after 
,obtaining ,informed ,consent ,from ,all ,of ,them. ,Totally ,118 ,patientswere ,screened ,and ,among 
,them ,40 ,who ,complied ,with ,the ,inclusion ,criteria ,were ,included ,in ,the ,study. , 
4f.4.Subject ,Selection: 
 , , , , , , , , , , , , ,Patients ,reporting ,with ,symptoms ,of ,Kalanjagapadai ,will ,be ,subjected ,to ,screening ,using 








• Age ,: ,20-65 ,years 
• Sex ,: ,Both ,male ,and ,female, ,Transgender , 
• History ,of ,Insulin ,Dependent ,Diabetes ,Mellitus 
• Itching ,(with ,or ,without) 
• Erythema 
• Scaling 
• Auspitz ,sign ,+ 
• Candle ,crease ,sign ,+ 
• Willing ,to ,give ,specimen ,of ,blood ,for ,the ,investigation ,whenever ,required. , 
• Willing ,to ,take ,photograph 




• History ,of ,Insulin ,Dependent ,Diabetes ,Mellitus 
• Pregnancy ,and ,lactation 
• History ,of ,Psoriasis ,with ,evidence ,of ,any ,other ,skin ,disease , ,or ,Evidences ,of 
,secondary ,infection ,in ,the ,lesions. 
• History ,of , ,Psoriatic ,arthropathy 
• History ,of ,Cardiac ,diseases 
• History ,of , ,Hansen’s ,disease 
• History ,of ,any ,other ,chronic ,illness 
Withdrawal ,Criteria  
• Intolerance ,to ,the ,drug ,and ,development ,of ,any ,serious ,adverse ,effect ,during ,drug 
,trial. 
• Poor ,patient ,compliance ,& ,defaulters 
• Patient ,unwilling ,to ,continue ,the ,course ,of ,clinical ,Study. 
• Occurrence ,of ,any ,other ,systemic ,illness. 
4f.5.Informed ,consent: 
 To ,respect ,the ,rights ,of ,the ,study ,participants ,the ,information ,sheet ,containing ,entire 
,details ,of ,the ,study ,was ,given ,to ,them. ,Then ,a ,written ,consent ,to ,participate ,in ,this ,study ,was 







 Required ,information ,was ,collected ,from ,each ,patient ,by ,using ,the ,following ,forms: 
Form ,– ,I Screening ,and ,selection ,Proforma 
Form ,– ,II History ,taking ,Proforma 
Form ,– ,III , Clinical ,assessment ,Proforma 
Form ,– ,IV , , , , , ,Laboratory ,investigation ,Proforma 
Form ,– ,V , , , , , , , ,Consent ,form 
Form ,– ,VI , , , , , ,Withdrawal ,form 
Form ,-VI-A Drug ,Compliance ,Form 
Form ,– ,VII , , , , ,Patient ,information ,sheet 
Form ,– ,VIII Dietary ,Advice ,Form 
Form ,– ,IX Adverse ,Reaction ,Form ,/ ,Pharmaco ,Vigilance ,Form 
4f.7.Assessment ,of ,efficacy ,parameters: 
Siddha ,parameters: , 
 Changes ,in ,symptoms, ,envagaithervu, ,naadi, ,neerkuri ,and ,neikuri ,and ,manikadainool. 
Clinical ,Assessment: , 
 Macules, ,Papules, ,Pustules, ,Plaques, ,Erythema, ,Scaling,Candle-greasesign, 
,Auspitzsign, ,Itching, ,Koebner’sphenomenon. 
Laboratory ,Investigation: 
 Blood: ,- ,TC, ,DC, ,Hb, ,ESR, ,Blood ,sugar, ,Lipid ,profile ,etc. 
 Renal ,Function ,Tests: 
  Blood ,Urea, ,Serum ,Creatinine, ,Uric ,acid. 
 Liver ,Function ,Tests: 
 Serum ,total ,bilirubin, ,direct ,bilirubin, ,indirect ,bilirubin, ,Serum ,Alkaline 
,phosphatase, ,SGOT, ,SGPT. 
 Urine: 
 Albumin, ,Sugar, ,Deposits. 
4f.8.Study ,Enrolment:  
o Patients ,reporting ,at ,the ,OPD ,with ,clinical ,feature ,of ,erythematous ,patches, ,silvery ,scaling , 
,are ,chosen ,for ,enrolment ,based ,on ,the ,inclusion ,and ,exclusion ,criteria. 
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o The ,enrolled ,patients ,will ,be ,informed ,about ,the ,study, ,trial ,drug, ,possible ,outcomes ,and ,the 
,objectives ,of ,the ,study ,in ,the ,language ,and ,terms ,understandable ,to ,them ,and ,getting 
,consent ,in ,the ,Informed ,Consent ,form ,(Form ,VI). 
o Complete ,clinical ,history, ,complaints ,and ,duration, ,examination ,findings-- ,all ,would ,be 
,recorded ,in ,the ,prescribed ,Proformas. 
o Screening ,Form- ,I ,will ,be ,filled ,up, ,Form ,–II ,and ,Form ,–III ,will ,be ,used ,for ,recording ,the 
,patients, ,history, ,clinical ,examination ,of ,symptoms ,and ,signs ,and ,laboratory ,investigations 
,respectively. ,If ,there ,is ,any ,abnormal ,laboratory ,reports ,obtained ,then ,excluded ,from ,this 
,study. ,Patients ,would ,be ,advised ,to ,take ,the ,trial ,drug ,and ,appropriate ,dietary ,advice ,(Form 
,VIII) ,would ,be ,given ,according ,to ,the ,patients, ,perfect ,understanding. 
4f.9.Conduct ,of ,the ,study: 
Group ,I ,: ,Trail ,drug ,without ,yogam ,in , ,OPD , ,patients. 
Group ,II ,: ,Trail ,drug ,with ,yogam ,in , ,IPD , ,patients. , 
4f.9.1.First ,day ,: 
Agathiyar ,kulambu , ,with ,200mg ,with ,30ml ,leaf ,juice ,of ,Sangankuppi ,(Azima 
,tetracantha) ,quantity ,was ,administered ,at ,early ,morning ,as ,purgative ,(Kazhichal ,Medicine) 
,before ,starting ,the ,treatment ,for ,restore ,equilibrium ,of ,dhoshams. 
4f.9.2.Second ,day ,: , 
 Oil ,bath ,with ,Arakku ,thylam , ,had ,taken ,at ,early ,morning ,for ,restore ,equilibrium ,of 
,udalthathus. 
4f.9.3.Third ,day ,onwards ,from , ,Sunday/Tuesday/Thursday ,for ,48 ,days ,: , 
 Internal ,Medicine: ,Parangipattai ,Kudineer, ,three ,times ,a ,day ,before ,food. 
External ,Medicine: ,Sivappu ,thylam 
4f.9..4.Advice ,for ,method ,of ,topical ,therapy ,: , , 
Oil ,applied ,in ,psoriatic ,lesion ,by ,cotton ,for ,4 ,hrs ,at , ,1pm ,to ,5pm ,and ,take ,sunbath ,at ,4pm 
,to ,5.30pm ,thereafter ,bath ,with ,warmwater ,used ,by ,greengram ,powder. , 
Yogam ,therapy ,(Agathavam ,Ettu) ,gave ,for ,IPD ,patients. ,Envagai ,Thervu , ,was 
,evaluvate ,before ,and ,after ,the ,treatment ,for ,40 ,patients. ,Nei ,Kuri ,was ,evaluvate ,0thday,15th 
,day,49th ,day ,of ,the ,treatment ,for ,opd ,and ,IPD ,patients. ,Manikadai ,Nool ,was ,measure ,before ,the 
,treatment ,for ,40 ,patients. , , , , , , 
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 OPD ,patients ,are ,requested ,to ,visit ,the ,hospital ,once ,in ,7 ,days. ,In ,each ,and ,every ,visit 
,clinical ,assessment ,and ,prognosis ,were , ,recorded. ,For ,IPD ,patients ,the ,clinical ,assessment ,and 
,prognosis ,were ,recorded ,daily. , 
 , , , , , , , , , , , , , ,,Laboratory ,investigations ,were ,done ,before ,and ,after ,the ,trial. ,For ,IPD ,patients, ,who ,are 
,not ,in ,a ,position ,to ,stay ,in ,the ,hospital ,for ,a ,long ,time ,are ,advised ,to ,attend ,the ,OPD ,for ,further 
,follow-up. ,At ,the ,end ,of ,the ,trial, ,the ,patients ,are ,advised ,to ,visit ,the ,OPD. , 
4f.9..5.Pharmaco-Vigilance ,(Adverse/serious ,adverse ,effects ,management): 
If ,the ,trial ,patient ,develops ,any ,adverse ,reaction, ,he/she ,would ,be ,immediately 
,withdrawn ,from ,the ,trial ,and ,he ,will ,be ,directed ,to ,take ,treatment ,in ,OPD ,of ,NIS. ,It ,will ,also ,be 
,reported ,to ,the ,Pharmaco-vigilance ,committee ,of ,NIS. ,In ,case ,of ,emergency, ,the ,patients ,will 
,be ,referred ,to ,nearby ,Government ,hospital ,for ,emergency ,management. 
4f.9.6.Dermatology ,Life ,Quality ,Index ,(DLQI): 
Recent ,studies ,have ,emphasized ,the ,association ,of ,psoriasis ,severity ,with ,impaired 
,physical ,and ,public ,functioning ,as ,well ,as ,with ,the ,emotional ,state. ,The ,DLQI ,is ,calculated ,by 
,summing ,the ,score ,of ,each ,question ,resulting ,in ,a ,minimum ,of ,0 ,and ,a ,maximum ,of ,30. ,The 
,higher ,the ,score, ,the ,more ,quality ,of ,life ,is ,impaired. , 
4f.9.7.Outcome ,measures: 
The ,outcome ,of ,the ,study ,was ,clinically ,observed ,by ,the ,PASI ,Score. 
PASI ,Score: ,- 
 * ,PASI ,25 ,= ,25% ,(Poor) ,reduction ,in ,the ,PASI ,Score ,in ,before ,and ,after ,treatment. 
 * ,PASI ,50 ,= ,50% ,(Moderate) ,reduction ,in ,the ,PASI ,Score ,in ,before ,and ,after 
,treatment. 
 * ,PASI ,75 ,= ,75% ,(Good) ,reduction ,in ,the ,PASI ,Score ,in ,before ,and ,after ,treatment. 
 
4f.9.8.Data ,analysis: , 
After ,enrolling ,the ,patients ,in ,the ,study, ,case ,report ,form ,book , ,for , ,patients ,will ,be 
,maintained. ,Study ,No. ,and ,patient’s ,No. ,will ,be ,entered ,on ,the ,top ,of ,the ,file ,for ,easy 
,identification. ,Whenever ,the ,patients ,visit ,OPD ,during ,the ,study ,period, ,necessary ,entries ,will 
,be ,made ,at ,the ,assessment ,forms. ,The ,screening ,forms ,will ,be ,filled ,separately. ,All ,forms ,will 
,be ,further ,scrutinized ,by ,Senior ,Research ,Officer ,(Statistics) ,for ,logical ,errors ,and 




5. ,OBSERVATION ,AND ,RESULTS ,WITH ,STATISTICAL ,ANALYSIS 
5.1.1.Authentication ,of ,the ,ingredients: 
The , ,ingredients ,of ,PPK ,were ,identified ,and ,authenticated ,by ,the ,Medicinal ,Botanist ,of 
,NIS ,(certificate ,number: ,NISMB3192018). 
5.1.2.Purification ,of ,ingredients: 
 The ,raw ,drugs ,were ,purified ,as ,per ,the ,methods ,mentioned ,in ,the ,Siddha ,literatures. , 
,After ,purification, ,the ,ingredients ,are ,dried ,in ,the ,shade. 
5.1.3.Preparation ,of ,PPK: 
The ,raw ,drugs ,were ,purified ,and ,crushed ,into ,coarse ,powder. , , , 
5.2.Pharmacognostical ,Standardisation: 
 Getting ,the ,identification ,of ,the ,herbal ,ingredients, ,they ,were ,tested ,for ,macroscopical 
,description. 
5.2.1.Physico ,- ,Chemical ,Characterisation ,as ,per ,AYUSH ,portal ,: , 
 










 , , , , , , , ,Table.5.1.Sample ,Description 
State Solid- ,Crude ,raw ,Material Decoction- ,Water ,Extraction 
Appearance Greenish ,Brown Reddish ,Brown 
Nature Hard ,Fibre/ ,Woody , Slightly ,viscous 
Odor Mild ,Characteristic Mild ,Characteristic 
 




5.2.3.Physico-Chemical ,analysis ,results: 
s.no Parameters Percentage 
1 Loss ,on ,drying 7.22 ,% 
2 Total ,ash ,value 6.18% 
3 Acid ,insoluble ,ash 1.73% 
4 Water ,soluble ,ash 1.77% 
5 Water ,soluble ,extraction 25.35% 
6 Alcohol ,soluble ,extraction 19.62% 
Table ,:5.2. ,Results ,of ,physicochemical ,parameters 
 
Loss ,on ,drying ,indicates ,the ,moisture ,content. ,The ,total ,ash ,substance ,is ,the ,measure ,of 
,inorganic ,substances ,present ,in ,the ,drug. ,High ,ash ,content ,proves ,its ,unsuitable ,nature ,to ,be 

















5.2.4.PARTICLE ,SIZE ,DETERMINATION ,: , 
 , , , , , , , , , , , , , ,  







Microscopic ,observation ,of ,the ,particle ,size ,analysis ,reveals ,that ,the ,average ,particle 
,size ,of ,the ,sample ,was ,found ,to ,be ,175.7 , ,± ,71.8 ,µm 
 , , , 




Figure.5.3.Sterility ,test ,by ,pour ,plate ,method , 
 
Observation 




No ,growth ,/ ,colonies ,were ,observed ,in ,any ,of ,the ,plates ,inoculates ,with ,the ,test ,sample. 
 
Table.5.3.Microbiological ,contaminant ,study 
Mean 175.7 
Std. ,Deviation 71.8 
Std. ,Error 29.31 
Test Result Specification As ,per ,AYUSH/WHO 
Total ,Bacterial ,Count Absent NMT ,105CFU/g As ,per ,AYUSH 
,specification 




5.2.6.TLC ,& ,HPTLC ,analysis ,of ,aqueousextract ,of ,Parangipattai ,Kudineer ,Chooranam 
,(PKC): 
 
TLC ,Analysis ,at ,366 ,nm  , , , , , , ,Track ,at ,All ,Wavelength 
 
Figure.10.4.TLC ,Analysis , 





 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,Table.5.4.HPTLC ,Peak ,Table 
REPORT 
HPTLC ,finger ,printing ,analysis ,of ,the ,sample ,PKC ,reveals ,the ,presence ,of ,six 
,prominent ,peaks ,corresponds ,to ,presence ,of ,six ,versatile ,phytocomponents ,present ,with 
,in ,it. ,Rf ,value ,of ,the ,peaks ,ranges ,from ,0.05 ,to ,0.71. ,Further ,the ,peak ,2 ,and ,6 ,occupies ,the 
,major ,percentage ,of ,area ,of ,37.55 ,and ,36.53 ,% ,which ,denotes ,the ,abundant ,existence ,of 
,such ,compound. ,Followed ,by ,this ,peak ,1 ,and ,3 ,occupies ,the ,percentage ,area ,of ,18.18 ,and 
,3.11 ,%. 
5.2.7.HEAVY ,METAL ,ANALYSIS ,BY ,AAS: 
The ,observed ,results ,of ,heavy ,metal ,analysis ,are ,tabulated ,below ,in ,table , 




Result ,Analysis Maximum ,Limit 
Mercury 253.7 ,nm BDL 1 ,ppm 
Lead 217.0 ,nm 1.185 10 ,ppm 
Arsenic 193.7 ,nm 0.460 3 ,ppm 
Cadmium 228.8 ,nm BDL 0.3 ,ppm 
BDL ,: ,Below ,Detection ,Limit , 
Table.5.5. , ,Results ,of ,heavy ,metal ,analysis 
 
REPORT ,AND ,INFERENCE ,: , 
• Results ,of ,the ,present ,investigation ,have ,clearly ,shows ,that ,the ,sample ,has ,no 
,traces ,of ,heavy ,metal ,Mercury ,and ,cadmium ,. ,Further ,the ,results ,show ,the 
,presence ,of ,Lead ,and ,Arsenic ,and ,cadmium ,at ,1.185 ,and ,0.460 ,ppm ,level. 










5.2.8.PESITICIDE ,RESIDUE ,: 
Pesticide ,Residue  
Sample ,PKC 
 
AYUSH ,Limit ,(mg/kg) 
I.Organo ,Chlorine ,Pesticides 
Alpha ,BHC  , , , , , , , , , , , , , , , , ,BQL  , , , , , , , , , , , ,0.1mg/kg 
Beta ,BHC  , , , , , , , , , , , , , , , , , ,BQL  , , , , , , , , , , , ,0.1mg/kg 
Gamma ,BHC  , , , , , , , , , , , , , , , , , ,BQL  , , , , , , , , , , , ,0.1mg/kg 
Delta ,BHC  , , , , , , , , , , , , , , , , , ,BQL  , , , , , , , , , , , , ,0.1mg/kg 
DDT  , , , , , , , , , , , , , , , , , ,BQL  , , , , , , , , , , , , , ,1mg/kg 
Endosulphan  , , , , , , , , , , , , , , , , , ,BQL 3mg/kg 
II.Organo ,Phosphorus ,Pesticides   
Malathion  , , , , , , , , , , , , , , , , , ,BQL 1mg/kg 
Chlorpyriphos  , , , , , , , , , , , , , , , , , ,BQL 0.2 ,mg/kg 
Dichlorovos  , , , , , , , , , , , , , , , , , ,BQL 1mg/kg 
III.Pyrethroid   
Cypermethrin  , , , , , , , , , , , , , , , , , ,BQL 1mg/kg 
BQL- ,Below ,quantification ,Limit 
Table.5.6.Test ,Result ,Analysis ,Of ,The ,Sample ,PKC 
Result: , 
The ,results ,showed ,that ,there ,were ,no ,traces ,of ,pesticides ,residues ,such ,as ,Organo 
,chlorine, ,Organo ,phosphorus ,and ,pyrethroids ,in ,the ,sample ,PKC. 
5.2.9.Aflatoxin ,Assay ,By ,TLC ,(B1,B2,G1,G2) ,: 
 
Aflatoxin Sample ,PKC AYUSH ,Specification ,Limit 
B1 Not ,Detected ,– ,Absent 0.5 ,ppm 
B2 Not ,Detected ,– ,Absent 0.1 ,ppm 
G1 Detected ,0.005 0.5 ,ppm 
G2 Not ,Detected ,– ,Absent 0.1 ,ppm 
Table.5.7. ,Aflatoxin ,Assay ,By ,TLC 
Result: , 
The ,results ,shown ,that ,there ,was ,no ,spots ,were ,been ,identified ,in ,the ,test ,sample 
,loaded ,on ,TLC ,plates ,with ,respect ,to ,aflatoxins ,B1,B2 ,and ,G2 ,when ,compare ,to 
,standard ,. ,Whereas ,presence ,of ,aflatoxin ,G1 ,were ,identified. ,This ,level ,of ,aflatoxins. 




5.2.10.Test ,for ,Specific ,Pathogen: 
Table.5.8. ,Specific ,Pathogen 
Observation 
No ,growth ,was ,observed ,after ,incubation ,period. ,Reveals ,the ,absence ,of ,specific 
,pathogen 
Result 
No ,growth ,/ ,colonies ,were ,observed ,in ,any ,of ,the ,plates ,inoculated ,with ,the ,test ,sample. 
 
Figure.5.6. ,Culture ,plates ,of ,test ,for ,specific ,pathogens 
 , , , , , , , , , , , , , , , , , , 











Organism Specification Result Method 
E-coli Absent Absent  
As ,per ,AYUSH 
,specification 
Salmonella Absent Absent 
Staphylococcus ,Aureus Absent Absent 




S.no Phytochemicals Test ,Name , H20 ,Extract 
1. Alkaloids Mayer’s ,Test -ve 
Wagner’s ,Test -ve 
Dragendroff’s ,Test -ve 
Hager’s ,Test -ve 
2. Carbohydrates Molisch’s ,Test +ve 
Benedict’s ,Test +ve 
3. Glycoside Modified ,Borntrager’s ,Test -ve 
Keller ,Killiani -ve 
4. Saponin Froth ,Test +ve 
Foam ,Test +ve 
5. Phytosterol Salkowski’s ,Test -ve 
6. Phenols Ferric ,chloride ,Test +ve 
7. Tannins Gelatin ,Test -ve 
8. Flavonoids Alkaline ,Reagent ,Test +ve 
Lead ,Acetate ,Test +ve 
9. Protein ,and ,amino ,acids Xanthoproteic ,Test -ve 
10. Diterpenes Copper ,Acetate ,test -ve 
11. Gum ,& ,Mucilage Extract ,+ ,Alcohol , -ve 
12. Fat ,& ,Fixed ,oil Spot ,test -ve 
13. Quinones NAOH+ ,Extract +ve 
+ve ,/-ve ,present ,or ,absent ,if ,component ,tested 
Table.5.9.Results ,of ,Phytochemical ,analysis 
 
The ,above ,table ,shows ,the ,presence ,of ,all ,secondary ,metabolites ,(Flavonoids, ,Phenolic 











5.4.CHEMICAL ,ANALYSIS ,: , 
 
S.No EXPERIMENT OBSERVATION INFERENCE 




2. Test ,for ,Silicate: 
c. A ,little ,(500mg) ,of ,the ,sample ,is 
,shaken ,well ,with ,distilledwater. 
d. A ,little(500mg) ,of ,the ,sampleis 








3. Action ,of ,Heat: 
A ,small ,amount ,(500mg) ,of ,the 
,sample ,is ,taken ,in ,a ,dry ,test ,tube ,and 












4. Ash ,Test: , 
A ,filter ,paper ,is ,soaked ,in ,a ,mixture ,of 
,sample ,and ,dil. ,cobalt ,nitrate ,solution 









S.No EXPERIMENT OBSERVATION INFERENCE 
1. Test ,For ,Sulphate: 
 
 , , , , , , , ,2ml ,of ,the ,above-prepared ,extract ,was 
,taken ,in ,a ,test ,tube ,and ,2ml ,of ,4% ,dil. 











Test ,For ,Acid ,Radicals 
 
6. Test ,For ,Fluoride ,& ,Oxalate: 
 
2ml ,of ,the ,extract ,was ,added ,with ,2ml ,of ,dil. 
,Acetic ,acid ,and ,2ml ,dil. ,calcium ,chloride 










7. Test ,For ,Nitrite: 
 
3drops ,of ,the ,extract ,was ,placed ,on ,a ,filter 
,paper, ,on ,that-2 ,drops ,of ,dil. ,acetic ,acid ,and ,2 









2. Test ,For ,Chloride: 
 , , , , , , , ,2ml ,of ,the ,above-prepared ,extracts ,was 
,added ,with ,2ml ,of ,dil-HNO3 ,until ,the 
,effervescence ,ceases ,off. ,Then ,2 ,ml ,of 








3. Test ,For ,Phosphate: 
 
 , , , , , , , ,2ml ,of ,the ,extract ,was ,treated ,with ,2ml 






 , , , , ,Presence ,of , , , , , , 
,Phosphate , 
4. Test ,For ,Carbonate: 
 
2ml ,of ,the ,extract ,was ,treated ,with ,2mldil. 






5. Test ,For ,Sulphide: 
 
1gm ,of ,the ,substance ,was ,treated ,with ,2ml 
,of ,the ,con.HCL 
 
Rotten ,Egg 








8. , Test ,for ,Borate: 
2 ,pinches ,of ,the ,substance ,is ,made ,into ,paste ,by 
,using ,sulphuric ,acid ,and ,alcohol ,(95%) ,and 
,introduced ,into ,the ,blue ,flame 
Bluish ,green 






Test ,For ,Basic ,Radicals 
 
1. Test ,For ,Lead: 
 
2ml ,of ,the ,extract ,was ,added ,with ,2ml ,of 












2. Test ,For ,Copper: 
 
One ,pinch ,(50mg) ,of ,substance ,was ,made ,into 
,a ,paste ,with ,con. ,HCl ,in ,a ,watch ,glass ,and 










, , , 
,Absent 
3. Test ,For ,Aluminium: 
 
In the 2ml of extract dil. sodium 
,hydroxide ,was ,added ,in ,5 ,drops ,toexcess. 
 
Yellow ,colour 







4. Test ,For ,Iron: 
 
c. To ,the ,2ml ,of ,extract ,add ,2ml ,of ,dil. 
,ammoniumsolution 
d. To ,the ,2ml ,of ,extract, ,2ml ,thiocyanate 
,solution ,and ,2ml ,of ,con ,HNo3 ,is ,added 
 
 









5. Test ,For ,Zinc: 
 
In ,2ml ,of ,the ,extract ,dil. ,sodium ,hydroxide 
,solution ,was ,added ,in ,5 ,drops ,to ,excess ,and ,dil. 








 , , , , , , ,Present 
6. Test ,For ,Calcium: 
 
2ml ,of ,the ,extract ,was ,added ,with ,2ml ,of ,4% 










7. Test ,For ,Ammonium: 
 
In ,2ml ,of ,extract ,1 ,ml ,of ,Nessler's ,reagent ,and 











8. Test ,For ,Potassium: 
 
A ,pinch ,(25mg) ,of ,substance ,was ,treated ,with 
,2ml ,of ,dil. ,sodium ,nitrite ,solution ,and ,then 
,treated ,with ,2ml ,of ,dil. ,cobalt ,nitrate ,in ,30% ,dil. 














9. Test ,For ,Sodium: 
 
2 ,pinches ,(50mg) ,of ,the ,substance ,was ,made 
,into ,a ,paste ,by ,using ,HCl ,and ,introduced ,into ,the 











10. Test ,For ,Mercury: 
 
2ml ,of ,the ,extract ,was ,treated ,with ,2ml ,of ,dil. 









11. Test ,For ,Arsenic: 
 













1. Test ,For ,Starch: 
 







2. Test ,For ,Reducing ,Sugar: 
 
5ml ,of ,Benedict's ,qualitative ,solution ,was ,taken 
,in ,a ,test ,tube ,and ,allowed ,to ,boil ,for 
,2minutesandadded8to10dropsofthe 
extract ,and ,again ,boil ,it ,for ,2 ,minutes. 
 







3. Test ,For ,The ,Alkaloids: 
 
c) 2ml ,of ,the ,extract ,is ,treated ,with ,2ml ,of 
,dil. ,Potassium ,iodide ,solution. 














4. Test ,For ,Tannic ,Acid: 
 
2ml ,of ,the ,extract ,was ,treated ,with ,2ml ,of ,dil. 










5. Test ,For ,Amino ,Acid: 
 
2 ,drops ,of ,the ,extract ,were ,placed ,on ,a ,filter 
,paper ,and ,dried ,well, ,and ,then ,20ml ,of ,Biuret 
,reagent ,was ,added ,to ,it. 
 
 







6. Test ,for ,Type ,of ,Compound: 
2 ,ml ,of ,the ,extract ,is ,treated ,with ,2 ,ml ,of ,ferric 
,chloride ,solution 










The ,above ,table ,shows ,the ,presence ,of ,Chloride,Phosphate, ,Carbonate ,, ,Iron, ,Zinc ,, ,Alkaloids, 















5.5.PHARMACOLOGICAL ,SCREENING ,OF ,PARANGIPATTAI ,KUDINEER 
,CHOORANAM ,: 
5.5.1.In-vitro ,Anti-Inflammatory ,Activity ,by ,Protein ,(Albumin) ,denaturation ,Assay 
 
Figure.5.8. ,Sample ,Description , 
Solubility ,Profile ,of ,PKC 
S.No Solvent , Observation 
1 Chloroform Insoluble 
2 Ethanol Slightly ,soluble 
3 Water Soluble 
4 Ethyl ,acetate Insoluble 
5 DMSO Soluble 
Table.5.10.Solubility ,Profile , 
 
 ,Statistical ,analysis 
Results ,are ,expressed ,as ,Mean ,± ,SD. ,The ,difference ,between ,experimental ,groups ,was 











Percentage ,Inhibition ,of ,Protein 
,Denaturation 
PKC ,100 16.09 , ,± ,0.58 
PKC ,200 24.33 , ,± ,0.83 
PKC ,300 37.11 , ,± ,0.71 
PKC ,400 45.97 , ,± ,2.18 
PKC , ,500 
61.2 , ,± ,1.84 
Diclofenac ,sodium , , , , , 
, , , , , , , , , , ,(100 ,µg) 99.5 , ,± ,0.38 
Table.5.11.Each ,value ,represents ,the ,mean ,± ,SD. ,N=3 
 
 
Figure.5.9. ,Percentage ,Inhibition ,of ,Protein ,Denaturation ,by ,PKC ,and ,Standard 
 
Result ,Analysis 
The ,result ,obtained ,from ,the ,present ,clearly ,indicates ,that ,the ,test ,drug ,PKC ,was 
,effective ,in ,inhibiting ,heat ,induced ,albumin ,denaturation. ,Maximum ,percentage ,inhibition ,of 
,about ,61.2 , ,± ,1.84% ,was ,observed ,at ,500 ,μg/ml ,when ,compare ,to ,that ,of ,the ,Diclofenac ,sodium, 
,a ,standard ,anti-inflammatory ,agent ,with ,the ,maximum ,inhibition ,99.5 , ,± ,0.38 ,at ,the 




From ,the ,result ,of ,the ,study ,it ,was ,concluded ,that ,the ,test ,drug ,PKC ,possess ,significant 
,anti-inflammatory ,property ,in ,protein ,denaturation ,assay. 
 
5.5..2.In ,vitro ,Immunomodulatory ,Activity ,of ,Siddha ,formulation , ,Parangipattai 
,Kudineer ,Chooranam ,(PKC) ,in ,RAW ,Macrophage ,Cell ,line ,: 
 
Immunomodulatory ,Evaluation ,Report 
 
Concentration ,(µg/ml) 
Concentration ,of ,Nitrites ,(µg) 
Control ,(LPS1µg/mL) 1153 ,± ,28.15 
 
PKC ,50 ,µg 506.7 ,± ,4.509 
 
PKC ,100 ,µg 444.3 ,± ,9.504 
 
PKC ,200 ,µg 230 ,± ,13.75 
 
 , , ,Table.5.12. ,Effect ,of ,Siddha ,Formulation ,PKC ,on ,Nitrite ,level ,in ,RAW ,264.7 ,Cell ,line. 
 
 








Concentration ,in ,µg/ml % ,cell ,Viability 
1 Control ,(LPS1µg/mL) 95.98 ,± ,1.90 
 
2 PKC , , ,50 ,µg 82.3 ,± ,2.18 
 
3 PKC , , ,100 ,µg 65.88 ,± ,3.33 
 
4 PKC , , ,200 ,µg 47.3 ,± ,0.60 
 
 














 , , , , , , , , , , , , , , , , , , , ,            ,LPS1µg/mL , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,Test ,drug ,PKC ,50 ,μg 
 , , , , , , , , , , , ,  
 , , , , , , , , , , , , ,Test ,drug ,PKC ,100 ,μg , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,  , , , , ,Test ,drug ,PKC ,200 ,μg 
 , , , , , , , , , , , , ,  
 
Figure.5.12.LPS ,induced ,proliferation ,in , ,Macrophage ,cell ,line ,RAW ,264.7 , , , , , , , , 
 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 
 
RESULT 
It ,was ,observed ,that ,there ,was ,dose ,dependent ,decrease ,in ,the ,nitrite ,level ,in ,RAW 
,264.7 ,medium ,incubated ,with ,test ,drug ,at ,the ,concentration ,ranges ,from ,50 ,to ,200 ,µg/ml. 
,Lipopolysaccharide ,(LPS) ,(1µg/mL) ,treated ,well ,was ,served ,as ,a ,control ,with ,maximum ,nitrite 
,level ,of ,about ,1153 ,± ,28.15 ,µg. ,The ,formulation ,PKC ,at ,the ,dose ,of ,50 ,µg/ml ,shown ,a 
,significant ,decrease ,in ,nitrite ,level ,of ,about ,506.7 ,± ,4.50 ,µg ,similarly ,at ,the ,concentration ,of 
,100 ,µg/ml ,it ,shows ,444.3 ,± ,9.504 ,µg ,and ,the ,maximum ,percentage ,decrease ,of ,nitrite ,level ,of 
,about ,230 ,± ,13.75 ,µg ,were ,observed ,at ,200 ,µg/ml. ,The ,reuslt ,obtained ,from ,the ,study ,reveals 
,that ,the ,percentage ,of ,cell ,viability ,of ,macrophase ,cell , ,line ,decreases ,with ,increase ,in 
,concentration ,of ,the ,test ,drug ,PKC , ,Least ,viability ,of ,cell ,was ,observed ,at ,the ,concentration ,of 
,200µg/ml ,shows ,47.3 ,± ,0.60 ,%. 
Observation 
 ,The ,test ,drug ,PKC ,has ,significantly ,reduced ,the ,nitrite ,level ,at ,the ,concentration ,ranges 
,from ,50 ,to ,200 ,µg/ml. ,Hence ,from ,the ,data’s ,it ,was ,concluded ,that ,the ,formulation ,PKC 







5.5.3.In ,vitro ,Anti-proliferative ,Activity ,of ,Siddha ,formulation ,Parangipattai ,Kudineer 
,Chooranam(PKC) ,in ,HaCaT ,cell ,line ,using ,MTT ,assay ,: 
 
Table.5.14.Effect ,of ,Test ,drug ,PKC ,on ,Cell ,viability ,of ,HaCaT ,cell ,line 
 
S.No 
Concentration ,in ,µg/ml % ,cell ,Viability 
1 10 80.33 ,± ,10.26 
2 50 64.91 ,± ,10.02 
3 100 52.56 ,± ,4.789 
4 150 40.08 ,± ,11.48 
5 200 18.83 ,± ,10.16 
6 250 11.62 ,± ,8.402 
 
 , , , , ,  





Table.5.15.Effect ,of ,Test ,drug ,PKC ,on ,Cell ,death ,of ,HaCaT ,cell ,line 
 
S.No 
Concentration ,in ,µg/ml % ,cell ,Death 
1 10 19.57 ,± ,10.33 
2 50 35.04 ,± ,9.975 
3 100 47.37 ,± ,4.829 
4 150 59.88 ,± ,11.43 
5 200 81.11 ,± ,10.14 
6 250 88.33 ,± ,8.424 
 
 
Figure.5.13. ,Effect ,of ,Test ,drug ,PKC ,on ,Cell ,death ,of ,HaCaT ,cell ,line 
IC ,50 ,Value ,of ,PKC 
IC ,50 ,Value ,of ,PKC  ,106.9 ,± ,26.31 ,µg/ml 
 




















 , , , , , ,Test ,Drug ,PKC ,- ,10 ,μg 
 
 , , , ,Test ,Drug ,PKC ,- ,50 ,μg
 
 , , , ,Test ,Drug ,PKC ,- ,100 ,μg ,
 
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 
 , , , ,Test ,Drug ,PKC ,- ,150μg
 
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 
 , , ,Test ,Drug ,PKC ,- ,200μg
 




 , , , ,Result ,and ,Discussion 
 , 
In-vitro ,anti-proliferative ,evaluation ,of ,test ,drug ,PKC ,on ,the ,cell ,viability ,against 
,HaCaT ,keratinocyte ,cell ,linewas ,performed ,at ,varying ,concentration ,ranges ,from ,10 ,to ,250 
,µg/ml ,.The ,reuslt ,obtained ,from ,the ,study ,reveals ,that ,the ,percentage ,of ,cell ,viability ,of ,HaCaT 
,celline ,line ,viability ,decrease ,with ,increase ,in ,concentration ,of ,the ,test ,drug ,PKC. ,Least 
,viability ,of ,cell ,was ,observed ,at ,the ,concentration ,of ,250µg/ml ,shows ,11.62 ,± ,8.402 ,%, 
,followed ,by ,this ,200µg/ml ,shows ,18.83 ,± ,10.16 ,%, ,similarly ,150, ,100,50 ,and ,10 ,µg/ml ,shows 
,40.08 ,± ,11.48,52.56 ,± ,4.789,64.91 ,± ,10.02 ,and ,80.33 ,± ,10.26 ,% ,cell ,viability ,in ,MTT ,assay. 
,The ,corresponding ,IC50 ,value ,was ,found ,to ,be ,106.9 ,± ,26.31 , ,µg/ml. 
 
5.5.4.Docking ,analysis ,: 




PDB Name ,of ,the ,Target 
1P9M IL- ,6 
2AZ5 TNF-alpha 
1NSI Nitric ,Oxide ,Synthase 
 
 
Crystalline ,structure ,of ,the ,target ,proteins ,IL- ,6(1P9M), ,TNF-alpha ,(2AZ5) ,and ,Nitric ,Oxide 
,Synthase ,(1NSI) ,was ,retrieved ,from ,protein ,data ,bank ,and ,protein ,clean-up ,process ,was ,done 
,and ,essential ,missing ,hydrogen ,atom ,were ,been ,added. ,Different ,orientation ,of ,the ,lead 
,molecules ,with ,respect ,to ,the ,target ,protein ,was ,evaluated ,by ,Autodock ,program ,and ,the ,best 











Figure.5.15.RECEPTOR ,STRUCTURE , 
 





Nitric ,Oxide ,Synthase ,(1NSI) 
 
 


















Anisaldehyde 136.148 C8H8O2 0 1 2 
Berberine 336.361 C20H18NO4 0 4 2 
Kaempferol 286.239 C15H10O6 4 6 1 
Protocatechuic ,acid 153.112 C7H6O4 3 1 1 
Nimbolide 466.523 C27H30O7 0 7 4 
Picein 
298.289 C14H18O7 4 7 4 






















Anisaldehyde -3.77 1.72 -4.37 382.53 
Berberine -6.20 28.66* -0.64 750.61 
Kaempferol -6.38 20.95* -6.85 626.40 
Protocatechuic ,acid -4.64 393.85* -4.93 406.07 
Nimbolide -8.40 691.97* -9.17 790.68 
Picein -6.69 12.40* -7.37 703.68 
Tacrolimus -5.65 72.15** -4.53 620.79 
 
















Anisaldehyde -2.95 6.88 -3.55 375.95 
Berberine -4.75 331.70* -5.36 530.60 
Kaempferol -4.96 230.90* -5.47 433.93 
Protocatechuic ,acid -3.85 1.57* -4.05 324.45 
Nimbolide -6.61 14.20* -7.36 556.19 
Picein -5.15 168.60* -5.66 483.95 
Tacrolimus -9.29 155.40** -8.44 721.58 
Table.5.20.Summary ,of ,the ,molecular ,docking ,studies ,of ,the ,lead ,compounds 














Anisaldehyde -4.15 908.35* -4.75 420.96 
Berberine -5.86 503.20* -6.47 683.60 
Kaempferol -5.73 63.42* -6.16 607.80 
Protocatechuic ,acid -4.31 694.39* -4.67 423.53 
Nimbolide -6.29 24.39* -7.06 641.73 
Picein -6.19 29.21* -6.85 626.87 









,Interactions Lead ,/ ,Standard 
Amino ,Acid ,Residue- ,Binding 
1 Anisaldehyde 134 ,THR 136 ,PHE 152 ,ALA 157 ,PRO  ,  ,  , 
2 Berberine 129 ,GLU 135 ,ASN 136 ,PHE 152 ,ALA 154 ,ARG 157 ,PRO 158 ,THR 
1 Kaempferol 104 ,PRO 129 ,GLU 130 ,THR 134 ,THR 135 ,ASN 136 ,PHE 157 ,PRO 
0 Protocatechuic ,acid 150 ,CYS 153 ,LYS 156 ,THR 159 ,SER 160 ,CYS 161THR  , 
1 Nimbolide 129 ,GLU 130 ,THR 134 ,THR 136 ,PHE 157 ,PRO  ,  , 
0 Picein 129 ,GLU 130 ,THR 135 ,ASN 152 ,ALA 154 ,ARG  ,  , 
3 Tacrolimus 109 ,ASN 123 ,GLU 125 ,ASP 157 ,PRO 158 ,THR  ,  , 
 
Amino ,acids ,such ,as ,109 ,ASN, ,157 ,PRO ,and ,158 ,THR ,are ,the ,core ,residue ,involved ,in 
,mediating ,the ,IL-6 ,activity ,.Binding ,of ,lead ,compounds ,with ,this ,core ,residue ,may ,inhibit ,the , 
,activity ,.Out ,of ,six ,compound’s ,Berberine ,has ,2 ,interactions ,similar ,to ,that ,of ,the ,standard 
,Tacrolimus. ,Other ,compounds ,such ,as ,Anisaldehyde ,, ,Kaempferol ,and ,Nimbolide ,has ,one 
,interaction ,similar ,to ,that ,of ,the ,standard. ,Hence ,these ,compounds ,possess ,promising ,IL-6 
,inhibition ,activity  
 





Amino ,acids ,such ,as ,59 ,TYR, 61 ,GLN,119 ,TYR ,and ,151 ,TYR ,are ,the ,core ,residue 
,involved ,in ,mediating ,the ,TNF- ,Alpha ,activity. ,Binding ,of ,lead ,compounds ,with ,this ,core 
,residue ,may ,inhibit ,the , ,activity. ,Out ,of ,six ,compound’s ,Picein ,and ,Anisaldehyde ,has ,4 
,interactions ,similar ,to ,that ,of ,the ,standard ,Tacrolimus. ,Other ,compounds ,such ,as ,Berberine, 
,Kaempferol, ,Protocatechuic ,acid ,and ,Nimbolide ,has ,three ,interaction ,similar ,to ,that ,of ,the 







,Interactions Lead ,/ ,Standard 
Amino ,Acid ,Residue- ,Binding 
4 Anisaldehyde 59 ,TYR 61 ,GLN 119 ,TYR 151 ,TYR  ,  ,  , 
3 Berberine 15 ,HIS 59 ,TYR 119 ,TYR 151 ,TYR  ,  ,  , 
3 Kaempferol 59 ,TYR 119 ,TYR 120 ,LEU 151 ,TYR  ,  ,  , 
3 Protocatechuic ,acid 59 ,TYR 61 ,GLN 119 ,TYR 151 ,TYR  ,  ,  , 
3 Nimbolide 59 ,TYR 61 ,GLN 119 ,TYR 151 ,TYR 155 ,ILE  ,  , 
4 Picein 15 ,HIS 59 ,TYR 61 ,GLN 119 ,TYR 149 ,GLN 151 ,TYR  , 
4 Tacrolimus 57 ,LEU 59 ,TYR 61 ,GLN 119 ,TYR 149 ,GLN 151 ,TYR 155 ,ILE 
149 
 
Table.5.23.Amino ,acid ,Residue ,Interaction ,of ,Lead ,and ,Standard ,against ,Nitric ,Oxide ,Synthase 
,(1NSI) 
 
Amino ,acids ,such ,as ,374 ,MET ,,377 ,GLN,381 ,ARG,461 ,TRP, ,465 ,VAL and ,467 
,PRO ,are ,the ,core ,residue ,involved ,in ,mediating ,the ,Nitric ,oxide ,synthase ,activity. ,Binding ,of 
,lead ,compounds ,with ,this ,core ,residue ,may ,inhibit ,the , ,activity ,. ,Out ,of ,six ,compound’s ,Picein 
,and ,Anisaldehyde ,has ,4 ,interactions ,similar ,to ,that ,of ,the ,standard ,Tacrolimus. ,Other 
,compounds ,such ,as ,Berberine, ,Kaempferol ,and ,Nimbolide ,has ,three ,interaction ,similar ,to ,that 
,of ,the ,standard. ,Hence ,these ,compounds ,possess ,promising ,Nitric ,oxide ,synthase ,enzyme 
,inhibition ,activity. 




,Interactions Lead ,/ ,Standard 












,ARG 461 ,TRP 462 ,ILE 463 ,TRP 
465 




,ARG 461 ,TRP 463 ,TRP 
465 









































Figure.5.17.FINAL ,DOCKING ,REPORT ,IL-6 ,: 
Anisaldehyde ,with ,IL- ,6 
,– ,PDB ,1P9M 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
 
 
 , , ,  
Berberine ,with ,IL- ,6 ,– 
,PDB ,1P9M 
HB ,Plotting ,Analysis Receptor ,Ligand ,Complex 
  
 
Kaempferol ,with ,IL- ,6 ,– 
,PDB ,1P9M 
HB ,Plotting ,Analysis Receptor ,Ligand ,Complex , , , , , , , , 
  
 
Protocatechuic ,acid ,with 
,IL- ,6 ,– ,PDB ,1P9M 
HB ,Plotting ,Analysis Receptor ,Ligand ,Complex 
  













Nimbolide ,with ,IL- ,6 ,– 
,PDB ,1P9M , , , , , , , , , , 
HB ,Plotting ,Analysis , 
 




Picein ,with ,IL- ,6 ,– ,PDB 
,1P9M 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
 
  
Tacrolimus ,with ,IL- ,6 ,– 
,PDB ,1P9M 
HB ,Plotting ,Analysis , 
 






Figure.5.18.FINAL ,DOCKING ,REPORT ,TNF ,- ,α ,: 
Anisaldehyde ,with ,TNF-alpha 
,(2AZ5) , , , , , , , , , , , , , , 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
   
Berberine ,with ,TNF-alpha 
,(2AZ5) 
HB ,Plotting ,Analysis , 
 




Kaempferol ,with ,TNF-alpha 
,(2AZ5) , , , , , , , , , , , , , , , , , , , , 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
 
  
Protocatechuic ,acid ,with ,TNF-
alpha ,(2AZ5) 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 













Nimbolide ,with ,TNF-alpha 
,(2AZ5) , , , , , , , , , , , , , , , 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
   
Picein ,with ,TNF-alpha 
,(2AZ5) 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
  
 
Tacrolimus ,with ,TNF-alpha 
,(2AZ5) 
HB ,Plotting ,Analysis , 
 






Figure.5.19.FINAL ,DOCKING ,REPORT ,NITRIC ,OXIDE ,SYNTHASE ,: 
Anisaldehyde ,with ,Nitric ,Oxide 
,Synthase ,(1NSI) , , , , , , , , , , , , , , , , , , , , 
HB ,Plotting ,Analysis , 
 




Berberine ,with ,Nitric ,Oxide 
,Synthase ,(1NSI) 
HB ,Plotting ,Analysis , 
 
Receptor ,Ligand ,Complex 
   
Kaempferol ,with ,Nitric ,Oxide 
,Synthase ,(1NSI) , , , , , , , , , , , , , , 
HB ,Plotting ,Analysis , 
 




Protocatechuic ,acid ,with ,Nitric 
,Oxide ,Synthase ,(1NSI) 
HB ,Plotting ,Analysis , 
 















Nimbolide ,with ,Nitric ,Oxide 
,Synthase ,(1NSI) , , , , , , , , , 
HB ,Plotting ,Analysis , 
 




Picein ,with ,Nitric ,Oxide 
,Synthase ,(1NSI) 
HB ,Plotting ,Analysis , 
 




Tacrolimus ,with ,Nitric , 
Oxide ,Synthase ,(1NSI) , , , , , 
HB ,Plotting ,Analysis , 
 






5.5.5.Sivappu ,Thylam , ,: , 
In-vitro ,Anti-Inflammatory ,Activity ,by ,Protein ,(Albumin) ,denaturation ,Assay 
 
Figure.5.20.Sample ,Description 
S.No Solvent ,Used Solubility ,/ ,Dispersibility 
1 Chloroform Soluble 
2 Ethanol Insoluble 
3 Water Insoluble 
4 Ethyl ,acetate , Soluble 
5 Hexane Soluble 
6 DMSO Insoluble 
Table.5.24.Solubility ,Profile ,of ,ST 
Sample ,Preparation: ,Chloroform ,Extract ,of ,the ,sample ,ST ,were ,been ,used ,for ,the ,assay 
 ,Statistical ,analysis 
Results ,are ,expressed ,as ,Mean ,± ,SD. ,The ,difference ,between ,experimental ,groups ,was 













Percentage ,Inhibition ,of ,Protein 
,Denaturation 
ST ,100 10.21 , ,± ,1.45 
ST ,200 20 , ,± ,1.38 
ST ,300 25.54 , ,± ,0.26 
ST ,400 36.71 , ,± ,2.47 
ST ,500 
50.91 , ,± ,0.99 
Diclofenac ,sodium , , , , , 
, , , , , , , , , , ,(100 ,µg) 97.19 , ,± ,3.80 
Table.5.25.Each ,value ,represents ,the ,mean ,± ,SD. ,N=3 
 
 
 , , , , , , , , , , , , , , , , , , , , ,Figure.5.21.Percentage ,Inhibition ,of ,Protein ,Denaturation 
 
Result ,Analysis 
The ,result ,obtained ,from ,the ,present ,clearly ,indicates ,that ,the ,test ,drug ,ST ,was ,effective 
,in ,inhibiting ,heat ,induced ,albumin ,denaturation. ,Maximum ,percentage ,inhibition ,of ,about 
,50.91 ,± ,0.99 ,% ,was ,observed ,at ,500 ,μg/ml ,when ,compare ,to ,that ,of ,the ,Diclofenac ,sodium, ,a 
,standard ,anti-inflammatory ,agent ,with ,the ,maximum ,inhibition ,97.19 ,± ,3.80 ,at ,the 
,concentration ,of ,100 ,μg/ml. 
Conclusion 
From ,the ,result ,of ,the ,study ,it ,was ,concluded ,that ,the ,test ,drug ,ST ,possess ,promising 





 Parangipattai ,Kudineer ,was ,administered ,single ,time ,at ,the ,dose ,of ,2gms/kg ,to ,rats ,and 
,observed ,for ,consecutive ,14 ,days ,after ,administration. ,According ,to ,the ,OECD ,guideline ,423 
,when ,there ,is ,information ,in ,support ,of ,non-toxicity ,or ,low ,and ,immortality ,nature ,of ,the ,test 
,substance, ,then ,the ,limit ,test ,at ,the ,dose ,level ,2 ,gms/kg ,body ,weights ,(highest ,starting ,dose 
,level) ,was ,conducted. ,All ,animals ,were ,observed ,daily ,once ,for ,any ,abnormal ,clinical ,signs. 
,Weekly ,body ,weight ,and ,food ,consumption ,were ,recorded. ,No ,mortality ,was ,observed ,during 
,the ,total ,period ,of ,the ,study. ,Data ,obtained ,in ,this ,study ,indicated ,no ,significance ,physical ,and 
,behavioural ,signs ,of ,any ,toxicity ,due ,to ,administration ,of ,Parangipattai ,Kudineer ,at ,the ,dose 
,of ,2gms/kg ,to ,rats. , 
At ,the ,14th ,day, ,all ,animals ,were ,observed ,for ,functional ,and ,behavioural ,examination. 
,In ,functional ,and ,behavioural ,examination, ,home ,cage ,activity, ,handheld ,activity ,were 
,observed. ,Home ,cage ,activities ,like ,Body ,position, ,Respiration, ,involuntary ,movement, 
,(Clonic ,and ,Tonic), ,Palpebral ,closure, ,Approach ,response, ,Touch ,response, ,Pinna ,reflex, 
,Sound ,responses, ,Tail ,pinch ,response ,were ,observed. ,Handheld ,activities ,(Reactivity ,and 
,Handling), ,Palpebral ,closure, ,Lacrimation, ,Salivation, ,Piloerection, ,Papillary ,reflex, 
,abdominal ,tone, ,Limb ,tone ,were ,observed. ,Functional ,and ,behavioural ,examination ,was 
,normal ,in ,all ,groups. ,Food ,consumption ,of ,all ,treated ,animals ,was ,found ,normal ,as ,compared 
,to ,control ,group. ,The ,results ,of ,functional ,and ,behavioural ,examination ,were ,elicited ,in ,(Table 
,5.26). 
Body ,weight ,at ,weekly ,interval ,was ,measured ,to ,find ,out ,the ,effect ,of ,PPK ,on ,the 
,growth ,rate. ,No ,significant ,body ,weight ,changes ,were ,observed ,between ,control ,and ,treatment 
,group. ,There ,were ,no ,treatment ,related ,mortality ,in ,both ,control ,and ,treatment ,groups 
,throughout ,the ,experimental ,period(Table.5.26.) 












Table.5.26. , ,Effect ,of ,PPK ,on ,Body ,weight ,of ,Wistar ,Rats ,in ,acute ,toxicity ,study 
 
Treatment 
Body  ,weight  ,(mean±SEM) 
Day  ,1 Day  ,7 Day  ,14 
PPK(2000mg/kg) 
 145± ,1.674* 148.00±1.515* 151.65±1.486* 
 
Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical ,significance ,(p) ,calculated ,by ,one ,way 
,ANOVA ,followed ,by ,dunnett’s.P< ,0.05 ,considered ,as ,significant ,by ,comparing ,treated ,group 


































BODY WEIGHT OF RATS IN ACUTE 
TOXICITY STUDY
DAY 1 DAY  7 DAY 14
160 
 
Table.5.27. , ,Clinical ,Observation ,of ,control ,and ,PPK ,treated ,experimental ,animals ,in 
,acute ,toxicity ,study 
Observations Signs  Signs 
Lethality X Stereotypies , ,(chewing) X 
Convulsion X Stereotypies 
(Head ,movements) 
X 
Tremor X Piloerection , X 
Straub ,tail X Scratching X 
Sedation 
#1 X Respiration X 
#2 X Aggressiveness X 
#3 X Fear X 
Excitation #1 X Reactivity ,to ,touch X 
#2 X Muscle ,tone X 
#3 





X Ptosis X 
Abnormal ,gait 
(tiptoe) 
X Exophthalmos X 
Jumps X Loss ,of ,grasping X 
Motor ,coordination X Akinesia X 
Loss ,of ,balance X Catalepsy X 
Fore ,paw ,treading X Loss ,of ,traction X 
Writhes X Loss ,of ,corneal ,reflex X 
Head ,twitches X Loss ,of ,righting 
Reflex 
X 
Salivation X Defecation X 
Lacrimation X Others , X 
 























,Figure.5.23. ,Gross ,Pathology ,of ,rat ,in ,acute ,toxicity ,study 
Table ,.5.28.Gross ,pathology ,observations ,of ,control ,and ,PPK ,treated ,experimental 
,animals , 
ORGANS OBSERVATION 
Brain No ,abnormal ,lesion ,observed 
Eyes No ,abnormal ,lesion ,observed 
Lymph ,node No ,abnormal ,lesion ,observed 
Trachea No ,abnormal ,lesion ,observed 
Oesophagus No ,abnormal ,lesion ,observed 
Lungs No ,abnormal ,lesion ,observed 
Heart No ,abnormal ,lesion ,observed 
Liver, ,Spleen No ,abnormal ,lesion ,observed 
Pancreas No ,abnormal ,lesion ,observed 





No ,abnormal ,lesion ,observed 
 
 
 ,Small ,and ,large ,intestine , No ,abnormal ,lesion ,observed 
Kidney No ,abnormal ,lesion ,observed 






No ,abnormal ,home ,cage ,activities, ,behavioural ,responses ,or ,neurological ,symptoms 
,were ,observed ,before ,and ,after ,the ,exposure ,of ,PPK. , 
All ,animals ,in ,this ,study ,were ,free ,of ,toxic ,clinical ,signs ,throughout ,the ,dosing , , ,period 
,of ,28 ,days. ,(Table). 
5.6.2.2. ,Mortality: 
Since ,examination ,of ,clinical ,signs ,plays ,main ,role ,in ,toxicological ,testing, ,mortality 
,and ,morbidity ,were ,recorded ,two ,times ,a ,day ,throughout ,the ,study. ,All ,animals ,in ,control ,and 
,in ,all ,the ,treated ,dose ,groups ,survived ,during ,the ,dosing ,period ,of ,28 ,days. 
5.6.2.3.Body ,weight: 
Results ,of ,body ,weight ,determination ,of ,animals ,from ,control ,and ,different ,dose ,groups 
,exhibited ,comparable ,body ,weight ,gain ,(throughout ,the ,dosing ,period ,of ,28 ,days ,(Table ,..). 
 
5.6.2.4.Food ,and ,water ,consumption: 
 , , , , , , , , , , , , , ,Feed ,and ,water ,consumption ,of ,PPK ,treated ,groups ,were ,found ,to ,be ,in ,significant ,in 
,both ,the ,sexe ,when ,compared ,to ,control. ,The ,faecal/urinary ,excretion ,patterns ,were ,also ,found 
,to ,be ,normal ,in ,PPK ,administered ,rats ,in ,comparison ,to ,the ,vehicle ,treated ,rats. , 
5.6.2.5.Relative ,organ ,Weight: 
 Effects ,of ,PPK ,on ,relative ,organ ,weights ,were ,shown ,in ,Table ,(). ,No ,statistically 
,significant ,changes ,in ,the ,relative ,organ ,weights ,of ,brain, ,heart, ,liver, ,spleen, ,lungs, ,kidneys 















Table.5.29.Clinical ,Observation ,of ,control ,and ,PPKtreated ,experimental ,animals ,in 
,subacute ,toxicity ,study 
Observations Signs  Signs 
Lethality X Stereotypies , ,(chewing) X 
Convulsion X Stereotypies 
(Head ,movements) 
X 
Tremor X Piloerection , X 
Straub ,tail X Scratching X 
Sedation 
#1 X Respiration X 
#2 X Aggressiveness X 
#3 X Fear X 
#4 X 
Excitation #1 X Reactivity ,to ,touch X 
#2 X Muscle ,tone X 







X Ptosis X 
Abnormal ,gait 
(tiptoe) 
X Exophthalmos X 
Jumps X Loss ,of ,grasping X 
Motor ,coordination X Akinesia X 
Loss ,of ,balance X Catalepsy X 
Fore ,paw ,treading X Loss ,of ,traction X 
Writhes X Loss ,of ,corneal ,reflex X 
Head ,twitches X Loss ,of ,righting 
Reflex 
X 
Salivation X Defecation X 
Lacrimation X Others , X 
 









Table5.30.Effect ,of ,Paranipattai ,Kudineer ,on ,Body ,weight ,of ,experimental ,Wistar ,rats ,in 
,28 ,days ,repeated ,oral ,toxicity ,study: 
 
Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical ,significance ,(p) ,calculated ,by ,one ,way 
,ANOVA ,followed ,by ,dunnett’s. ,ns ,P>0.05 ,considered ,as ,not ,significant, ,*P< ,0.05 ,considered ,as 
,significant, ,**P< ,0.01 ,considered ,as ,very ,significant, ,***P< ,0.001 ,considered ,as ,extremely 
,significant ,by ,comparing ,treated ,group ,with ,control ,group ,using ,Graph ,Pad ,Prism ,3.1.. ,Animal 
,body ,weight ,slightly ,increased , ,some ,group ,as ,per ,guidline. 
 
 



















BODY WEIGHT OF RATS IN SUBACUTE 
TOXICITY STUDY 
DAY 1 DAY 7 DAY 14 DAY 21 DAY 28
 
Treatment 
Body ,weight ,(mean±SEM) 
1st ,day 7th ,day 14th ,day 21st ,day 28th , ,day 
Control , 122±4 139.75±4.17** 147.35±5.49ns 156.20±7.41ns 180.20±8.16* 
9 ,mg ,PPK/kg 
,p.o/day 
 137±3 149.40±3.67* 161.70±2.05** 171.55±2.21** 196.80±5.52*** 
18mg ,PPK/kg 
,p.o/day 
 143±4 156.88±3.91* 163.30±4.23ns 171.55±6.09ns 188.70±10.41ns 
27mg ,PPK/kg 
,p.o/day 
 151±4 159.58±2.94ns 165.13±2.75ns 178.78±4.01* 196.50±7.67* 
166 
 
Table.5.31. ,Effect ,of ,Paranipattai ,Kudineer ,on ,Organ ,weight ,of ,experimental ,Wistar ,rats 




 Relative ,organ ,weight ,(g ,%) ,(mean±SEM) 
Brain Lungs Heart Liver Kidney , Spleen Sex ,organs 
Testis Ovaries 

















































































Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical ,significance ,(p) ,calculated ,by ,one ,way 
,ANOVA ,followed ,by ,dunnett’s. ,ns ,P>0.05 ,considered ,as ,not ,significant, ,by ,comparing ,treated 
,group ,with ,control ,group ,using ,Graph ,Pad ,Prism ,3.1. , 
 
 







0.77 0.73 0.75 0.73























Figure.5.27. ,Effect ,of ,PPK ,on ,relative ,organ ,weights ,in ,WA ,rats 
 









0.89 0.8 0.86 0.82















































Figure.5.29.Effect ,of ,PPK ,on ,ovaries ,weight 
 
5.6.2.6.Hematological ,investigations 
The ,haemopoietic ,system ,serves ,as ,vital ,goal ,for ,toxic ,chemicals ,and ,is ,a ,susceptible 
,index ,for ,pathological ,conditions ,both ,in ,humans ,and ,animals. ,The ,results ,of ,hematological 
,investigations ,conducted ,on ,day ,29 ,does ,not ,revealed ,any ,significant ,changes ,in ,the ,values ,of 
,various ,parameters ,observed ,when ,compared ,with ,those ,of ,respective ,controls(Table ,7.7.7). 
5.6.2.7.Biochemical ,Investigations 
Clinical ,biochemistry ,and ,hematological ,data ,holds ,major ,role ,in ,determining ,the 
,toxicity ,induced ,by ,drugs. ,Transaminases ,(SGPT ,and ,SGOT) ,are ,good ,indicator ,of ,liver 
,function ,and ,biomarkers ,to ,calculate ,the ,possible ,toxicity ,of ,drugs. ,Any ,elevation ,pertaining ,to 
,these ,enzymes ,specifies ,their ,out ,flow ,into ,the ,blood ,stream ,due ,to ,injure ,in ,liver ,parenchymal 
,cells. ,Results ,of ,Biochemical ,investigations ,conducted ,on ,days ,29 ,does ,not ,revealed ,significant 
,changes ,in ,the ,values ,of ,hepatic ,serum ,enzymes ,studied ,when ,compared ,with ,those ,of 





























Table.5.32. ,Effect ,of ,Paranipattai ,Kudineer ,on ,Hematological ,Parameters ,of 





RBC: ,red ,blood ,corpuscles; ,Hb: ,hemoglobin; ,MCH: ,mean ,corpuscular ,hemoglobin; ,WBC: 
,white ,blood ,cells ,PCV: ,packed ,cell ,volume. ,Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical 
,significance ,(p) ,calculated ,by ,one ,way ,ANOVA ,followed ,by ,dunnett’s. ,P> ,0.05 ,considered ,as 
























































2.87±0.10 1.83±0.13 0±0.00 86.61±0.50 3.28±0.09 













2.81±0.17 1.86±0.20 0.1±0.10 85.93±1.46 3.19±0.12 












2.58±0.13 1.7±0.15 0±0.00 85±1.42 3.88±0.41 



















RBC ,Levels ,in ,PPK ,treated ,Rats , WBC ,Levels ,in ,PPK ,treated ,Rats 
  
  


















































CONTROL 9mg/kg 18mg/kg 27mg/kg
Figure 5.30. Effect of PPK over Hematological Parameters in Rats 
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MCH ,Levels ,in ,PPK ,treated ,Rats , , , , , , , , , , , , , , , , , ,Lymphocyte ,Levels ,in ,PPK ,treated ,Rats 
 , , , , , , , ,  
 
Platelet ,Levels ,in ,PPK ,treated ,Rats , Monocyte ,Levels ,in ,PPK ,treated ,Rats 
 , , ,  ,  
  
Neutrophil ,Levels ,in ,PPK ,treated ,Rats  , , , , , , ,Eosinophil , ,Levels ,in ,PPK ,treated ,Rats 




























































CONTROL 9mg/kg 18mg/kg 27mg/kg
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Table.5.33.Effect ,of ,Paranipattai ,Kudineer ,on ,biochemical ,parameters ,of ,experimental 





TGL: ,triglycerides, ,SGOT: ,Serum ,Glutamic ,oxaloacetic ,Transaminase, ,SGPT: ,serum ,glutamic 
,pyruvic ,transaminase, ,ALP: ,Alkaline ,phosphatase. 
Values ,are ,expressed ,as ,mean ,± ,SEM. ,Statistical ,significance ,(p) ,calculated ,by ,one ,way 
,ANOVA ,followed ,by ,dunnett’s. ,P>0.05 ,considered ,as ,not ,significant ,, ,P<0.05 ,considered ,as 
,significant ,(but ,within ,normal ,value ,)by ,comparing ,treated ,group ,with ,control ,group ,using 





























































9 ,mg ,/kg 
,p.o/day 












18 ,mg ,/kg 
,p.o/day 












27 ,mg ,/kg 
,p.o/day 



















 , , , ,TGL ,Levels ,in ,PPK ,treated ,Rats , T.Cholesterol ,Levels ,in ,PPK ,treated ,Rats 




HDL ,Levels ,in ,PPK ,treated ,Rats   LDL ,Levels ,in ,PPK ,treated ,Rats 














































CONTROL 9mg/kg 18mg/kg 27mg/kg






 , , , ,VLDL ,Levels ,in ,PPK ,treated ,Rats , , , , , , , , ,T.BILIRUBIN ,Levels ,in ,PPK ,treated ,Rats 
 , , , ,  
 
SGPT ,Levels ,in ,PPK ,treated ,Rats , , , , , SGOT ,Levels ,in ,PPK ,treated ,Rats 
  
    
 , , , ,BUN ,Levels ,in ,PPK ,treated ,Rats   , , , , ,Creatinine ,Levels ,in ,PPK ,treated ,Rats 




























































Histopathological ,studies ,give ,supportive ,evidence ,for ,biochemical ,and ,haematological 
,observations. ,The ,histopathological ,examination ,carried ,out ,in ,the ,control ,and ,high ,dose 
,animals ,treated ,with ,PPK. ,In ,histopathological ,examination, ,revealed ,normal ,architecture ,in 
,comparison ,with ,control ,and ,all ,treated ,group ,animals ,(Table ,7.7.9). 
 




Brain , No ,abnormal ,lesion ,observed 
Heart No ,abnormal ,lesion ,observed 
Lung No ,abnormal ,lesion ,observed 
 , , , , , , , , , , , , , ,Stomach , No ,abnormal ,lesion ,observed 
Liver No ,abnormal ,lesion ,observed 
Spleen No ,abnormal ,lesion ,observed 
Kidney No ,abnormal ,lesion ,observed 
Uterus No ,abnormal ,lesion ,observed 
Ovary No ,abnormal ,lesion ,observed 

























    Heart ,satellite ,Control ,40x 
 , , , , , , , , , , , , ,Heart ,satellite ,Hig 





Brain ,Control ,40x 
 
 
Brain ,High ,dose ,10x 
 
 












Plate: ,Effect ,of ,PPK ,on ,Brain ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity , 
study. , 
Group Impression 
Control No ,changes , 
High ,dose No ,changes , 
 , , , , , , 




Heart ,Control ,10x 
  
 
Heart ,Control ,40x 
  
 
Heart ,High ,dose ,10x 
    
 
  
 Heart ,satellite ,Control ,40x 
 , , , , , , , , , , , , ,Heart ,satellit 
 















High ,doPlate: ,Effect ,of ,PPK ,on ,Heart ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity ,study. , 
Group Impression 
Control No ,changes , 
High ,dose No ,changes , 
     
Figure 5.32. Effect of PPKon Histopathological changes in Rat 












Lungs ,Control ,10x 
 
 
Lungs ,control ,40x 
 
 
Lungs ,High ,dose ,10x 
 
 




Plate: ,Effect ,of ,PPK ,on ,Lungs ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity ,study. , 
Group Impression 
Control No ,changes , 






Stomach ,Control ,10x , 
 
  




Stomach ,High ,dose 
,10x
 




Plate: ,Effect ,of ,PPK , ,on ,Stomach , ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity 
,study. , 
Group Impression 
Control No ,changes , 











Liver ,Control ,10x , 
 
 
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 
Liver ,Control ,40x 
 
 
Liver ,High ,dose ,10x 
 , , ,
 
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , 




Plate: ,Effect ,of ,PPKon ,Liver ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity ,study. , 
Group Impression 
Control No ,changes , 






Spleen ,Control ,10x , , , 
 
 
, , , , , , , , , , 
Spleen ,Control ,40x 
 ,
 
Spleen ,High ,dose ,10x 
 , , , , , , , , , , , , ,
 





Plate: ,Effect ,of ,PPK ,on ,Spleen ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity ,study. , 
Group Impression 
Control No ,changes , 













Kidneys ,Control ,10x , 
 , , , , ,
 
, , , , , , , 
Kidneys ,Control ,40x 
 
 
Kidneys ,High ,dose ,10x 
 
 
, , , , , , , , , , , , , 






Plate: ,Effect ,of ,PPKon ,Kidneys ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral 
,toxicity ,study. , 
Group Impression 
Control No ,changes , 







Uterus ,Control ,10x , , , 
 
 , 
, , , , , , , , , 
Uterus ,Control ,40x , , 
 
 
Uterus ,High ,dose ,10x , 
 , , ,
 
, , , , , , , , , 





Plate: ,Effect ,of ,PPK ,on ,Uterus ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity 
,study. , 
Group Impression 
Control No ,changes , 





 , , , ,OVARY 
Ovary ,Control ,10x , 
 , , , , , ,
 
, , , , , , 
Ovary ,Control ,40x 
 , ,
 
Ovary ,High ,dose ,10x , 
 
 
, , , , , , , , , , , , 





Plate: ,Effect ,of ,PPK ,on ,Ovary ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity ,study. , 
Group Impression 
Control No ,changes , 






 , , ,TESTIS 
 
 
Plate: ,Effect ,of ,PPK ,on ,Testis ,in ,Wistar ,albino ,rats ,- ,28 ,day ,repeated ,oral ,toxicity ,study. , 
Group Impression 
Control No ,changes , 
High ,dose No ,changes , 
 
 
Testis ,Control ,10x , ,
 
 
Testis ,Control ,40x 
 
 
Testis ,High ,dose ,10x , 
 
 
, , , , , , , , 





5.7.Clinical ,study: , 
 118 ,subjects ,were ,screened ,for ,Psoriasis ,at ,National ,Institute ,of ,Siddha. ,Subjects ,those 
,fulfilled ,the ,inclusion ,criteria ,were ,recruited ,after ,obtaining ,informed ,consent. ,Totally ,43 
,numbers ,of ,Kalanjagapadai ,(Psoriasis) ,individuals ,of ,both ,genders ,were ,recruited ,in ,this 
,study. ,3 ,patients ,had ,withdrawn ,from ,the ,study. ,40 ,patients ,had ,completed ,the ,entire ,course ,of 
,trial ,period. 
Number ,of ,patients ,screened ,for ,eligibility: ,118 
Number ,of ,patients ,included ,in ,trial: ,43 
Number ,of ,patients ,withdrawn ,from ,the ,trial: ,3 
Number ,of ,patients ,who ,reported ,adverse ,drug ,reactions: ,0 
Duration ,of ,trial: ,48 ,days ,(Treatment ,period) , , 
 
5.7.1.Gender ,distribution: 
S.NO Sex No ,of ,Cases Percentage 
1. Male 30 75% 
2. Female 10 25% 
 
 , , , ,  
   , , , ,  Figure5.7.1. ,Gender ,distribution 
Observation: 








5.7.2. ,Distribution ,of ,age ,interval ,: 
 
Sl. ,No Age No ,of ,Cases Percentage 
1 18-30 11 27.5% 
2 31-40 10 25% 
3 41-50 10 25% 




   Figure5.7.2. ,Distribution ,of ,age ,interval 
 
Observation: 
 The ,patients ,selected ,were ,from ,all ,age ,groups ,as ,given ,above ,and ,the ,maximum 












18-30 31-40 41-50 51-60



















5.7.3. ,Kaalam ,Distribution ,(According ,to ,Age): 
  
Sl ,No Kaalam No ,of ,Cases Percentage 
1 Vaatha ,Kaalam ,(1-33 ,Years) 15 37.5% 
2 Pitha ,Kaalam ,(34-66 ,years) 25 62.5% 
3 Kaba ,Kaalam ,(67-100 ,years) 0 0% 
 
  
    Figure. ,5.7.3. ,Kaalam ,Distribution 
 
Observation: 






















5.7.4. ,Distribution ,of ,the ,occupation ,of ,the ,trial ,subjects: 
 
S. ,No Occupation No ,of ,Cases Percentage 
1 Homemaker 
 
 , , , , , , , , , , ,4 10 ,% 
2 Student 
 
1 2.5 ,% 
3 Field ,work ,with ,intellectual ,job 
 
7 17.5 ,% 
4 Field ,work ,with ,physical ,exertion 
 
28 70 ,% 
 
 
  Figure. ,5.7.4. ,Distribution ,of ,the ,occupation ,of ,the ,trial ,subjects 
 
Observation: 














Field work with intellectual job
Field work with physical exertion
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5.7.5. ,Family ,History ,: 
 
Sl. ,No Criteria No ,of ,Cases Percentage 
1 
 
Family ,History ,(+ve) 
 
6 15 ,% 
2 
 
Family ,History ,(-ve) 
 





























5.7.6.History ,of ,Remissions ,and ,Relapses: 
 
Sl. ,No Remissions ,and ,relapses No ,of ,Cases Percentage 
1 Present 36 90 ,% 




























5.7.7. ,Diet ,habits ,of ,the ,trial ,participants: 
 
Sl. ,No Dietary ,Habits No ,of ,Cases Percentage 
1 Vegetarian 6 15 ,% 



















5.7.8. ,Distribution ,of ,habits ,in ,the ,study ,participants: 
 
S.No Habits No ,of ,Cases Percentage 
1 Smoking 0 0 , ,% 
2 Tobacco 3 7.5 ,% 
3 Alcohol 4 10 , ,% 
4 Smoking ,and 
,Alcohol 




  Figure.5.7.8.Distribution ,of ,habits 
 
Observation: 
 Out ,of ,40 ,patients, ,67.5 ,% ,of ,patients ,had ,no ,habits ,0% ,of ,patients ,had ,smoking ,habits, 
,7.5% ,of ,patients ,had ,tobacco ,chewing ,habits, ,Smoking ,and ,alcohol ,15 ,% , ,and ,10% ,of ,patients 



























Sl. ,No Thinai No. ,of ,Cases Percentage 
1 Kurinji ,(Hill ,Area) 7 17.5% 
2 Mullai ,(Forest ,Area) 8 20% 
3 Marutham ,(Fertile ,Land) 3 7.5 ,% 
4 Neithal ,(Coastal ,Area) 22 55 ,% 




    Figure ,5.7.9 ,Thinai ,Reference 
 
Observation: 
 7.5% ,of ,the ,patients ,were ,from ,Marutham ,(Fertile ,Land) ,, ,17.5% ,of ,the ,patients ,were 
,fromKurinji ,(Hill ,Area),20% ,of ,the ,patients ,were ,fromMullai ,(Forest ,Area) ,and 














Kurinji Mullai Marutham Neithal Paalai
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ParuvaKaalam No. ,of ,Cases Percentage 
1 Kaar ,kaalam ,(Aavani ,& ,Purattasi) 15 37.5 ,% 
2 Koothir ,Kaalam ,(Aippasi&Kaarthigai) 7 17.5 ,% 




 Figure ,5.7.10 ,Incidence ,of ,Kalanjagapadai ,in ,various ,Paruvakaalam 
 
Observation: 
 Patient ,enrollement ,period ,was ,various ,seasons ,especially ,Kaar ,kaalam,Koothir 
,kaalam, ,Munpanikaalam ,only ,and ,didn’t ,enroll ,of ,patient ,in ,other ,seasons. 











INCIDENCE OF KJP IN VARIOUS SEASON
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5.7.11.Body ,constitution ,of ,the ,trial ,participants ,(YaakaiIlakkanam): 
 
Sl. ,No YaakaiIlakkanam No. ,of ,Cases Percentage 
1 VaathaUdal 13 32.5% 
2 PithaUdal 15 37.5 ,% , 
3 KabaUdal 3  , , , , , , , , ,7.5 ,% 
4 ThonthaUdal 9 22.5 ,% 
 
 
   Figure.5.7.11.Yaakai ,ilakkanam 
Observation: 
















5.7.12.Distribution ,of ,Gunam ,(Quality ,and ,Characters): 
 
Sl. ,No Gunam No ,of ,Cases Percentage 
1 Sathuva ,Gunam 0 0 ,% 
2 Rajo ,Gunam 40 100 ,% 
3 Thamo ,Gunam 0 0% 
 
 
   , , , , , , , , ,Figure. ,5.7.12. ,Distribution ,of ,Gunam 
Observation: 











5.7.13. ,Duration ,of ,Illness: 
 
Sl. ,No Duration ,of ,Illness No ,of ,Cases Percentage 
1. 1-6 ,Months 6 15 ,% 
2. 7-12 ,Months 0 0 ,% 
3.  , , , , , , , ,1-3 ,years 14 35 ,% 
4.  , , , , , , , , ,4-6 ,years 12 30 ,% 





   Figure ,5.7.13 ,Duration ,of ,Illness 
 
Observation: 
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years

















Before ,Treatment After ,Treatment 
No ,of ,Cases Percentage No ,of ,Cases Percentage 
1 Mei 40 100 ,% , 11 27.5% 
2 Vaai 0 0%  , , , , , , , , ,0 0% 
3 Kan 0 0% 0 0% 
4 Mooku 0 0% 0 0% 
5 Sevi 0 0% 0 0% 
 
Observation: 
 Before ,treatment ,mei ,were ,found ,to ,be ,affected ,in ,all ,the ,40 ,patients.. ,After ,treatment 
,mei ,were ,found ,to ,be ,affected ,in ,27.5% ,of ,patients. , 
 













1 Kai 0 0% 0 0% 
2 Kaal 0 0%  , , , , , , , ,0 0% 
3 Vaai 0 0% 0 0% 
4 Eruvai 01 2.5 ,% 0 0% 
5 Karuvai 0 0% 0 0% 
 
Observation: 
 Before ,treatment ,eruvai ,were ,found ,to ,be ,affected ,in ,one ,patients.. ,After ,treatment 
,eruvai ,were ,found ,to ,be ,no ,abnormalities. 
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1 Annamayakosam 03 7.5 ,% 0 0% 
2 Pranamayakosam 01 2.5 ,%  , , , , , , , , ,01 2.5 ,% 
3 Manomayakosam 40 100 ,% 13 32.5 ,% 
4 Vingnanamayakosam 0 0% 0 0% 
5 Anandhamayakosam 0 0% 0 0% 
Observation: 
 Before ,treatment ,were ,found ,to ,be ,affected ,7.5% ,patients ,in ,annamayakosam, ,2.5% ,in 
,pranamayakosam,100% ,in ,manomayakosam. ,After ,treatment ,were ,found ,to ,be ,affected ,0% 
,patients ,in ,annamayakosam, ,2.5% ,in ,pranamayakosam,32.5% ,in ,manomayakosam. 
5.7.17.Distribution ,of ,Mukkutram 






Before ,Treatment After ,Treatment 
No ,of ,Cases Percentage No ,ofCases Percentage 
1 Pranan 01 2.5 ,% 1 2.5 ,% 
2 Abanan 1 2.5 ,% 0 0% 
3 Udhanan 40 100 ,% 16 40 ,% 
4 Samanan 40 100 ,% 16 40 ,% 
5 Viyanan 40 100 ,% 16 40 ,% 
6 Nagan 0 0% 0 0% 
7 Koorman 0 0% 0 0% 
8 Kirukaran 03 7.5% 0 0% 
9 Devathathan 9 22.5 ,% 0 0% 




Observation:   
 Before ,treatment ,Udhanan,Samanan ,and ,Viyanan ,were ,found ,to ,be ,affected ,in ,all ,the 
,100% ,patients.Pranan ,was ,found ,to ,be ,in ,2.5% ,of ,patients, ,Abanan ,was ,found ,to ,be ,in ,2.5% ,of 
,patients, ,Kirukaran ,was ,found ,to ,be ,in ,7.5% ,of ,patients, ,Devathathan ,was ,found ,to ,be ,affected 
,in ,22.5% ,of ,patients. ,After ,treatment ,Udhanan,Samanan ,and ,Viyanan ,were ,found ,to ,be 






Before ,Treatment After ,Treatment 




1 Anarpitham 03 7.5% 0 0% 
2 Ranjagapitham 40 100 ,% , 11 27.5 ,% , 
3 Sathagapitham 0 0% 0 0% 
4 Pirasagapitham 40 100 ,% 11 27.5 ,% 
5 Alosagapitham 0 0% 0 0% 
Observation: 
 Before ,treatment ,Ranjagapitham,Prasagapitham ,was ,affected ,in ,all ,the ,cases ,and 
,anarpitham ,was ,affected ,in ,7.5% ,patients. ,After ,treatment ,Ranjagapitham,Prasagapitham ,was 
,affected ,in ,27.5% ,patients. 





Before ,Treatment After ,Treatment 
No ,of ,Cases Percentage No ,of ,Cases Percentage 
1 Avalambagam 01 2.5 ,% 01 2.5 ,% 
2 Kiledhagam 03 7.5%  , , , , , , , , ,0 0% 
3 Pothagam 0 0% 0 0% 
4 Tharpagam 0 0% 0 0% 





 Before ,treatment ,kiledhagam ,was ,affected ,in ,7.5%.Before , ,and ,after ,treatment 
,Avalambagam ,thee ,was ,affected ,in ,one ,case. , 
 






Before ,Treatment After ,Treatment 
No ,of 
,Cases 
Percentage No ,of ,Cases Percentage 
1 Saaram 40 100% 11 27.5% 
2 Senneer 40 100% 11 27.5 ,% 
3 Oon 40 100% 11 27.5 ,% 
4 Kozhuppu 0 0% 0 0% 
5 Enbu 0 0% 0 0% 
6 Moolai 0 0% 0 0% 
7 Sukkilam/Suronitham 0 0% 0 0% 
 
 














 Before ,treatment ,; ,Saaram ,and ,Seneer, ,Oon ,were ,affected ,in ,100% ,of ,cases. ,After 
,treatments ,Saaram, ,Seneer, ,Oon ,were ,affected ,in ,27.5% ,of ,cases. 
 , , 













1 Naadi   
  
 
a. ,Vaathapitham 2 5 ,% 31 77.5 ,% 
b. ,Pithavaatham 25 62.5 8 20 , ,% 
c. ,Pithakabam 7 17.5 ,% 1 2.5 ,% 
d. ,Kabapitham 1 2.5 ,% 0 0% 
e.Vathakabam 5 12.5 ,% 0 0% 
2 Sparisam 40 100 ,% 11 27.5 ,% 
3 Naa 0 0% 0 0% 
4 Niram 40 100 ,% 11 27.5 ,% 
5 Mozhi 0 0% 0 0% 
6 Vizhi 0 0% 0 0% 
7 Malam 1 2.5 ,% 0 0% 





 Figure. ,5.7.15.Nadinadai ,in ,PPK ,treated ,patients ,before ,and ,after ,treatment 
   Figure ,5.7.16. ,Effect ,of ,PPK ,on ,Envagai ,Thervugal 
Observation: 
 In ,Envagai ,thervugal, ,before ,treatment ,Niram ,and ,Sparisam ,were ,found ,affected ,in ,all 
,the ,40 ,cases, ,Malam ,was ,found ,affected ,in ,1 ,cases. ,The ,Naadinadai ,seen ,in ,Kalanjagapadai 
,patients ,were ,Vaathapitham ,5%, ,Pithavaatham ,62.5 ,%, , ,Pithakabam ,17.5 ,%, ,Kabapitham 
,2.5%, ,Vathakabam ,12.5%. ,After ,treatment ,Niram,sparisam ,affected ,in ,11 ,cases, ,The ,Naadi 
,nadai ,seen ,in ,Kalanjagapadai ,patients ,were ,Vaathapitham ,77.5%, ,Pithavaatham ,20 ,%, , ,Pitha 







































Neerkkuri, ,Neikkuri ,Inference: , 
Sl. 
,No 














5 12.5 ,% 












16 40 ,% 
4 
Reddish 
,yellow ,colour , 
1 2.5 ,% 















0 0 ,% 0 
0 ,% 02 5% , 
2 Pitham ,(Ring) 0 0 ,% 5 




22 55 ,% 15 
37.5 ,% 5 12.5 ,% 






4 VP 02 5 ,% 5 12.5 , ,% 1 2.5 , ,% 
5 PP 2 5 ,% 0 0% 0 0% , 




0 0 ,% 0 
0 ,% 4 10 ,% 
8.  , , ,        , , , , , ,VK 0 0% 1 2.5% 0 0% 





12  , , , ,30 , ,% 11 
 










 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,Figure. ,5.7.17. ,Neerkkuri ,Reference 
 


































































































In ,this ,study ,; 
On ,Neerkuri ,; ,before ,treatment ,the ,majority ,of ,patients ,had ,Citrus ,aurantium ,fruit ,colour 
,(47.5%) ,and ,wild ,citrus ,medica ,fruit ,colour ,37.5%, ,Hey ,soaked ,rain ,water ,colour 
,12.5%,Reddish ,yellow ,colour ,2.5%.After ,treatmentthe ,majority ,of ,patients ,had ,Citrus 
,aurantium ,fruit ,colour ,(40%) ,and ,wild ,citrus ,medica ,fruit ,colour ,5%, ,Hey ,soaked ,rain ,water 
,colour ,55%. 
On ,Neikuri ,: 
 On ,1st ,day ,the ,patients ,had ,Kabam ,(Pearl) ,Neikuri ,pattern ,(55%), ,VP ,Neikuri ,pattern 
,(5%),PP ,Neikuri ,pattern ,(5%), ,PV ,Neikuri ,pattern ,(2.5%), ,Mukkuttram ,Neikuri 
,pattern(2.5%) ,and ,Severe ,Kabam ,(Saladaikan ,pattern) , ,(30%). 
 On ,15th , ,day ,the ,patients ,had ,Kabam ,(Pearl) ,Neikuri ,pattern ,(37.5%),Pitham ,Neikuri 
,pattern(12.5%) ,, ,VP ,Neikuri ,pattern ,(12.5%), ,PV ,Neikuri ,pattern ,(5%),VK ,Neikuri ,pattern 
,(2.5%),Mukkuttram ,Neikuri ,pattern ,(2.5%) ,and ,Severe ,Kabam ,(Saladaikan ,pattern) , ,(27.5%). 
 On ,49th , ,day ,the ,patients ,had ,Vatham ,Neikuri ,pattern ,(5%), ,Pitham ,Neikuri ,pattern 
,(30%),Kabam ,(Pearl) ,Neikuri ,pattern ,(12.5%), ,VP ,Neikuri ,pattern ,(2.5%),PV ,Neikuri ,pattern 
,(25%),PK ,Neikuri ,pattern ,(10%),Mukkuttram ,Neikuri ,pattern(2.5%) ,and ,Severe ,Kabam 















Figure. ,5.7.19.PROGNOSIS ,OF ,TREATMENT ,IN ,NEIKURI , ,WITHIN ,20 
,MINUTES ,: 
Op ,no/Age 1st ,Day:Pasi ,Score: ,72 , , , 15th ,Day ,Pasi ,Score ,: ,64.4 49th ,Day ,: , 










Pearl ,pattern ,– ,Kabam ,kuttram Irregular ,with ,coin ,pattern ,- ,Vatha 
,pitham , , 
 
Aazhi ,pattern ,– 
 ,Pitham ,kuttram 
Op ,no/Age 1st ,Day:Pasi ,Score: ,32.4 15th , ,Day ,Pasi ,Score ,: ,28 49th ,Day ,: , 








Pearl ,pattern ,–Kabam ,kuttram 
 
Irregular ,with ,coin ,pattern ,- 
,Vatha ,pitham 
 
Irregular , ,pattern ,– 




















Aazhi , ,pattern ,– ,Pitha ,kuttram 





Op ,no/Age 1st  ,Day:Pasi ,Score: ,28 15th , ,Day ,Pasi ,Score ,: ,53.9 49th ,Day ,: , 
Pasi ,Score ,: ,3.3 
1526-
18/21M 




Pearl , ,pattern ,–Kabam ,kuttram 
 
 
Irregular ,with ,coin ,pattern ,– 
,Vatha ,Pitham ,kuttram 
Bottle ,guard , ,pattern ,– 















Saladaikan ,(Seive ,filter ,holes) 
,pattern ,– ,Severe ,Kabam 
,kuttram 
 
Saladaikan ,(Reduced ,number 
,and ,size ,of ,Seive ,filter ,holes) 
,pattern ,– ,Severe ,Kabam 
,kuttram 
Aazhi ,pattern ,– ,Pitham 
 ,kuttram 
 
Op ,no/Age 1st  ,Day:Pasi ,Score: ,32.1 15th ,Day ,Pasi ,Score ,: ,26.1 49th ,Day ,: , 
Pasi ,Score ,: ,0.4 
0033-
19/34M 




Regular ,with ,irregular ,size ,coin , 
,pattern ,– ,Pithathil ,pitham 
,kuttram 
 
Irregular ,with ,Seive ,filter ,hole 
,pattern ,– ,Vatham ,Kabam 
,kuttram 







Op ,no/Age 1st  ,Day:Pasi ,Score: ,72 , , , 15th ,Day ,Pasi ,Score ,: ,19.7 49th ,Day ,: , 









Irregular ,with ,Irregular ,coin 
,pattern ,– ,Vatham ,Pitham 
,kuttram 
Irregular ,with ,Irregular ,coin 
,pattern ,– ,Vatham ,Pitham 
,kuttram 
 
Irregular , ,pattern ,– , 
















5.7.20.MANIKADAI ,NOOL , ,: 
 
Sl. ,No Finger 
,breadth 
Before ,Treatment 
No ,of ,Cases Percentage 
1. 7 ,¾ 1 2.5 ,% 
2. 8 2 5 ,% 
3. 8 ,¼ 0 0% 
4. 8 ,½ 29 72.5 ,% 
5. 8 ,¾ 0 0% 
6. 9 2 5 ,% 
7. 9 ,¼ , 1 2.5 ,% 
8. 9 ,½ 1 2.5 ,% 
9. 9 ,¾ 1 2.5 ,% 
10. 10 1 2.5 ,% 
11. 11 2 5 ,% 
 
 
   Figure. ,5.7.20.Manikadainool 
Observation: 









































 Figure. ,5.7.21.Medicine ,started ,day ,and ,their ,prognosis 
Observation: 
 In ,this ,study, ,45% ,of ,patients ,started ,medicine ,on ,Sunday,27.5% ,of ,patients ,started 
,medicine ,on ,Tuesday ,,27.5% ,of ,patients ,started ,medicine ,on ,Thursday.The ,majority ,of ,patient 































MEDICINE STARTING DAY 
Medicine starting day & Prognosis












Sunday 18 45 ,% 
Good 16 
 Moderate 2 
 Poor 0 
2 
 
Tuesday 11 27.5 ,% 
Good 7 
 Moderate 3 
 Poor 1 
3 
 
Thursday 11 27.5 ,% 
Good 5 
 Moderate 3 
 Poor 3 
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,Treatment  ,13.92 ,±1.82 7747.50±2108.10 4.77 ,±0.56 2.83 ,±0.67 
After 





0.9999 0.3378 0.8096 0.6942 
t ,value 
0.000 0.9645 0.2417 0.3946 
 
Inference: , 
The ,Hematological ,parameters ,tested ,for ,the ,patients ,treated ,with ,PPK ,that ,there ,was ,no 
,major ,difference ,both ,before ,and ,after ,treatment. ,This ,result ,proved ,for ,the ,safety ,of ,the ,trial 
,drug ,adminstered ,as ,the ,values ,were ,well ,within ,normal ,limits.Values ,expressed ,in ,Mean ,± 
,SEM; ,Statistical ,analysis ,was ,performed ,using ,Student ,‘t’ ,test ,using ,Graph ,Pad ,Prism ,3.1. 
 

































Two ,tailed ,p 
,value 0.1061 0.3060 0.2934 0.1884 0.2392 


















 , ,86.40 
,±26.61 





18.49±4.66  ,0.99 , , ,±0.13 0.75±0.37 
Two ,tailed ,p ,value 0.0638 0.7916 0.7318 0.3379 




The ,Biochemical ,parameters ,tested ,for ,the ,patients ,treated ,with ,PPK ,that ,there ,was ,no 
,major ,difference ,both ,before ,and ,after ,treatment. ,This ,result ,proved ,for ,the ,safety ,of ,the ,trial 
,drug ,administered ,as ,the ,values ,were ,well ,within ,the ,normal ,limits. ,Values ,expressed ,in ,Mean 
,± ,SEM ,; ,Statistical ,analysis ,was ,performed ,using ,Student ,‘t’ ,test ,using ,Graph ,Pad ,Prism ,3.1 
 





Before ,Treatment After ,Treatment 
Frequency Percentage Frequency Percentage 
1 Erythema 40 100% 17 42.5 ,% 
2 Scaling 40 100% 12 30 ,% 
3 Itching 40 100% 
5 1.5 ,% 
 ,4 Fissure 5 12.5 ,% 0 0% 
 ,5 Pustule 3 7.5 ,% 0 0% 
6 Auspitz ,sign , 40 100% 6 15 ,% 







Figure. ,Figure. ,5.7.22. ,The ,effect ,of ,Parangipaatai ,Kudineer ,on ,the ,clinical ,features 
 
Observation: 
Before ,treatment ,all ,the ,patients ,had ,the ,clinical ,features ,of ,erythema, ,scaling, ,itching, ,Auspitz 
,sign, ,Candle ,grease ,sign ,and , ,12.5 ,% , ,of ,cases ,had , ,Fissure, ,7.5 ,% , ,of ,cases ,had , ,pustule. ,After 
,treatment ,42.5% ,of ,cases ,had ,erythema, ,30% ,of ,cases ,had ,scaling, ,1.5% ,of ,cases ,had ,itching, 
,15% ,of ,cases ,had ,Auspitz ,sign, ,30% ,of ,cases , ,had , , ,Candle ,grease ,sign. 
 
5.7.25.Shape ,& ,Site ,of ,Lesion 
 
S.NO Shape ,of ,Lesion No.of ,Case Percentage 
1 Irregular 37 92.5 ,% 
2 Coin 03 7.5 ,% 
3 Dispersed 0 0% 
S.NO Site ,of ,Lesion No.of ,Case Percentage 
1 Head 40 100 ,% 































Clinical features in BT & AT 
The effect of PPK on the clinical features
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3 Lower ,limb 40 100 ,% 
4 Trunk 40 100 ,% 
5 Nail ,Changes 02 5 ,% 
6 Palmo ,plantar 07 17.5 ,% 
7 Joint ,Involvement 0 0% 
 
Observation: 
 92.5% ,of ,cases ,had ,irregular ,shape ,of ,lesion. , 
 
5.7.26.Effect ,of ,Parangipaatai ,Kudineer ,on ,Clinical ,signs/symptoms ,in ,each ,visit: 
Clinical ,features Visit 
1st 2nd 3rd 4th 5th 6th 7th 
Erythema 40 40 40 40 40 23 17 
Scaling 40 40 40 38 31 25 12 
Itching 40 40 36 36 31 17 5 
Fissure 5 4 4 2 1 0 0 
Pustule 3 2 0 0 0 0 0 
Auspitz ,sign , 40 39 35 26 17 12 6 
Candle ,Grease ,sign 
40 40 39 35 27 15 12 
 
Clinical ,features Percentage , 
1st 2nd 3rd 4th 5th 6th 7th 
Erythema 100% 100% 100% 100% 100% 57.5 ,% 42.5 ,% 
Scaling 100% 100% 100% 95 ,% 77.5 ,% 62.5 ,% 30 ,% 
Itching 100% 100% 90 ,% 90 ,% 77.5% 42.5 ,% 12.5 ,% 
Fissure 12.5 ,% 10 ,% 10 ,% 5 ,% 2.5 ,%  ,0 ,%  ,0 ,% 
Pustule 7.5 ,% 5 ,%  ,0 ,%  ,0 ,%  ,0 ,%  ,0 ,%  ,0 ,% 
Auspitz ,sign , 100% 97.5 ,% 87.5 ,% 65 ,% 42.5 ,% 30 ,% 15 ,% 
Candle ,Grease ,sign 
























1st Visit 2nd Visit 3rd Visit 4 th visit 5th visit 6th visit 7 th visit
Erythema











1st Visit 2nd Visit 3rd Visit 4 th visit 5th visit 6th visit 7 th visit













1st Visit 2nd Visit 3rd Visit 4 th visit 5th visit 6th visit 7 th visit
Itching









 The ,most ,common ,discomfort ,encountered ,by ,the ,patients ,who ,had ,Psoriasis ,was 
,Itching ,and ,scaling. ,40 ,patients ,out ,of ,40 ,(100%) ,had ,this ,symptom ,and ,the ,test ,drug ,PPK 
,corrected , ,symptom ,of ,itching ,in , ,87.5% ,of ,the ,patients ,and ,corrected ,symptoms ,of ,scaling ,in 
,70 ,% ,of ,patients. ,The ,symptom ,of ,erythema ,was ,found ,all ,patients ,(100%). ,This ,was ,cleared 














































,pustule ,(7.5%) ,was ,found ,in , ,the ,patients. ,This ,was ,cleared ,all ,patients ,who ,had ,fissure ,and 
,pustule ,complaint.The ,most ,common ,signs ,in , ,the ,patients ,who ,had ,Psoriasis ,was ,auspitz ,sign 
,and ,candle ,grease ,sign. ,40 ,patients ,out ,of ,40 ,(100%) ,had ,this ,signs ,and ,the ,test ,drug ,PPK ,clear 
,the ,sign ,of ,auspitz ,sign ,in , ,85% ,of ,the ,patients ,and ,candle ,grease ,sign ,in , ,70% ,of ,the ,patients. 










Score 0-1 Score 2-5 Score 6-10 Score 11-20 Score 21-30

































Score ,0-1 0 0 ,% 19 47.5 ,% 
2 
 
Score ,2-5 0  ,0 ,% 11 27.5 ,% 
3 
 
Score ,6-10 0  ,0 ,% 1 2.5 ,% 
4 
 
Score ,11-20 0  ,0 ,% 7 17.5 ,% 




 Quality ,of ,life ,score ,in ,before ,treatment ,score ,21-30 ,in ,40 ,patients. ,After ,treatment 
,score ,0-1 ,in ,19 ,patients, ,score ,2-5 ,in ,11 ,patients, ,score ,6-10 ,in ,1 ,patients, ,and ,score ,11-20 ,in ,7 
,patient. ,Score ,21-30 ,in ,2 ,patients. 
 
5.7.28.Assessment ,of ,Treatment ,response ,with ,PASI ,Score ,in ,Group ,I ,: ,Trail ,drug 
,without ,yogam ,in , ,OPD , ,patients ,: , 
 
 
 Figure.5.7.25. , ,Treatment ,response ,with ,PASI ,Score ,in ,group ,I , ,patients 
Inference: , , 
 Treatment ,assessment ,response ,in ,group ,I ,was ,shown ,42.07±6.98 ,on ,first ,day ,(BT) 
,and ,it ,was ,12.39±5.08 ,on ,it ,49th ,day ,(AT).Till ,15th ,day, ,there ,is ,a ,gradually ,increase ,of ,PASI 





























PASI SCORE IN GROUP I














,day 49th ,day 
MEAN 42.07 43.67 44.43 37.76 31.96 25.06 17.16 12.39 
SEM 6.98 7.34 7.11 5.86 5.29 4.45 4.35 5.08 
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Assessment ,of ,the ,Treatment ,response ,with ,PASI ,Score ,in ,Group ,II ,: ,Trail ,drug ,with 





,day 15th ,day 
22nd 
,day 29th ,day 36th ,day 




MEAN 43.46 43.46 42.90 35.89 26.06 19.18 8.59 4.22 
SEM 
7.77 7.77 6.72 7.40 6.03 5.82 3.19 2.16 
 
 
 Figure. ,5.7.26 ,Treatment ,response ,with ,PASI ,Score ,in , ,group ,II , ,patients 
 
Inference: , , 
 Treatment ,assessment ,response ,in ,group ,II ,was ,shown ,43.46±7.77 ,on ,first ,day ,(BT) 
































PASI SCORE IN GROP II
PASI SCORE OP Linear (PASI SCORE OP) Linear (PASI SCORE OP)
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,day 49th ,day 
MEAN 42.76 43.56 43.67 36.82 29.01 22.12 12.87 8.3 




 Figure. ,5.7.27.Treatment ,response ,with ,PASI ,Score ,in ,both ,group ,patients 
 
Inference: , , 
 Treatment ,assessment ,response ,in ,both ,group ,(all ,patient) ,was ,shown ,42.76±7.30 ,on 
,first ,day ,(BT) ,and ,it ,was ,8.3±4.27 ,on ,it ,49th ,day ,(AT).Till ,15th ,day, ,there ,is ,a ,gradually 
,increase ,of ,PASI ,score ,i.e. ,upto ,43.67±6.84 , ,and ,after ,15th ,day of the treatment, ,the ,PASI ,score 

































PASI SCORE IN TREATED WITH TRAIL DRUG IN  BOTH GROUP 
PASI SCORE OP Linear (PASI SCORE OP) Linear (PASI SCORE OP)
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Paired ,Sample ,Statistics ,(PASI ,Score ,Before ,Treatment ,and ,After ,Treatment) ,: 
 



















t ,= ,4.866 p ,<0.0001 
 
 
   Figure ,5.7.28.Paired ,Sample ,Statistics 
Inference: 
 The ,mean± ,SEM ,of ,PASI ,score ,at ,before ,and ,after ,treatment , ,in ,group ,I ,were 
,42.07±6.98 ,and ,12.39±5.08 ,respectively ,which ,is ,statistically ,very ,significant ,(t ,= ,3.438, ,p 
,<0.0014). , 
 The ,mean± ,SEM ,of ,PASI ,score ,at ,before ,and ,after ,treatment , ,in ,group ,II ,were 
,43.46±7.77 ,and ,4.22±2.16 ,respectively ,which ,is ,statistically ,extremely ,significant ,(t ,= ,4.866, 
,<0.0001). , , 
Observation ,of ,assessment ,of ,treatment ,response ,with ,PASI ,Score ,: 
 According ,to ,above ,the ,inferences ,; ,Initially ,the ,symptoms ,of ,psoriasis ,may ,be  
,aggravated ,and ,then ,gradually ,declines ,by ,the ,trail ,drug. 
 As ,per ,paired ,sample ,statistics ,, ,Group ,II ,( ,with ,yogam) ,was ,shown ,excellent ,outcome 


































    Figure ,5.7.29.Outcome 
 
Observation: 
 The ,outcome ,of ,this ,study ,showed ,promising ,results. ,In ,group ,I ,: ,Good ,improvement 
,was ,observed ,in ,13 ,patients ,(65%), ,moderate ,improvement ,in ,4 ,patients ,(20%), ,and ,poor 
,improvement ,in ,3 ,(15%) ,cases. ,In ,group ,II ,: ,Good ,improvement ,was ,observed ,in ,16 ,patients 







MODERATE, 20% POOR, 15.00%, 
GOOD, 80%





























No ,of , ,Cases 
,Group ,II 
Percentage 
1 Good  , , , , , , , , ,13 65% 16 80 ,% 
2 Moderate  ,4 20% 4 20 ,% 
3 Poor 3 , , 15% , 0 0 ,% 
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5.7.30.EFFECT ,OF ,THE ,TRIAL ,DRUG , ,IN ,VARIOUS ,TYPE ,OF ,KJP ,: 
 
Observation: 
 The ,outcome ,of ,this ,study ,in ,various ,type ,of ,psoriasis , ,showed ,bright ,results. ,Good 
,improvement ,was ,observed ,in ,Psoriasis ,vulgaris , ,18 ,patients ,(45 ,%),Psoriasis ,vulgaris ,with 
,Pustular ,psoriasis ,1 ,patient ,(2.5 ,%),Guttate ,psoriasis ,8 ,patients ,(20 ,%),Guttate ,psoriasis ,with 
,Pustular ,psoriasis ,1 ,patient ,(2.5 ,%), ,Psoriasis ,vulgaris ,with ,inverse ,psoriasis ,1 ,patient ,(2.5 ,%). 
,Moderate ,improvement ,was ,observed ,in ,Psoriasis ,vulgaris , ,6 ,patients ,(15 ,%),Guttate ,psoriasis 


















 ,No ,of 
,Cases 
Percentage 
1 Psoriasis ,vulgaris 27 67.5 ,% 
Good 18 45 ,% 
Moderate 6 15 ,% 
Poor 3 7.5 ,% 
2 
Psoriasis ,vulgaris ,with 
,Pustular ,psoriasis 
1 2.5 ,% Good 1 2.5 ,% 
3 Guttate ,psoriasis 10 25 ,% 
Good 8 20 ,% 
Moderate 2 5 ,% 
Poor 0 0 ,% 
4 
Guttate ,psoriasis ,with 
,Pustular ,psoriasis 
1 2.5 ,% Good 1 2.5 ,% 
5 
Psoriasis ,vulgaris ,with 
,inverse ,psoriasis 




























































EFFECT OF THE TREATMENT IN VARIOUS TYPE OF PSORIASIS
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Figure : 5.7.31 : BT – PASI 46.3 

















































CASE : 2 
 





Figure :5.7.32  : BT – PASI 72 


































































































CASE : 3 
 
1st  DAY : PASI : 72 
 
 
Figure :5.7.33 : BT – PASI 72 











































































Figure :5.7.34 : BT – PASI 63.6 




































Figure :5.7.35 : BT – PASI 64.8 



































CASE : 6 
 
 
1st  DAY : PASI -72 
 
 
Figure : 5.7.36: BT – PASI 72 


























































 Kalanjagapadai ,(Psoriasis) ,is ,important ,to ,the ,clinician ,because ,it ,is ,common ,and ,has 
,treatment ,implications ,beyond ,the ,care ,of ,skin ,lesions. ,Psoriasis ,is ,a 
,physically,emotionally,socially ,invalidating ,multifactorial ,chronic ,skin ,disorder ,with ,a 
,significant ,impact ,on ,the ,patient’s ,quality ,of ,life. , 
The ,raw ,drugs ,of ,Parangipattai ,Kudineer ,were ,identified ,and ,authentication ,certificate 
,was ,obtained. , ,Then ,the ,raw ,drugs ,were ,purified ,and ,PPK ,was ,prepared ,as ,per ,the ,text 
,Pharmacopoeia ,of ,hospital ,of ,Indian ,medicine. 
 
"Å¡¾ÁÄ¡Ð ,§ÁÉ¢ ,¦¸¼¡Ð" 
 
 , , ,- ,§¾Ãý ,§º¸ÃôÀ¡ 
§¾¸ò¾¢ý ,´Ç¢Ôõ ,Åý¨ÁÔõ ,¦¸ÎÅ¾üìÌ ,ÅÇ¢ìÌüÈ§Á ,Ó¾ü¸¡Ã½Á¡Ìõ. 
As ,per ,siddha ,system ,taste ,and ,potency ,of ,the ,drug ,was ,important ,to ,act ,on ,regulate ,the 
,humors. ,Both ,trail ,drug ,has ,mostly ,bitter,spicy,sweet ,taste ,and ,hot ,potency.Basically ,hot 
,potency , ,mitigate , ,vatham ,humor ,and ,alliviate ,the ,kaba ,disease, ,allergies. ,Bitter ,taste ,act ,on , 
,toxic ,substance ,from ,the ,body ,and ,healing ,of ,skin ,diseases(Kuttam). ,Spicy ,taste ,act ,on , ,toxic 
,substance ,from ,the ,body ,and ,healing ,of ,skin ,diseases,wounds ,(Kuttam).Sweet ,taste ,act ,on , 
,,vatha ,pitham ,humor ,eliminates ,the ,pitham ,and ,toxic ,substance ,and ,give ,the ,strength ,to 
,udalthathukkal (body constituents) ,and ,glowing ,of ,skin. ,Hence ,these ,compounds ,possess 
,promising ,act ,against ,Kuttam ,( ,Kalanjgapadai ,). 
Analytical ,specifications ,: 
Solid- ,Crude ,raw ,Material ,of ,PPK ,was ,greenish ,brown ,in ,colour ,and ,Decoction- ,Water 
,Extraction ,of ,PPK ,was ,reddish ,brown ,in ,colour.Due to  ,pH ,value ,of ,4.5 of PPK ,and ,it is 
available in intestine without getting affected. 
 ,This ,formulation ,satisfy ,the ,Pharmacopoeial ,standards ,and ,as ,per ,the ,WHO ,Guidelines. 
,Microscopic ,observation ,of ,the ,particle ,size ,analysis ,reveals ,that ,the ,average ,particle ,size ,of ,the 
,PPK ,sample ,was ,found ,to ,be ,175.7 , ,± ,71.8 ,µm. , 
The ,drug ,is ,free ,of ,microbial ,contamination, ,pesticide ,residues ,and ,aflatoxins. ,The 
,heavy ,metals ,were ,not ,detected ,(arsenic, ,mercury, ,cadmium) ,except ,lead ,which ,was ,within ,the 
AYUSH & WHO ,permissible ,limit. ,It ,was ,may ,be ,evident ,of ,drug’s ,ingredients ,had ,lead 
,content ,herb ,as ,per ,followed ,Siddha ,literature, , 
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"º£ó¾¢ø ,Å¢Ø¾¢ ,º¢ÚÀ£¨Ç ,¦ÅûÇÚÌõ 
 ,²ó¾¢¨ÆÂ£ ,Ã£ÂãÄ¢" , 
 , , , , , , , , , , , , , , ,- ,Ì½ôÀ¡¼õ;¾¡Ð ,º£Å ,ÅÌôÒ 
One ,of ,the ,drug’s ,ingredients ,was ,Tinospora ,cordifolia , ,which ,was ,lead ,content ,herb. 
 ,HPTLC ,finger ,printing ,analysis ,of ,the ,sample ,PKC ,reveals ,the ,presence ,of ,six ,prominent ,peaks 
,corresponds ,to ,presence ,of ,six ,versatile ,phyto-components ,present ,with ,in ,it. ,Rf ,value ,of ,the 
,peaks ,ranges ,from ,0.05 ,to ,0.71. ,Further ,the ,peak ,2 ,and ,6 ,occupies ,the ,major ,percentage ,of ,area 
,of ,37.55 ,and ,36.53 ,% ,which ,denotes ,the ,abundant ,existence ,of ,such ,compound. ,Followed ,by 
,this ,peak ,1 ,and ,3 ,occupies ,the ,percentage ,area ,of ,18.18 ,and ,3.11 ,%. 
Preliminary ,Phytochemical ,Screening ,: 
Flavonoids, ,Phenolic ,Compounds ,and ,Quinones, ,Saponins,Carbohydrates ,were ,presnt 
,in ,this ,drug.Their ,presence ,indicates ,antioxidant, ,antimicrobial, ,anti-allergic, ,antifungal ,and 
,anti-inflammatory ,properties ,of ,the ,drug. ,Saponins ,has ,phytosterol ,of ,sarsasapogenin ,which ,it 
,is ,act ,as ,steroid. 
Chemical ,Analysis ,: 
Chloride ,and ,Carbonate ,(acid ,base ,equilibrium,regulate ,fluid ,balance), ,Phosphate 
,(Regulate ,Parathyroid ,hormone,Vitamin ,D,Acid ,base ,balance). ,Iron ,(Effective 
,immunocompetence), ,Zinc ,(Maintain ,immune ,status ,, ,Anti-inflammatory, ,Inhibit 
,keratinocytes, ,modulates ,production ,of ,TNF-α,IL-6) ,,Alkaloids ,( ,Antifungal.Antimicrobial, 
,antioxidant), ,Tannic ,acid ,( ,Aniseptic,antiallergy,antidote) ,and , ,oxyquinole ,(Antimicrobial) 
,epinephrine ,(anaphylaxsis,vasoconstricor) ,and ,pyro ,catechol ,( ,Antioxidant) ,were ,presnt ,in ,this 
,drug. 
In ,-Vitro , ,Pharmacological ,Screening ,of ,PPK ,( ,Internal ,drug ,) ,: 
In-vitro ,pharmacological ,activities ,has ,been ,done ,for ,PPK ,drug ,and ,this ,drug ,had 
,activities ,of ,anti-inflammatory ,(protein ,denaturation ,assay), ,immunomodulatory, ,anti-
proliferative ,(HaCaT ,keratinocyte ,cell ,line) 
 
In ,docking ,analysis ,on ,PPK ,( ,Internal ,drug ,) , , ,: , 
Amino ,acid ,Residue ,Interaction ,of ,Lead ,and ,Standard ,against ,IL- ,6 ,– ,PDB ,1P9M ,: 
Out ,of ,six ,compound’s ,Berberine ,has ,2 ,interactions ,similar ,to ,that ,of ,the ,standard 
,Tacrolimus. ,Other ,compounds ,such ,as ,Anisaldehyde ,, ,Kaempferol ,and ,Nimbolide ,has ,one 




Amino ,acid ,Residue ,Interaction ,of ,Lead ,and ,Standard ,against ,TNF-alpha ,(2AZ5) ,: 
Out ,of ,six ,compound’s ,Picein ,and ,Anisaldehyde ,has ,4 ,interactions ,similar ,to ,that ,of ,the 
,standard ,Tacrolimus. ,Other ,compounds ,such ,as ,Berberine, ,Kaempferol, ,Protocatechuic ,acid 
,and ,Nimbolide ,has ,three ,interaction ,similar ,to ,that ,of ,the ,standard. ,Hence ,these ,compounds 
,possess ,promising ,TNF- ,alpha ,inhibition ,activity. 
Amino ,acid ,Residue ,Interaction ,of ,Lead ,and ,Standard ,against ,Nitric ,Oxide ,Synthase ,: 
Out ,of ,six ,compound’s ,Picein ,and ,Anisaldehyde ,has ,4 ,interactions ,similar ,to ,that ,of ,the 
,standard ,Tacrolimus. ,Other ,compounds ,such ,as ,Berberine, ,Kaempferol ,and ,Nimbolide ,has 
,three ,interaction ,similar ,to ,that ,of ,the ,standard. ,Hence ,these ,compounds ,possess ,promising 
,Nitric ,oxide ,synthase ,enzyme ,inhibition ,activity. 
In ,-Vitro ,Pharmacological ,Screening ,of ,Sivappu ,thylam ,( ,External ,drug ,) , , ,: 
In-vitro ,pharmacological ,activities ,has ,been ,done ,for ,external ,medicine ,of ,Sivappu 
,thylam , ,and ,this ,drug ,had ,activities ,of ,anti-inflammatory ,property ,in ,protein ,denaturation 
,assay. 
Toxicity ,study ,: 
The ,Acute ,and ,28 ,days ,repeated ,oral ,toxicity ,studies ,did ,not ,show ,any ,toxic ,effects ,in 
,the ,animals. 
Clinical ,study: 
 For ,this ,study, ,40 ,patients ,were ,selected ,and ,20 ,patients ,were ,treated ,in ,the ,OPD, ,20 
,patients ,were ,treated ,in ,the ,IPD ,at , ,department ,of ,Sirappu ,Maruthuvam, ,in ,Ayothidoss 
,Pandithar ,Hospital ,of , ,National ,Institute ,of ,Siddha, ,Tambaram ,Sanatorium, ,Chennai ,– ,600 ,047. 
Group ,I ,: ,Trail ,drug ,without ,yogam ,in , ,(20) ,OPD , ,patients. 
Group ,II ,: ,Trail ,drug ,with ,yogam ,in ,(20) ,IPD , ,patients. , 
First ,day ,: 
Agathiyar ,kulambu , ,with ,200mg ,with ,30ml ,leaf ,juice ,of ,Sangankuppi ,(Azima 
,tetracantha) ,quantity ,was ,administered ,at ,early ,morning ,as ,purgative ,(Kazhichal ,Medicine) 
,before ,starting ,the ,treatment ,for ,restore ,equilibrium ,of ,uyirthathus. 
Second ,day ,: , 
 Oil ,bath ,with ,Arakku ,thylam , ,has ,taken ,at ,early ,morning ,for ,restore ,equilibrium ,of 
,udalthathus. 
Third ,day ,onwards ,from , ,Sunday ,/ ,Tuesday ,/ ,Thursday ,for ,48 ,days ,: , 
 Internal ,Medicine: ,Parangipattai ,Kudineer, ,three ,times ,a ,day ,before ,food. 
External ,Medicine: ,Sivappu ,thylam 
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Advice ,for ,method ,of ,topical ,medicine ,: , 
Oil ,applied ,in ,psoriatic ,lesion ,by ,cotton ,for ,4 ,hrs ,at ,1pm ,to ,5pm ,and ,take ,sunbath ,at ,4pm 
,to ,5.30pm ,thereafter ,bath ,with ,warmwater ,used ,by ,greengram ,powder. , , 
Benefit ,of ,sunbath: 
 Exposure ,to ,sunlight ,is ,thought ,to ,increase ,the ,brain’s ,release ,of ,hormone ,called 
,serotonin.Serotonin ,is ,help ,a ,patient ,feel ,calm ,and ,focus ,and ,reduced ,depression ,mood. 
,Sunlight ,induced ,synthesis ,of ,Vitamin ,D.Vit ,D ,might ,represent ,a ,key ,modulator ,of ,immune ,and 
,inflammation ,mechanisms. 
OPD ,patients ,are ,requested ,to ,visit ,the ,hospital ,once ,in ,7 ,days. ,In ,each ,and ,every ,visit 
,clinical ,assessment ,and ,prognosis ,were , ,recorded. ,For ,IPD ,patients ,the ,clinical ,assessment ,and 
,prognosis ,were ,recorded ,daily. , 
 , , , , , , , , , , , , ,In ,Siddha ,investigation ,of , ,Envagai ,Thervu ,will ,be ,evaluvate ,before ,and ,after ,the 
,treatment ,for ,40 ,patients. ,Nei ,Kuri ,will ,be ,evaluvate ,0th ,day,15th ,day,49th ,day ,of ,the ,treatment 
,for ,opd ,and ,IPD ,patients. ,Manikadai ,Nool ,will ,be ,measure ,before ,treatment ,for ,40 ,patients. , 
In ,Moderen ,; ,Laboratory ,investigations ,were ,done ,before ,and ,after ,the ,trial. ,There ,were 
,no ,variations ,in ,hepatic, ,renal ,and ,other ,parameters. ,For ,IPD ,patients, ,who ,are ,not ,in ,a ,position 
,to ,stay ,in ,the ,hospital ,for ,a ,long ,time ,are ,advised ,to ,attend ,the ,OPD ,for ,further ,follow-up. ,At ,the 
,end ,of ,the ,trial, ,the ,patients ,are ,advised ,to ,follow-up ,for ,2 ,months ,in ,visit ,the ,OPD , ,. , 
 Based ,on ,various ,criteria, ,the ,data ,were ,collected ,and ,tabulated. ,The ,criteria ,were 
,family ,history, ,sex ,predominance, ,age ,distribution, ,occupation, ,dietary ,habits ,and ,incidence 
,of ,the ,disease ,with ,reference ,to ,thinai, ,seasonal ,variation, ,clinical ,manifestations ,and 
,assessment ,of ,the ,improvement ,in ,the ,prognosis ,of ,the ,disease ,with ,the ,trial ,drug. , 
 40 ,patients ,of ,both ,genders ,were ,recruited ,for ,this ,study. ,Among ,the ,40 ,cases, ,30 
,(75%) ,were ,males ,and ,10 ,(25%) ,were ,females. ,Generally the prevalance  ,Kalanjagapadai ,may 
,observed  ,in ,males ,more than ,female ,during ,study ,period ,of ,kaarkalam ,(mid ,augest ,to ,mid 
,october), ,koothirkalam ,(mid ,october ,to ,mid ,december),munpanikalam ,( ,mid ,december ,to ,mid 
,february). 
 Out ,of ,40 ,cases, , ,27.5% ,patients ,were ,between ,18 ,to ,30 ,years ,old, , ,25% ,patients 
,between ,31 ,to ,40 ,years, , ,25% ,patients ,between ,41 ,to ,50 ,years, ,(22.5%) ,patients ,between ,51 
,and ,60 ,years,. ,Kalanjagapadai ,can ,appear ,at ,birth ,as ,well ,in ,very ,old ,age. ,In ,this ,present ,study, 
,considerable ,number ,of ,patients ,were ,reported ,(11 ,patients) ,between ,the ,ages ,of ,18-30 ,among 
,study ,sample.There ,were ,no ,differences ,in ,age ,in ,the ,onset ,of ,psoriasis ,between ,men ,and 
,women ,with ,psoriasis. 
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 Among ,40 ,cases, ,15 ,in ,Vaatha ,kaalam ,(1-33 ,Years) ,and ,the ,remaining ,25 ,patients 
,reported ,in ,Pitha ,kaalam ,(34-66 ,Years).The ,age ,group ,between ,18 ,to ,45 ,years ,experienced 
,more ,frequent ,problems ,related ,to ,occupation, ,finance ,and ,work-related ,stresses ,as ,a ,result ,of 
,their ,psoriasis. 
Out ,of ,40 ,patients ,reported, ,the ,high ,prevalence ,of ,psoriasis ,was ,in ,working ,people ,field 
,work ,with ,physical ,exertion ,70%, ,field ,work ,with ,intellectual ,job ,17.5%, ,house-wife ,10%, ,and 
,students ,2.5%. ,The ,results ,did ,not ,declare ,psoriasis ,as ,an ,occupational ,related ,disease. 
 Family ,history ,was ,a ,risk ,factor ,for ,psoriasis. ,In ,this ,present ,study ,15% ,of ,patients ,had 
,family ,history.85% ,of ,the ,patients ,showed ,negative ,family ,history.Remissions ,and ,relapse ,of 
,this ,disease ,are ,quite ,common. ,90% ,of ,patients ,had ,the ,previous ,history ,of ,remission ,and 
,relapse. 
 Among ,the ,40 ,patients ,selected ,for ,this ,study, ,85% ,were ,non-vegetarian. ,In ,the ,text 
,Yugimuni ,800, ,non-vegetarian ,diet ,is ,mentioned ,as ,one ,of ,the ,causes ,for ,Kuttam. ,In ,this 
,present ,study ,the ,above ,cause ,has ,been ,proved. 
 Out ,of ,40 ,patients, ,7.5% ,of ,patients ,had ,tobacco ,chewing ,habits,Smoking ,and ,alcohol 
,15 ,% , ,and ,10% ,of ,patients ,had ,alcohol ,consuming ,habits.There ,is ,a ,strong ,association 
,between ,smoking, ,alcohol ,consuming, ,tobacco ,chewing ,habits ,and ,psoriasis ,lesions. ,In ,this 
,present ,study ,it ,has ,been ,proved ,that ,risk ,factors ,for ,psoriasis ,are ,smoking, ,alcohol, ,diet ,and 
,stressful ,life ,events. 
 In ,this ,present ,study, ,7.5% ,of ,the ,patients ,were ,from ,Marutham ,(Fertile ,Land), ,17.5% 
,of ,the ,patients ,were ,from ,Kurinji ,(Hill ,Area), ,20% ,of ,the ,patients ,were ,from ,Mullai ,(Forest 
,Area) ,and ,the ,remaining ,55% ,from ,Neithal ,(Coastal ,Area).Considerable ,numbers ,of ,patients 
,were ,reported ,from ,neithal. ,According ,to ,Siddha ,literature ,coastal ,area ,is ,more ,prone ,to ,skin 
,diseases. , 
 Patient ,enrollement ,period ,was ,various ,seasons ,especially ,Kaar ,kaalam,Koothir 
,kaalam,Munpanikaalam ,only ,and ,didn’t ,enroll ,of ,patient ,in ,other ,seasons. ,In ,this ,study, ,the 
,highest ,number ,of ,patients ,reported ,in ,(45%) ,Munpani ,kaalam. 
 In ,this ,study, ,The ,maximum ,numbers ,of ,patients ,had ,Pitha ,udal ,( ,37.5 ,%) ,and ,100 ,% ,of 
,the ,patients ,had ,Rajo ,Gunam. 
 Out ,of ,40 ,patients, ,35 ,% ,of ,the ,patients ,were ,suffering ,with ,during ,of ,the ,illness ,for ,1-
3 ,years. , 
 In ,Poripulan ,; ,Before ,treatment ,mei ,were ,found ,to ,be ,affected ,in ,all ,the ,40 ,patients.. 
,After ,treatment ,mei ,were ,found ,to ,be ,affected ,in ,27.5% ,of ,patients. , 
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 In ,Kanmendhiriyam ,; ,Before ,treatment ,eruvai ,were ,found ,to ,be ,affected ,in ,one 
,patients.. ,After ,treatment ,eruvai ,were ,found ,to ,be ,no ,abnormalities. 
 In ,kosam ,; ,Before ,treatment ,were ,found ,to ,be ,affected ,7.5% ,patients ,in 
,annamayakosam, ,2.5% ,in ,pranamayakosam,100% ,in ,manomayakosam. ,After ,treatment ,were 
,found ,to ,be ,affected ,2.5% ,in ,pranamayakosam,32.5% ,in ,manomayakosam. 
 In ,Vatham ,; ,Before ,treatment ,Udhanan,Samanan ,and ,Viyanan ,were ,found ,to ,be 
,affected ,in ,all ,the ,100% ,patients.Pranan ,was ,found ,to ,be ,in ,2.5% ,of ,patients, ,Abanan ,was 
,found ,to ,be ,in ,2.5% ,of ,patients, ,Kirukaran ,was ,found ,to ,be ,in ,7.5% ,of ,patients, ,Devathathan 
,was ,found ,to ,be ,affected ,in ,22.5% ,of ,patients. ,After ,treatment ,Udhanan,Samanan ,and 
,Viyanan ,were ,found ,to ,be ,affected ,in ,40% ,of ,patients. ,Pranan ,was ,found ,to ,be ,in ,2.5% ,of 
,patients. 
 In ,Pitham ,; ,Before ,treatment ,Ranjagapitham,Prasagapitham ,was ,affected ,in ,all ,the 
,cases ,and ,anarpitham ,was ,affected ,in ,7.5% ,patients. ,After ,treatment 
,Ranjagapitham,Prasagapitham ,was ,affected ,in ,27.5% ,patients. 
 In ,Kabam ,; ,Before ,treatment ,kiledhagam ,was ,affected ,in ,7.5%.Before , ,and ,after 
,treatment ,Avalambagam ,thee ,was ,affected ,in ,one ,case. , , 
 In ,Udal ,Kattukkal ,; ,Before ,treatment ,; ,Saaram ,and ,Seneer, ,Oon ,were ,affected ,in ,100% 
,of ,cases. ,After ,treatments ,Saaram, ,Seneer, ,Oon ,were ,affected ,in ,27.5% ,of ,cases. 
 In ,Envagai ,thervugal, ,before ,treatment ,Niram ,and ,Sparisam ,were ,found ,affected ,in ,all 
,the ,40 ,cases, ,Malam ,was ,found ,affected ,in ,1 ,cases. ,The ,Naadinadai ,seen ,in ,Kalanjagapadai 
,patients ,were ,Vaathapitham ,5%, ,Pithavaatham ,62.5 ,%, , ,Pithakabam ,17.5 ,%, ,Kabapitham 
,2.5%, ,Vathakabam ,12.5%. ,After ,treatment ,Niram,sparisam ,affected ,in ,11 ,cases, ,The ,Naadi 
,nadai ,seen ,in ,Kalanjagapadai ,patients ,were ,Vaathapitham ,77.5%, ,Pithavaatham ,20 ,%, 
 ,Pitha ,kabam ,2.5 ,%. 
 On ,Neerkuri ,; ,Before ,treatment ,the ,majority ,of ,patients ,had ,Citrus ,aurantium ,fruit ,colour 
,(47.5%) ,and ,wild ,citrus ,medica ,fruit ,colour ,37.5%, ,Hey ,soaked ,rain ,water ,colour 
,12.5%,Reddish ,yellow ,colour ,2.5%.After ,treatmentthe ,majority ,of ,patients ,had ,Citrus 
,aurantium ,fruit ,colour ,(40%) ,and ,wild ,citrus ,medica ,fruit ,colour ,5%, ,Hey ,soaked ,rain ,water 
,colour ,55%. 
On ,Neikuri ,: 
 On ,1st  ,day ,the ,patients ,had ,Kabam ,(Pearl) ,Neikuri ,pattern ,(55%), ,VP ,Neikuri ,pattern 
,(5%),PP ,Neikuri ,pattern ,(5%), ,PV ,Neikuri ,pattern ,(2.5%), ,Mukkuttram ,Neikuri 
,pattern(2.5%) ,and ,Severe ,Kabam ,(Saladaikan ,pattern) , ,(30%). 
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 On ,15th , ,day ,the ,patients ,had ,Kabam ,(Pearl) ,Neikuri ,pattern ,(37.5%),Pitham ,Neikuri 
,pattern(12.5%) ,, ,VP ,Neikuri ,pattern ,(12.5%), ,PV ,Neikuri ,pattern ,(5%),VK ,Neikuri ,pattern 
,(2.5%),Mukkuttram ,Neikuri ,pattern ,(2.5%) ,and ,Severe ,Kabam ,(Saladaikan ,pattern) , ,(27.5%). 
 On ,49th , ,day ,the ,patients ,had ,Vatham ,Neikuri ,pattern ,(5%), ,Pitham ,Neikuri ,pattern 
,(30%),Kabam ,(Pearl) ,Neikuri ,pattern ,(12.5%), ,VP ,Neikuri ,pattern ,(2.5%),PV ,Neikuri ,pattern 
,(25%),PK ,Neikuri ,pattern ,(10%),Mukkuttram ,Neikuri ,pattern(2.5%) ,and ,Severe ,Kabam 
,(Saladaikan ,pattern) , ,(12.5%).By ,this ,study , ,proved ,to ,assessment ,of ,prognosis , ,of ,the 
,treatment. 
 In ,Mankadainool, ,before ,treatment ,the ,majority ,of ,patients ,had ,8 ,½ ,finger ,breadth 
,(72.5%) ,. 
 In ,this ,study, ,45% ,of ,patients ,started ,medicine ,on ,Sunday, ,27.5% ,of ,patients ,started 
,medicine ,on ,Tuesday ,, ,27.5% ,of ,patients ,started ,medicine ,on ,Thursday ,as ,per ,Siddha 
,literature. ,The ,majority ,of ,patient ,had ,medicine ,on ,Sunday ,with ,good ,improvement.So ,from 
,this ,result ,medicine ,started ,on ,Sunday ,was ,Uthamam ,as ,per ,Siddha ,literature. , 
 The ,haematological ,and ,biochemical ,parameters ,were ,tested ,for ,the ,patients ,treated 
,with ,PPK ,and ,it ,was ,found ,that ,there ,was ,no ,major ,difference ,both ,before ,and ,after ,treatment. 
,This ,vouches ,for ,the ,safety ,of ,the ,trial ,drug ,administered ,as ,the ,values ,were ,well ,within ,the 
,normal ,limits. , 
Before ,treatment ,all ,the ,patients ,had ,the ,clinical ,features ,of ,erythema, ,scaling, ,itching, 
,Auspitz ,sign, ,Candle ,grease ,sign ,and , ,12.5 ,% , ,of ,cases ,had , ,Fissure, ,7.5 ,% , ,of ,cases ,had , ,pustule. 
,After ,treatment ,42.5% ,of ,cases ,had ,erythema, ,30% ,of ,cases ,had ,scaling, ,1.5% ,of ,cases ,had 
,itching, ,15% ,of ,cases ,had ,Auspitz ,sign, ,30% ,of ,cases , ,had , , ,Candle ,grease ,sign. ,92.5% ,of ,cases 
,had ,irregular ,shape ,of ,lesion. , 
 The ,most ,common ,discomfort ,encountered ,by ,the ,patients ,who ,had ,Psoriasis ,was 
,Itching ,and ,scaling. ,40 ,patients ,out ,of ,40 ,(100%) ,had ,this ,symptom ,and ,the ,test ,drug ,PPK 
,corrected , ,symptom ,of ,itching ,in , ,87.5% ,of ,the ,patients ,and ,corrected ,symptoms ,of ,scaling ,in 
,70 ,% ,of ,patients. ,The ,symptom ,of ,erythema ,was ,found ,all ,patients ,(100%). ,This ,was ,cleared 
,in ,most ,of ,the ,patients ,(57.5%) ,who ,had ,this ,complaint.The ,symptom ,of ,fissure ,(12.5%) ,, 
,pustule ,(7.5%) ,was ,found ,in , ,the ,patients. ,This ,was ,cleared ,all ,patients ,who ,had ,fissure ,and 
,pustule ,complaint.The ,most ,common ,signs ,in , ,the ,patients ,who ,had ,Psoriasis ,was ,auspitz ,sign 
,and ,candle ,grease ,sign. ,40 ,patients ,out ,of ,40 ,(100%) ,had ,this ,signs ,and ,the ,test ,drug ,PPK ,clear 
,the ,sign ,of ,auspitz ,sign ,in , ,85% ,of ,the ,patients ,and ,candle ,grease ,sign ,in , ,70% ,of ,the ,patients. 
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  ,Psoriasis ,is ,a ,disease ,that ,impacts ,the ,quality ,of ,life ,of ,patients, ,particularly ,in ,its 
,severe ,clinical ,forms. ,Quality ,of ,life ,score ,in ,before ,treatment ,score ,21-30 ,in ,40 ,patients. ,After 
,treatment ,score ,0-1 ,in ,19 ,patients, ,score ,2-5 ,in ,11 ,patients, ,score ,6-10 ,in ,1 ,patients, ,and ,score 
,11-20 ,in ,7 ,patient. ,Score ,21-30 ,in ,2 ,patients. 
 
Inference ,of ,the ,treatment ,assessment ,response ,with ,PASI ,Score ,: , 
 ,Group ,I ,was ,shown ,42.07±6.98 ,on ,first ,day ,(BT) ,and ,it ,was ,12.39±5.08 ,on ,it ,49th ,day 
,(AT).Till ,15th , , ,there ,is ,a ,gradually ,increase ,of ,PASI ,score ,i.e. ,upto ,44.43±7.11 ,and ,after ,15th 
,day day of the treatment, ,the ,PASI ,score ,declines ,to ,12.39±5.08 ( 49th day) 
 Group ,II ,was ,shown ,43.46±7.77 ,on ,first  ,day ,(BT) ,and ,it ,was ,4.22±2.16 ,on ,it ,49th ,day 
,(AT).Till ,49th ,day, ,there ,is ,a ,gradually ,declines ,of ,PASI ,score. , 
 Both ,group , ,(all ,patient) ,was ,shown ,42.76±7.30 ,on ,first  ,day ,(BT) ,and ,it ,was ,8.3±4.27 
,on ,it ,49th ,day ,(AT).Till ,15th ,day, ,there ,is ,a ,gradually ,increase ,of ,PASI ,score ,i.e. ,upto 
,43.67±6.84 , ,and ,after ,15th ,day of the treatment, ,the ,PASI ,score ,declines ,to ,8.3±4.27 (49th day). 
, 
Paired ,Sample ,Statistics ,( ,mean± ,SEM ,PASI ,Score ,Before ,Treatment ,and ,After 
,Treatment) ,: , 
 Group ,I ,was ,shown ,42.07±6.98 ,and ,12.39±5.08 ,respectively ,which ,is ,statistically ,very 
,significant ,(t ,= ,3.438, ,p ,<0.0014). , , , 
 Group ,II ,was ,shown ,43.46±7.77 ,and ,4.22±2.16 ,respectively ,which ,is ,statistically 
,extremely ,significant ,(t ,= ,4.866, ,<0.0001). , , 
Observation ,of ,assessment ,of ,the ,treatment ,response ,with ,PASI ,Score ,: 
 According ,to ,above ,the ,inferences ,; ,Initially ,the ,symptoms ,of ,psoriasis ,may ,be , 
,aggravated ,and ,then ,gradually ,declines ,by ,the ,trail ,drug. 
 As ,per ,paired ,sample ,statistics ,, ,Group ,II ,( ,with ,yogam) ,was ,shown ,excellent ,outcome 
, ,of ,the ,treatment ,greaterthan ,Group ,I ,( ,without ,yogam). , 
Outcome ,: 
 The ,outcome ,of ,this ,study ,showed ,promising ,results. ,In ,group ,I ,: ,Good ,improvement 
,was ,observed ,in ,13 ,patients ,(65%), ,moderate ,improvement ,in ,4 ,patients ,(20%), ,and ,poor 
,improvement ,in ,3 ,(7.5%) ,cases. ,In ,group ,II ,: ,Good ,improvement ,was ,observed ,in ,16 ,patients 





Effect ,of ,trial ,drug , ,in ,various ,type ,of ,KJP ,: 
 The ,outcome ,of ,this ,study ,in ,various ,type ,of ,psoriasis , ,showed ,bright ,results. ,Good 
,improvement ,was ,observed ,inPsoriasis ,vulgaris , ,18 ,patients ,(45 ,%),Psoriasis ,vulgaris ,with 
,Pustular ,psoriasis ,1 ,patient ,(2.5 ,%),Guttate ,psoriasis ,8 ,patients ,(20 ,%),Guttate ,psoriasis ,with 
,Pustular ,psoriasis ,1 ,patient ,(2.5 ,%), ,Psoriasis ,vulgaris ,with ,inverse ,psoriasis ,1 ,patient ,(2.5 ,%). 
,Moderate ,improvement ,was ,observed ,in ,Psoriasis ,vulgaris , ,6 ,patients ,(15 ,%),Guttate ,psoriasis 

























 The ,raw ,drugs ,of ,PPK ,were ,identified ,and ,authentication ,certificate ,was ,obtained. , , 
 The ,analytical ,specifications ,of ,the ,prepared ,drug ,revealed ,that ,it ,was ,in ,the ,standard 
,quality. 
 HPTLC ,finger ,printing ,analysis ,of ,the ,sample ,PKC ,reveals ,the ,presence ,of ,six 
,prominent ,peaks ,corresponds ,to ,presence ,of ,six ,versatile ,phyto-components ,present 
,with ,in ,it. ,Rf ,value ,of ,the ,peaks ,ranges ,from ,0.05 ,to ,0.71. ,Further ,the ,peak ,2 ,and ,6 
,occupies ,the ,major ,percentage ,of ,area ,of ,37.55 ,and ,36.53 ,% ,which ,denotes ,the ,abundant 
,existence ,of ,such ,compound. ,Followed ,by ,this ,peak ,1 ,and ,3 ,occupies ,the ,percentage 
,area ,of ,18.18 ,and ,3.11 ,%. 
 The ,toxic ,elements ,like ,Mercury, ,Arsenic ,and ,Cadmium ,are ,not ,detected. ,Further ,the 
,results ,show ,the ,presence ,of ,Lead ,and ,Arsenic ,and ,cadmium ,at ,1.185 ,and ,0.460 
,ppmlevel.The ,reported ,heavy ,metal ,seems ,very ,low ,when ,compare ,to ,the ,allowed 
,within ,the ,AYUSH & WHO  ,permissible ,limit. 
 In-vitro ,pharmacological ,activities ,has ,been ,done ,for ,PPK ,drug ,and ,this ,drug ,had 
,activities ,of ,anti-inflammatory ,(protein ,denaturation ,assay), ,immunomodulatory, ,anti-
proliferative ,(HaCaT ,keratinocyte ,cell ,line) 
 In ,docking ,analysis ,on ,PPK , ,: , ,PPK ,compounds ,possess ,promising ,IL-6 ,inhibition 
,activity, ,TNF- ,alpha ,inhibition ,activity, ,Nitric ,oxide ,synthase ,enzyme ,inhibition 
,activity. 
 In-vitro ,pharmacological ,activities ,has ,been ,done ,for ,external ,medicine ,of ,Sivappu 
,thylam , ,and ,this ,drug ,had ,activities ,of ,anti-inflammatory ,property ,in ,protein 
,denaturation ,assay. 
 The ,safety ,profile ,study ,has ,been ,approved ,by ,IAEC ,of ,NIS.[Date ,of ,IAEC ,Approval 
,& ,its ,number: ,NIS/IAEC ,VI ,/24/04/2018/09]. , 
 The ,study ,shows ,that ,PPK ,did ,not ,produce ,any ,toxic ,effect ,at ,dose ,of ,2000 ,mg/kg. ,So 
,No-Observed-Adverse-Effect-Level ,(NOAEL) ,of ,PPK ,is ,2000 ,mg/kg. 
 NOAEL ,of ,PPK ,was ,found ,to ,be ,greater ,than ,27 ,mg/kg/p.o/day ,in ,rats. 
 This ,study ,has ,been ,approved ,by ,IEC ,of ,NIS.[Date ,of ,IEC ,Approval ,& ,its ,number: 
,NIS/13-IEC/2017-1-08/22-11-2017]. , 
 The ,disease ,Kalanjagapadai ,was ,taken ,for ,the ,clinical ,study ,with ,Parangipattai 
,Kudineer ,(Internally), ,Sivappu ,thylam( ,Externally) ,and ,40 ,cases ,were ,selected ,based 




▪ Group ,I ,: ,Trail ,drug ,without ,yogam ,in , ,(20) ,OPD , ,patients. 
▪ Group ,II ,: ,Trail ,drug ,with ,yogam ,in ,(20) ,IPD , ,patients. , 
 Animal ,studies ,were ,done ,after ,obtaining ,approval ,from ,the ,Animal ,Ethical 
,Committee ,(IAEC). ,Hence ,the ,study ,was ,safely ,executed ,on ,patients ,and ,there ,was ,no 
,adverse ,drug ,reactions ,noted ,during ,the ,study ,period. 
 The ,detailed ,study ,on ,Kalanjagapadai ,with ,reference ,to ,its ,etiology, ,pathogenesis, 
,investigations, ,clinical ,features, ,diagnosis ,and ,treatment ,with ,trial ,drug ,was ,done. , 
 
Inference ,of ,the ,treatment ,assessment ,response ,with ,PASI ,Score ,: , 
 ,Group ,I ,was ,shown ,42.07±6.98 ,on ,first ,day ,(BT) ,and ,it ,was ,12.39±5.08 ,on ,it ,49th ,day 
,(AT).Till ,15th , , ,there ,is ,a ,gradually ,increase ,of ,PASI ,score ,i.e. ,upto ,44.43±7.11 ,and ,after ,15th 
,day day of the treatment, ,the ,PASI ,score ,declines ,to ,12.39±5.08 ( 49th day) 
 Group ,II ,was ,shown ,43.46±7.77 ,on ,first  ,day ,(BT) ,and ,it ,was ,4.22±2.16 ,on ,it ,49th ,day 
,(AT).Till ,49th ,day, ,there ,is ,a ,gradually ,declines ,of ,PASI ,score. , 
 Both ,group , ,(all ,patient) ,was ,shown ,42.76±7.30 ,on ,first  ,day ,(BT) ,and ,it ,was ,8.3±4.27 
,on ,it ,49th ,day ,(AT).Till ,15th ,day, ,there ,is ,a ,gradually ,increase ,of ,PASI ,score ,i.e. ,upto 
,43.67±6.84 , ,and ,after ,15th ,day of the treatment, ,the ,PASI ,score ,declines ,to ,8.3±4.27 (49th day). 
 
Paired ,Sample ,Statistics ,( ,mean± ,SEM ,PASI ,Score ,Before ,Treatment ,and ,After 
,Treatment) ,: , 
 Group ,I ,was ,shown ,42.07±6.98 ,and ,12.39±5.08 ,respectively ,which ,is ,statistically ,very 
,significant ,(t ,= ,3.438, ,p ,<0.0014). , , , 
 Group ,II ,was ,shown ,43.46±7.77 ,and ,4.22±2.16 ,respectively ,which ,is ,statistically 
,extremely ,significant ,(t ,= ,4.866, ,<0.0001). , , 
Observation ,of ,assessment ,of ,the ,treatment ,response ,with ,PASI ,Score ,: 
 According ,to ,above ,the ,inferences ,; ,Initially ,the ,symptoms ,of ,psoriasis ,may ,be ,become 
,aggravated ,and ,then ,gradually ,declines ,by ,the ,trail ,drug. 
 As ,per ,paired ,sample ,statistics ,, ,Group ,II ,( ,with ,yogam) ,was ,shown ,excellent ,outcome 








 The ,outcome ,of ,this ,study ,showed ,promising ,results. ,In ,group ,I ,: ,Good ,improvement 
,was ,observed ,in ,13 ,patients ,(65%), ,moderate ,improvement ,in ,4 ,patients ,(20%), ,and ,poor 
,improvement ,in ,3 ,(7.5%) ,cases. ,In ,group ,II ,: ,Good ,improvement ,was ,observed ,in ,16 ,patients 
,(80%), ,moderate ,improvement ,in ,4 ,patients ,(20%). 
 
Effect ,of ,trial ,drug , ,in ,various ,type ,of ,KJP ,: 
 The ,outcome ,of ,this ,study ,in ,various ,type ,of ,psoriasis , ,showed ,bright ,results. ,Good 
,improvement ,was ,observed ,inPsoriasis ,vulgaris , ,18 ,patients ,(45 ,%),Psoriasis ,vulgaris ,with 
,Pustular ,psoriasis ,1 ,patient ,(2.5 ,%),Guttate ,psoriasis ,8 ,patients ,(20 ,%),Guttate ,psoriasis ,with 
,Pustular ,psoriasis ,1 ,patient ,(2.5 ,%), ,Psoriasis ,vulgaris ,with ,inverse ,psoriasis ,1 ,patient ,(2.5 ,%). 
,Moderate ,improvement ,was ,observed ,in ,Psoriasis ,vulgaris , ,6 ,patients ,(15 ,%),Guttate ,psoriasis 
,2 ,patients ,(5 ,%).and ,poor ,improvement ,in ,Psoriasis ,vulgaris , ,3 ,patients ,(7.5 ,%). 
In ,this ,study, ,no ,adverse ,events ,were ,observed ,during ,the ,course ,of ,the ,treatment. ,At ,the 
,end ,of ,the ,study, ,all ,the ,patients ,were ,advised ,to ,attend ,out-patient ,department ,of ,Sirappu 





















The ,poly ,herbal ,formulation ,Parangipattai Kudineer ,(PPK) ,exhibited ,no ,toxicity ,on 
,short ,term ,administration. 
PPK drug had , activities ,of , In-vitro; anti-inflammatory ,(protein ,denaturation ,assay),  
In-vitro; ,immunomodulatory, , In-vitro; anti-proliferative ,(HaCaT ,keratinocyte ,cell ,line) and  in 
,docking ,analysis ,on ,PPK , ,: , ,PPK ,compounds ,possess ,promising ,IL-6 ,inhibition ,activity, ,TNF- 
,alpha ,inhibition ,activity, ,Nitric ,oxide ,synthase ,enzyme ,inhibition ,activity.   
Sivappu ,thylam ,drug ,had ,activities ,of In-vitro;,anti-inflammatory ,property ,in ,protein 
,denaturation ,assay.   
The ,present ,clinical ,study ,confirms ,the ,efficacy ,and ,safety ,of ,the ,trial ,drug 
,“Parangipattai ,Kudineer ,(Internally) ,and ,Sivappu ,thylam ,(Externally)” ,which ,is ,Siddha ,poly 
,herbal ,formulation. ,It ,was ,found ,to ,be ,highly ,effective ,on ,Kalanjagappadai ,patients ,in ,reducing 
,clinical ,signs ,and ,symptoms ,like ,itching, ,scaling ,and ,erythema. 
 The ,outcome ,of ,this ,study ,showed ,promising ,results. ,In ,group ,I ,: ,Good ,improvement 
,was ,observed ,in ,13 ,patients ,(65%), ,moderate ,improvement ,in ,4 ,patients ,(20%), ,and ,poor 
,improvement ,in ,3 ,(7.5%) ,cases. ,In ,group ,II ,: ,Good ,improvement ,was ,observed ,in ,16 ,patients 
,(80%), ,moderate ,improvement ,in ,4 ,patients ,(20%).  
, , , , , , , ,From ,the ,above ,results, ,the ,trail ,drug ,“Parangipattai ,Kudineer ,(Internally) ,and ,Sivappu 
,thylam ,(Externally)” ,was ,responded ,well ,with ,Yogam ,therapy ,more ,than ,without ,yogam , ,in ,the 
,treatment ,of ,Kalanjagappadai. , , 
 , , , , , , , ,As ,a ,conclusion ,it ,can ,be ,stated ,that ,the ,Siddha ,herbal ,formulation ,PPK & ST ,can ,be 
,used ,as ,a ,safe ,and ,extremely ,efficacious ,drug ,with ,Yogam ,therapy ,more ,than ,without ,yogam , 
,towards ,the ,management ,of ,Kalanjagapadai ,which ,takes ,a ,huge ,toll ,of ,inducing ,psychological 
,stress ,and ,impact ,on ,the ,cosmetic ,purposes.    
 


































































































































































































































































 INVESTIGATIONS  


















BT AT BT AT BT AT BT AT  BT AT BT AT 
P1 
14.2 14.4 4.4 4.5 22 19 30 25  7700 8200 1.7 1.8 
P2 
14.8 14.5 5.6 5.6 32 20 64 44  6300 5800 2.7 2.3 
P3 
16.5 15.5 4.9 4.9 40 20 51 40  9300 6000 2.8 2.3 
P4 
15.8 15 4.5 5.2 14 3 20 10  7300 6600 1.4 1.4 
P5 
14.8 15 5.2 5.5 14 6 18 10  6400 6700 2.5 2.5 
P6 
12.4 13 4.2 4.4 20 22 40 39  9200 9300 2.5 2.7 
P7 
13.9 14.1 3.8 3.7 10 6 22 12  9800 7600 3.9 3.1 
P8 
12.6 13.1 4.7 4.8 20 6 40 12     6400 5600 3.4 3.1 
P9 
13.5 14.2 4.8 4.8 16 10 34 22  12800 10400 4.3 4.3 
P10 
10.8 10.9 4.1 4.2 16 20 32 42  5900 6600 2.2 2.1 
P11 
11.5 12 4.5 4.6 10 16 20 30  12100 10600 3.2 3.3 
P12 
12 13 4.6 4.6 14 12 22 26  7700 6600 2.7 2.2 
P13 
15.6 15.3 4.8 4.6 14 6 18 12  8900 8400 2.3 2.1 
P14 
12.4 13 4.2 4.3 24 18 50 26  9600 9400 2.4 2.1 
P15 
15.7 15.2 5.5 5.5 14 10 30 22  8100 8800 3.1 3.4 
P16 
14.6 13.6 4.9 4.3 6 6 12 12  9900 8300 3 2.8 
P17 
15.8 14.8 5.8 5.4 16 40 32 82  10100 8200 2 2.4 
P18 
13.2 14 4.5 4.7 12 6 24 12  7000 8100 2.8 2.9 
P19 
13.6 13.7 4.6 4.8 6 14 12 20  6400 8400 3.7 3.8 
P20 



















BT AT BT AT BT AT BT AT  BT AT BT AT 
P21 
12 14.2 4.7 5.1 22 6 50 12  4000 5200 2.9 2.7 
P22 
9.8 10.6 4.4 5 20 18 40 36  6600 6700 4.2 4.3 
P23 
15.1 14.7 4.6 4.6 4 4 10 10  6200 6100 2.4 2.6 
P24 
15.5 16 4.6 4.6 4 6 10 12  6500 6700 3 3.5 
P25 
10.8 11.7 4.8 5.2 12 8 24 16  5400 5600 2.7 2.9 
P26 
16.2 14.9 5.6 5.1 2 4 6 8  5100 7300 3.2 3.4 
P27 
11.6 13.1 4.2 4.8 20 10 40 22  7400 6600 3 3.2 
P28 
15.1 15.4 5.2 5.4 12 6 24 12  9700 7600 2.9 3.3 
P29 
14.9 15.1 5.5 5.5 12 12 24 26  5100 4800 2.6 2.4 
P30 
16.4 15.5 5.6 5.4 12 14 24 28  4500 4300 1.9 2 
P31 
15.3 15.2 4.6 4.5 12 6 24 12  7600 8600 2.5 2.8 
P32 
15.3 14.9 4.6 5.3 12 6 14 12  7600 7200 2.8 2.5 
P33 
13 14.7 4.4 4.9 20 7 40 14  7900 5400 2.3 2 
P34 
13.3 11.9 4.1 3.5 10 8 20 16  5700 5500 2.6 2.1 
P35 
14.1 13 6.4 5.8 8 7 16 14  11900 8500 3.6 2.7 
P36 
14.9 13.8 4.6 4.4 6 6 12 12  5700 9100 3.3 3.9 
P37 
14.6 13.9 3.8 3.8 8 7 16 14  6900 8100 2 1.9 
P38 
14.8 14.4 5.2 5 6 8 12 16  8100 7900 3.3 2.9 
P39 
13.5 13.5 4.7 4.6 30 18 60 36  8100 7200 3.5 3.5 
P40 













SGOT (IU/L) SGPT (IU/L) 
Alkaline 
Phosphatase 
BT AT BT AT BT AT BT AT BT AT BT AT 
P1 
1.2 0.8 




0.5 0.8 0.2 0.3 0.3 0.5 17 15 3 3 191 150 
P3 
1.1 1.4 0.4 0.5 0.7 0.9 45 30 63 22 65 48 
P4 
0.5 0.5 0.2 0.1 0.3 0.2 14 18 17 20 81 82 
P5 
0.5 0.4 0.2 0.1 0.3 0.3 20 18 25 21 81 66 
P6 
0.3 1.1 0.1 1.1 0.2 0.3 20 26 12 21 88 74 
P7 
0.9 0.7 0.3 0.3 0.6 0.4 35 30 42 21 107 91 
P8 
0.6 0.7 0.2 0.3 0.4 0.4 22 40 19 16 71 76 
P9 
0.6 0.3 0.2 0.1 0.4 0.2 30 20 31 28 119 105 
P10 
0.6 0.4 0.2 0.2 0.4 0.2 29 31 19 25 88 103 
P11 
0.4 0.2 0.2 0.1 0.2 0.1 20 30 15 29 98 92 
P12 
2.1 2.1 0.7 0.7 1.4 1.4 16 21 15 19 76 67 
P13 
1.2 1.2 0.6 0.7 0.3 1.2 28 26 25 32 83 66 
P14 
0.8 0.4 0.4 0.2 0.4 0.2 16 18 14 20 61 66 
P15 
0.9 1.2 0.3 0.4 0.6 0.8 15 23 29 33 92 79 
P16 
1.7 1.2 0.6 0.4 1.1 0.7 26 24 26 28 78 73 
P17 
0.7 0.5 0.3 0.2 0.4 0.3 19 19 29 20 107 97 
P18 
0.8 0.4 0.3 0.3 0.4 0.4 19 22 34 38 155 170 
P19 
0.9 0.7 0.3 0.2 0.6 0.5 21 24 27 36 76 59 
P20 
0.7 0.9 0.3 0.4 0.4 0.5 24 19 27 19 58 54 







SGOT (IU/L) SGPT (IU/L) 
Alkaline 
phosphatase 
BT AT BT AT BT AT BT AT BT AT BT AT 
P21 
0.7 0.4 




0.2 0.55 0.14 0.22 0.2 0.3 14 15.4 14.5 10.7 84 70 
P23 
0.36 0.6 0.2 0.2 0.3 0.4 18 27 28 36 55 50 
P24 
0.5 0.5 0.3 0.2 0.5 0.3 38 23 25 22 92 55 
P25 
0.8 0.9 0.2 0.3 0.6 0.6 31 41 39 84 77 91 
P26 
0.8 0.7 0.4 0.3 0.4 0.4 16 16 14 18 46 31 
P27 
0.8 0.5 0.3 0.2 0.3 0.3 23 74 15 73 91 96 
P28 
0.6 0.3 0.2 0.1 0.4 0.2 20 17 14 25 65 53 
P29 
0.6 0.7 0.3 0.3 0.4 0.4 23 30 17 29 71 63 
P30 
0.7 0.9 0.33 0.4 0.5 0.5 25.7 51 42.2 92 76 68 
P31 
0.8 0.84 0.4 0.31 0.5 0.5 17 19.5 17 25 105 97 
P32 
0.9 1.1 0.4 0.4 0.5 0.7 17 24 17 25 105 72 
P33 
0.9 0.35 0.1 0.15 0.3 0.2 19 35.9 32 63.3 76 71 
P34 
0.4 0.5 0.22 0.2 0.3 0.3 22 24 16.7 18 60 53 
P35 
0.51 0.7 0.31 0.3 0.5 0.4 17.3 20 20.2 18 81 59 
P36 
0.82 1.2 0.6 0.5 0.8 0.7 51 16 46 11 118 74 
P37 
1.4 0.9 0.65 0.4 0.9 0.5 31.6 20 26.4 17 87 79 
P38 
1.58 0.6 0.3 0.2 0.4 0.4 16 22 26 36 89 71 
P39 
0.7 0.6 0.35 0.2 0.4 0.4 22.8 35 21.2 22 78 66 
P40 






































BT AT BT AT 
P1 82 
90 121 86 19 6 
0.7 
0.7 













P2 80 83 91 99 12 14 1 1 Nil Nil Nil Nil Nil Nil 
3 to 5 
1 to 
2 
4 to 6 
1 
to2 
P3 108 104 168 179 14 25 1 1.1 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
1 to 2 
1 to 
2 
P4 83 92 85 91 22 18 1 1.2 Nil Nil Nil Nil Nil Nil 






P5 93 92 96 94 20 14 1.2 1.2 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
3 
2 to 3 
1 to 
3 
P6 94 96 115 88 17 13 0.9 0.9 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
1 to 2 
1 to 
2 










105 99 162 172 19 16 1 1 
Nil Nil Nil Nil Nil Nil 
Nil Nil Nil nil 










P10 88 86 93 99 15 14 0.9 0.9 Nil Nil Nil Nil 4.3 Nil 
2 to 4 
1 to 
2 
2 to 4 
1 to 
2 
P11 86 77 98 107 17 17 0.7 0.7 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
4 to 5 
1 to 
2 
P12 102 76 120 115 15 20 0.9 0.9 Nil Nil Nil Nil Nil Nil 
 1to 3 
2 to 
3 
1 to 3 
2 to 
3 
P13 96 89 127 117 23 20 1.1 1.1 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
1 to 2 
1 to 
2 
P14 142 130 276 212 19 16 1 1 2+ 2+ 2+ 2+ Nil Nil 
2 to 3 
2 to 
3 
2 to 3 
2 to 
3 
P15 128 122 235 264 16 29 0.9 0.9 2+ 1+ 2+ 1+ Nil Nil 
 1to 2 
1 to 
2 
1 to 2 
1 
to2 
P16 99 109 147 165 16 18 0.8 0.9 Nil Nil Nii Nil Nil Nil 






P17 97 101 115 123 22 22 1 1 Nil Nil Nil Nil Nil Nil 
 1to 2 
1 to 
2 
1 to 2 
2 to 
3 
P18 104 33 138 104 24 22 0.8 1 Nil Nil Nil Nil Nil Nil 
4 to 6 
1 to 
2 
2 to 4  
1 to 
2 
P19 101 94 123 134 18 22 0.9 0.9 Nil Nil Nil Nil Nil Nil 
 1to 2 
6-8 
2 to 3 
2 to 
3 
P20 99 82 144 234 16 20 1.2 1.2 1+ 1+ 1+ 1+ Nil Nil 
1 to 2 
2-3 





















BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
P21 77 89.8 133 89 24 23.3 
1 
1.1 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
1 to 2  
1 to 
2 













4 to 6 
2 to 
4 
P24 82 93 113 88 13 15 1.1 1 Nil Nil Nil Nil Nil Nil 
1 to 3 
1 to 
2 
1 to 3 
1 to 
2 
P25 100 100 149 127 22 15 0.9 1 Nil Nil Nil Nil Nil Nil 
1 to 2 
2 to 
4 
2 to 4 
1 to 
2 
P26 91 86 117 116 18 19 1.1 1 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
1 to 2  
1 to 
2 
P27 88 90 124 127 19 29 0.8 0.8 Nil Nil Nil Nil Nil Nil 
1 to 3 
2 to 
4  2to 4 
 2to 
4 
P28 88 79 91 116 16 23 1.1 1 Nil Nil Nil Nil Nil Nil 
1 to 2 
2 to 
4 
1 to 2  
1 to 
2 
P29 86 76 108 84 19 21 1.1 1 Nil Nil Nil Nil Nil Nil 
2 to 4 
1 to 
2 
2 to 4 
1 to 
2 
P30 89.2 91 115 124 18.3 16 1.11 1 Nil Nil Nil Nil 4.3 Nil 
1 to 2 
1 to 
2 
1 to 2  
1 to 
2 
P31 96 73.1 128 85 27 15.4 0.8 0.85 Nil Nil Nil Nil Nil Nil 
2 to 4 
 1 to 
2 
1 to 2 
2 to 
3 
P32 96 81 119 99 27 18 0.8 1.2 Nil Nil Nil Nil Nil Nil 
 2 to 4 
1 to 
2 
1 to 2 
1 to 
2 
P33 86 79.6 95 125 16 17.1 1.1 1.09 Nil Nil Nil Nil Nil Nil 
1 to 2 
2 to 
3 
1 to 2 
2 to 
4 
P34 86.8 84 113 114 23.5 20 1.13 1.1 Nil Nil Nil Nil Nil Nil 
1 to 2 
1 to 
2 
1 to 2 
1 to 
2 
P35 75.7 77 125 96 17.7 16 1.03 1 Nil Nil Nil Nil Nil Nil 
2 to 3 
2-3 
2 to 3 
1 to 
2 
P36 81 77 111 91 18 16 1 0.9 Nil Nil Nii Nil Nil Nil 
1 to 2 
2-3 
3 to 5 
3 to 
5 
P37 77.5 76 82 93 17.4 24 1.09 1.1 Nil Nil Nil Nil Nil Nil 
1 to 2 
1-2 
1 to 2 
1 to 
2 
P38 85 73 98 103 22 18 1 1 Nil Nil Nil Nil Nil Nil 
1 to 2 
2-4 
1 to 2 
2 to 
3 
P39 82 71 164 130 21 20 0.94 0.9 Nil Nil Nil Nil Nil Nil 
1 to 2 
6-8 
1 to 2 
1 to 
2 
P40 93 88 113 189 20 17 1 1 Nil Nil Nil Nil Nil Nil 
1 to 2 
2-3 






S.NO S. CHOL 
 
HDL LDL VLDL TGL 
BT AT BT AT BT AT BT AT BT AT 
P1 139 152 53 60 73 81 7 10 38 49 
P2 223 215 48 49 95.8 121 34 31 173 156 
P3 161 173 43 42 129 98 40 43 199 215 
P4 197 195 55 50 109 90 21 20 107 105 
P5 170 132 49 26 137 100 36 49 181 184 
P6 145 161 41 47 78 87 35 23 175 114 
P7 203 171 41 49 114 92 33 29 164 145 
P8 182 143 55 44 87 78 26 30 132 150 
P9 181 226 45 56 79 112 18 38 89 188 
P10 199 179 58 49 92.8 87 14 14 72 68 
P11 132 122 55 41 93 54 11 16 56 78 
P12 114 113 41 31 95.6 53 22 33 110 164 
P13 179 168 59 49 72 79 26 19 130 95 
P14 119 125 40 38 88.5 52 15 12 77 106 
P15 218 188 38 35 45.7 103 62 61 310 302 
P16 239 217 45 44 69 118 50 35 250 176 
P17 194 173 52 46 83.6 89 23 22 114 110 
P18 162 154 37 35 107 77 20 21 98 110 
P19 260 248 49 54 80.3 147 36 45 180 224 
P20 177 175 47 45 97 98 18 27 89 137 
 
 
 S.NO S. CHOL 
 
HDL LDL VLDL TGL 
BT AT BT AT BT AT BT AT BT AT 
     P21 127 136 36 44 72 70.6 19 10.2 98 50.9 
P22 165 169 47.6 56 133 89.3 20.2 15 101.2 75.1 
P23 219 216 54 52 92 120 36 30 179 150 
P24 225 250 57 54 110 143 29 44 145 219 
P25 217 228 53 41 92 124 35 29 176 146 
P26 154 132 85 55 82 56 16 15 78 75 
P27 206 221 63 58 109 112 17 22 88 110 
P28 165 154 45 39 108 72 37 30 184 435 
P29 153 140 52 39 102 69 10 12 53 61 
P30 177 158 54.3 40 108 77 18.7 16 93.7 77 
P31 185 172 51 96.2 60 50.1 17 874 84 19.2 
P32 179 135 33.9 33 57 70 45.7 25 228.3 124 
P33 143 184 31 37.2 93 96.8 30 61.5 148 307.6 
P34 171 166 33.9 36 64 92 26.6 33 132.9 163 
P35 194 141 154.6 36 117 70 96.4 27 30.9 113 
P36 176 145 84 38 118 74 12 20 62 100 
P37 192 153 62.1 45 92 75 13.7 21 68.6 104 
P38 207 175 44 40 80 97 29 23 148 119 
P39 177 186 43.6 42 140 106 16.2 40 80.9 200 











ASO CRP VDRL HBsAg 
BT AT BT AT BT AT BT AT BT AT 
P1 
















































































































































ASO CRP VDRL HBsAg 
BT AT BT AT BT AT BT AT BT AT 
P21 Negative 

















































































































































Principal  Investigator:                 Guide:       
Dr.K.Archana,                                Dr.M.V.Mahadevan M.D(s), 
PG scholar,                                          Lecturer, 
Department of SPM,               Department of SPM, 
National Institute of Siddha,                                   National Institute of Siddha, 
Chennai-47.                                                            Chennai-47. 
   
 
From         
Dr.K.Archana,  
 PG Scholar, 
 Department of Sirappu Maruthuvam, 
 National Institute of Siddha, 
 Chennai-47. 
To  
 The Director, 
 National Institute of Siddha, 
 Chennai- 47. 
Through Proper Channel 
Respected Madam, 
  Sub: Submission of my Dissertation Protocol -  regarding 
 I have selected “Pre clinical and comparative clinical trial of Siddha drugs 
Parangipattai Kudineer (Internally)  and Sivappu Thylam (Externally) in the treatment of 
Kalanjagapadai (Psoriasis) with and without Yogam therapy (Agathavam Ettu)”as my 
dissertation work for the partial fulfillment of the requirement to degree of Doctor of Medicine 
in Sirappu Maruthuvam. I am herewith submitting my Protocol for your kind perusal and seek 
your permission to undertake my dissertation work. 
                                                      Thanking you, 
Place:                                         Yours faithfully, 






“Pre clinical and comparative clinical trial of Siddha drugs   Parangipattai Kudineer 
(Internally)  and Sivappu Thylam (Externally) in the treatment of Kalanjagapadai (Psoriasis) 















Principal  Investigator: 
                Dr.K.Archana,  
                PG scholar, 
                     Department of Sirappu Maruthuvam, 
                     National Institute of Siddha, 
                     Chennai-47. 
Guide: 
        Dr.M.V.Mahadevan M.D(s), 
                    Lecturer, 
                    Department of Sirappu Maruthuvam, 
         National Institute of Siddha, 
                    Chennai-47. 
 
1.FULL TITLE OF STUDY: 
“Pre clinical and comparative clinical trial of Siddha drugs Parangipattai Kudineer 
(Internally) and Sivappu Thylam (Externally) in the treatment of Kalanjagapadai (Psoriasis) 
with and without Yogam therapy (Agathavam Ettu)” 
2.Name of the Candidate   : Dr.K.Archana,  
                                                PG Scholar, 
Department                        :  Sirappu Maruthuvam. 
Name of the Institution     :  National Institute of Siddha, 
                                                Chennai-47. 
                                                Telephone No: 044-22411611 
                                                Fax: 044-22381314 
                                                          nischennaisiddha@yahoo.co.in 
                                                Website: www.nischennai.org. 
3.Name of the Guide           : Dr.M.V.Mahadevan M.D(s), 
                                                Lecturer, 
                                                Department of Sirappu Maruthuvam, 
                                                National Institute of Siddha, 
                                                Chennai-47. 
4.BACKGROUND: 
                      Siddha system of Medicine, one of the traditional system of practiced in India 
from time immortal known for its proven ability in curing long standing diseases and their life 
threatening complications. Siddhars have listed the diseases of mankind as 4448 based on the 
Mukkutram ie.,Vali, Azhal, Iyyam. Among them, the skin diseases are classified into 18 
varieties by Siddhar Yugi Munivar. But he has not explained “Kalanjagapadai” as a separate 
entity. Instead of that he has described under the classification of vaadha diseases about 
“Kalanjagavatham” which may be correlated  with  Psoriatic arthropathy.   
In the textbook “Siddha Maruthuvam Sirappu”, Dr.R.Thiagarajan has described about 
Kalanjagapadai. The clinical features of Kalanjagapadai are correlated to psoriasis as described 
in modern dermatology. 
In the Siddha system, skin disorders are brought under the clinical entity “Kuttam”.  
In the text book “Aathma Ratchamirtham ennum Vaiththiya saarasangiragam” the 
characteristics of kuttam are described as; white scaly patches will appear in foot, wrist and 
typical extensor distribution.  
In the textbook “Siddha medical dictionary”, Mr.T.V.Sambasivam pillai has described  
about “Kuttam” means cutaneous affections and so it is a comprehensive term used for various 
skin diseases. In this book “Sori kuttam” has been compared to psoriasis, a kind of leprosy with 
diffuse papular eruption with ulceration on the entire surface of the body marked by intense 
itching and burning sensation followed by exfoliation of the epidermis or browny scales 
(Eczematous psoriasis, lepra icthyosis).  
Psoriasis is a common, chronic non infectious skin disease characterized by well defined 
slightly raised, dry erythematous macules with silvery scales and typical extensor distribution. 
(Ref: Practice of Dermatology- P.N.Bhel, Page no:253)  
 Psoriasis is a common chronic disfiguring inflammatory and proliferative epidermal skin 
disorder mediated by T cell that affect approximately 1 to 3% of the world population, 
multifactorial inheritance most likely a family history of psoriasis is found in 30% of 
patient.(Ref: Essential in Dermatology, pg. no: 82)  
Psoriasis is universal in occurrence. There is a growing number of population-based studies 
providing worldwide prevalence estimates of psoriasis. Prevalence of psoriasis varies in 
different parts of the world. According to published reports, prevalence in different populations 
varies from 0% to 11.8%.Prevalence studies from India are mostly hospital-based. The 
prevalence of psoriasis to be 0.8% among the skin patients but the sample size of the study was 
very small. The ratio of male to female (2.46:1) was very high which could not be clearly 
accounted for. Highest incidence was noted in the age group of 20-39 years and the mean age 
of onset in males and females was comparable. (Ref:IJDVL-Indian Journal of Dermatology, 






Some of the previous Dissertation study drugs for managing Psoriasis in National Institute of 
Siddha 
S.No INTERNAL MEDICINE EXTERNAL MEDICINE YEAR  
1. Chithiramoola Rasayanam Veppannai Thylam March2010   
2. Kirandimega Chooranam Avuri Ennai March2011  
3. Soolaikku perumarunthu 
chooranam 
Viranangalukku Ennai March2013  
4. Gandhaga Rasaayanam 
 
Vettiver Thylam March2014  
 
 5. Karunchoorai chooranam Kodiveli Thylam March2015 
 
            The number of Kalanjagapadai patients attending the National Institute of Siddha   
hospital is increasing day by day. Patient is very much agitated and subjected to physical and 
mental suffering. However clinical symptoms can be relieved considerably with Siddha 
treatment.Siddhars identified numerous number of herbal for treating psoriasis. One such 
Siddha herbal formulation “Parangipattai Kudineer” (Internal) and “Sivappu Thylam” 
(External) mentioned in “Pharmacopoeia of hospital of Indian medicine” which is said to be 
cost effective, efficacious and simple formulation. This formulation has not undergone any 
clinical trial so far. 
The ingredients of Parangipattai Kudineer are, 
1.Parangipattai (Smilax china Linn.):  
            Anti-inflammatory,Anti-diabetic,Antispasmodic. 
2.Kadugu Rohini (Picrorhiza kurroa Royle_):  
           Anti-inflammatory, Antioxident. 
3.Manjitti (Rubia cordifolia Linn.):   
            Anti-inflammatory,Antianalgesic,Antipyretic. 
4.Mara Manjal (Coscinium fenestratum Colebr.):  
            Antifungal, Antimicrobial, Anti-inflammatory, Antioxident,Antianalgesic. 
5.Kadukkai (Terminalia chebula Retz.):  
             Antifungal, Antimicrobial, Anti-inflammatory, Antioxident. 
 
6.Thandrikai (Terminalia bellarica Roxb.):  
             Antifungal, Antimicrobial, Anti-inflammatory. 
7.Vasambu (Acorus calamus Linn):  
            Antifungal, Antimicrobial,Anti-inflammatory,Antianalgesic,Antipyretic,Antioxident. 
8.Sombu (Pimpinella anisum Linn.) :  
            Anti-inflammatory,,Antianalgesic,Antifungal. 
9.Veppampattai (Azadirachta indica A.Juss.):  
            Antifungal,Antimicrobial,Anti-inflammatory,Antianalgesic,Antipyretic,Antioxident. 
10.Seendhil (Tinospora cordifolia Miers.): 
            Anti-inflammatory, Antianalgesic,Antipyretic,Anti-diabetic,Antispasmodic 
The ingredients of Sivappu Thylam are, 
1. Pungan Ver (Pongamia pinnata Pierre.): 
             Anti-inflammatory,,Antianalgesic,Antifungal,Antimicrobial 
2. Manjitti (Rubia cordifolia Linn.:)        
             Anti-inflammatory,,Antianalgesic,Antipyretic. 
3. Nannari (Hemides musindicus R.Br.)  :    
             Antioxident,Anti-inflammatory 
 4. Manjal Mezhugu (Cera wax) : 
              Anti-inflammatory 
 5. Vellai Kungiliyam (Vateria indica Linn.):    
               Antispasmodic,Anti-inflammatory 
6. Chevvallikkodi (Dioscoreapurpurea):   
             Anti-inflammatory 
7. SurulPattai(Cinnamomumverum.Juss.):      
          Anti-inflammatory,,Antianalgesic 
8. Coconut Oil (CocosnuciferaLinn.):        
          Anti-inflammatory,,Antianalgesic 
So that I hope this medicine will be effective in the treatment of “KALANJAGAPADAI”. 





5.1.PRIMARY OBJECTIVE:   
 To evaluate the safety and therapeutic efficacy of Siddha drugs, 
Parangipattai kudineer (Internally) And Sivappu Thylam(Externally) in the treatment of 
Kalanjagapadai (Psoriasis) 
5.2.SECONDARY OBJECTIVES 
❖ To study the Siddha diagnostic methods such as Envagai thervu and Manikkadai Nool  
as complementary measures for diagnosis in Kalanjagapadai patients. 
❖ To carry out the biochemical analysis of trail medicine Parangipattai kudineer 
(Internally) 
❖ To evaluate the toxicity study of trail medicine Parangipattai kudineer (Internally) 
6.JUSTIFICATION FOR THE CONDUCT OF THE STUDY: 
              Siddhars identified numerous number of herbal for treating psoriasis. One such Siddha 
herbal formulation “Parangipattai Kudineer” (Internal) and “Sivappu Thylam” 
(External) mentioned in “Pharmacopoeia of hospital of Indian medicine” which is said to be 
cost effective, efficacious and simple formulation. This formulation has not undergone any 
clinical trial so far.The ingredients of Parangipattai kudineer (Internally) are Parangipattai 
(Smilax china.Linn.),Kadugu Rohini (Picrorhiza kurroa.Royle_), Manjitti (Rubia 
cordifolia.Linn.), Mara Manjal (Coscinium fenestratum.Colebr.), Kadukkai (Terminalia 
chebula Retz.), Thandrikai (Terminalia bellarica.Roxb.), Vasambu (Acorus calamus.Linn), 
Sombu (Pimpinella anisum.Linn.), Veppampattai (Azadirachta indicaA.Juss.),Seendhil 
(Tinospora cordifoliaMiers.) are also having Antifungal, Antimicrobial, Anti-inflammatory, 
Antioxident, Antianalgesic. So that I hope this medicine will be effective in the treatment of 
KALANJAGAPADAI. Therefore I have selected the drug for clinical study. 
7.METHODOLOGY: 
7.1. STUDY TYPE     :    A preclinical and clinical study. 
7.2. STUDY DESIGN: 
Study Place                 :   OPD and IPD of AyothidossPandithar Hospital,  
                                          National Institute of Siddha, 
                                          Tambaram Sanatorium, Chennai - 47. 
Study Period               :    18 Months 
Year                             :     2016-2019. 
Sample Size                 :    40 patients  (20 Patients in OPD and 20 Patients in IPD) 
 PATIENT SCREENING 
Inclusion/Exclusion 
INCLUSION CRITERIA EXCLUSION CRITERIA 





 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY AND 
TRIAL DRUG 
INFORMED CONSENT FORM 
ADVERSE REACTION 
ADVICED TO TAKE 





FURTHER MANAGEMENT OF 
ADVERSE DRUG REACTION 
 7.3.DISEASE CONDITION: 
                               Psoriasis is a common, chronic non infectious skin disease characterized by 
well defined slightly raised, dry erythematous macules with silvery scales and typical extensor 
distribution Kalanjagapadai  correlated with Psoriasis.  
                               The symptoms of Kalanjagapadai  like red plaque,silvery white scales,on 
removal of scales minute bleeding point. 
  
7.4 TRAIL DRUG : 
  Internal Medicine                          : Parangipattai kudineer 
Dosage   : 30 ml , Three times a day (Before food) 
Duration of Treatment :  4 5 days 
Reference   :  Pharmacopoeia of hospital of Indian medicine 
Page .No   :  3 
Edition   :  2nd edition 1995 
Edited & Publish by             : Directorate of Indian medicine & Homeopathy. 
  External Medicine                          : Sivappu Thylam 
Reference   : Pharmacopoeia of hospital of Indian medicine 
Page.No   : 33  
Edition   : 2nd edition 1995 
Dosage   : Q.S.  (Applied externally over the affected part) 
Edited & Publish by             : Directorate of Indian medicine & Homeopathy.             
Standard Operating Procedure: 
Source of raw drugs: 
The required raw drugs for the trial medicine will be purchased from a well reputed 
country raw drug shop and drugs will be authenticated by the competent authority Medicinal 
Botany and CCRS. After that the raw drugs will be purified separately then the trial drugs 







 INTERNAL DRUG: PARANGIPATTAI  KUDINEER 
Ingredients: 
1.Parangipattai (Smilax chin. Linn.)           ---1.000kg 
2.KaduguRohini (Picrorhiza kurroa.Royle )        ---1.000kg 
3.Manjitti (Rubia cordifolia.Linn.)        ---1.000kg 
4.MaraManjal (Coscinium fenestratum.Colebr.)---1.000kg 
5.Kadukkai (Terminalia chebula.Retz.)       ---1.000kg 
6.Thandrikai (Terminalia bellarica.Roxb)       ---1.000kg 
7.Vasambu (Acorus calamus.Linn.)        ---1.000kg 
8.Sombu (Pimpinella anisum.Linn)       ---1.000kg 
9.Veppampattai (Azadirachta indica.A.Juss)     ---1.000kg  
10.Seendhil (Tinospora cordifolia.Miers)           ---1.000kg 
METHOD OF PURIFICATION OF RAW DRUGS:         
1. Parangipattai (Smilax china Linn.) 
It should be cleaned with white cloth then  the outer layer of parangipattai root bark to 
be peeled out.(Ref: Sigicharathina theebam:28)     
2. KaduguRohini (Picrorhiza kurroa.Royle. )  
 It should be soaked in the neemleaf  juice  for 3 hours and it should be dried under 
sunlight.(Ref: Sigicharathina theebam:30) 
3. Manjitti (Rubia cordifolia.Linn.)   
It  should be dried under  sunlight.(Ref: Sigicharathina theebam:30)      
4. Mara Manjal (Coscinium fenestratum.Colebr)  
  The outer skin should be removed.(Ref: Sigicharathina theebam:29)      
5. Kadukkai( Terminalia chebula.Retz)    
 The seed removed and rinds alone to be used for preparation.(Ref:Sigicharathina 
theebam:30)      
 
6. Thandrikai ( Terminalia bellarica.Roxb)    
              The seed removed and rinds alone to be used for preparation.(Ref: Sigicharathina 
theebam:30)    
7. Vasambu ( Acorus calamus.Linn)    
         It should be cleaned with white cloth then  the outer layer of vasambu root bark to be 
peeled out (Ref: Sigicharathina theebam:30)     
8. Sombu ( Foeniculum vulgare.Linn)    
          It should be dried for six hours under sunlight.  (Ref: Sigicharathina theebam:29) 
9. Veppam pattai ( Azadirachta indica .A.Juss.)    
          It should be cleaned with white cloth then  the outer layer of veppampattai’s bark to 
be peeled out.(Ref: Sigicharathina theebam:28)    
10. Seendhil ( Tinospora cordifolia .Miers.) 
The outer skin of stem should be removed. (Ref: Sigicharathina theebam:33). 
METHOD OF PREPARATION:  
 All the drugs should be purified and crushed into coarse powder.  Then adding 8 times of water 
with the coarse powder before boiling   Preparing the decoction by reducing  it into 1/8. Then 
filter and keep it for use. 
7.5. Dosage   : 30ml , Three times a day (Before food). 
EXTERNAL MEDICINE:  SIVAPPU  THYLAM 
Ingredients: 
1. Pungan Ver (Pongamia pinnata Pierre.)         -- 4kg   
2. Manjitti (Rubia cordifolia Linn.)                     -- 62.5gm   
3. Nannari (Hemidesmus indicus R.Br.)              -- 62.5gm  
 4. Manjal Mezhugu (Cera wax)                          -- 62.5gm   
5. Vellai Kungiliyam (Vateria indica Linn.)       -- 62.5gm   
6. Chevvallikkodi (Dioscorea purpurea)            -- 20gm   
7. Surul Pattai (Cinnamomum verum.Juss.)      -- 30gm   
8. Coconut Oil (Cocos nucifera Linn.)             -- 1 Lr  
 
METHOD OF PREPARATION :  
             Boil the Manjitti, Nannari, Chevvallikodi, PunganVer, adding 8 times of water. 
Prepare the decoction by reducing it into 1/8.Then equal quantity of oil should be mixed with 
the decoction and again to be boil.The yellow wax should be cut into pieces and added them 
into the melted thick consistency. After melting, it will be taken from the oven in the texture 
of sand.  Then the pulverized Surulpattai (lavangapattai) added into it and stirr well.Then filter 
and keep it for use. 
Drug Storage: 
The trial drug Parangipattai Kudineer powder is stored in clean and dry container. 
Sivappu Thylam is stored in clean and dry narrow mouthed bottles. 
Dispensing: 
The Parangipattai Kudineer powder 10gram/time is given in packets and Sivappu 
Thylam quantity sufficient is given in bottles. 
7.6.Duration                           : 45 days 
7.7. Number of patients         : 40 patients  (20 Patients in OPD and 20 Patients in IPD) 
Subject Selection: 
             Patients reporting with symptoms of Kalanjagapadai will be subjected to screening 
using screening Proforma. Then they will be allowed for the study fulfilling the following 
criteria: 
7.8.Inclusion Criteria 
• Age : 20-65 years 
• Sex : Both male and female, Transgender  
• History of Insulin Dependent Diabetes Mellitus 
• Itching (with or without) 
• Erythema 
• Scaling 
• Auspitz sign + 
• Candle crease sign + 
• Willing to give specimen of blood for the investigation whenever required.  
• Willing to take photograph 





• History of Insulin Dependent Diabetes Mellitus 
• Pregnancy and lactation 
• History of Psoriasis with evidence of any other skin disease  or Evidences of 
secondary infection in the lesions. 
• History of  Psoriatic arthropathy 
• History of Cardiac diseases 
• History of  Hansen’s disease 
• History of any other chronic illness 
Withdrawal Criteria  
• Intolerance to the drug and development of any serious adverse effect during drug 
trial. 
• Poor patient compliance & defaulters 
• Patient unwilling to continue the course of clinical Study. 
• Occurrence of any other systemic illness. 
Tests and assessments: 
            1. Clinical assessment  
2. Siddha system assessment 
3. Routine investigations 






• Thickness  
• Scaling 
• Plaques 
• Hyper or hypopigmentation 
• Candle-grease sign 






7.10. Investigations based on Siddha System: 








8. Moothiram ●  Neerkkuri :  ●  Neikkuri   : 
     II. Manikadai Nool (Wrist circumetric sign):  Finger breadths.  
    III. ELU UDAL THADHUKKAL: 
1. Saaram : 
2. Seneer : 
3. Oon : 
4. Koluppu : 
5. Enbu  : 
6. Moolai  : 




• Total WBC Count 
• Polymorphs 
• Lymphocytes  
• Eosinophils 
• Monocytes  
• Basophils  
• Total RBC count  
• ESR : ½ Hr:       1 Hr: 
• Blood sugar : Fasting:  PP: 
• Serum cholesterol 
Urine 
• Albumin 
• Sugar  (F)                (PP) 
• Deposits 
Renal Function Tests 
             Blood Urea 
             Serum Creatinine 
             Uric acid 
Liver Function Tests 
              Serum total bilirubin 
              Direct bilirubin 
              Indirect bilirubin 
              Serum Alkaline phosphatases 
              SGOT  
              SGPT 





➢ Good outcome     - Clearance of lesions and Reduction of PASI Score from 3, 4 to 1,0 
➢ Moderate outcome - Partial clearance of lesions and Reduction of PASI Score from 3, 4 to 
2. 
➢ Mild outcome -  Slight clearance  of lesions  and Reduction of PASI Score from 4 to 3 
➢ Nil outcome            - No Clearance of lesions or No reduction PASI Score   
 
Psoriasis Area and Severity Index (PASI) 
A Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring 
the severity of psoriatic lesions based on area coverage and plaque appearance 
Erythema / Thickness / Scaling-Rating score     Area Scoring 
0 - None      0-Nil   
1- Slight      1-1-9% 
2- Moderate      2- 10%-29% 
3-Severe      3-30%-49% 
4-Very severe      4-50%-69% 
        5-70%-89% 
        6-90%-100% 




                                                PASI CALCULATION 
Plaque Characteristic Rating Score 









0 = None         
Thickness 
1 = Slight 
        
2 = Moderate 
Scaling 
3 = Severe 
        
4 = Very Severe 
      Totals     
Weighting Factor     x 0.1    x 0.2   x 0.3    x 0.4 
Surface area totals     
  
Degree of involvement as  
% for each body region  
affected (score each  
region between 0 and 6) 
0 = None 
    
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Surface area totals x % involvement totals 
Sum Scores above = 
    
• Add together each of Erythema/Thickness/Scaling scores for each of the body 
regions to give 4 separate sub totals A1, A2, A3 and A4 
• Multiply each sub total by amount of body surface area represented by that region 
i.e. A1 x 0.1 for head, A2 x 0.2 for upper limbs, A3 x 0.3 for trunk, A4 x 0.4 for 
lower limbs to give a value B1, B2, B3 and B4 for each body region respectively.A1 
x 0.1=B1;   A2 x 0.2=B2; A3 x0.3=B3; A4 x 0.4=B4 
• For each body region multiply sub total B1, B2, B3 and B4 by the score(0-6) of the 
% of body region involved to give 4 sub totals C1, C2, C3 and C4 
• The patient’s PASI score is the sum of C1+C2+C3+C4 
 10. Conduct of the study: 
Group I : Trail drug without yogam in  OPD  patients. 
Group II : Trail drug with yogam in  IPD  patients.  
First day : 
Agathiyar kulambu  with 200mg with 30ml leaf juice of Sangankuppi (Azima 
tetracantha) quantity was administered at early morning as purgative (Kazhichal Medicine) 
before starting the treatment for restore equilibrium of dhoshams. 
Second day :  
 Oil bath with Arakku thylam  has taken at early morningfor restore equilibrium of 
udalthathus. 
Third day onwards from  Sunday,Tuesday,Thursday for 48 days :  
 Internal Medicine: Parangipattai Kudineer, three times a day before food. 
External Medicine: Sivappu thylam 
Advice for method of topical therapy :   
Oil applied in psoriatic lesion by cotton for 4 hrs at  1pm to 5pm and take sunbath at 
4pm to 5.30pm thereafter bath with warmwater used by greengram powder.  
Yogam therapy (Agathavam Ettu) will be given for IPD patients. Envagai Thervu will 
be evaluvate before and after the treatment for 40 patients. Nei Kuri will be evaluvate 
0thday,15th day,49th dayof the treatment for opd and IPD patients. Manikadai Nool will be 
measure before the treatment for 40 patients.       
 OPD patients are requested to visit the hospital once in 7 days. In each and every visit 
clinical assessment and prognosis were  recorded. For IPD patients the clinical assessment and 
prognosis were recorded daily.  
                          Laboratory investigations were done before and after the trial. For IPD 
patients, who are not in a position to stay in the hospital for a long time are advised to attend 
the OPD for further follow-up. At the end of the trial, the patients are advised to visit the OPD.  
 
  
CLINICAL APPLICATION OF MANIKADAI NOOL TECHNIQUE : 
Manikadai nool  is one among the tool of examination in siddha system to diagnose the 
disease as well as to assess its prognosis. This unique method was revealed by siddhar  
AGATHIYR to his disciple Vedhamamuni.The literary meaning of the terminology ; 
PROCEDURE ;  
                         The circumference of the forearm of an individual at the region of 4 finger 
breadth proximal to the radial protuberance of wrist is measured by using a thread, which 
should be non elastic. Then the length of the thread is converted in terms of finger breadth units 
(viral kadai ) of the concerned individual patient. 
11.Ethical issues: 
 The internal drug was mentioned in the List of books of Drugs and Cosmetics Act 1940. 
Hence no preclinical and toxicity studies will be carried out. 
 The patient will be informed about the treatment and other procedures in his vernacular 
language. After getting the consent only (language understandable to the patient) they 
will be enrolled in the study.  
 To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments will 
be used.                         
 The data collected from the patient will be kept confidential.  
 Treatment will be provided free of cost.  
 If any adverse reactions occur  it will be reported to the Pharmacovigilance committee 
of NIS. And they will be advised to take treatment at the OPD of National Institute of 
Siddha. 
12.Data collection: 
Required information will be collected from each patient by using the following forms: 
Forms:  
Form I            Screening and selection Proforma 
Form II           History taking &Clinical assessment Proforma 
Form III          Laboratory investigation Proforma 
Form IV         Drug compliance form 
Form V          Patient information sheet 
Form VI         Consent form 
Form VII       Withdrawal form 
Form VIII      Dietary Advice form 
Study Enrolment:  
o Patients reporting at the OPD with clinical feature of erythematous patches, silvery scaling  
are chosen for enrolment based on the inclusion and exclusion criteria. 
o The enrolled patients will be informed about the study, trial drug, possible outcomes and 
the objectives of the study in the language and terms understandable to them and getting 
consent in the Informed Consent form (Form VI). 
o Complete clinical history, complaints and duration, examination findings-- all would be 
recorded in the prescribed Proformas. 
o Screening Form- I will be filled up, Form –II and Form –III will be used for recording the 
patients, history, clinical examination of symptoms and signs and laboratory investigations 
respectively. If there is any abnormal laboratory reports obtained then excluded from this 
study. Patients would be advised to take the trial drug and appropriate dietary advice (Form 
VIII) would be given according to the patients, perfect understanding. 
13.Pharmaco-Vigilance (Adverse/serious adverse effects management): 
If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and he will be directed to take treatment in OPD of NIS. It will also 
be reported to the Pharmaco-vigilance committee of NIS.  
 
14.Dermatology Life Quality Index (DLQI): 
Recent studies have emphasized the association of psoriasis severity with impaired 
physical and public functioning as well as with the emotional state. The DLQI is calculated by 
summing the score of each question resulting in a minimum of 0 and a maximum of 30. The 
higher the score, the more quality of life is impaired.  
15.Outcome measures: 
The outcome of the study was clinically observed by the PASI Score. 
PASI Score: - 
 * PASI 25 = 25% (Poor) reduction in the PASI Score in before and after treatment. 
 * PASI 50 = 50% (Moderate) reduction in the PASI Score in before and after 
treatment. 
 * PASI 75 = 75% (Good) reduction in the PASI Score in before and after treatment. 
16.Data analysis: 
After enrolling the patients in the study, a separate file for each patient will be maintained and 
all forms will be kept in the file. Study No. and patient’s No. will be entered on the top of the 
file for easy identification. Whenever the patients visit OPD during the study period, necessary 
entries will be made at the assessment forms.  
The screening forms will be filled separately. All forms will be further scrutinized by Senior 
Research Officer (Statistics) for logical errors and incompleteness of data to avoid any bias. 
No modification in the results is permitted for unbiased reports 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI  KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) WITH 
AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).  
Principal Investigator: Dr.K.ARCHANA         CTRI REG.NO  : CTRI/2018/07/015115 
 
FORM - SCREENING & SELECTION PROFORMA 
 
1.SERIAL NO:      2. OP /IP NO:                 
3. NAME:            4. AGE/GENDER:  
5. OCCUPATION:                 6. INCOME:  
 
INCLUSION CRITERIA 
• Age : 20-60 years       YES\ NO 
• Sex : Male,Female and Transgender    M \ F\T 
• History of Non-Insulin Dependent Diabetes Mellitus   YES\ NO 
• Erythema        YES\ NO 
• Thickness                     YES\ NO  
• Scaling         YES\ NO 
• Itching :with or without itching     YES\ NO 
• Auspitz sign +       YES\ NO 
• Candle crease sign +      YES\ NO 
• Willing to attend OPD or admission in IPD for the trial  YES\ NO 
• Willing to give specimen of blood for the investigation   YES\ NO 
• Willingness for consent       YES\ NO 
• Willing to take photograph before and after treatment.            YES\ NO 
 
EXCLUSION CRITERIA 
• History of Insulin Dependent Diabetes Mellitus   YES\ NO 
• Pregnancy and lactation      YES\ NO 
• Psoriasis with evidence of any other skin disease  YES\ NO 
• Psoriatic arthropathy      YES\ NO 
• Cardiac disease       YES\ NO 
• Hansen’s disease       YES\ NO 
• Evidences of secondary infection in the lesions   YES\ NO 
• Any other chronic illness                                YES\ NO 
ADMITTED TO TRAIL 
YES  NO  
If Yes, OPD  IPD  
  Serial NO:  
 
Date:        
Station: 
Signature of the Investigator:  
Signature of the Lecturer:                                          Signature of the HOD:                                        
DEPARTMENT OF SIRAPPU MARUTHUVAM 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI  KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) WITH 
AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU). 
FORM- INFORMATION SHEET 
 
Name of Principal Investigator    : Dr.K.ARCHANA 
CTRI REG.NO                              : CTRI/2018/07/015115 
 
Name of the institute                   :   National Institute of Siddha, 
                                                           Tambaram Sanatorium, 
                                                           Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL: 
I, Dr.K.Archana Studying as M.D (Siddha) at National Institute of  Siddha, Tambaram 
Sanatorium is doing a trial on the study Kalanjagapadai (Psoriasis). Psoriasis is a most 
common persistent skin disease, occurring throughout the world. The symptoms of 
Kalanjagapadai  like red plaque, silvery white scales, on removal of scales minute bleeding 
point. This condition is being treated in NIS with many siddha formulations. As a part of 
M.D(S) research programme and developing new efficacious medicine, I  propose to study the 
Parangipattai Kudineer formulation for treating the Kalanjagapadai. This formulation has 
been mentioned in siddha literature and empirical evidence with contemporary tools is required 
for documentation. You can the receive medicines free of cost Parangipattai Kudineer powder 
(Internal medicine) 10g three times a day Sivappu Thylam (External medicine), for 7 days in a 
duration of 45 days without any cost. You have to visit OPD 7 days once (7 visits) during the 
45 days and if you wish to stay in the In Patient ward and Yogam therapy (Agathavam Ettu)-
Surya namaskaram (Sun salutation), Padmasanam (Lotus position),Nadi suddhi pranayamam ( 
Alternate nostril breathing practice), Paschimottanasanam ( Forward bend pose), Makarasanam 
(Crocodile pose) will be given for IPD patients. I will assess the effect of treatment  after 
completion of 45 days of treatment using clinical and lab parameters. 
 At each visit, the study physician (investigator) will be examine you. Blood tests 
will be carried out before study initiation and after the study completed. Blood will be collected 
at that time .Blood collection involves prick with a sterile needle and syringe. 
 In this regard, I need to ask you few questions. I  will maintain confidentiality 
of your comments and data obtained from you. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this study. 
Taking part in this study is voluntary. No compensation will be paid to you for taking 
part in this study. You can choose not to answer any specific question. In this study, you will 
get treatment benefits and free investigations. Taking part in the study may be of benefit to the 
community, as it may help us to develop medicine for Kalanjagapadai . In case of any adverse 
symptoms which is expected for few patients during the treatment, please report to me and care 
will be taken in OPD of NIS. You can withdraw from the study at the midst of treatment period, 
if you are not interested to continue and you will receive our usual treatment without condition. 
If you agree to be a participant in this study, you will be screened as per the study protocol.   
 If you wish to find out more about this study before taking part, you can ask me 
all the questions by contact Dr.K.Archana PG scholar cum principal investigator of this study, 
attached to the National Institute of Siddha, Chennai (Mobile phone no:8675544027). You can 
also contact the Chairman/Member-secretary of Ethics committee, National Institute of Siddha, 




§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
FORM - ¾¸Åø ÀÊÅõ 
¸¡Ç¡ïº¸ôÀ¨¼ §¿¡öì¸¡É º¢ò¾ ÁÕóÐ ÀÈí¸¢ôÀð¨¼ì ÌÊ¿£÷ (¯ûÁÕóÐ)  
º¢ÅôÒò ¨¾Äõ (¦ÅÇ¢ ÁÕóÐ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  
¾¸Åø ÀÊÅõ.  
 Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :  ÁÕ. ¸.«÷îºÉ¡   
  CTRI REG.NO          : CTRI/2018/07/015115  
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ÁÕ.¸.«÷îºÉ¡ ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ 
ÀÂ¢ýÚ ÅÕ¸¢§Èý. ¸¡Ç¡ïº¸ôÀ¨¼ ±ýÛõ §¿¡Â¡ÉÐ º¢ò¾ ÁÕòÐÅò¾¢ø §¾¡¨Äô 
À¡¾¢ìÌõ ´Õ §¿¡Â¡Ìõ. þó¾ §¿¡Â¢ø §¾¡Ä¢ø º¢ÅôÒ ¿¢Èò ¾¢ðÎ¸¨Ç ²üÀÎò¾¢ 
«¾¢ø ¦º¾¢ø §À¡ø ¯¾¢Ã ¦ºöÔõ º¢Ä ºÁÂõ «Ã¢ôÒ¼§É¡ «øÄÐ «Ã¢ôÀ¢ýÈ¢§Â¡ 
¸¡½ôÀÎõ. -Ð ÁüÈÅ÷¸ÙìÌ ÀÃÅ ÜÊÂ §¿¡ö «øÄ.  þó§¿¡öìÌ §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ 
Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç ÀÂýÀÎòÐõ §¿¡ì¸¢ø 
ÀÈí¸¢ôÀð¨¼ì ÌÊ¿£÷ (¯ûÁÕóÐ)  º¢ÅôÒò ¨¾Äõ (¦ÅÇ¢ ÁÕóÐ) ÁÕó¾¢¨É 
þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, ÁüÚõ 
ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í £¸¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. 
±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 45 ¿¡ð¸û ¬Ìõ. 7 ¿¡ð¸ÙìÌ ´ÕÓ¨È §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ 7 ¿¡ð¸Ùì¸¡É ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. 
¯û§¿¡Â¡Ç÷¸ÙìÌ §Â¡¸ ÁÕòÐÅõ («¸ò¾Åõ ±ðÎ) - ÝÃ¢Â ¿ÁŠ¸¡Ãõ, ÀòÁ¡ºÉõ, 
¿¡ÊÍò¾¢ À¢Ã¡½Â¡Áõ, Àðº¢§Á¡ò¾¡ºÉõ, Á¸Ã¡ºÉõ ¾¢ÉÓõ ÀÃ¢óÐ¨Ã ¦ºöÂôÀÎõ. 
þó¾ ¬ö× ºõÀó¾Á¡É ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û ¸ ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ.45 ¿¡ð¸û 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ 
ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý 
¸ñ¼È¢ÂôÀÎõ.    
       
      þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. 
¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ 
À¾¢× ¦ºöÂôÀÎõ. þó¾ ¬öÅ¢ø ¾í¸¨Ç ¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ 
Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
        
      ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ 
§¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. 
§¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ.þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ 
±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ 
§ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯ ¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ. 
¸¡Ç¡ïº¸ôÀ¨¼ §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ 
¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ.þó¾ ¬öÅ¢ý §À¡Ð ¯ ¼ÖìÌ 
§ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø þõÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ Á¡üÚº¢¸¢î¨º «Ç¢ì¸ÀÎõ. 
þó¾ ¬öÅ¢¨Éò¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ×õ, þõÁÕòÐÅÁ¨ÉÂ¢ø 
ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ 
«È¢×Úò¾ôÀÎ¸¢È£÷¸û.  
      
      þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨ Åì¸ôÀÎõ..¿£í¸û þó¾ ¬öÅ¢ø 
Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û. 
 
      ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ 
Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ 
ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å¢ ÁÕ. ¸.«÷îºÉ¡ 
¬¸¢Â ±ñ¨½ 8675544027 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û 
þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22711611 ±ýÈ 
±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.             
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
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AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).  
Principal Investigator: Dr.K.ARCHANA  
CTRI REG.NO          : CTRI/2018/07/015115 
     
 
FORM – CONSENT FORM 
 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to 
my satisfaction.  
            I consent voluntarily to participate as a participant in this study and understand that 
I have the   right to withdraw from the study at any time without in any way it affecting my 
further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm individual has given 







Signature of a witness  
(Selected by the participant bearing no connection with the survey team)   






Left thumb Impression of the Participant 
 
 §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
FORM – ´ôÒ¾ø ÀÊÅõ  
¸¡Ç¡ïº¸ôÀ¨¼ §¿¡öì¸¡É º¢ò¾ ÁÕóÐ ÀÈí¸¢ôÀð¨¼ì ÌÊ¿£÷ (¯û ÁÕóÐ)  
º¢ÅôÒò ¨¾Äõ (¦ÅÇ¢ ÁÕóÐ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  
´ôÒ¾ø ÀÊÅõ.  
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¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð : 
¿¡ý ¸¡Ç¡ïº¸ôÀ¨¼ ±ýÛõ §¿¡Â¢ý ¬ö¨Åì ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ 
§¿¡Â¡Ç¢ìÌô ÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
§¾¾¢:                                                ¨¸¦Â¡ôÀõ: 
 
þ¼õ:                          ¦ÀÂ÷:   
 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ  þó¾  ÁÕòÐÅ  ¬öÅ¢ý  ¸¡Ã½ò¨¾Ôõ,  ÁÕó¾¢ý ¾ý¨Á  ÁüÚõ 
ÁÕòÐÅ  ÅÆ¢Ó¨È  ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ  ±ÉÐ  ¯¼ø  þÂì¸ò¨¾ì  ¸ñ¸¡½¢ì¸×õ, 
«¾¨Éô  À¡Ð¸¡ì¸×õ  ÀÂýÀÎõ ÁÕòÐÅ  ¬ö×ìÜ¼  ÀÃ¢§º¡¾¨É¸û  ÀüÈ¢  ¾¢Õô¾¢ 
«Ç¢ìÌõ  Å¨¸Â¢ø  ¬ö×  ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì  ÜÈôÀð¼Ð. ¿¡ý  þó¾ ÁÕòÐÅ  
¬öÅ¢ý  §À¡Ð, ±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ  þó¾  ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ  
¦¸¡ûÙõ  ¯Ã¢¨Á¨Âò ¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
¿¡ý  ±ýÛ¨¼Â  Í¾ó¾¢ÃÁ¡¸ò  §¾÷×  ¦ºöÔõ  ¯Ã¢¨Á¨Âì  ¦¸¡ñÎ  
¸¡Ç¡ïº¸ôÀ¨¼ §¿¡öì¸¡É ÀÈí¸¢ôÀð¨¼ì ÌÊ¿£÷ (¯ûÁÕóÐ)  º¢ÅôÒò ¨¾Äõ 
(¦ÅÇ¢ ÁÕóÐ)  ÁÕó¾¢¨É  ÀÃ¢¸Ã¢ôÒò  ¾¢È¨Éì  ¸ñ¼È¢Ôõ  ÁÕòÐÅ  ¬öÅ¢üÌ  
±ý¨É  ¯ðÀÎò¾ ´ôÒ¾ø  «Ç¢ì¸¢§Èý. 
                                                    º¡ðº¢ì¸¡Ã÷ :1.¨¸¦Â¡ôÀõ: 
§¾¾¢:                                                ¦ÀÂ÷:                          
þ¼õ:            ¯È×Ó¨È:  
          2.¨¸¦Â¡ôÀõ: 
             ¦ÀÂ÷:                          
                  ¯È×Ó¨È:  
 
Å¢Ã¢×¨ÃÂ¡Ç¡÷ ¨¸¦Â¡ôÀõ:                         Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ: 
 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) 
WITH AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).  
Principal Investigator: Dr.K.ARCHANA  
CTRI REG.NO          : CTRI/2018/07/015115 
 
FORM : HISTORY TAKING PROFORMA 
 
STUDY  NO:   OP / IP NO: 
NAME: AGE / GENDER: 
ADDRESS: CONTACT NO : 
 RELIGION :  H / C / M / O. 
OCCUPATION: INCOME: 
MARITAL STATUS :       1. Married 2. Unmarried 
DATE OF INTIAL ASSESSMENT:  
 COMPLAINTS & DURATION: 
(BEFORE TREATMENT) 








                                                                                                                                                                   
PERSONAL HISTORY: 





Smoking     
Betel leaf , Tobacco Chewing     
Alcohol     
Narcotic  Drug Addiction     
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 
FAMILY HISTORY: 
Whether this problem runs in family? 1. Yes            2. No    










DIETARY STYLE: 1. Vegetarian    2. Non-vegetarian 
 




ANY ALLERGY HISTORY : 
 
FORM II B  
GENERAL EXAMINATION:                         Before treatment     After treatment 
1. Conscious / Oriented /Co-operative /  
Comfortable / Unconscious /Comatose : 
2. Body weight [Kg]    :                      
3. Height [cms]                       :     
4. BMI                                              :                    
5. Body Temperature [F]       :   
6. Blood Pressure (mm/Hg)  :      
7. Pulse Rate /min.   : 
8. Heart Rate / min.    : 
9. Respiratory Rate /min.  :   
10. Facies                                            : 
11. Head and neck                              : 
12. Mouth and oral cavity                  : 
13. Skin and Hair                               : 
14.  Extremities                                  : 
15. Joints                                            : 
16. Genitalia                                       : 
17. Hernial orifices                            : 
18. Abdominal distension                  :                         
                                                                                       
19. Pallor   :   
20. Icterus   :   
21. Clubbing   : 
22. Cyanosis   : 
23. Pedal Oedema   : 
24. Lymphadenopathy      :  
25. Jugular venous pulsation  :  
 
 
SYSTEMIC EXAMINATION        : Before treatment        After treatment 
  Cardiovascular system  :  
  Respiratory system   :  
  Gastro-intestinal system  :  
  Central Nervous system  :  
  Urogenital system   :  
  Endocrine system              :  
 
 
SIDDHA SYSTEM OF EXAMINATION 





2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji(Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
 
3. KAALAM:                         Before treatment        After treatment 
1. Kaarkaalam (Aavani-Purattasi)            
2. Koothirkaalam (Ippasi-Kaarthigai) 
3. Munpanikaalam (Maargazhi-Thai) 
4. Pinpanikaalam (Maasi-Panguni) 
5. Ilavenilkaalam (Chithirai-Vaigasi) 







5. PORIPULANGAL (SENSORY ORGANS):          
 
 
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
 
7.KOSANGAL (SHEATH):           
 
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 


















 Before treatment After treatment 
Kai(Upper limb) Normal  /Affected Normal  /Affected 
Kaal(Lower limb) Normal  /Affected Normal  /Affected 
Vai (Oral cavity) Normal  /Affected Normal  /Affected 
Eruvai(Anal region) Normal  /Affected Normal  /Affected 
Karuvai(Uro-Genital 
region) 
Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Annamayakosam Normal  /Affected Normal  /Affected 
Pranamayakosam Normal  /Affected Normal  /Affected 
Manomayakosam Normal  /Affected Normal  /Affected 
Vignanamayakosam Normal  /Affected Normal  /Affected 
Ananthamayakosam Normal  /Affected Normal  /Affected 
 
 














41th day 48th day 
Praanan         
Abaanan         
Samaanan         
Udhaanan         
Viyaanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         















Analakam         




       
Prasakam          



















Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam         
 
10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI 1st  day 8th day 15th day 22ndday 29thday 36th  day 41thday 48th day 




II. SPARISAM: [PALPATION] 
 
Day SPARISAM 
1st   day  
8th day  
15th  day  
22nd  day  
29th  day  
36th  day  
41th day  





III. NAA: [TONGUE] 
 
NAA 1st day 8thday 15thday 22ndday 29thday 36thday 41thday 48th day 
        
 
 
IV.NIRAM: [COMPLEXION] :  BEFORE TREATMENT :AFTER TREATMENT 
 
V.MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
VI.VIZHI: [EYES] 
VIZHI 1st   day 8th day 15thday 22ndday 29thday 36th  day 41thday 48thday 
         
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
VIII. MOOTHIRAM [URINE EXAMINATION]  
NEERKKURI: 
 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   





Neikkuri Before treatment After treatment 
Aravananeedathu/ 
Snake like pattern 
 











Other patterns   
 
11. MANIKADAINOOL (WRIST CIRCUMETRIC SIGN): 
                   BEFORE TREATMENT     Finger Breadths : 
12. CLINICAL EXAMINATION:        
 
   CLINICAL EXAMINATION OF SKIN :  
1.Site 
2.Shape:    Coin shape                Irregular                  Dispersed  
3. Erythema:     Present          Absent 
4. Macule              :     
5. Papule               : 
6. Pustule              :  
7. Itching:     No         Mild                  Moderate              Severe 
8. Scaling:     Mild                    Moderate                 Severe 
9.Fissures :     Present                      Absent 
10.Oozing:          No          Mild                Moderate              Severe          
11.Lichenification   :              Present                        Absent 
12. Auspitz sign      :  Present            Absent 
13. Koebner’s phenomenon: Present             Absent 
14. Candle grease sign: Present             Absent 
 
 
EXAMINATION OF NAILS: 
1.  Pitting:     Present  Absent 
2   Thickening:    Present                  Absent 
3.  Collection of Hyperkeratotic debris: Present Absent 
4.  Separation of distal portion of nail: Present Absent 
 
EXAMINATION OF JOINTS: 
                      YES                            NO 
                          Joint Involvement      
 
 
PSORIASIS AREA AND SEVERITY INDEX (PASI) 
A Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for 
measuring the severity of psoriatic lesions based on area coverage and plaque 
appearance 
Erythema/ Thickness/Scaling-Rating score Area Scoring 
0 - None      0-Nil   
1- Slight      1-1-9% 
2- Moderate      2- 10%-29% 
3-Severe      3-30%-49% 
4-Very severe      4-50%-69% 
        5-70%-89%  
                                                                                     6-90%-100% 
 
PASI CALCULATION 
Plaque Characteristic Rating Score 









0 = None         
Thickness 
1 = Slight 
        
2 = Moderate 
Scaling 
3 = Severe 
        
4 = Very Severe 
      Totals     
Weighting Factor     x 0.1    x 0.2   x 0.3    x 0.4 
 
 
Surface area totals     
  
Degree of involvement as  
% for each body region  
affected (score each  
region between 0 and 6) 
0 = None 
    
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Surface area totals x % involvement totals 
Sum Scores above = 
    
 
 
• Add together each of Erythema/Thickness/Scaling scores for each of the body 
regions to give 4 separate sub totals A1, A2, A3 and A4 
• Multiply each subtotal by amount of body surface area represented by that region 
i.e. A1 x 0.1 for head, A2 x 0.2 for upper limbs, A3 x 0.3 for trunk, A4 x 0.4 for 
lower limbs to give a value B1, B2, B3 and B4 for each body region 
respectively.A1 x 0.1=B1;   A2 x 0.2=B2; A3 x0.3=B3; A4 x 0.4=B4 
• For each body region multiply subtotal B1, B2, B3 and B4 by the score(0-6) of 
the % of body region involved to give 4 sub totals C1, C2, C3 and C4 
• The patient’s PASI score is the sum of C1+C2+C3+C4 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
 
PROGRESS OF TREATMENT 
PASI 
SCORE 








          
 
ãAY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors. 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) 
 
Hospital No: ……………………………………. Date:          ……………………. 
Name:           ……………………………………. Score:        ……………………. 
Address:      ……………………………………. 
                      ……………………………………. 
Diagnosis: ……………………. 
The aim of this questionnaire is to measure how much your skin problem has affected your life 
OVER THE LAST WEEK. Please tick (ü) one box for each question. 
 
1. Over the last week, how itchy, sore, painful or stinging 
has your skin been? 
 Very much 
A lot 
A little 






2. Over the last week, how embarrassed or self conscious 
have you been because of your skin? 
 Very much 
A lot 
A little 






3. Over the last week, how much has your skin interfered with 
you going shopping or looking after your home or garden?      
 Very much 
A lot 
A little 













4. Over the last week, how much has your skin influenced the 
clothes you wear? 
 Very much 
A lot 
A little 













5. Over the last week, how much has your skin affected any 
social or leisure activities? 
 Very much 
A lot 
A little 













6. Over the last week, how much has your skin made it difficult 
for you to do any sport?  
 Very much 
A lot 
A little 













7. Over the last week, has your skin prevented you from 
working or studying? 
 
If "No", over the last week how much has your skin been a 
problem at work or studying? 



















Over the last week, how much has your skin created 
problems with your partner or any of your close friends or 
relatives?   
 Very much 
A lot 
A little 













9. Over the last week, how much has your skin caused any 
sexual difficulties? 
 Very much 
A lot 
A little 













10. Over the last week, how much of a problem has the 
treatment for your skin been, for example by making your 
home messy, or by taking up time?  
 Very much 
A lot 
A little 














Please check you have answered EVERY question. Thank you.  
ãAY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors. 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) - INSTRUCTIONS FOR USE 
 
The Dermatology Life Quality Index questionnaire is designed for use in adults, i.e. patients over the age of 
16. It is self explanatory and can be simply handed to the patient who is asked to fill it in without the need for 





The scoring of each question is as follows: 
Very much     scored 3 
A lot      scored 2 
A little      scored 1 
Not at all      scored 0 
Not relevant     scored 0 
Question 7, ‘prevented work or studying’ scored 3 
 
The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum 
of 0. The higher the score, the more quality of life is impaired.  
 
 
HOW TO INTERPRET MEANING OF DLQI SCORES 
 
0 – 1 no effect at all on patient's life 
2 – 5 small effect on patient's life 
6 – 10 moderate effect on patient's life 
11 – 20 very large effect on patient's life 





Finlay AY and Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine 
clinical use. Clin Exp Dermatol 1994; 19:210-216. 
 
Basra MK, Fenech R, Gatt RM, Salek MS and Finlay AY. The Dermatology Life Quality Index 1994-2007: a 
comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997-1035. 
 
Hongbo Y, Thomas CL, Harrison MA, Salek MS and Finlay AY. Translating the science of quality of life into 




There is more information about the DLQI, including over 85 translations, at www.dermatology.org.uk. The 
DLQI is copyright but may be used without seeking permission by clinicians for routine clinical purposes. For 
other purposes, please contact the copyright owners. 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU 
MARUTHUVAM 
 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI  KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) WITH 
AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).  
Principal Investigator: Dr.K.ARCHANA  
CTRI REG.NO          : CTRI/2018/07/015115 
  
1. SERIAL NO:       
2. OP /IP NO:                              
3. NAME:             
4. AGE/GENDER: 













T.WBC (cells/cu.mm) 4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 

















Fasting 70-110   
PP 80-140   
Random 80-120   
RFT (mg/dl) Blood urea 16-50   
Serum Creatinine 0.6-1.2   
LFT (mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-1.2   
Indirect bilirubin 0.2-0.7   
SGOT 0-40   
SGPT 0-35   
Alkaline 
phosphatise 














Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
 
 
URINE INVESTIGATION BEFORE TMT( DATE) AFTER TMT ( DATE) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI  KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) WITH 
AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).  
Principal Investigator: Dr.K.ARCHANA  
CTRI REG.NO          : CTRI/2018/07/015115 
 
   FORM – DRUG COMPLIANCE FORM 
STUDY  NO:   OP / IP NO: 
NAME: AGE / GENDER: 
 
INTERNAL DRUG  
On 1st     day-Date:  Drugs issued:    (Gms) Drugs returned:    (Gms) 
On 8th   day-Date:   Drugs issued:    (Gms) Drugs returned:    (Gms) 
On 15th day-Date:              Drugs issued:    (Gms) Drugs returned:    (Gms) 
On 22th day-Date:           Drugs issued:    (Gms) Drugs returned:    (Gms) 
On 29th day-Date:             Drugs issued:   (Gms) Drugs returned:    (Gms) 
On 36th day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 42th day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 48th day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
EXTERNAL DRUG  
On 1st     day-Date:  Drugs issued:    (ml) Drugs returned:    (ml) 
On 8th   day-Date:   Drugs issued:    (ml) Drugs returned:    (ml) 
On 15th day-Date:              Drugs issued:    (ml) Drugs returned:    (ml) 
On 22th day-Date:           Drugs issued:    (ml) Drugs returned:    (ml) 
On 29th day-Date:             Drugs issued:   (ml) Drugs returned:    (ml) 
On 36th day-Date:              Drugs issued:  (ml) Drugs returned:    (ml) 
On 42th day-Date:              Drugs issued:  (ml) Drugs returned:    (ml) 
On 48th day-Date:              Drugs issued:  (ml) Drugs returned:    (ml) 
 
 
 Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
 
   Day    Date          Morning   Evening   Day    Date    Morning   Evening 
Day 1    Day25    
Day2    Day26    
Day3    Day27    
Day4    Day28    
Day5    Day29    
Day6    Day30    
Day7    Day31    
Day8    Day32    
Day9    Day33    
Day10    Day34    
Day11    Day35    
Day12    Day36    
Day13    Day37    
Day14    Day38    
Day15    Day39    
Day16    Day40    
Day17    Day41    
Day18    Day42    
Day19    Day43    
 
Day20    Day44    
Day21    Day45    
Day22    Day46    
Day23    Day47    
Day24    Day48    
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI  KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) WITH 
AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).   
Principal Investigator: Dr.K.ARCHANA  
Ctri Reg.No          : CTRI/2018/07/015115 
FORM -DIETARY ADVICE FORM 
 
1.SERIAL NO:      2. OP /IP NO:                 





þÉ¢ôÒ §¸¡¨Å (Ivy gourd) 
¦ÅûÇÃ¢ô À¢ïÍ (Baby cucumber) 
¸ò¾Ã¢ô À¢ïÍ (Baby brinjal) 
«Å¨Ãô À¢ïÍ (Lablab bean) 
§¾í¸¡ö (Coconut) 
ÀÈí¸¢¸¡ö (Cucurbita maxima) 
ÓûÇí¸¢ (Radish) 
¦Åñ¨¼ì¸¡ö (Lady’s finger) 
Å¡¨Æôâ (Plantain flower) 
Å¡¨Æò¾ñÎ(Plantain stem) 
§¸Ãð (Carrot) 
¸¢îº¢Ä¢ (Kolunji naraththai-Tangerine) 
¯Õ¨Çì¸¢ÆíÌ (Potato) 
¾ÊÂý¸¡ö (White pumpkin) 
Í¨Ãì¸¡ö (Bitter bottle gourd) 
Íñ¨¼ (Unarmed night shade) 
«¸ò¾¢ì¸£¨Ã(Sesban green)  
º¢Ú¸£¨Ã(Chirukiirai) 
¦ÅüÈ¢¨Ä (Betal leaf) 
¦¸¡ò¾Å¨Ã (Cluster bean) 
ÁÃÅûÇ¢ì¸¢ÆíÌ(Cassava tapioca) 
§ºôÀí¸¢ÆíÌ (Colocasia root) 
ºì¸ÃÅûÇ¢ì¸¢ÆíÌ (Chakkaravalli) 
¸Õ¨½¸¢ÆíÌ (Elephant yam) 
Å¡¨Æì¸¡ö (Raw banana) 
¸¡Ç¡ý (Mushroom) 
À¡¸ü¸¡ö (Bitter gourad) 
À£÷ì¸í¸¡ö (Ribbed luffa) 
ÒÇ¢ (Tamarind fruit) 
¸¡Ä¢ôÀ¢ÇÅ÷ (Cauliflower) 
¦¸¡òÐÁøÄ¢Å¢¨¾ (Coriander seed) 
ÅÃÌ «Ã¢º¢ (Kodo millet) 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
¾ì¸¡Ç¢ (Cape gooseberry ) 
Á½ò¾ì¸¡Ç¢ (Black night shade green)  
«¨Ã¸£¨Ã (Araikkirai) 
¸Ã¢º¡¨Ä (Trailling eclipta) 
Ó¨Ç¸£¨Ã (Mulaikiirai) 
Àº¨Äì¸£¨Ã (Portulaca quadrifida.Linn)  
Ò¾¢É¡ (Marsh mint ) 
Ìô¨À§ÁÉ¢ (Indian acalypha green)  
º¢Ú ÌÈ¢ïº¡ý (Periploca of the woods 
green )  
¦À¡ýÉ¡í¸¡½¢ (Sessile plant) 
ÅøÄ¡¨Ã (Indian pennywort) 
àÐÅ¨Ç (Climbing brinjal green) 
Ó¼ì¸üÈ¡ý £¸¨Ã (Ballon-vine) 
ÓÕí¨¸ ¸£¨Ã,À¢ïÍ ¸¡ö (Drumstick) 
¦¸¡òÐÁøÄ¢ ¸£¨Ã,Å¢¨¾ (Coriander seed) 
âñÎ (Garlic) 
þïº¢ (Ginger) 
¯ÙóÐ (Black gram) 
À¡º¢ÀÂÚ (Green gram) 




²Äõ (Cardamom seed) 
¸º¸º¡ (Opium poppy) 
Á¢ÇÌ (Pepper) 
¦Åó¾Âõ (Fenugreek) 
¸ÎÌ (Black mustard seed) 
º£Ã¸õ (Cumin seed ) 
ÍìÌ (Dried ginger) 
Óó¾¢Ã¢ ÀÆõ,ÀÕôÒ (Fruit,Cashew nut) 
þÄó¨¾ôÀÆõ (Ber fruit) 
«ò¾¢ (Fig) 
¬ôÀ¢û (Apple) 
§ÀÃ£îÍ (Date palm) 
±ÖÁ¢î¨º (Lemon) 
ºô§À¡ð¼¡ (Sapota) 
ÀîºÃ¢º¢ (Raw rice) 
§¸¡Ð¨Á (Wheat) 
±û (Sesame seed,oil) 
§Å÷¸¼¨Ä (Pea nut) 
¸¼¨Ä (Bengal gram) 
¸õÒ (Pear millet) 
§¸úÅÃÌ (Ragi) 
¸¡Ã¡Á½¢ (Cow gram) 
§º¡Çõ (Great millet) 
¦¸¡ûÙ (Horse gram) 
¾¢¨É (Italian millet) 
º¡¨Á( Little millet) 
¾ð¼ÀÂÚ (Flat bean) 
¦Á¡î¨ºôÀÂÚ (Lablab purpureus.Linn) 
¸¡ôÀ¢ì¦¸¡ð¨¼ (Coffee) 
¸Ç¢ôÀ¡ìÌ (Areca nut) 
«Õ¦¿øÄ¢ (Countrg goose berry) 
«ýÉ¡º¢ÀÆõ (Pineapple) 
¦¸¡öÂ¡(Guava) 
º£ò¾¡ÀÆõ (Custard apple) 
ÀÄ¡ÀÆõ (Jack fruit) 
Á¡õÀÆõ (Mango) 
À¨ÉÀÆõ (Palmyra palm fruit) 
Á¡Î ¸È¢ (Beaf) 






¿¡Åø ÀÆõ (Jambul)  





Å¢ÇõÀÆõ (Wood apple ) 
¸ÕõÒ (Sugarcane) 
«Ú¸õÒø (Barmuda grass juice)  
¿ýÉ¡Ã¢ (Indian sarsaparilla sarbath)  
¦ºõÀÃò¨¾ (Hibiscus rosa sinensis Tea) 
ÐÇº¢ (Holy basil water) 
¦ÅûÇ¡Î À¡ø (Goat milk) 
¦ÅûÇ¡Î ¸È¢ Mutton 




§¾í¸¡ö ±ñ¦½ö (Coconut oil) 




±Õ¨ÁôÀ¡ø (Buffalo milk) 
¦ºõÁÈ¢Â¡Îô À¡ø(Sheep milk) 
¦ºõÁÈ¢Â¡Îì ¸È¢(Sheep) 
ÀýÈ¢ì¸È¢ (Pig) 
ãì¸¢Ãð¨¼ (Boerhavia diffusa) 
°Ú¸¡ö (Pickle)  
ÒÇ¢ôÒ ¾Â¢÷ (Sour curd) 









NATIONAL INSTITUTE OF SIDDHA 
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                             FORM -  WITHDRAWAL FORM 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................   
3. NAME: ………………………    
4.AGE: …………        
5.GENDER:...........                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Reluctant to continue the study                                         Yes/ No 
 
Poor patient compliance &defaulters                                Yes/ No 
 
Increase in severity of symptoms                                       Yes/ No 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU 
MARUTHUVAM 
PRE CLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUGS 
PARANGIPATTAI KUDINEER (INTERNALLY) AND SIVAPPU THYLAM 
(EXTERNALLY) IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS) WITH 
AND WITHOUT YOGAM THERAPY (AGATHAVAM ETTU).  
Principal Investigator: Dr.K.ARCHANA  
CTRI REG.NO          : CTRI/2018/07/015115 
 
FORM  – ADVERSE REACTION FORM / PHARMACO VIGILANCE FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 













Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
 
 






Please note:  i.  All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even if  
             it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
 
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 





2. Description of the suspected Adverse Reactions (please complete boxes below) 
 




reaction   
 
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by the 






& Vehicle – 
Adjuvant 









     









Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the drug 
used 
   
 
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used as 
self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      











Signature of the reporter:       Date: 
Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
 
 




This filled-in ADR report may be sent within one month of observation /occurrence of 




Date:                                                                              
Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
          
Date :      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                  Signature of the HOD 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
Name & address of the RRC-
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CTRI Number CTRI/2018/07/015115 [Registered on: 30/07/2018] - Trial Registered Prospectively
Last Modified On 26/07/2018
Post Graduate Thesis Yes
Type of Trial Interventional
Type of Study Drug
Siddha
Other (Specify) [Yogam] 
Study Design Single Arm Trial
Public Title of Study “Clinical trial of Siddha drugs Parangipattai Kudineer (Internally) and Sivappu Thylam (Externally) in
the treatment of Kalanjaga Padai (Psoriasis) with and without Yogam therapy”
Scientific Title of
Study
“Preclinical and comparative clinical trial of Siddha drugs Parangipattai Kudineer (Internally) and
Sivappu Thylam (Externally) in the treatment of Kalanjagapadai (Psoriasis) with and without Yogam
therapy (Agathavam Ettu)”






Details of Principal Investigator
Name Dr K Archana
Designation MD Siddha
Affiliation Ayothidass pandithar hospital, National Institute of Siddha
Address Department of Sirappu Maruthuvam, Ayothidass pandithar hospital,











Details Contact Person (Scientific Query)
Name Dr N J Muthukumar
Designation Head of the Department
Affiliation Ayothidass pandithar hospital, National Institute of Siddha
Address Department of Sirappu Maruthuvam, Ayothidass pandithar hospital,










Details Contact Person (Public Query)
Name Dr M V Mahadevan
Designation Lecturer
Affiliation Ayothidass pandithar hospital, National Institute of Siddha
Address Department of Sirappu Maruthuvam, Ayothidass pandithar hospital,
National Institute of Siddha, Tambaram Sanatorium, Chennai
Kancheepuram
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Source of Monetary or
Material Support
Source of Monetary or Material Support
> Self (K Archana PG Scholar National Institute of Siddha Tambaram sanatorium chennai 47
Primary Sponsor Primary Sponsor Details
Name Dr K Archana
Address Ayothidass pandithar hospital, National Institute of Siddha,
Tambaram Sanatorium, Chennai









Sites of Study Name of Principal
Investigator 
Name of Site Site Address Phone/Fax/Email
































Patients Patients with symptoms of dry erythematous
macules with silvery scales without any structural





(Internally) and Sivappu Thylam
(Externally)
Parangipattai Kudineer is a
polyherbal formulation in a
dosage of 30ml internally,Three
times a day and Sivappu
Thylam applied externally in the
affected areas for 48 days.
Comparator Agent NA NA
Inclusion Criteria Inclusion Criteria
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Age From 20.00 Year(s)
Age To 65.00 Year(s)
Gender Both
Details 1)History of Non Insulin Dependent Diabetes Mellitus
2)Dry erythematous macules with silvery scaly lesion without any





7)Candle crease sign +
8)Willing to give specimen of blood for the investigation whenever
required.
9)Willing to take photograph
10)Willing to participate in trial and signing consent by fulfilling the
condition of Proforma.
Exclusion Criteria Exclusion Criteria
Details 1.History of Insulin Dependent Diabetes Mellitus
2.Pregnancy and lactation
3.History of Psoriasis with evidence of any other skin disease or
Evidences of secondary infection in the lesions.
4.History of Psoriatic arthropathy
5.History of Cardiac diseases
6.History of Hansen’s disease








Primary Outcome Outcome Timepoints
Efficacy of the trial drug measured by PASI
Score.
1-48 DAYS
Secondary Outcome Outcome Timepoints
1.To study the Siddha diagnostic methods such
as Envagai thervu and Manikkadai Nool as
complementary measures for diagnosis in
Kalanjaga padai patients.
2.To carry out the biochemical analysis of trail
medicine Parangipattai kudineer (Internally)
3.To evaluate the toxicity study of trail medicine
Parangipattai kudineer (Internally)
1-48 DAYS
Target Sample Size Total Sample Size=40
Sample Size from India=40
Final Enrollment numbers achieved (Total)=Applicable only for Completed/Terminated trials
Final Enrollment numbers achieved (India)=Applicable only for Completed/Terminated trials
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Publication Details Archana.K.,et al , Polyherbal Siddha Formulation Parangipattai Kudineer : A Review, ejbps , 2018,
Volume 5, Issue 6, 196-201.
Brief Summary
                    Siddhars identified numerous number of herbal for treating Kalanjagapadai (Psoriasis). One such Siddha herbal formulation “Parangipattai Kudineer” (Internal) and “Sivappu Thylam” (External) mentioned in “Pharmacopoeia of hospital of Indian medicine” which is
said to be cost effective, efficacious and simple formulation. This formulation has not undergone any a preclinical study and clinical study with yogam so far.The ingredients of Parangipattai kudineer (Internally) are Parangipattai (Smilax china Linn.),Kadugu Rohini (Picrorhiza kurroa Royle),Manjitti (Rubia
cordifolia Linn.), Mara Manjal (Coscinium fenestratum Colebr.),Kadukkai (Terminalia chebula Retz.),Thandrikai (Terminalia bellaricaRoxb.),Vasambu (Acorus calamus Linn),Sombu (Pimpinella anisum Linn.),Veppampattai (Azadirachta indica A.Juss.),Seendhil (Tinospora cordifolia Miers.) are also having Antipsoriatic,
Immunomodulator, Anti-Inflammatory, Antifungal, Antimicrobial, Antianalgesic. So that I hope this medicine will be effective in the treatment of Kalanjagapadai (Psoriasis). Therefore I have selected the drug for clinical study.   
Powered by TCPDF (www.tcpdf.org)
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